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Manufacturing of Non-Egg Based Influenza Vaccine
Abstract
Influenza is an annual health hazard with only about one-third of people in the United States receiving
vaccinations for this pathogen. Epidemics are estimated to affect between 5% and 15% of the global
population annually. Annually, the WHO estimates epidemics to result in between 3 and 5 million severe
cases which lead to between 250,000 and 500,000 deaths. In industrialized countries, most of these deaths
occur among victims who are chronically ill or are 65 years of age or older. In developing countries,
particularly in tropic areas where transmission occurs year round, there is a higher rate of death to infection.
For example in 2002, Madagascar experienced 800 deaths in 27,000 recorded cases of influenza over a 3
month period (WHO).
Recently, international awareness, spearheaded by the World Health Organization (WHO), has been paid to
influenza since the pandemic outbreak and subsequent vaccine shortage during the H1N1 outbreak. Since
then the WHO has published a set of guidelines to encourage production of safer and increasingly potent
influenza vaccines for a greater number of recipients each year. WHO is attempting to increase public and
private sector awareness of the importance of influenza vaccination to prevent any subsequent pandemics.
Current vaccines are produced in live, embryonated chicken eggs resulting in potential allergic reactions from
animal products in the vaccines. Furthermore, this process is time-consuming and labor intensive, and the live,
attenuated virus is considered to be a potential health risk for populations with suppressed immune function
such as children, the elderly, and those who are sick or immunocompromised. Egg shortages can cause
massive vaccine shortages, especially since only two companies currently produce most of the United States'
influenza vaccines. We propose that virus- like particles offer a more robust and safer alternative to current
vaccine manufacturing. Currently, FluBlok is a product that utilizes recombinant influenza antigens to
produce a vaccine. We plan to take this strategy another step to creating replication-deficient, native
conformation viruses to induce an immune response. These particles will retain all structural similarity to
native virus and have been shown to produce more robust responses with smaller doses. Furthermore, these
particles will carry no risk of influenza infection upon administration. Virus-like particles will become the next
generation of vaccines, such as those for human papilloma virus currently manufactured, and should rectify
the problems associated with egg-based production of influenza vaccines.
The proposed process is a fed-batch operation that will create about 100 million influenza vaccines during
each influenza infection season from November to February, using insect cell lines and the baculovirus
expression vector system (BEVS) to induce lytic formation of virus-like particles. This process will be
performed in a single-use, disposable fermentation train with single-use components integrated in the
purification process to take advantage of the timesaving techniques and disposable equipment. The
production of influenza vaccines is time-sensitive with a limited duration of vaccine production from WHO's
publishing strains to product shipment. Single-use equipment will be used to allow maximization of
production time and minimization of down-time in this process.
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1.0 Abstract
 
Influenza is an annual health hazard with only about one-third of people in the 
United States receiving vaccinations for this pathogen. Epidemics are estimated to affect 
between 5% and 15% of the global population annually. Annually, the WHO estimates 
epidemics to result in between 3 and 5 million severe cases which lead to between 
250,000 and 500,000 deaths. In industrialized countries, most of these deaths occur 
among victims who are chronically ill or are 65 years of age or older. In developing 
countries, particularly in tropic areas where transmission occurs year round, there is a 
higher rate of death to infection. For example in 2002, Madagascar experienced 800 
deaths in 27,000 recorded cases of influenza over a 3 month period (WHO).  
Recently, international awareness, spearheaded by the World Health Organization 
(WHO), has been paid to influenza since the pandemic outbreak and subsequent vaccine 
shortage during the H1N1 outbreak. Since then the WHO has published a set of 
guidelines to encourage production of safer and increasingly potent influenza vaccines 
for a greater number of recipients each year. WHO is attempting to increase public and 
private sector awareness of the importance of influenza vaccination to prevent any 
subsequent pandemics.  
 Current vaccines are produced in live, embryonated chicken eggs resulting in 
potential allergic reactions from animal products in the vaccines. Furthermore, this 
process is time-consuming and labor intensive, and the live, attenuated virus is 
considered to be a potential health risk for populations with suppressed immune function 
such as children, the elderly, and those who are sick or immunocompromised.  Egg 
shortages can cause massive vaccine shortages, especially since only two companies 
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?????????????????? ????????????????????????????????????????????? We propose that virus-
like particles offer a more robust and safer alternative to current vaccine manufacturing. 
Currently, FluBlok? is a product that utilizes recombinant influenza antigens to produce 
a vaccine. We plan to take this strategy another step to creating replication-deficient, 
native conformation viruses to induce an immune response. These particles will retain all 
structural similarity to native virus and have been shown to produce more robust 
responses with smaller doses. Furthermore, these particles will carry no risk of influenza 
infection upon administration. Virus-like particles will become the next generation of 
vaccines, such as those for human papilloma virus currently manufactured, and should 
rectify the problems associated with egg-based production of influenza vaccines. 
 The proposed process is a fed-batch operation that will create about 100 million 
influenza vaccines during each influenza infection season from November to February, 
using insect cell lines and the baculovirus expression vector system (BEVS) to induce 
lytic formation of virus-like particles. This process will be performed in a single-use, 
disposable fermentation train with single-use components integrated in the purification 
process to take advantage of the timesaving techniques and disposable equipment. The 
production of influenza vaccines is time-sensitive with a limited duration of vaccine 
???????????????? ???????????????????????????????????????????????????-use equipment 
will be used to allow maximization of production time and minimization of down-time in 
this process. 
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2.0 Introduction 
 Vaccines are an increasingly important cost-effective prophylactic measure 
against widespread disease, particularly for diseases of high morbidity or mortality or of 
pandemic proportions. Influenza is a virus that fits the latter category, for many of its 
strains have caused global pandemics and it recurs on a yearly basis. The entire 
population is at risk of contracting influenza, and it is especially virulent in children and 
the elderly, especially since it spreads as an aerosol. Influenza is responsible for about 
17,000 to 51,000 deaths annually in the United States and global pandemic death tolls 
reach the millions (Kang).  
 Influenza is a lipid-encapsulated RNA virus consisting of four surface proteins 
essential for infection and replication: M1, M2, neuraminidase (NA) and hemagglutinin 
(HA). There exist two subclasses of influenza, A and B. Each year, the World Health 
Organization (WHO) issues a recommendation of the influenza A and B HA and NA 
variants most likely to cause disease. Classically, based on these recommendations, 
trivalent influenza vaccines have been produced in embryonated chicken eggs, consisting 
of two influenza A variants and a single influenza B variant, which are then activated and 
adjuvanted to increase the immune response. These vaccines are inefficient in children 
and the elderly, and antigenic drift can greatly decrease their efficacy in the rest of the 
population. Lately, egg shortages combined with increasingly virulent influenza strains 
(H1N1) have rendered this method of vaccine production archaic and inefficient for 
meeting the ever-increasing demand for yearly vaccination. A new method of vaccine 
production involving industrial cell culture would greatly increase the number of 
vaccines available. 
	   4	  
 Current influenza vaccines are either produced from inactivated egg-grown virus 
particles or from trivalent recombinant HA proteins (rHA) grown in mammalian cells 
(Flucelvax, approved November 2012). While the recombinant protein vaccine is egg-
free, it requires expensive mammalian cell culture and yields a protein product that is not 
entirely in its native conformation. Recently, virus-like particles (VLPs) have become a 
popular alternative to traditional inactivated or recombinant protein vaccines such as the 
human papilloma virus (HPV) vaccine currently on the market. VLPs can display any 
protein of interest on their surface in the native conformation found on the mimicked 
virus. However, these VLPs do not contain the necessary components for replication or 
infection (see Figure 2.1), so serve as a method to safely introduce antigenic material to 
????????????????????????????????????????????????? 
 
 
 
 
 
 
 
 
 
 
 
 
F igure 2.1 Virus particles(left) compared to VLPs (right). Note the missing 
genomic material in the VLPS as well as the simplified proteins in the 
membrane compared to the fully functional virus. The electron micrographs 
demonstrate their similarity in macrostructure. Reprinted from Landry, N. 
PLoS One.Volume 8, 2010. 
	   5	  
VLPs present a much smaller chance of infection or side-effects when compared with the 
other vaccines available, and their immunogenic response is considerably more robust, on 
the order of a five-fold increase (Kushnir). Influenza is a lipid membrane-enclosed virus, 
obtaining this coating from the infected cell as it buds involving no internal protein 
capsid. This simplicity of viral structure allows for a simplified purification process, since 
it is considerably more thermodynamically stable than a VLP containing capsid proteins, 
keeping the downstream processing equipment similar to that used for rHA or inactivated 
virus vaccines (Roldao).  
 In the case of influenza VLPs, studies have demonstrated that the M1 matrix ion 
channel proteins in combination with HA are necessary and sufficient to induce VLP 
formation (Galarza). These VLPs tend to form with diameters between 80 and 120nm, 
about the same size as the influenza virus particles. Since these requirements for VLP 
budding are minimal, most of the protein production of the cells can be directed towards 
the production of HA rather than M1, such that the majority of the protein produced is 
HA on the surface of individual VLPs. The efficacy of vaccine is related to its ability to 
present HA in its native conformation to the immune system. The immunogenicity of 
VLPs is already about five-fold greater than that of rHA proteins or inactivated viruses. 
HA production will be dominant in the insect cells by insuring the upstream promoter is 
activated earlier in the life cycle of the virus than the promoter upstream of the M1 
protein. Then, upon progression of the virus, HA will be considerably more concentrated 
than M1, creating VLPs densely populated with HA surface proteins for a more robust 
vaccine.  
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The baculovirus expression vector system consists of the infection of an insect 
cell line with the baculovirus, which is only virulent to insect cells. These baculoviruses 
are recombinant and contain a DNA that the host cell will produce. Upon infection the 
host insect cells will produce large amounts of protein encoded by the recombinant 
baculovirus DNA. These proteins, mostly HA and in much smaller quantities, a matrix 
protein, will induce the formation of VLPs at sites of aggregation near the insect cell 
membrane. This process will result in VLPs made of insect cell membrane with the 
desired antigenic material to immunize against influenza on the surface. The 
baculoviruses are consumed in the process of VLP formation. The design and execution 
of the baculovirus constructs for each HA subtype and the method of promoter selection 
to provide the correct relative amounts of HA and M1 production are outside of the scope 
of this project, but have been mentioned for completeness of theoretical design. 
Furthermore, the verification of VLP budding and the average concentration of HA on 
the surface of each VLP would be carried out on the bench-top using HA activity assays 
and electron microscopy to determine the exact characteristics of the influenza VLPs. 
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2.1 Project Charter 
 
Project Name: Influenza Virus-Like Particle Vaccine Biopharmaceutical Process 
 
Project Team: Erin Kinnevy, Ian Penkala, April Soohoo, John Vogel 
 
Project Goal: Design a biopharmaceutical plant and process to produce egg-free influenza 
vaccines 
 
Project Scope: 
 
In-Scope 
 
? Observe cGMP in producing influenza vaccines, obeying all safety and health 
regulations 
? Design the production stream from small scale fermentation to final product 
purification 
? Design both a pilot- and a manufacturing-scale plant 
? Deliver a product from R&D to final production in under six months 
? Maintain a profit margin 
? Price the vaccine competitively with egg-based vaccines 
? Create an animal-free influenza vaccine 
 
Out-of-Scope 
 
? Baculovirus research and formulation 
? Influenza strain research 
? Toxicology studies 
? Proof-of-Concept studies 
? Clinical trials 
? Product packaging & distribution 
? Cell-line screening and testing 
? Air flow profiles of facility 
 
Deliverables 
 
? Production timeline & individual batch timeline 
? Achievement of regulatory requirements 
? Technical feasibility assessment & supporting literature 
? Business feasibility assessment & cost sensitivity analysis 
? WHO vaccine guideline fulfillment 
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2.2 Innovation Map 
 
Overall, the production of a non-egg based influenza vaccine is innovative, as it is 
a relatively new to the market.  In regards to the production facility, the upstream 
??????????????????????????????????????????single-use, stirred-tank bioreactors, and choice of 
other single-use technologies.  
The downstream process follows the same path as traditional influenza vaccines, 
and thus the only innovation is the use of disposable technology as opposed to stainless 
steel equipment.  As a result, an innovation map for the downstream process has not been 
included; the single-use technology innovations have the same advantages as in the 
upstream process. 
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F igure 2.2 Upstream Process Innovation Map.  The innovation map identifies key features of the upstream process for 
the non-egg based influenza vaccine system based on the process design and equipment choice.  
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2.3 Expression System Selection 
 
 A major focus of biopharmaceutical companies is to develop new technologies as 
alternatives to egg-based culture for production of viral vaccine antigens. Alternatives 
currently under development involve direct expression of selected viral antigens in 
mammalian cells, insect cells, plant cells, and avian cells. For the purposes of this design 
project, all of these alternatives were explored for their potential to overcome both the 
safety and efficacy limitations of egg-based vaccine production.  
 The mammalian cell lines under investigation included Madin-Darby Canine 
Kidney (MDCK) cells, Vero cells, and PERC6 cells. While these cell lines have been 
associated with high-titer productivity of influenza strains, few studies have reported on 
large-scale production. Other possible limitations involved with mammalian cell lines 
include the difficulty in selecting defined cell lines with the ability to propagate in a 
chemically defined medium under serum-free conditions and the vigorous testing 
required for clearance of adventitious or oncogenic agents (Montomoli). Plant cell lines 
and prokaryotic cell lines were eliminated based on the difficulties involving land and 
?????????????????????????????????????????????????????????????????? 
Avian and insect cell lines showed the most benefits with high suspension growth, 
scalability, inexpensive growth conditions, and rapid turn-over rates. After analyzing the 
benefits and challenges associated with each of the alternatives, the insect cell line, SF2, 
similar to the SF+ line developed by Protein SciencesTM, was designed by the R&D 
group as the VLP production system. Rather than using a cell culture-based platform, 
hemagglutinin (HA), the active component of the influenza vaccine, will be produced 
using recombinant DNA methods and the baculovirus expression vector system (BEVS). 
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Table 2.1 shows several influenza vaccines that are in development by different 
biopharmaceutical companies (PCAST).  
Table 2.1 Competing influenza vaccines made from non-egg based platforms that are currently in development, in 
clinical trials or on the market (PCAST). 
Vaccine/Manufacturer Type Mode of Preparation Adjuvant 
F luBlok?/Protein 
Sciences 
Soluble protein 
(HA), trivalent 
Insect Cell 
Culture/Baculovirus None 
PanBlock/Protein 
Sciences 
Soluble protein 
(HA) 
Insect Cell 
Culture/Baculovirus None 
Influenza/Novavax VLP Insect Cell Culture/Baculovirus None 
Pandemic & Seasonal 
Influenza/Lentigen VLP 
Human Cell 
Culture/Lentivirus None 
Pandemic & Seasonal 
Influenza/Medicago VLP Plant Cell Culture None 
Pandemic & Seasonal 
Influenza/Vaxinnate 
Soluble human 
and avian protein 
(HA) 
E. Coli Flagellin 
Universal 
Influenza/Dynavax Soluble protein E. Coli CpG 
 
The insect cells will be cultured in bioreactors and infected with the recombinant 
baculovirus, which is then purified and formulated into a vaccine. The specific cell line to 
be used for the vaccine production is SF2, a cell line derived from SF9 cells with a 
specific phenotype and genotype ideal for biomanufacturing. SF2 cells have been proven 
to be non-tumorigenic, free of adventitious agents and retroviruses, and can remain stable 
for at least 50 passages, according to prior studies during the development phase of this 
cell line.  
The BEVS platform offers several advantages over the other methods: (1) the 
recombinant HA is highly purified without egg derivatives, (2) the cloning, expression, 
and manufacturing of the recombinant HA is less time-consuming, (3) the production 
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system is highly scalable, (4) recombinant HA in insect cells has been tested in clinical 
trials with a positive safety record (McPherson). 
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2.4 Baculovirus Expression System 
 
 The baculovirus expression system (BEVS) has been chosen as the basis for the 
influenza vaccine production for its proven effectiveness in a variety of research 
applications. Baculovirus expression vectors have been used extensively for the 
production and characterization of virus-like particles (VLPs). The expression of 
baculovirus in insect cell cultures in particular represents a robust method for producing 
recombinant glycoproteins, and has been shown to be a reliable system for recombinant 
protein expression (Kushnir). 
 The pharmaceutical industry has shown that BEVS is an industrially relevant 
?????????????????????????????????????????????????????????????????????????????????????
CervarixTM, a bivalent human papillomavirus vaccine was produced using the BEVS and 
was approved in 2009 for commercialization in the USA. Other candidate vaccines 
produced using the BEVS such as PanBlockTM and NovavaxTM are in late-stage 
development, and one, FluBlokTM, has been approved by the FDA. The biosafety of 
baculoviruses provide additional advantages to using this system. Baculoviruses are 
incapable of infecting mammals and plants and they have a restricted range of hosts that 
they can infect, which is typically restricted to a closely related insect species. The well-
documented safety profile of this expression system has lead to its increasing use in the 
production of biologics and other research applications (Kost). 
 The expression system works by designing baculoviruses to display foreign peptides 
and proteins on virus particles. When using the BEVS for vaccine production, 
mathematical models are used to help predict optimal conditions, aid in the control and 
operation of the process and help to formulate novel hypotheses. The overall 
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development process is predominantly characterized by the cell growth period, which is 
followed by the addition of the virus. The cell growth period is typically modeled 
exponentially and constrained by either depletion of a limiting nutrient or by 
accumulation of toxic metabolic by-products. In the case of insect cells, however, no 
limiting nutrients or toxic metabolic by-products have currently been identified (Kost, 
Aucoin). 
 An additional concern when using the BEVS is the distribution of virus and 
quantification of baculovirus. The uptake of the virus once it is added to the system can 
have many important implications on further processing. For example, the amount of 
baculovirus added to the system can dramatically affect the production capacity of the 
system. However, the multiplicity of infection and the distribution between the insect 
cells in the population and the virus are aspects of this process that remain outside the 
scope of this design project. 
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3.0 Concept Stage 
3.1 Total Market and Competitive Analysis 
 The company is targeting the annual production of seasonal influenza vaccines in 
the North American and European markets.  In addition, the company must be able to 
respond to a pandemic.  In 2004, the world market for influenza vaccines was $1,525 
million in revenues, and in 2008, $3,400.1 million.  Based on a compound annual growth 
rate of 14.0% from 2008-2013, it is projected that in 2013 the world market for influenza 
vaccines will reach $6,546 million in revenues (World Market), of which approximately 
two thirds, or $4,364 million can be estimated as part of the target markets. 
 Currently, the market is dominated by the production of influenza vaccines in an 
egg-based platform.  However, this platform limits the population the vaccine is available 
to due to egg and feather allergies.  In addition, this platform is also associated with long 
lead times, difficulties scaling up, and a less consistent, reproducible means of vaccine 
production, along with vulnerabilities from egg shortages from issues such as the avian 
flu.  In particular, the egg-based platform struggles to create enough vaccines in a timely 
manner for a pandemic situation (Harding).   
 Vaccine companies are now branching out to produce flu vaccines using 
alternative expression systems from cell cultures in order to overcome these challenges.  
The FDA recently approved two seasonal flu vaccines produced from cell cultures- 
FlucelvaxTM, by NovartisTM, produced from MDCK cells, in November 2012, and 
FluBlokTM, by Protein SciencesTM, produced from insect cells, in January 2013 
(Willyard).  With growing research in the field of cell culture vaccine production, the 
company must be able to compete with both these vaccines, as well as vaccines produced 
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from the egg-based platform.  Influenza vaccines produced from cell cultures remains a 
largely new innovative field, which leaves room for this company to grow and expand 
into this market share.  Furthermore, this company has the potential to expand into the 
market for other vaccines, since this method of production is also feasible system for 
other types of vaccines besides influenza. 
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3.2 Principal Competition Production Level and Sales 
 As a world-leading vaccine company, production must meet or exceed that of 
other major companies.  Currently, NovartisTM, Sanofi PasteurTM, AstraZenecaTM, 
GSKTM, and CSLTM are leaders in the flu vaccine market (Kresse).  In 2011, Sanofi 
PasteurTM produced over 200 million seasonal vaccine doses (Sanofi Pasteur fact sheet).  
Based on this number and annual growth of the market, it is estimated that the company 
will need to produce 100 million vaccine doses for the North American and European 
markets in 2013. 
 In response to the A(H1N1) 2009 pandemic, Sanofi Pasteur? recorded the 
production of over 250 million vaccine doses (Sanofi Pasteur fact sheet).  This number 
represents an estimated maximum production level this new platform must be able to 
meet. Overall, in order to remain competitive in the market, the company must be able to 
produce each flu vaccine at a cost of $1 per dose. 
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3.3 Customer Requirements 
  As an alternative to the egg-based flu vaccine, this new insect cell based flu 
vaccine must meet the same general customer requirements.  These would include 
manufacturing protocols following FDA guidelines as well as FDA approval of the final 
flu vaccine product.  In addition, the vaccine must also be stable, and either meet or 
exceed the industry standard for quality for a price similar to those of current competitive 
egg-based vaccine products. 
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3.4 Block F low Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure 3.1 Block Flow Diagram. Outlines the process flow of the upstream and downstream systems.  Note that three 
separate upstream and downstream process designs will operate in the facility to run each of the influenza strains. 
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4.0 Process F low Diagrams 
 
 The following pages contain the process flow diagrams and material balances 
describing the manufacturing platform for the production of the non-egg based influenza 
vaccine. Although not shown in the block separate process flow diagrams, four lines will 
be included in the upstream and downstream processes. This is to ensure complete 
separation and purification of each of the viral strains to be included in the final product 
and a back-up line for the sake of a potential pandemic outbreak. 
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4.1Upstream Process 
 
 
 
 
 
F igure 4.1 Upstream Process Diagram. Outlines the process flow of the upstream system using SuperPro Designer.  
Note that three separate upstream process designs will operate in the facility to run each of the influenza strains. 
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4.2 Downstream Process 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure 4.2 Downstream Process Diagram. Outlines the process flow of the downstream system using SuperPro 
Designer.  Note that three separate downstream process designs will operate in the facility to run each of the influenza 
strains. 
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4.3 Overall Material Balance  
 
Table 4.1 Overall Component Balance. Outlines initial values, final values, inputs, outputs, and change in values for 
each component in the overall system. 
 
Overall Component Balance (kg/batch) 
Component Input Output Produced Consumed/Lost Out-In 
E X C E L L 
Medium 102.71 34.51 0 68.20 0 
Biomass .0.0000126 12.60 12.60 0 0 
V LP ( 3 strains) 0 0.42 0.60 0.18 0 
Glucose 19.10 0 0 19.10 0 
Pluronic F-68 3.3348 3.3348 0 0 0 
Dry A ir 13360.149 10554.52 0 2805.63 0 
Sodium 
Bicarbonate 1.10 0 0 1.10 0 
T riton X-100 10500 10500 0 0 0 
T NBP 3150 3150 0 0 0 
Water 3334.8 3334.8 0 0 0 
 
  
	   24	  
4.4 Utility Requirements 
 
(I) Amount Per 3 Batches (L iters) 
Number Sets of 
Batches Total (L) 
Cost 
(USD/L)   
Water 
(Low 
Endotoxin) 
3334.8 6 20008.8 15.125   
(I I) Heat Exchanger Requirement (kg/sec) 
Heat Exchanger 
Requirement 
(L /sec) 
Operation T ime 
(Seconds) 
Number of 
Heat 
Exchangers 
Total (L) 
Cost (USD 
per foot 
cubed) 
Water 0.88673809 0.88673809 15778800 9 125924966.8 0.03 
(I I I) 
E lucidation and 
Column Water (L per 
train) 
Number of 
Downstream T rains 
Number of 
Batches Total (L) Cost  
Water 
(Low 
Endotoxin) 
20 3 6 360 15.125  
(I I I) Amperage per Pump (Amperes) 
Voltage per Pump 
(Volts) 
Power Per 
Pump (kW) 
Number of 
Pumps 
Operatio
n T ime 
(H rs) 
Power 
Needed 
(kW-hr) 
E lectricity 6.5 115 0.7475 27 4383 88459.8975 
(I V) 
Estimated Additional 
Plant E lectricity 
(kW-hr) 
Estimated Plant 
Operation 
E lectricity Cost     
E lectricity 5547335.738 338387.48 
(From Lang: 2% 
of Equipment 
Cost)    
       
Utility Annual Requirement Annual Cost (USD)     
Water (L) 125924966.8 $133,410.07     
Low 
Endotoxin 
Water (L) 
20368.8 $308,078.10     
E lectricity 
(kW-hr) 5635795.635 $343,783.53     
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5.0 Process Descriptions 
5.1 Upstream Process 
The upstream process is used to culture SF2 cells, and then infect the cells to 
produce VLPs.  For each of the three influenza strains produced each year, a separate 
upstream process is run.  The process begins with a vial thaw of 1.4x107 cells, scaled up 
to 1.4x1013 cells with fermentation using a series of shake flasks and bioreactors. After 
cell growth is complete, cells are infected to produce VLPs before entering the 
downstream process for isolation and purification. 
 
5.1.1 Shake F lasks (P-1/T T R-101, P-2/SF R-101, P-3/SF R-102) 
The scaling of SF2 cells begins in shake flasks sized at 250mL, 2L, and 
3L.  Shake flasks will have a working volume that is a fraction of the flask size (50mL, 
250 mL, 1000mL respectively) and will be used to grow cells at a ten-fold for each scale-
up. Each scaling will take 3.32 days. 
 
5.1.2 Bioreactors   
Following the use of the shake flasks, bioreactors will be used to continue the 
scale-up of the number of SF2 cells for vaccine production.  Each bioreactor will be filled 
to a particular working volume, and will be used to grow cells to a final a ten-fold 
concentration.  For this growth rate, the time spent in each bioreactor is 3.32 days.  The 
bag bioreactors will receive media in a fed-batch process while under constant 
monitoring and feedback control of temperature, pH, dissolved oxygen (DO), and 
biomass. In the final 2000L bioreactor in each upstream process train, a virus titer will be 
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added to each bioreactor in order to provide a multiplicity of infection (MOI) of one. This 
will insure that the maximum number of cells will be infected without causing excessive 
infection. The contents will continue to be fermented for three days to insure maximum 
VLP production then harvested and sent to the downstream process train. 
 
5.1.3 Harvest Bags 
Harvest bags will be used to line the bioreactors as part of the single-use 
technology implementation. The bags are fitted with ports and disposable probes for 
simple interfacing with the bioreactor shells.  This technology will eliminate CIP, SIP, 
and WFI requirements in the upstream process, decreasing both costs and batch turnover 
time.  The harvest bags come sterilie-wrapped and ready to line the bioreactors.  The bags 
will be changed in between batches, and will be disposed as solid biohazard waste. 
 
5.1.4 Media Prep 
Dry media for SF2 cells will be enriched with sodium bicarbonate to maintain pH 
and mixed with filtered air and sterile water before being fed to the bioreactors. The 
media comes enriched with appropriate amounts of glucose, glutamine, pyruvate, 
calcium, and Pluronic F-68 to reduce shear. The media will be diluted in a ratio of 30.8 
grams of media to one liter of water.  Media will be sterile filtered and warmed to 28ºC 
before addition to the flask or bioreactor. 
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5.1.5 Media Holding Bags 
Media holding bags made of biologically inert low-density polyethylene (LDPE) 
will be used to line the holding totes in order to create a disposable process.  This will 
eliminate CIP, SIP, and WFI requirements, thus decreasing costs and batch turnover time. 
These bags can be discarded in the solid biohazard waste stream and can be replaced 
within an hour. The bags will be pressurized slightly to maintain positive pressure, 
preventing contamination. 
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5.2 Downstream Process 
The downstream process for the purification of influenza viruses includes 
clarification, concentration methods centered on diafiltration and centrifugation, chemical 
inactivation and treatment, further chromatography separations, and final polishing. 
Competing vaccine production companies generally require: whole virion inactivated cell 
culture-derived human influenza vaccines (1) 15 µg of HA per strain and dose, (2) total 
protein content no more than 100 µg of protein per virus strain and human dose, (3) 
bacterial endotoxins must be less than 25 IU per human dose, and (4) residual host cell 
DNA must be less than or equal to 10 ng per single human dose (Wolff).  
 
5.2.1 Disk-Stack Centrifugation 
To concentrate the influenza virus, high-speed centrifugation is used. 
Centrifugation is a preferred method for clarifying cell cultures from batch sizes of 2,000 
L or larger. When a disk-stack centrifuge is used, cell debris in the centrifuge is 
minimized for better cell recovery and concentrate clarification ????????).  
 
5.2.2 Depth F iltration 
Depth filtration is used to concentrate insoluble larger particles from the 
suspending medium. This process is conducted in two phases: first a filter with an open-
pore structure removes cell debris, then a filter with a tighter pore structure removes 
colloidal matter. The disposable depth filtration system consists of a set of inlet and outlet 
single-use manifolds with vents and a flexible number of capsule filters placed between 
the manifolds. Permeate flux, transmembrane pressure, and pore size are important 
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parameters that influence process efficiency. To minimize losses, a pore diameter of 172 
nm or less should be used for influenza A and B. An optimal pore size of 300 kDa and a 
wall shear rate of 5700 Hz have been previously identified for influenza strains. Under 
these conditions, virus losses based on HA activity were negligible (Vincente 2011), with 
total protein and host cell DNA reduction of 90% and 93% (Wolff 2008). 
 
5.2.3 V irus Inactivation 
To prohibit the advancement of untreated viral particles into the downstream 
purification process, any remaining baculovirus must undergo inactivation. Incubation for 
30 minutes in 1% Triton X-100 and 0.3% tri(n-butyl)phosphate (TNBP) is sufficient to 
inactivate all remaining baculovirus particles in the fermentation broth. The filtrate will 
be transferred to a 1000L tank and charged with Triton X-100 and TNBP at 1% and 0.3% 
respectively post-mixing. Incubation at room temperature for 30 minutes will disrupt any 
remaining virus. This process can continue for several hours without damaging the VLPs 
at the detergent concentrations used (Rueda 2000, Pantua 2006) 
 
5.2.4 Anion Exchange Chromatography 
Ion exchange chromatography is a separation method, which relies on charge 
interactions between the virus particle and the charges on the chromatography resin. This 
step follows size exclusion chromatography to remove residual host cell DNA, protein 
contaminants, amino acids, and ions remaining from the fermentation reactions in a 
positive and negative mode. The detergents used to inactivate remaining baculovirus 
particles and inactivated baculovirus particles will also be removed during this 
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chromatography step. Influenza VLPs have an acidic pI of 5.0, making anionic exchange 
more favorable for this process. The Sepharose Q ion exchange matrix is used with a 
loading buffer conditioned with 0.65 M NaCl. The resin capacity can be improved with 
optimal loading and washing conditions, which have been found to be at a pH of 6.0 
(Bernd, Kalfbuss, Wolff). This process will largely remove media components and host 
cell DNA. 
 
5.2.5 Size Exclusion Chromatography 
           Size exclusion chromatography (SEC) is used to separate the virus particles from 
contaminating host cell proteins and nucleic acids as well as inactivated baculovirus 
particles. Sepharose chromatography with a fractionation range of 70-40,000 kDa 
typically leads to a viral recovery of approximately 38%. The combination of 
ultrafiltration with size-exclusion chromatography leads to an overall virus recovery of 
36% with a protein and DNA reduction of 96% and 99%, respectively (Liu, Wolff). 
            
5.2.6 Tangential F low F iltration 
Following the chromatography units, tangential flow filtration is carried out to 
further concentrate the VLPs. Tangential flow filtration with microfiltration membranes 
produces a clear stream that requires minimal filtration before loading on a column. The 
buffer composition for this process is composed of 137 mM sodium chloride, 2.7 mM 
potassium chloride, 1.5 mM potassium dihydrogen phosphate, and 10 mM sodium 
phosphate dibasic (2). In this type of filtration, the fluid is pumped tangentially along the 
surface of the membrane and an applied pressure serves to force a portion of the fluid 
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through the membrane to the filtrate side. Molecules that are too large to pass through the 
membrane pores are swept away by the tangential flow (T. Brien, L. Brown, D. Battersby 
et al.).  
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6.0 Major Unit Descr iptions 
 
6.1 Equipment Selection 
The selection of insect cells for the process allows for the choice between 
stainless steel and disposable equipment based facilities.  Traditionally, stainless steel 
facilities are used for vaccine production, however currently there is a greater push in the 
industry to move towards disposable facilities, particularly in the areas of contract 
development and manufacturing.   
With these two types of equipment sets available, there are three options that may 
be used moving forward for a commercial manufacturing facility.  The first option uses 
traditional stainless steel equipment, which requires both SIP and CIP 
accommodations.  The second option utilizes all disposable technologies, and the third 
option uses a combination of both traditional and disposable equipment. 
Traditional facilities are advantageous in that large companies most commonly 
use them, and thus are already approved by regulatory agencies.  In addition, the stainless 
steel equipment provides barriers for pathogens from the environment.  The traditional 
facilities also are more environmentally friendly than disposable systems, since there 
would be less solid wastes and plastic accumulation (Mauter). 
However, despite challenges that arise from using innovative technology such as 
disposable systems, disposable facilities offer several advantages.  For example, 
disposable equipment provides several areas for cost savings, including initial equipment 
capital, process footprint, plant design costs, and removing the requirement for costly and 
timely CIP and SIP processes.  In addition, disposable facilities increase efficiency of 
production by reducing process turnaround time and increasing safety in product 
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changeover by eliminating cross-contamination and easing site-to-site transfer of 
materials (Whitford, Eibl).  Despite rises in environmental impact from solid wastes from 
disposable equipment, these systems offer the advantage of decreasing the use of 
environmentally toxic cleaning agents and a lesser need for water treatments 
(Mauter).  The single use equipment comes sterilized and will be replaced for each batch, 
thus eliminating exhaustive cleaning and validation procedures. 
Disposable systems are a newer technology and the industry is still cautious about 
them.  At the present time, disposable equipment has scalability limitations with an upper 
limit of a 2000L vessel.  ???????????????????????????????????????????????????????
irrelevant.  Another major concern with the use of disposable equipment is the potential 
of extractables and leachables into the vaccine development process.  Currently, there is a 
greater push for regulations and guidelines to minimize potential problems (Martin). 
An in depth economic analysis was completed to further compare the different 
types of facilities.  Based on a quantitative analysis comparing single-use disposable 
technology versus traditional stainless steel vessels for a monoclonal antibody process on 
a 2000L fermentation scale from 2012 (Sinclair, Monge).  This study estimates the 
investment cost of the disposable facility at approximately $25.6 million versus a 
stainless steel facility at approximately $32.5 million.  The difference in cost is largely 
due to the removal of costly procedures such as CIP and SIP.  Using a 7-year MACRS 
table, these estimations were used as total depreciable capital.  Profits were estimated 
based on production of 100 million doses, priced at $8.12 each, for a total profit of $1.2 
billion each year.  After depreciation, profits, interest rates, and tax rates are taken into 
account, the present value of the disposable facility is found to cost approximately $21.2 
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million, while the present value of the traditional facility is found to be $26.9 million (see 
Appendix A).  Based on this the cost analysis and other benefits such as increased 
efficiency and faster batch turn around, a single-use disposable facility was chosen for the 
????????????????????????????? 
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6.2 Upstream Process 
6.2.1 Shake F lasks (P-2/SF R-101, P-3/SF R-102, P-4/SF R-103) 
Polycarbonate flasks (250mL, 2L, 3L) will be purchased from Corning for 
growing SF2 cell in suspension culture, passaging cell lines, and seeding the 50L 
bioreactor. These flasks are gamma-irradiation sterilized and individually packaged to 
ensure no culture contamination. The lids are filter-vented to insure sterility and prevent 
contamination while allowing adequate gas exchange. They will be incubated in shaking 
incubators at 28°C at 90rpm. These flasks will be manipulated within a biosafety cabinet 
and are disposable in the biohazard waste stream.  
 
6.2.2 Aseptic T ransfer Equipment (S-101, S-102, S-104) 
As shown in the process flowsheet, the streams labeled as S-101, S-102, and S-
104 will be used Biosafe® Aseptic Transfer Equipment for transferring the material from 
the shake flasks. The equipment will be supplied from Sartorius Stedim with the purchase 
of storage tanks and bags. The aseptic transfer ports offer reliable and easy-to-use 
solutions for secure transfer of fluids. They are cost effective and have enhanced sterility 
assurance. All materials are compliant with 21 CFR Part 177.2600, 21 CFR Part 
177.1630, and CFR Part 177.2470. The recommended temperature range for this 
equipment is 5-30ºC, which is compliant with the 28ºC temperature associated with the 
insect cell culture and processing. The materials of construction are stainless steel AISI 
316 L, PETP, and silicone/EPDM for the gaskets.  
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6.2.3 Main Bioreactors (P-6/SF R-103, P-7/SF R-104, P-17/SF R-105) 
The 50L, 500L, and 2000L bioreactors are the Xcellerex model from GE Life 
Sciences, and are sized at maximum capacity to enable room for larger culture sizes and 
future scale-up. The minimum working volumes are 20% of the maximum working 
volumes: 10L, 100L, and 400L respectively. The reactors are placed in series from 50L to 
2000L, with each ?????????????????????????????????????????????????????????????????????
fermentation. These reactors are outfitted for disposable operation such that only the 
plastic liners need to be replaced between batches, cutting the time required between 
batch operations to just under one hour. This disposable technology also eliminates the 
necessity of both SIP and CIP procedures.  
These reactors are outfitted with 2 pH probes, 2 DO probes, three pumps, an 
integrated electrical safety circuit, temperature control hardware, a sparger, and an 
agitator. 
The disposable culture bags have an inert USP Class VI low-density polyethylene 
culture contact surface, a disposable pressure sensor, four Brooks mass flow controllers, 
complementary tubing, multiple culture access ports, filtered gas lines, multiple supply 
ports, and an agitation system. The agitation system consists of a high-density 
polyethylene impeller mounted at the bottom with a set of microporous stainless steel 
disks. Control of the system is based on the Rockwell/Allen Bradley Controller with 
Wonderware HMI. The controller allows for a closed loop monitoring and control of 
agitation, gas mixing, liquid agitation & removal, pH, weight, sparging, gas overlay, 
temperature, and DO. The control system also features real-time data collection, 
reporting, and trending, using PID control to aggressively maintain steady-state 
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conditions. The reactors will be purchased from GE at $213,519, $233,717, and 
$930,446, respectively.  
In the last bioreactor in the upstream process, the cells will be infected at the 
beginning of day 2 after beginning fermentation in the vessel. This will be preformed 
under aseptic conditions with a high-titer virus stock developed and prepared by R&D. 
This stock will contain the baculoviruses necessary for the infected cells to produce VLPs 
with the correct HA surface protein. The cells will be infected at a MOI of one to insure 
adequate infection: not many cells will survive the lytic VLP production process, and 
there will be no excess of virus remaining post-production. This MOI allows simple and 
efficient deactivation of the virus and separation of the few remaining host cells while 
providing a maximum number of active VLPs. 
 
6.2.4 Pump (S-105, S-106) 
The pumps connecting the final shake flask in the line to the first bioreactor and 
the first bioreactor to the 500 L bioreactor will be purchased from Cole-Palmer TM for 
$4,640. Cole-Palmer TM provides peristaltic pumps for large-scale biopharmaceutical 
processes to ensure sterility and a high degree of precision. The Masterflex® B/T® (12-
321 rpm, 115 V) with variable-speed wash-down will be used to transfer the cell broth to 
the bioreactors. This model includes a new Rapid-Load pump head for fast and easy 
tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer and the 
gentle peristaltic action is ideal for pumping shear sensitive fluids.  
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6.2.5 Harvest Bags 
Harvest bags are fitted to particular bioreactors, and thus will be purchased 
alongside each bioreactor from the same manufacturer.  From Xcellerex, 50L, 500L, and 
2000L fully-integrated XDR bioreactor bags will be purchased for $447 each.  These 
harvest bags are of USP Class VI, and have a LDPE fluid contact layer.  The bags are 
also gamma irradiated, and follow validation guides.  Each bag includes C-flex tubing, 
aspetic connectors, multiple feed/addition lines, a harvest line, filters (exhaust, sparge, 
overlay), a pressure sensor, sampling and probe ports, a thermowell, and a proprietary 
XDR impeller/sparge system. 
 
6.2.6 Pumps (S-103, S-112, S-113) 
The pumps connecting the media holding tank to the 3L shake flask and 50L and 
200L bioreactors will be purchased from Cole-Palmer TM  for $4,640. Cole-Palmer TM 
provides peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility 
and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with 
variable-speed wash-down will be used to transfer the material from the 500 L media 
tank to the shake flasks and reactors. This model includes a new Rapid-Load pump head 
for fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-
transfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.  
 
6.2.7 Media Holding Bags 
Flexel® bags from Sartorious will be purchased with the plastic holding tanks for 
a combined cost of $1,682 or $2,915, depending on the volume.  These are single use 
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bags designed for processing, mixing, storage, and transport of large volume of 
biopharmaceutical solutions.  After use, the media holding bags will be disposed as solid 
biohazard waste. 
 
6.2.8 500 L Holding Tanks (P-8/V-101, P-10/V-102) 
For media and intermediate cell culture storage, the Plastic Palletank® from 
Sartorious will be used. For the first line, transferring media to the Shake Flask, and first 
two bioreactors, a 500 L storage tank will be purchased for $2,915.  This tank is designed 
for storage and processing of biopharmaceutical fluids, and can be used for both media 
storage and bulk intermediate hold in the upstream process.  They are designed to be 
lined with Flexel® 3D bags, and meet in-process and storage requirements while 
minimizing required floor space in a plant. 
 
6.2.9 Pump (S-107, S-108, S-114, S-115) 
The pump connecting media to the filtration unit will be purchased from Cole-
Palmer TM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale 
biopharmaceutical processes to ensure sterility and a high degree of precision. The 
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to 
transfer the material from the media tank to the filtration unit. This model includes a new 
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is 
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping 
shear sensitive fluids.  
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6.2.10 Sterile F iltration (P-9/M F-101, P-14/M F-102) 
Sterile filtration is a further clarification step that will be used for reactor medium. 
The upstream process will consist of two media storage tanks per line, one for media 
transferred to the final shake flask and first two bioreactors in series, and the second for 
media transferred to the production bioreactor. 
The filtration system is made of cellulose fibers that are designed to trap 
submicron particles in their crevices. The Encapsulated Zeta Plus (EZP) System will be 
purchased from 3M Purification Inc. for $9,000. 
This is a single-use system designed for production scale biomanufacturing, 
which consists of a filter holder, top and bottom manifolds and capsules. The EZP system 
features ergonomically designed holders that can pivot for easy loading and unloading, 
and a translucent plastic shell for convenient liquid level detection. The large holder 
(model 16EZB) accommodates up to 17.5 m2 of filter media and has the capability of 
processing up to 5000 L of liquid. The system requires the Zeta Plus EXT filter media 
(Zeta Plus 60SP02A), which is available in a single-use format (EZP Data Sheet). 
 
6.2.11 3000 L Holding Tanks (P-13/V-103, P-15/V-104) 
For media and intermediate cell culture storage before transfer to the 2000 L 
Bioreactor, the Palletank® In-Process Fluid Handling Tank from Sartorious Stedim will 
be used. This tank is designed for storage and processing of biopharmaceutical fluids, and 
can be used for both media storage and bulk intermediate hold in the upstream 
process.  They are designed to be lined with Flexel® 3D bags, and meet in-process and 
storage requirements while minimizing required floor space in a plant. 
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6.2.12 Heat Exchanger (P-11/H X-101, P-16/H X-102) 
           For warming the medium prior to tank charging and cooling of the fermentation 
broth to prepare for downstream processing, it will be necessary to add heat to the liquid 
media streams through cGMP certified heat exchanger units. These units will operate 
such that the contents remain sterile throughout the heat transfer process and will be 
optimized to handle the maximum flow rates from the pump units. The heat exchangers 
were designed by our team and the unit most closely resembling our heat transfer area 
calculations will be purchased from Enerquip for this purpose. 
 
6.2.13 Cooler (P-18/H X-103) 
           A cooler is necessary to chill the jackets of medium storage tanks and to chill the 
fermentation broth after completion of the upstream process. It will function as a 
refrigeration unit that sends coolant through pipes leading to vessel jackets. This system 
will allow the process to be flexible in terms of cooling requirements in case of added 
load or added storage vessels during periods of high demand. 
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6.3 Downstream Process 
 
After the upstream process is complete, the medium will be aseptically transferred 
to a different location for the downstream purification. This will be done through a 
single-use transfer system with presterilized connectors and tubing. In addition to faster 
production, this system eliminates time that would be spent on CIP and SIP and reduces 
the risk of cross contamination.  
 
6.3.1 Disk-Stack Centrifuge (P-1/DS-101) 
Centrifugation with disk-stack bowls is used as the first step in the downstream 
processing. This method is preferred in biopharmaceutical processing for clarifying cell 
cultures from batch sizes larger than 2000 L. The harvested fluid and cultivation broth are 
clarified with low-speed centrifugation and the virus is later purified in an 
ultracentrifugation step. The virus solution is centrifuged through a sucrose gradient, 
which generally ranges from 20-60%, with the target virus at 40-45% sucrose.  
The Carr® UniFuge® Pilot from Carr Centritech Separation Systems is purchased 
?????????????????????????????????????????????????????????????????????-use bioreactor 
connections. This single-use disposable module is designed for gentle harvesting of 
shear-sensitive biological materials. Due to its single-use feature, this centrifugation 
system has no CIP or SIP requirements. The UniFuge® module is completely automated 
with flexible cycle parameter entry so that once the module has filled with cells, the 
controllers stops the rotor and discharges. The machine operating conditions include a 
feed flow range of 0.1-4 liters per minute and a bowl capacity of 1.6 liters (UniFuge® 
Data Sheet). 
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6.3.2 Pump (S-102) 
The pump connecting the centrifuge to the virus inactivator tank will be 
purchased from Cole-Palmer? for $4,640. Cole-Palmer? provides peristaltic pumps for 
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision. 
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be 
used to transfer the material from the centrifuge to the inactivator. This model includes a 
new Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is 
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping 
shear sensitive fluids.  
 
6.3.3 Detergent Storage Tank (P-12/V-106) 
The detergent for viral inactivation will be stored in the Plastic Palletank® from 
Sartorius Stedim for $1,682. This storage tank is a single-use piece of equipment to 
ensure process and user safety. Sartorius Stedim provides these single-use platforms for 
lower initial investment, process optimization, and faster time to market. The Palletank® 
is available in volumes of 200L and 500L and must be used with the Flexel® 3D Bags.  
 
6.3.4 Pump (S-103)  
The pump connecting the storage tank to the virus inactivator tank will be 
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for 
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision. 
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be 
used to transfer the material from the storage tank to the inactivator. This model includes 
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a new Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® 
is suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for 
pumping shear sensitive fluids.  
 
6.3.5 V irus Inactivation Tank (P-9/V-103) 
To prohibit the advancement of untreated viral particles into the downstream 
purification process, any remaining baculovirus must undergo inactivation. Incubation for 
30 minutes in 1% Triton X-100 and 0.3% tri(n-butyl)phosphate (TNBP) is sufficient to 
inactivate all remaining baculovirus particles in the fermentation broth. The filtrate will 
be transferred to a 1000L tank and charged with Triton X-100 and TNBP to final volume 
percentages of 1% and 0.3% respectively. Incubation at room temperature for 30 minutes 
will disrupt any remaining baculovirus particles.  This process can continue for several 
hours without damaging the VLPs at the detergent concentrations used (Rueda 2000, 
Pantua 2006). The vessels will be purchased from Sartorius Stedim at a cost of $1,682.  
 
6.3.6 Pump (S-104) 
The pump connecting the virus inactivator tank to the depth filtration device will 
be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps 
for large-scale biopharmaceutical processes to ensure sterility and a high degree of 
precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down 
will be used to transfer the material from the inactivator tank to the filtration device. This 
model includes a new Rapid-Load pump head for fast and easy tubing changes. The 
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Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action 
is ideal for pumping shear sensitive fluids.  
 
6.3.7 Depth F iltration (P-3/D F-101) 
Depth filtration is a further clarification step that follows the initial disk-stack 
centrifugation in downstream processing. The depth filtration system is made of cellulose 
fibers that are designed to trap submicron particles in their crevices. The Encapsulated 
Zeta Plus (EZP) System will be purchased from 3M Purification Inc. for $9,000.  
This is a single-use system designed for production scale biomanufacturing, 
which consists of a filter holder, top and bottom manifolds and capsules. The EZP system 
features ergonomically designed holders that can pivot for easy loading and unloading, 
and a translucent plastic shell for convenient liquid level detection. The large holder 
(model 16EZB) accommodates up to 17.5 m2 of filter media and has the capability of 
processing up to 5000 L of liquid. The system requires the Zeta Plus EXT filter media 
(Zeta Plus 60SP02A), which is available in a single-use format.  
 
6.3.8 Pump (S-105) 
The pump connecting the depth filter to the holding tank will be purchased from 
Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale 
biopharmaceutical processes to ensure sterility and a high degree of precision. The 
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to 
transfer the material from depth filter to the holding tank. This model includes a new 
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is 
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suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping 
shear sensitive fluids.  
 
6.3.9 Depth F iltration Holding Tank (P-7/V-101) 
The fluid from the depth filtration unit will be stored in the Plastic Palletank® 
from Sartorius Stedim for $1,682. This storage tank is a single-use piece of equipment to 
ensure process and user safety. Sartorius Stedim provides these single-use platforms for 
lower initial investment, process optimization, and faster time to market. The Palletank® 
is available in volumes of 200L and 500L and must be used with the Flexel® 3D Bags.  
 
6.3.10 Pump (S-106) 
The pump connecting the holding tank to the ion exchange chromatography 
column will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides 
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a 
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-
speed wash-down will be used to transfer the material from the holding tank to the ion 
exchange chromatography column. This model includes a new Rapid-Load pump head 
for fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-
transfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.  
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6.3.11 Chromatography Resin Storage Tank (P-11/V-105) 
The chromatography resin for the first line of ion exchange chromatography 
columns will be stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This 
storage tank is a single-use piece of equipment to ensure process and user safety. 
Sartorius Stedim provides these single-use platforms for lower initial investment, process 
optimization, and faster time to market. The Palletank® is available in volumes of 200L 
and 500L and must be used with the Flexel® 3D Bags.  
 
6.3.12 Pump (S-107) 
The pump connecting the chromatography resin tank to the ion exchange 
chromatography column will be purchased from Cole-PalmerTM for $4,640. Cole-
PalmerTM provides peristaltic pumps for large-scale biopharmaceutical processes to 
ensure sterility and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 
V) with variable-speed wash-down will be used to transfer the resin material from its tank 
to the chromatography column. This model includes a new Rapid-Load pump head for 
fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-
transfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.  
 
6.3.13 Anion Exchange Chromatography Column (P-4/IN X-101) 
Ion exchange chromatography is used for further purification and separation of 
the product. Ion exchange chromatography uses the principle of binding based on charge 
differences between the resin and the product. The ReadyToProcess Q Sepharose FF 
chromatography column from GE Life Sciences will be used for this process and 
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purchased for $166,000. This system is designed for scale-up and production of 
?????????????????????????????????????????????-use, disposable platform. These columns 
are closed units and the design allows easy disposal after completion. The system 
includes a column tube, lids, support nets, support screens, stream stoppers, hose 
connections, welding tubing, filter holders, media packing valves, a hose for the inlet 
tubing, O-rings, and TC gaskets. The column hardware and components are made from 
polypropylene, polyetheretherketone, Tygon 2275 Polyolefin, Fluorocarbon rubber, and 
Ethylenpropylenediene. The column has a bed volume of 2.5 L, with a minimum liquid 
temperature of 4ºC and a maximum pressure of 1.2 bar (17 psi).   
The column is pre-packed with bioprocess medium. Capto Q is a strong anion 
exchanger, and is resistant to chemical agents used in recovery. This media allows for 
fast mass transfer and is intended for capture and intermediate large-scale purification. 
The Capto Q media must be stored in 20% ethanol, at a pH between 2 and 12, and at a 
temperature between 4ºC and 30ºC. The filtrate containing the VLPs will be sent through 
the column at 300cm/h flow rate, and the column will be primed to bind DNA and any 
remaining baculovirus after the inactivation step while allowing the VLPs to flow 
through the column with less of an ionic affinity (GE Data sheet). The column will then 
be eluted into the waste stream and reset for the next batch. This column will remove the 
remaining medium components not filtered out during the filtration step or consumed 
during the fermentation reaction. The column run time is about 20 minutes per VLP 
strain batch based on size and flow rate calculations from column size and flow rate data 
shown on the process specification page. 
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6.3.14 Pump (S-108) 
The pump connecting the ion exchange chromatography product to the holding 
tank will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides 
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a 
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-
speed wash-down will be used to transfer the product from the first chromatography 
column to the holding tank. This model includes a new Rapid-Load pump head for fast 
and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer 
and the gentle peristaltic action is ideal for pumping shear sensitive fluids.  
 
6.3.15 Ion Exchange Holding Tank (Sartorius Stedim, P-18/V-107) 
The remaining product from the first line of chromatography columns will be 
stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a 
single-use piece of equipment to ensure process and user safety. Sartorius Stedim 
provides these single-use platforms for lower initial investment, process optimization, 
and faster time to market. The Palletank® is available in volumes of 200L and 500L and 
must be used with the Flexel® 3D Bags.  
 
6.3.16 Pump (S-101) 
The pump connecting the holding tank to the size exclusion chromatography 
column will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides 
peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a 
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-
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speed wash-down will be used to transfer the material from the holding tank to the 
second chromatography column. This model includes a new Rapid-Load pump head for 
fast and easy tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-
transfer and the gentle peristaltic action is ideal for pumping shear sensitive fluids.  
 
6.3.17 Chromatography Resin Storage Tank (Sartorius Stedim, P-10/V-104) 
The chromatography resin for the second line of chromatography columns will be 
stored in the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a 
single-use piece of equipment to ensure process and user safety. Sartorius Stedim 
provides these single-use platforms for lower initial investment, process optimization, 
and faster time to market. The Palletank® is available in volumes of 200L and 500L and 
must be used with the Flexel® 3D Bags.  
 
6.3.18 Pump (S-110) 
The pump connecting the chromatography resin tank to the size exclusion 
chromatography column will be purchased from Cole-PalmerTM for $4,640. Cole-
PalmerTM provides peristaltic pumps for large-scale biopharmaceutical processes to 
ensure sterility and a high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 
V) with variable-speed wash-down will be used to transfer the resin from the holding 
tank to the column. This model includes a new Rapid-Load pump head for fast and easy 
tubing changes. The Masterflex® B/T® is suitable for high-flow bulk-transfer and the 
gentle peristaltic action is ideal for pumping shear sensitive fluids.  
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6.3.19 Size Exclusion Chromatography Column (P-5/C-101) 
Chromatography is performed to bind and elute host cell impurities. The 
ReadyToProcess platform from GE Life Sciences is used for its single-use features and 
large-scale purification capabilities. Benefits of this column include quick start-up times 
and fast on-site maintenance without special tools or trained personnel. The system will 
be purchased for $166,000.  
The Capto Core 700 chromatography resin from GE Life Sciences will be used 
for this process. Capto Core 700 was recommended for its design, which focuses on 
intermediate purification and polishing of viruses. Capto Core 700 offers many 
performance advantages over typical gel filtration, which often causes a bottleneck in 
processing due to low flow rates and limited sample loads. Capto Core 700 is designed 
for high capacity, high flow velocities, and a high number of operational cycles.  Capto 
Core 700 is composed of an inactive shell of highly cross-linked agarose, which excludes 
large molecules with a molecular weight cut off of 700 kDA. The inner core is ligand 
activated, hydrophobic and positively charged to induce binding of viral contaminants. 
The HA molecules on the VLP coat will prevent strong affinity for the column core, as 
described in the equipment test presented on the equipment data sheet. The column run 
time is about 40 minutes under average flow rate conditions but will be optimized to elute 
VLPs on a laboratory scale prior to manufacturing scale production. 
 
6.3.20 Pump (S-111) 
The pump connecting the size exclusion chromatography column to the holding 
tank will be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides 
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peristaltic pumps for large-scale biopharmaceutical processes to ensure sterility and a 
high degree of precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-
speed wash-down will be used to transfer the product from the column to the holding 
tank. This model includes a new Rapid-Load pump head for fast and easy tubing changes. 
The Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic 
action is ideal for pumping shear sensitive fluids. 
 
6.3.21 Size Exclusion Holding Tank (Sartorius Stedim, P-19/V-108)     
The product from the second line of chromatography columns will be stored in 
the Plastic Palletank® from Sartorius Stedim for $1,682. This storage tank is a single-use 
piece of equipment to ensure process and user safety. Sartorius Stedim provides these 
single-use platforms for lower initial investment, process optimization, and faster time to 
market. The Palletank® is available in volumes of 200L and 500L and must be used with 
the Flexel® 3D Bags.  
 
6.3.22 Pump (S-114) 
The pump connecting the holding tank to the tangential flow filtration device will 
be purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps 
for large-scale biopharmaceutical processes to ensure sterility and a high degree of 
precision. The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down 
will be used to transfer the material from the holding tank to the TFF device. This model 
includes a new Rapid-Load pump head for fast and easy tubing changes. The 
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Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action 
is ideal for pumping shear sensitive fluids.  
 
6.3.23 Tangential F low F iltration (P-6/D F-102) 
Tangential flow filtration, also referred to as cross-flow filtration, with 
microfiltration membranes is used to clarify the culture broth. A major advantage of this 
process is that it requires minimal filtration before loading on a column. The Pellicon 
XL50 series from Millipore is purchased for $200,000. The system is capable of 
processing batch sizes of 1 to 10,000 liters of feed material. The Pellicon XL50 system is 
composed of a positive displacement type pump for low shear operation, pressure 
sensors, temperature sensors, and magnetic flowmeters on feed. The filtration tank has a 
total volume of 890 L and a working volume of 600 L (Pellicon XL50 Data sheet). The 
filtration will be used to reduce the water in the downstream process from 1000 L to 20 
L, which will simplify and economize downstream processing. This unit operation will 
also reduce the mass of remaining medium components from the fermentation reactions 
based on the amount of water lost. The concentration of these ions will be the same on 
both sides of the membrane, so a reduction of water from 1000 L to 200 L will result in a 
loss of 80% of the medium components considered to be contaminants in the downstream 
process. 
 
6.3.24 Pump (S-109) 
The pump connecting the tangential flow filtration tank to the holding tank will be 
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for 
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large-scale biopharmaceutical processes to ensure sterility and a high degree of precision. 
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be 
used to transfer the material from the filtration tank to the holding tank. This model 
includes a new Rapid-Load pump head for fast and easy tubing changes. The 
Masterflex® B/T® is suitable for high-flow bulk-transfer and the gentle peristaltic action 
is ideal for pumping shear sensitive fluids.  
 
6.3.25 Tangential F low F iltration Holding Tank (P-8/V-102) 
The product from the tangential flow filtration unit will be stored in the Plastic 
Palletank® from Sartorius Stedim for $1,682. This storage tank is a single-use piece of 
equipment to ensure process and user safety. Sartorius Stedim provides these single-use 
platforms for lower initial investment, process optimization, and faster time to market. 
The Palletank® is available in volumes of 200L and 500L and must be used with the 
Flexel® 3D Bags.  
 
6.3.26 Pump (S-112) 
The pump connecting the holding tank to the freeze dryer will be purchased from 
Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for large-scale 
biopharmaceutical processes to ensure sterility and a high degree of precision. The 
Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be used to 
transfer the material from the holding tank to the freeze dryer. This model includes a new 
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is 
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suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping 
shear sensitive fluids.  
 
6.3.27 Pump (S-113) 
The pump connecting the product from the freeze dryer to the filler will be 
purchased from Cole-PalmerTM for $4,640. Cole-PalmerTM provides peristaltic pumps for 
large-scale biopharmaceutical processes to ensure sterility and a high degree of precision. 
The Masterflex® B/T® (12-321 rpm, 115 V) with variable-speed wash-down will be 
used to transfer the material from the freeze dryer to the filler. This model includes a new 
Rapid-Load pump head for fast and easy tubing changes. The Masterflex® B/T® is 
suitable for high-flow bulk-transfer and the gentle peristaltic action is ideal for pumping 
shear sensitive fluids.  
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7.0 Additional Equipment/Processes 
7.1 Formulation & F inal Packaging 
Once the Active Pharmaceutical Ingredient has been obtained through 
downstream processing, the formulation procedure will be taken care of by another 
facility to prepare the product for the domestic market. The product will be shipped to a 
Formulation, Filling, and Packaging group where the secondary process parameters will 
be performed. 
 
7.2 F ilter Integrity Tester 
Filters are used for sterilization of process components, specifically media 
ingredients, so it is imperative that these filters work properly to prevent adventitious 
agents from forming in the many fermentation stages. The integrity tester from Sartorius 
is compatible with the Sartorius filters used in this process. The filter tester is automated 
and simple to use. The filters are tested before installation into the process in the inter-
batch phase of operation. This tester is required per regulatory requirements and to insure 
cGMP operating conditions. 
 
7.3 Tube Fusers/Tube Sealers 
The sterile tube fuser is a fully automated device used to connect thermoplastic 
tubing in a sterile operation. The use of sterile tube fusing eliminates the need for a 
laminar flow cabinet. The tube fuser machine uses infrared technology along with 
disposable, single-use blades. The unit can connect large diameter tubing for easy transfer 
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of large volumes, and each fusing cycle is approximately two minutes. The tube fuser 
will be purchased from Sartorius Stedim for $15,300. 
The tube sealer is used in conjunction with the tube fuser to seal bioprocess bags 
and bioreactors. The combined unit does not require compressed air or cooling water or 
any other additional accessories for operation. The tube sealer will be purchased from 
Sartorius Stedim for $10,200. 
 
7.4 Biosafety Cabinet  
Biosafety cabinets are essential for laboratory scale cell culture work to provide 
both sterility and workplace safety. They operate using sterile-filtered laminar air flow to 
prevent contamination and provide a clean workspace for cell manipulations. These will 
be essential for the small scale manipulations required for seeding the larger fermenters. 
Shake flasks will be manipulated within the biosafety cabinet, and samples will be 
removed from reactors and manipulated under the biosafety cabinets for cGMP 
compliance testing protocols. These cabinets will have an 8 in. sash and will contain all 
of the necessary equipment for cell culture manipulations. They will be purchased from 
and installed by Thermo Fisher Scientific. 
 
7.5 Incubator 
A shaking incubator kept at 28ºC is necessary for optimum cell growth while in 
shake flasks. The incubator will remain sterile and have copper surfaces to prevent 
microbial and fungal growth and will have a self-autoclaving feature. The incubator will 
be used to grow cells in all stages of shake-flask culture and will operate at 90rpm.  
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7.6 C ryopreservation Bank 
A cryopreservation bank will be used for storage of the insect cell culture. Due to 
pre-existent cell culture lines within the facility, the -80ºC and ultra-low -160ºC freezers 
from Panasonic will already be provided in the manufacturing plant. Equipment and 
protocols for cell preservation will be followed according to Sigma-??????????Cell 
Culture Laboratory Handbook-2nd Edition. 
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8.0 Unit Specification Sheets 
 The following pages contain the unit specification sheets for the equipment used 
in this vaccine manufacturing facility. Equipment models and prices have been obtained 
through contact with vendors, from equipment lists from CDI Engineering Group, or 
from sources such as BioProcess International and BioPharm International. 	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8.1 Upstream Section 	  
250  mL  Shake  Flask  (P-­2/SFR-­101)  
     
Function:   First  phase  of  cell  growth  in  50  mL  from  storage  in  liquid  nitrogen  
     
Vendor:   Corning  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   3.08  g  
   Biomass   0.042  g  
   Water   100  g  
   Total   103.1  g  
        
Characteristics:   Model:   250mL  Polycarbonate  Erlenmeyer  Flask  with  
Vent  Cap  
   Material:   Polycarbonate  
   Flask  Type:   Sterile  
   Working  Volume:   50  mL  
   Total  Volume:   250  mL  
   Sterilization:   Single  use  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
   Speed:   90  rpm  
   pH:   6.2  
        
Purchase  Cost:   $595.89   (50  flasks)  	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2  L  Shake  Flask  (P-­3/SFR-­102)  
     
Function:   Second  phase  of  cell  growth  to  increase  biomass,  250  mL  working  volume  
     
Vendor:   Corning  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   7.7  g  
   Biomass   0.42  g  
   Water   250  g  
   Total   258.1  g  
        
Characteristics:   Model:   2L  Polycarbonate  Erlenmeyer  Flask  with  Vent  
Cap  
   Material:   Polycarbonate  
   Flask  Type:   Sterile  
   Working  Volume:   0.25  L  
   Total  Volume:   2  L  
   Sterilization:   Single  use  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
   Speed:   90  rpm  
   pH:   6.2  
        
Purchase  Cost:   $204.55   (6  flasks)  	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3L  Shake  Flask  (P-­2/SFR-­101)  
     
Function:   Third  phase  of  biomass  production,  2  L  working  volume  
     
Vendor:   Corning  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   61.6  g  
   Biomass   4.2  g  
   Water   2000  g  
   Total   2065.8  g  
        
Characteristics:   Model:   3L  Polycarbonate  Erlenmeyer  (Fernbach  
Design)  Flask  with  Vent  Cap  
   Material:   Polycarbonate  
   Flask  Type:   Sterile  
   Working  Volume:   2  L  
   Total  Volume:   3  L  
   Sterilization:   Single  use  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
   Speed:   90  rpm  
   pH:   6.2  
        
Purchase  Cost:   $236.60   (4  flasks)  	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Pump  (S-­105)  
     
Function:   To  transfer  material  to  the  first  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   308  g  
   Biomass   4.2  g  
   Water   10000.00  g  
   Total   10312.2  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	  	   	  
	   64	  
50  L  Bioreactor  (P-­6/SBR-­103)  
     
Function:   Fourth  phase  of  biomass  production,  10  L  working  volume  
     
Vendor:   GE  Life  Sciences  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   308  g  
   Biomass   42  g  
   Water   10000.00  g  
   Total   10350  g  
        
Characteristics:   Working  Volume:   10  L  
   Total  Volume:   50  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1.1  atm  
   pH:   6.2  
   Sparging:   0.3  L  O2  min-­1  
   Controller:   Rockwell/Wonderware  
   Agitation:   90  rpm  
        
Purchase  Cost:   $213,519.00   (includes  shell,  control  components,  3  pumps)  	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Pump  (S-­106)  
     
Function:   To  transfer  material  from  the  first  bioreactor  to  the  second  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   308  g  
   Biomass   4.2  g  
   Water   10000.00  g  
   Total   10312.2  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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500  L  Bioreactor  (P-­7/SBR-­104)  
     
Function:   Fifth  phase  of  biomass  production,  100  L  working  volume  
     
Vendor:   GE  Life  Sciences  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   3080  g  
   Biomass   420  g  
   Water   100000.00  g  
   Total   103500  g  
        
Characteristics:   Working  Volume:   100  L  
   Total  Volume:   500  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1.1  atm  
   pH:   6.2  
   Sparging:   0.3  L  O2  min-­1  
   Controller:   Rockwell/Wonderware  
   Agitation:   90  rpm  
        
Purchase  Cost:   $233,717.00   (includes  shell,  control  components,  3  pumps)  	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Pump  (S-­117)  
     
Function:   To  transfer  material  from  the  second  bioreactor  to  the  third  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   3080  g  
   Biomass   42  g  
   Water   100000  g  
   Total   103122  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
   Sterilization:   SIP/CIP  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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2000  L  Bioreactor  (P-­7/SBR-­104)  
     
Function:   Fifth  phase  of  biomass  production,  100  L  working  volume  
     
Vendor:   GE  Life  Sciences  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   30800  g  
   Biomass   4200  g  
   Water   1000000  g  
   Total   1035000  g  
        
Characteristics:   Working  Volume:   1000  L  
   Total  Volume:   2000  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1.1  atm  
   pH:   6.2  
   Sparging:   0.3  L  O2  min-­1  
   Controller:   Rockwell/Wonderware  
   Agitation:   90  rpm  
        
Purchase  Cost:   $930,466.00   (includes  shell,  control  components,  3  pumps)  	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Pump  (S-­119)  
     
Function:   To  transfer  material  from  the  third  bioreactor  to  the  cooling  unit  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   30800  g  
   Biomass   4200  g  
   Water   1000000  g  
   Total   1035000  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­103)  
     
Function:   To  transfer  material  from  the  media  storage  tank  to  the  3  L  flask  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media  
Water  
138.6  g  
4500  g  
   Total   4638.6  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Media  Storage  Tank  (P-­8/V-­101)  
     
Function:   To  hold  media  for  the  filtration  unit  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   100000  g  
   Media   3080  g  
Total   103080  g  
        
Characteristics:   Model:   Flexel  3D  Palletank  
   Working  Volume:   100  L  
Total  Volume:   200  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $1,682.00   (includes  shell,  control  components,  3  pumps)  	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Media  Storage  Tank  (P-­13/V-­103)  
     
Function:   To  hold  media  for  the  filtration  unit  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Filtration  Media   4.5  L  
   Total   4.5  L  
        
Characteristics:   Model:   Flexel  3D  Palletank  
   Working  Volume:   100  L  
Total  Volume:   200  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $1,682.00   (includes  shell,  control  components,  3  pumps)  	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Media  Storage  Tank  (P-­10/V-­102)  
     
Function:   To  store  media  from  the  filtration  unit  and  supply  to  shake  flask  and  bioreactors  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   1112000  g  
   Media   34250  g  
Total   1146250  g  
        
Characteristics:   Model:   Flexel  3D  Palletank  
   Working  Volume:   100  L  
Total  Volume:   500  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $2,915.00   (includes  shell,  control  components,  3  pumps)  	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Final  USP  Storage  Tank  (P-­19/V-­105)  
     
Function:   To hold the product from the 2000 L bioreactor and transfer to downstream process 
(centrifugation unit)  
     
Vendor:   Sartorius Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Medium   30800  g  
   Biomass   4200  g  
   Water   1000000  g  
   Total   1035000  g  
        
Characteristics:   Model:   Flexel  3D  Palletank  
   Total  Volume:   2000  L  
   Sterilization:   Single  use  bags  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $2,915.00   (includes  shell,  control  components,  3  pumps)  	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Pump  (S-­118)  
     
Function:   To  transfer  material  from  the  heat  exchanger  to  third  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   1110000  g  
   Media   34188  g  
   Total   1144188  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­116)  
     
Function:   To  transfer  material  from  the  media  storage  tank  to  the  heat  exchanger  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   1110000  g  
   Media   34188  g  
   Total   1144188  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­115)  
     
Function:   To  transfer  material  from  the  filtration  unit  to  the  storage  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   15400  g  
   Water  
Total  
500000  g  
515400  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­114)  
     
Function:   To  transfer  material  from  the  media  storage  tank  to  the  filtration  unit  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   15400  g  
   Water  
Total  
500000  g  
515400  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­107)  
     
Function:   To  transfer  material  from  the  media  storage  tank  to  the  3  L  flask  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   3080  g  
   Water   100000  g  
   Total   103080  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­108)  
     
Function:   To  transfer  material  from  the  filtration  unit  to  the  media  storage  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   3080  g  
   Water   100000  g  
   Total   103080  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     
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Pump  (S-­109)  
     
Function:   To  transfer  material  from  the  media  storage  tank  to  the  heat  exchanger  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   3080  g  
   Water   100000  g  
   Total   103080  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­113)  
     
Function:   To  transfer  filtered  media  to  the  second  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   3080  g  
   Water   100000  g  
   Total   103080  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Pump  (S-­112)  
     
Function:   To  transfer  filtered  media  to  the  first  bioreactor  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   308 g  
   Water   10000 g  
   Total   10308 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   28°C  
   Pressure:   1  atm  
        
Purchase  Cost:   $4,640.00     	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Depth  Filtration  Unit  (P-­9/MF-­101)  
     
Function:   To  sterilize  media  and  remove  bacteria  from  stream  before  entering  bioreactors  
     
Vendor:   3M  Purification,  Inc.  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media     34266  g  
   Water   1113000  g  
   Total   1147266  g  
        
Characteristics:   Model:   Encapsulated  Zeta  Plus  
   Material:   Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
   Filtration  Area:   2.5  m2  
   Sterilization:   1  cycle  autoclave  (30  min  @  126°C)  
Size:   ???  
Additional  Features:   Disposable/Single  use  
        
Operating  Conditions:   Max  Operating  Temp:   40°C  
   Max  Operating  Temp   3.1  bar  (45  psi)  
        
Purchase  Cost:   $9,000.00     	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Depth  Filtration  Unit  (P-­14/MF-­102)  
     
Function:   To  sterilize  media  and  remove  bacteria  from  stream  before  entering  bioreactors  
     
Vendor:   3M  Purification,  Inc.  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   500  L  
Total   500  L  
        
Characteristics:   Model:   Encapsulated  Zeta  Plus  
   Material:   Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
   Filtration  Area:   2.5  m2  
   Sterilization:   1  cycle  autoclave  (30  min  @  126°C)  
Size:   ???  
Additional  Features:   Disposable/Single  use  
        
Operating  Conditions:   Max  Operating  Temp:   40°C  
   Max  Operating  Pressure:   3.1  bar  (45  psi)  
        
Purchase  Cost:   $9,000.00     	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8.2 Downstream Section 
 
Disc-­Stack  Centrifuge  (P-­1/DS-­101)  
     
Function:   To  remove  cells  and  biomass  solids  
     
Vendor:   Carr Centritech Separation Systems  
     
Operation:   Continuous  
     
Materials  Handled:   Input   Quantity  
   Biomass   4200  g  
   Water   1000000  g  
   VLP  
Medium  
200  g  
30800  g  
   Baculovirus   trace  
   Total   1035200  g  
        
Characteristics:   Model:   Unifuge(R)  
   Material:   USP Class VI: 
Polycarbonate 
Polyurethane 
Silicone 
Bioprene 
C-Flex 
Polypropylene  
   Feed  Flow  Range:   0.1-­4  L/min  
   Bowl  Capacity:   1.6  L  
Additional  Features:   Disposable/Single  use  
        
Operating  Conditions:   Max  Operating  Temp:   100ºC  
   Max  Operating  Pressure   N/A    
        
Purchase  Cost:   $400,000.00     	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Pump  (S-­102)  
     
Function:   To  transfer  material  from  centrifugation  unit  to  inactivator  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Biomass   0  
   Water   990200 g  
   Medium   30800  g  
   Baculovirus   trace  
   Total   1021000 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	  	   	  
	   88	  
Detergent  Storage  Tank  (P-­12/V-­106)  
     
Function:   To  hold  the  detergent  for  the  virus  inactivation  process  
     
Vendor:   Sartorius Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   200000 g  
   TNBP   3150 g  
   Triton X-100   10500 g  
Total   213650 g 
        
Characteristics:   Material:   Stainless  steel  
   Working  volume:   202.6  L  
   Total  volume:   500  L  
   Sterilization:   SIP/CIP  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00   (shell)  	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Pump  (S-­103)  
     
Function:   To  transfer  material  from  centrifugation  unit  to  inactivator  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Biomass     0  g  
   Water   990200  g  
   VLP  
Medium  
200  g  
30800  g  
   Baculovirus  
Total  
Trace  
1021200  g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Virus  Inactivation  Tank  (P-­9/V-­103)  
     
Function:   To  inactivate  the  virus  
     
Vendor:   Sartorius Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Biomass   0 g  
   Water   1100200 g  
   TNBP   3150 g  
Medium   30800 g 
VLP   189 g 
Triton X-100   10500 g 
Baculovirus   Trace 
Total   1144839 g 
        
Characteristics:   Material:   Stainless  steel  
   Total  volume:   1100  L  
   Sterilization:   SIP/CIP  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00   (shell)  	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Pump  (S-­104)  
     
Function:   To  transfer  material  from  inactivator  tank  to  depth  filter  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Baculovirus   0 g  
   Water   1100200 g  
   TNBP   3150 g  
   Medium   30800 g  
   VLP   190 g  
   Triton X-100   10500 g  
   Total   1144840 g 
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Depth  Filtration  Unit  (P-­3/DF-­101)  
     
Function:   To  sterilize  supernatant  of  centrifugation  process  and  remove  bacteria  from  
stream  
     
Vendor:   3M  Purification,  Inc.  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Media   30800 g  
   Water   1100200 g  
   Triton X-100   10500 g  
   TNBP   3150 g  
   VLP   190 g  
   Baculovirus   Trace  
   Total   114480 g  
        
Characteristics:   Model:   Encapsulated  Zeta  Plus  
   Material:   Polycarbonate  
Silicone  
Polypropylene  
Thermoplastic  Elastomer  
Nylon  
   Filtration  Area:   2.5  m2  
   Sterilization:   1  cycle  autoclave  (30  min  @  126°C)  
Size:   ???  
Additional  Features:   Disposable/Single  use  
        
Operating  Conditions:   Max  Operating  Temp:   40°C  
   Max  Operating  Pressure:   3.1  bar  (45  psi)  
        
Purchase  Cost:   $9,000.00     	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Pump  (S-­105)  
     
Function:   To  transfer  material  from  filter  to  holding  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Biomass   0  g  
   Water   200000  g  
   TNBP   573  g  
   Media   5600 g  
   VLP   190 g  
   Triton X-100   1909 g  
   Total   208272 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Depth  Filtration  Holding  Tank  (P-­7/V-­101)  
     
Function:   To  hold  the  purified  product  from  the  depth  filtration  device  
     
Vendor:   Sartorius Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   200000 g  
   TNBP   573 g  
   Media   5600 g  
   VLP   171 g  
   Triton X-100   1909 g  
   Total   208253 g  
        
Characteristics:   Material:   Stainless  steel  
   Total  Volume:   500  L  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00     	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Pump  (S-­106)  
     
Function:   To  transfer  material  from  the  holding  tank  to  the  IEX  column  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Biomass   0 g  
   Water   200000 g  
   TNBP    573 g   	  
   Medium   5600 g  
   VLP   171 g  
   Triton X-100   1909 g  
   Total   208253 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Chromatography  Resin  Tank  (P-­11/V-­105)  
     
Function:   To  hold  the  IEX  chromatography  resin  
     
Vendor:   Sartorius Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Capto Q Medium   50 L  
        
Characteristics:   Material:   Stainless  steel  
   Total  Volume:   50  L  
   Sterilization:   Column  CIP  medium  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00     	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Pump  (S-­107)  
     
Function:   To  transfer  material  from  the  resin  tank  to  the  IEX  column  
     
Vendor:   Cole-Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Capto Q Medium   50 L  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
  
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Anion  Exchange  Chromatography  Column  (P-­4/INX-­101)  
     
Function:   To specifically bind and elute the product in the anion exchange chromatography 
resin  
     
Vendor:   GE Life Sciences  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   TNBP   573 g  
   Medium   5600 g  
VLP   171 g 
Triton X-100   1909 g 
Total   28253 g 
        
Characteristics:   Model:   ReadyToProcess Q Sepharose FF  
   Material:   Stainless Steel 316 L, glass borosilicate  
   Column Volume:   215.9844949 L   	  
Column Height:   0.4 m   	  
Column Diameter:   0.5 m   	  
Sterilization:   1 M NaOH, 30& isopropanol  
        
Operating  Conditions:   Minimum  Temp:   4°C  
   Maximum  Pressure:   1.2  bar  (17  psi)  
Bed Volume:   78.53981634 L   
Resin:   Capto Q  
Binding Capacity:   .22 mmol Cl- /mL medium  
Flow Rate   0.981747704 LPM  
VLP Run Time   20.37183272 min  
     
        
Purchase  Cost:   $166,000.00     	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Pump  (S-­101)  
     
Function:   To  transfer  material  from  the  IEX  column  to  the  holding  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000  
   TNBP   0  
   Medium Components   0  
   VLP   162  
   Triton X-100   0  
   Total   20162 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	  	   	  
	   100	  
Ion  Exchange  Holding  Tank  (P-­18/V-­107)  
     
Function:   To  hold  the  purified  product  from  the  IEX  column  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   Media   0 g  
   VLP   162 g  
   Total   20162 g  
        
Characteristics:   Material:   Stainless  steel  
   Total  Volume:   500  L  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00     	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Pump  (S-­108)  
     
Function:   To  transfer  material  from  the  holding  tank  to  the  SEC  column  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g   
   Media   0 g  
   VLP   162 g  
   Total   20162 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Size  Exclusion  Chromatography  Column  (P-­5/C-­101)  
     
Function:   To specifically bind and elute the product in the size-exclusion chromatography 
resin  
     
Vendor:   GE Life Sciences  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000  
   Media   0 g  
   VLP   162 g  
Tris-HCl   4.8 g 
NaCl   14 g 
Total   20180.8 g 
        
Characteristics:   Model:   ReadyToProcess Q Sepharose FF  
   Material:   Stainless Steel 316 L, glass borosilicate  
   Column Volume:   12.56637061 L   	  
Column Height:   0.4 m   	  
Column Diameter:   0.5 m   	  
Sterilization:   CIP buffer, 30% isopropanol in 1M NaOH  
        
Operating  Conditions:   Temp:   22°C  
   pH:   7.5    
Resin:   Cross-linked agarose  
Flow Velocity   0.05 m/min  
Volume Medium   5 L  
Flow Rate   0.628318531 LPM  
Run Time   39.78873577 min  
   Binding Capacity:   13 mg/mL medium  
  
Purchase  Cost:   $166,000.00     	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Pump  (S-­111)  
     
Function:   To  transfer  material  from  the  SEC  column  to  the  holding  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   Media   0 g  
   VLP   154 g  
   NaCl   14 g  
   Tris-HCl   4.8 g  
   Total   20172.8 g  
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Size  Exclusion  Holding  Tank  (P-­19/V-­108)  
     
Function:   To  hold  the  purified  product  from  the  SEC  column  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   Media   0 g  
   VLP   154 g  
   NaCl   14 g  
   Tris-HCl   4.8 g  
   Total   20172.8 g  
        
Characteristics:   Material:   Stainless  steel  
   Total  Volume:   500  L  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00     	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Pump  (S-­114)  
     
Function:   To  transfer  material  from  the  holding  tank  to  the  TFF  unit  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   Media   0 g  
   VLP   154 g  
   Total   26544.27 g 
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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Tangential  Flow  Filtration  Unit  (P-­6/DF-­102)  
     
Function:   To  filter  product  of  size  exclusion  chromatography  for  any  remaining  contaminants  
and  to  insure  small  to  no  presence  of  detergents  and  media  ions.    
     
Vendor:   Millipore  
     
Operation:   Continuous  
     
Materials  Handled:   Input   Quantity  
   Water   20000 g  
   Media   0 g  
   VLP   154 g  
   Total 20146 g 
        
Characteristics:   Model:   Encapsulated  Zeta  Plus  
   Material:   304  L  Stainless  steel  
Polyethylene  
Nylon  
Polysulfone  
Silicone  
   Flow  Rate:   0.4-­4  L/min  
   Sterilization:   No  CIP/SIP  
Surface  area:   0.1-­0.5  m1  
Additional  Features:   Disposable/Single  use  
        
Operating  Conditions:   Max  Operating  Temp:   20-­45°C  
   Max  Operating  Pressure:   3.45  bar  (50  psi)  
        
Purchase  Cost:   $200,000.00     	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Pump  (S-­109)  
     
Function:   To  transfer  material  from  the  TFF  unit  to  the  holding  tank  
     
Vendor:   Cole-­Palmer  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   10000 g  
   Media   0 g  
   VLP   146 g  
   Total   10146 g 
        
Characteristics:   Model:   Masterflex®  B/T  ®  
   Pump  Type:   Peristaltic  
   Flow  Rate:   42  L/min  
   Power:   6.5  Amps  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $4,640.00     	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TFF  Holding  Tank  (P-­8/V-­102)  
     
Function:   To  hold  the  purified  product  from  the  TFF  device  
     
Vendor:   Sartorius  Stedim  
     
Operation:   Batch  
     
Materials  Handled:   Input   Quantity  
   Water   10000 g  
   Media   0 g  
   VLP   146 g  
   Total   10146 g 
        
Characteristics:   Material:   Stainless  steel  
   Total  Volume:   500  L  
        
Operating  Conditions:   Temp:   22°C  
   Pressure:   1.1  atm  
        
Purchase  Cost:   $1,682.00     	  
. 	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9.0 Cost Summary 
 
9.1 Upstream Section 
 
Upstream Process Equipment 
Name Type Size Vendor Equipment Name Purchase Cost ($/Unit) 
P-1/TTR-101 Test Tubes 300 mL Freund Container 2 ml Sterile Plastic Vials $255.00 (500 vials) 
P-2/SFR-101 Shaker Flask 250 mL Corning Polycarbonate Erlenmeyer $595.89 (50 flasks) 
P-3/SFR-102 Shaker Flask 2 L Corning Polycarbonate Erlenmeyer $204.55 (6 flasks) 
P-4/SFR-103 Shaker Flask 4 L Corning Polycarbonate Erlenmeyer $236.60 (4 flasks) 
P-6/SBR-103 Bioreactor 50 L GE Life Sciences Xcellerex® Skid $213,519.00 
P-7/SBR-104 Bioreactor 500 L GE Life Sciences Xcellerex® Skid $233,717.00 
P-17/SBR-105 Bioreactor 2000 L GE Life Sciences Xcellerex® Skid $930,446.00 
 
Bioreactor Bags 50-2000L GE Life Sciences Xcellerex® Bags $1,000.00 
P-18/HX-103 Heat Exchanger 1.5 m Enerquip Pharmaceutical Enerquip Exchanger $109,082.86 
P-11/HX-101 Heat Exchanger 1.5 m Enerquip Pharmaceutical Enerquip Exchanger $109,082.86 
P-16/HX-102 Heat Exchanger 1.5 m Enerquip Pharmaceutical Enerquip Exchanger $109,082.86 
P-19/V-105 Storage Tank 200 L Sartorius Stedim Flexel 3D Palletank® with tote $1,682.00 
P-10/V-102 Media Storage Tank 200 L Sartorius Stedim Flexel 3D Palletank® with tote $1,682.00 
P-15/V-104 Media Storage Tank 500 L Sartorius Stedim Flexel 3D Palletank® with tote $2,915.00 
P-9/MF-101 Sterile Filter 
 
3M Purification ZetaPlus Encapsulated $4,500.00 
P-14/MF-102 Sterile Filter 
 
3M Purification ZetaPlus Encapsulated $4,500.00 
P-8/V-101 Media Storage Tank 200 L Sartorius Stedim Flexel 3D Palletank® with tote $1,682.00 
P-13/V-103 Media Storage Tank 500 L Sartorius Stedim Flexel 3D Palletank® with tote $2,915.00 
 Raw M aterials     
 Triton X-100  Millipore  $13311.51 
 Tributyl phosphate  Millipore  $914.58 
 Sodium Hydrogen Carbonate 2.5 kg Millipore  $96.45 
 Sodium Hydrogen Carbonate 12 kg Millipore  $548.77 
 Sodium Hydrogen Carbonate 25 kg Millipore  $307.63 
 EXCELL-405 Medium  Sigma-Aldrich  $96,820.00 
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9.2 Downstream Section 
 
Downstream Process Equipment 
Name Type Size Vendor Equipment Name Purchase Cost ($/Unit) 
 
Cell Harvest/Primary Recovery 
    P-1/DS-101 Disk-Stack Centrifuge 
 
Carr Centritech Unifuge® $400,000.00 
S-102 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-12/V-106 Storage Tank 200 L Sartorius Stedim Palletank® $1,682.00 
S-103 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-9/V-103 Inactivator Tank 500 L Sartorius Stedim Palletank® $4,500.00 
S-104 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-3/DF-101 Depth Filter 
 
3M Purification ZetaPlus Encapsulated $4,500.00 
 
Depth Filtration Cassettes 
 
3M Purification ZetaPlus $4,500.00 
S-105 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-7/V-101 Holding Tank 200 L Sartorius Stedim Palletank® $1,682.00 
 
Chromatography 
    S-106 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-11/V-105 Chromatography Resin Tank 200 L Sartorius Stedim Palletank® $1,682.00 
 
Chromatography Resin 
 
GE Life Sciences Sepharose Q XL 
 P-4/INX-101 Ion Exchange Chromat. Column 
 
GE Life Sciences ReadyToProcess $166,000.00 
S-107 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
S-101 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-18/V-107 Holding Tank 200 L Sartorius Stedim Palletank® $1,682.00 
P-10/V-104 Chromatography Resin Tank 200 L Sartorius Stedim Palletank® $1,682.00 
S-108 Pump 
 
Cole-Palmer MasterFlex® B/T $12,500.00 
S-110 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-5/C-101 Size Exclusion Chromat. Column 
 
GE Life Sciences ReadyToProcess $166,000.00 
 
Chromatography Resin 
 
GE Life Sciences Sepharose 4 FF 
 S-111 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-19/V-108 Holding Tank 200 L Sartorius Stedim Palletank® $1,682.00 
 
F iltration 
    S-114 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-6/DF-102 Tangential Flow Filtration (TFF) 
 
Millipore Pellicon XL50 $200,000.00 
S-109 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-8/V-102 Holding Tank 200 L Sartorius Stedim Palletank® $4,500.00 
S-112 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
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9.3 Additional Equipment and Processes 
 
Additional Equipment & Processes 
Name Type Size Vendor Equipment Name Purchase Cost ($/Unit) 
P-17/FDR-101 Freeze Drier 
   
$4,500.00 
S-113 Pump 
 
Cole-Palmer MasterFlex® B/T $4,640.00 
P-13/FL-101 Filler 
 
-- 
  P-14/LB-101 Labeling 
 
-- 
  P-15/BX-101 Packaging 
 
-- 
  P-16 Removal 
 
SteriCycle  
 --- Incubator  Sartorius Stedim  
--- Tube Fusers  Sartorius Stedim  
--- Tube Sealers  Sartorius Stedim  
--- Cryopreservation Bank  Sigma-Aldrich  
--- Temperature Control Module    
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10.0 Important Considerations 
 
10.1 Scheduling 
 10.1.1 Gantt Chart 
 
 
 
 
 
 
 
 
 
F igure 10.1 Gantt Chart. Shows scheduling times relative to each process equipment to give overall batch time. 
 
Note: The change time of the bag liner of the bioreactors and storage tanks are 1 hour 
each, and they are included in the fill time of the corresponding unit. 
 
 
 
 
 
 
 
 
 
 
 
0	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   20	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  Fill	  200L	  Bioreactor	  Ferment	  200L	  Bioreactor	  Fill	  2000L	  Bioreactor	  Ferment	  2000L	  Bioreactor	  Fill	  and	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  in	  Hold	  Tank	  1	  Centrifuge	  Fill	  Inactivation	  Tank	  Inactivation	  Tangential	  Flow	  Filtration	  Fill	  and	  Store	  in	  Hold	  Tank	  2	  Ion	  Exchange	  Chromatography	  Fill	  and	  Store	  in	  Hold	  Tank	  3	  Size	  Exclusion	  Fill	  and	  Store	  in	  Hold	  Tank	  4	  Tangential	  Flow	  Filtration	  Fill	  and	  Store	  in	  Hold	  Tank	  5	  Packaging	  into	  Vial	  
Days	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10.2 Environmental Concerns 
 
Biosynthesis of our vaccine product results in a number of waste streams. The 
process produces a substantial amount of solid biohazard waste which may contain 
recombinant baculovirus, insect cells, and metabolic waste products from the 
fermentation process. The solid waste components are collected into red biohazard 
receptacles within the facility for a biohazard waste removal service, Stericycle, to collect 
and treat. This waste will be incinerated to remove any potentially hazardous effects on 
the environment so that only greenhouse emissions from incineration are the only 
environmental impact. The facility will use StericycleTM as the solid biohazard 
management service to insure proper waste disposal protocols are rigidly maintained. 
None of the components used in the fermentation steps of this process are 
particularly dangerous or toxic to wildlife or the environment, since many of them are 
required for cell growth of any organism and are often found in nature. Many of these 
components will be heat-treated to sterilize the fermentation broth after removal of the 
VLPs through the downstream components. This sterilization procedure will denature 
any potential problematic proteins in the mixture. This waste will be neutralized in pH to 
insure no detrimental effects to wildlife in the location of disposal. The detergents used in 
the deactivation of baculovirus are collected as liquid waste via diafiltration. The filtrate 
is collected and retained as hazardous liquid waste. 
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10.3 Current Good Manufacturing Practices 
The United States Food and Drug Administration (FDA) is responsible for 
overseeing and enforcing Good Manufacturing Practices in the United States. Current 
Good Manufacturing Processes (cGMP) guidelines are found in the Code of Federal 
Regulation 21 Part 211 (21 CFR 211). The purpose of cGMP regulations is to ensure that 
drug products are manufactured in a manner making them safe for human consumption 
by monitoring how drug products are sterilized and purified.  
Sterilization and purity are monitored by paying careful attention to the process, 
quality of manufacturing equipment components, raw materials, as well as characteristics 
of cell lines used in recombinant processes. The manufacturing facility design and layout, 
as well as frequent testing are quintessential in ensuring quality consistent with FDA 
cGMP regulations. All authorized persons allowed to enter designated limited access 
areas, such as the production floor will have the proper training. 
All equipment purchased is certified as being GMP approved by the FDA. 
Bioreactors with disposable bags and disposable transfer lines are used to ensure sterility, 
while reducing time between batches. The disposable bags and transfer lines are GMP 
certified and guaranteed by their manufacturers, therefore there is no need for CIP and 
SIP procedures on the bioreactors, which reduces change over time between batches. 
Tube fusers as well as sterile tube connectors are used to ensure that chance of 
contamination is minimized during transfer. 
Specific guidelines pertaining to vaccine manufacture are described by the FDA 
????Guidance for Industry, Characterization and Qualification of Cell Substrates and 
Other Biological Materials Used in the Production of Viral Vaccines for Infectious 
	   115	  
?????????????????????????????????????????????????????????????????? ?????????????????????
cells used for recombinant DNA, purity of vaccine, potential sources of contamination, 
and validation of purity at many stages during the vaccine manufacture. 
We have selected the SF+ insect cell line as our cell substrate. These are not bovine or 
human derived; therefore there is low pathogenic transmission risk. This eliminates 
adventitious agents affiliated with human or bovine cell lines, as well as retroviruses, 
such as HIV, and bovine diseases such as Bovine spongiform encephalopathy which can 
be transmitted to humans.  
Research and Development (R&D) is responsible for characterizing the growth 
characteristics and life expectancy of the SF Plus cells according to 21 CFR 
610.18(c)(1)(iii). This includes documenting species of origin, tissue type, tumorigenic 
properties, and ability to harbor latent viruses or express infectious prion proteins (PrP). 
They will also create a master cell bank (MCB) for each virus strain. Every season, R&D 
will renew the MCB. Working Cell Banks (WCB) will be derived from their 
corresponding MCB for each batch. All WCB used to create the VLPs for a particular 
strain will be derived from their corresponding MCB. R&D will periodically test the 
MCB and WCB for cell viability and stability. The history of all WCB will be 
documented by Quality Assurance (QA) according to 21 CFR 610.18(c)(1)(i), including 
agents used in same biosafety cabinets and conditions under which the cells were 
passaged. 
R&D will also be responsible for characterizing and documenting the viral seed. 
For our production methods, the baculovirus will be used to insert the desired influenza 
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?????????????????????????????????????????????????????????????????????????????? ????????????
R&D as well. Other documentation includes amino acids used in the growth media. 
To minimize potential contamination, human contact with cells will be minimized. All 
employees working with the cells directly or on the production floor are required to wear 
the proper attire as set in 21 CFR 211. Once the shaker flasks are inoculated with the SF 
Plus cells, the cells will not be exposed to the ambient air. The transfer methods during 
the scale up are such that the cells need not be exposed, minimizing potential 
contamination opportunities. All cells drawn from the working cell bank (WCB) will be 
tested by the Quality Control (QC) group to ensure they do not contain infectious viruses 
or retroviruses.  
The identity and purity of all raw materials will be checked by QC to ensure that 
they fall within the specifications approved by the FDA for the specific vaccine 
production method. This will occur before they are moved onto the production floor. No 
serums are used, therefore there is no need to concern ourselves with irradiation of raw 
materials. 
During production, all specific markers relevant to the SF Plus cell line will be 
analyzed by QC and tracked throughout the different manufacturing passage levels. The 
ability of the cells to produce recombinant protein will be tracked, evaluating each copy 
number and the stability at each relevant passage. 
Our interpretation of the definition of purity used by the FDA is removing 99% of 
cell growth media, cell substrate DNA, as well as any other adventitious agents that may 
be the product of cell debris.  Size exclusion chromatography will be used because the 
VLP vaccine has a diameter of 90 to 120 nanometers and DNA has a diameter of 2.2 to 
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2.6 nanometers. This will allow for removal of 99.9% of DNA debris from the cell 
substrate. An ion exchange column will be used to remove any charged cell debris. 
QC will also use a control set of cells, which are uninfected cell substrate. These 
cells will be grown in parallel at the same time as each batch with identical conditions to 
the batches of cells that are to be infected. This will emulate the conditions of the 
bioreactors and allow QC to determine any adventitious agents naturally produced by the 
cell substrate. The cells used for QC must be from the same WCB as the ones used in the 
bioreactor for validity of the control test. All assays will be validated and signed off by 
Quality Assurance (QA). All tests will be consistent with 21 CFR 610.18(c)(1)(iv). 
After harvest, QC will test for adventitious agents in a method consistent with 21 
CFR 610.30. Since our production method uses a lytic infection, it is not necessary to 
check for surviving cells before harvest. To maintain full compliance with FDA 
regulations, QC will ensure there are no surviving cells. Chances are slim due to the lytic 
infection, but if surviving cells remain, the batch will be checked for adventitious agents. 
At this point the harvested batch can be filtered. Post filtration, QC will test each batch 
for bacterial and fungal sterility. Finally, each batch will be tested for residual cellular 
proteins and cellular nucleic acids. All residual cells and low levels of cell-substrate DNA 
will be removed to assure safety, identity, purity, potency, and quality. 
In accordance with 21 CFR, all process automation will be consistent with Part 
211.68; Filtration will be consistent with Part 211.72; Storage will be consistent with 
Parts 211.80, 211.82, and 211.94; Quality testing will be consistent with Parts 211.84, 
211.87, and 211.89; Process time speculations will be consistent with Part 211.111; 
Contamination Control will be consistent with Part 211.113; Holding and Distribution 
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will be consistent with parts 211,142 and 211,158; Control Units and software will be 
consistent with Part 211.160. Standard Operation Procedures will be developed for all 
actions necessary during the manufacturing production, including sterilization, facility 
cleaning, and training consistent with 21 CFR Parts 211.100, 211.101, 21.110. All 
Record keeping will be consistent with 21 CFR Part 211 Subpart J. 
All relevant information regarding GMP was found on the FDA website and taken 
from C FR- Code of Federal Regulations Title 21. 
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10.4 Laboratory and Production Facility Layout 
The diagram shown below is a typical layout of a vaccine manufacturing facility. 
The insect cell culture and influenza vaccine development facility will be modeled after 
this depiction and retrofit into an existing site used for additional vaccine manufacturing. 
For a goal of 100 million doses per year, the facility will have to be approximately 140K 
square feet. Single-use equipment will be used throughout the facility to reduce change-
over time, fixed piping, cleaning and validation costs, and to increase operational 
flexibility. 
 The layout is designed to maintain multiple disposable bioreactors up to 2000 L in 
size. The facility design criteria will meet the BSL-2 requirements with inoculum and cell 
culture in class C, cell culture, downstream processing, and media and buffer preparation 
in class D. The media and buffer will be stored in controlled, non-classified areas. The 
batch duration will be approximately 8 weeks, including change-over times. This 
simplifies to 4 weeks allotted to inoculum and cell culture, 2 weeks for bioreactor 
production, and 2 weeks for further purification and downstream processing.  
 
 
F igure 10.2 Design schematic for single-use influenza vaccine manufacturing facility with insect cell culture 
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10.5 Labor Costs and Structure 
  
The influenza vaccine facility will operate under the Global Manufacture and 
Supply chain.  Under this, the two major branches concerned with this process are quality 
and manufacturing.  The quality side handles paperwork and checks that all products and 
processes fall within regulations.  Manufacturing????????????????????????????????????
facility and is split between process engineering and procurement.  Positions of contract 
specialist manager, operators, and contractors within the warehouse will be paid on an 
hourly wage, while the general contract specialists, engineers, and the warehouse 
manager will be paid on a salary wage.   
Positions such as internal auditors and higher management in procurement do not 
fall under the fixed costs for this facility.  Based on average wages in Durham, North 
Carolina, the total cost of a labor force of 71 employees for the year is estimated at $1.75 
million.  However, since the influenza vaccine production only operates for half the year, 
with only four months of production, only a third of the total cost of labor is accountable 
to this process, $584,000 (see Appendix A, Labor Costs for calculations).  This cost will 
go into fixed costs for each year the facility is operating.   
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F igure 10.3 Diagram showing the labor structure for the vaccine manufacturing facility.  The Global Manufacture and 
Supply Group for the vaccine plant branches into two major operations: quality and manufacture. 
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11.0 Economic Analysis 
11.1 Market Analysis 
The influenza virus is a seasonal virus that typically affects the upper respiratory 
track. In severe cases, it can lead to pneumonia and even death. Annually, the World 
Health Organization (WHO) estimates epidemics to affect anywhere from 5% to 15% of 
??????????????????????????????????????). Most patients affected by the influenza virus 
will suffer illness for a week, without requiring medical attention. This can lead to 
anywhere from three to five million cases of severe illness; it is estimated that there is an 
annual death rate of about 250,000 to 500,000 globally ?????????????). These deaths 
usually occur among the chronically ill, the elderly, and the young.  
The most common vaccine used to prevent the influenza virus is a trivalent 
vaccine containing an A type Subtype H3N2 virus strain, an A type Subtype H1N1 virus 
strain, ????????????????????????????????????). The common method for vaccine 
production is allowing the virus to proliferate in chicken eggs, and then harvesting the 
influenza virus from the chicken embryo. The large costs of treating the cases of 
influenza outbreak paired with the threat of pandemic outbreak have also led to a larger 
demand for influenza vaccine. New methods, such as the use of MDKC to produce the 
virus capsid and elicit an immune response have been investigated as potential methods 
to meet the growing demand ????????????????????????????????????).  
Between 2010 and 2011, the global market value reached $4 billion US Dollars 
(USD) for all seven of the ma?????????????????????? ????????????????????). Between 
2008 and 2010, the influenza vaccine market grew a stunning 65%, driven primarily by 
the threat of a pandemic H1N1 outbreak (Wood). Market growth this large is not 
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expected to continue long term, however. The compound annual growth rate is expected 
to be ??????????????????????????????????????? ?). By 2018, this market value is expected 
to reach ??????????????????????????????????). Currently, there are only five influenza 
vaccine producers in the US market with Sanofi Pasteur capturing the largest market 
share of $1 billion USD. It is also estimated that annual influenza outbreak in the USA 
costs $80 billio???????????????????). The large market value is appealing to 
pharmaceutical companies that can effectively produce an influenza vaccine.  
There are seven major vaccine markets globally. Seen in Figure 10.4 
?????????????), the US is the largest market share of an individual country, occupying 
about 40% of ?????????????????????? ???????????????????). Germany, Italy, Spain, 
France, the UK, and Japan are the other major vaccine market players. The European 
players (Germany, Italy, Spain, France, and the UK) account for about 50% of the 
European ?????????? ?????????????????????????). The Japanese market accounts for the 
remaining 10% of the influenza vaccine market.  
 
 
 
 
 
 
 
 
 
 
 
F igure 10.4 This shows the market share of the 7 major vaccine markets globally. It was used to show the 
feasibility of the market share we expect to capture.  ?????????????? 
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Currently, WHO estimates the USA as being one of the leaders in influenza 
vaccination, consuming approximately 40% of total vaccines produced annually, seen in 
Figure 10.4. The threat of pandemic flu outbreak has led WHO to issue recommendations 
to increase vaccination u???????????????????????????????????????????). To meet the 
increase in demand, we investigated the production of an influenza vaccine via the 
baculovirus in the SF+ insect cell line. In order for the vaccine to be lucrative and capture 
a share of the influenza vaccine market, production cost of the vaccine must be 
competitive with current egg-based production methods.  
In 2009, the 149 million doses of the seasonal influenza vaccine were supplied to 
Europe, as seen in Figure 10.5 (Hombach). From Figure 10.6 ?????????????), it is seen 
that 143 million doses of seasonal influenza vaccine were supplied to the United States in 
2009 (Kresse). Based on current market growth rates, 3.9% compounded annual 
?????????? ?), it is expected that the percentage of people vaccinated in Germany, Italy, 
Spain, France, the UK, the United States, and Japan will increase from 28.9% in 2011 to 
32.9% by 2018. Based on these expected vaccination rates, the number of vaccines 
supplied to Europe and the US will increase from 292 million seasonal influenza doses to 
approximately 330 million doses. 
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F igure 10.5 This shows the supply of influenza vaccines different countries globally between 2005 and 2009. It was 
used to determine the global market share and determine the number of doses that our company could potentially 
supple to the market. (Hombach) 
 
F igure 10.6 This shows the number of influenza vaccine doses supplied to the United States in 2009. It also shows the 
share of each company. This data was used in determining the number of doses our company can supply to the US. 
?????????????? 
 
Sanofi PasteurTM was responsible for producing 200 million doses of trivalent 
egg-based seasonal influenza vaccinations in 2010, as well as 126 million pandemic 
influenza vaccine doses (Sanofi Pasteur). From Figure 10.6 ?????????????), it can be 
seen that they supplied 25% of their doses to the United States. For a company to enter 
the market and hold a large market share in Europe, a similar number of doses must be 
supplied to Europe as well; therefore, our company plans to manufacture and 100 million 
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doses of seasonal influenza to the United States and European markets. Half of the doses 
will be distributed to Europe, and half will be distributed to the United States.  
This is a reasonable market stake, and feasible to produce in a single facility. 
Sanofi PasteurTM????????????????????????????????????????????????????????????????????
million doses of trivalent seasonal influenza vaccine doses annually (Sanofi Pasteur). In 
2009, members of The International Federation of Pharmaceutical Manufacturers & 
Associations (IFPMA) International Vaccine Supply (IVS) Task Force supplied 449 
million doses of seasonal influenza vaccine, accounting for 75% of total influenza 
vaccines distributed (Palache). Therefore, the market is approximately 600 million 
seasonal influenza vaccines, annually. Our production goal of 100 million vaccines 
would increase the global market by 16.7%, moving the w??????????????????? ??????????
of 750 million doses of influenza vaccine produced annually.  
Since only 5 companies globally produce and supply an influenza vaccine, there 
is room for entry into the market. Our company will supply 86,184,000 doses of trivalent 
seasonal influenza vaccine to the market. This would capture about 14.7% of the global 
market share, supplying to only Europe and the United States. 
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11.1.1 Investor Interest 
Health and Biotechnology sectors are known for their large profits. While it is 
true that there are potentially large returns in the pharmaceutical, biotechnology, and 
healthcare industries, it comes with a large investment risk. The risk comes from the 
?????????????????????????????????????????????????????????????????????????????alue 
being spent on research (Golec). Outside of the biotechnology industry, an average of 3% 
???????????????????????????????????????????????????????? 
There is more risk on the failure of products to reach the market. Approximately 
only 1 in every 10,000 compounds being investigated ? commonly referred to as 
investigational new drugs (INV) ? make it to market. When a drug makes it to market, it 
is quintessential that the company recovers money lost on research and clinical trials, as 
well as sunk costs from failed investigated new drugs. In 2011, the biotechnology market 
as a whole increased revenue to a 1% margin over costs, increasing revenue a full 8% 
from 2009 (Suresh). The small revenue margin is due to large research costs, clinical 
testing costs, and the sunk costs of failed products. 
To succeed in a market with high failure rates, successful drugs must have high 
mark ups. In 2012, GSKTM and Sanofi PasteurTM had an overall product profit margin of 
29% and 32%, respectively, in their vaccine divisions (Angelmar). The overall 
pharmaceutical industry mark-up is approximately 30% across the industry (Angelmar). 
Therefore, our company must be capable of producing our trivalent influenza vaccine 
with at least a 30% profit margin. 
From the time a company files for a patent, they have 17 years before other 
companies can manufacture a generic form of the drug. Influenza vaccines are different 
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because the strain changes annually. Because of antigenic drift, there is no patented 
influenza vaccine, or generic brand. The influenza vaccine is less proprietary than other 
drug products. The production method of the vaccine, the dosing, and method of delivery 
is where the proprietary value lies in the influenza vaccine market. Producing a non-egg 
based method with less lag time by using recombinant insect cell culture technology 
therefore has large value.  
Currently, only egg-based methods and a recombinant mammalian cell culture are 
used to produce the influenza vaccine. FluBokTM a recombinant influenza vaccine 
produced using Chinese Hamster Ovary (CHO) cells, a mammalian cell culture. 
FluBokTM is the only approved non-egg based influenza vaccine on the market. With the 
push to move away from egg-based production methods that have large lead times, our 
company has room to enter the market. 
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11.2 Profitability Analysis 
 To determine the profitability of the vaccine manufacturing facility, the 
profitability analysis worksheet (Version 3.0), developed by Nickish Consulting was 
used. The analysis is broken down into equipment costs and total permanent investment, 
working capital, utilities, fixed costs, and other variable costs.  
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11.2.1. Equipment Costs and Total Permanent Investment 
 The purchase cost of all raw materials and equipment was determined by direct 
contact with ???????????????????????????????????????????????????????????????????????
through sources such as BioPharm International or BioProcess International. The bare 
module factors for all units were gathered from Chapter 22 of Product and Process 
Design Principles.  
 The Total Permanent Investment accounts for the cost of site preparations, service 
facilities, contingencies and contractor fees, and plant start-up. As listed in Chapter 22 of 
Product and Process Design Principles, the cost of site preparations will be 5.0% of the 
total bare module cost, the cost of service facilities will be 5.0% of the Total Bare 
Module cost, the cost of contingencies and contractor fees will be 18.0% of the Total 
Depreciable Capital, and the cost of plant start-up will be 10.0% of the Total Depreciable 
Capital. Since this manufacturing facility will be retrofit to an existing site, there will be 
no cost associated with land.  
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      Equipment Costs 
    Fabricated Equipment Purchase Cost Quantity Bare Module Factor Bare Module Cost 
 
Test Tubes/Plastic Vials $255.00 1 1.00 $255.00 
 
Shaker Flasks - 250 mL (pack of 6) $160.57 1 1.00 $160.57 
 
Shaker Flasks - 2 L $51.71 6 1.00 $310.26 
 
Shaker Flasks - 4 L $150.25 6 1.00 $901.50 
 
Disposable Bioreactors -50 L $213,519.00 4 4.16 $3,552,956.16 
 
Disposable Bioreactors -500 L $233,717.00 4 4.16 $3,889,050.88 
 
Disposable Bioreactors- 2000L $930,446.00 4 4.16 $15,482,621.44 
 
Disposable Reactor Bags -50 L $1,000.00 4 1.10 $4,400.00 
 
Disposable Reactor Bags -500 L $1,000.00 4 1.10 $4,400.00 
 
Disposable Reactor Bags -2000 L $1,000.00 4 1.10 $4,400.00 
 
Depth Filtration Unit (DSP) $4,500.00 4 1.10 $19,800.00 
 
Depth Filtration Cassettes -- 4 1.10 -- 
 
Sterile Filtration Unit (USP) $4,500 8 1.10 $39,600.00 
 
Filtration Cassettes -- 8 1.10 -- 
 
Chromatography Columns $166,000.00 8 1.10 $1,460,800.00 
 
pH Adjustment Tank $20,000.00 1 4.16 $83,200.00 
      Process Machinery Purchase Cost Quantity Bare Module Factor Bare Module Cost 
 
Disk-Stack Centrifuge $400,000.00 4 2.03 $3,248,000.00 
 
Pumps $4,640.00 27 3.30 $459,360.00 
 
Virus Inactivation Tank $4,500.00 4 4.16 $74,880.00 
 
Holding Tanks $1,682.00 16 4.16 $111,953.92 
 
Chromatography Resin Tanks $1,682.00 8 4.16 $55,976.96 
 
Tangential Flow Filtration Unit $200,000.00 4 2.32 $1,856,000.00 
 
Heat Exchangers $109,082.82 9 3.291 $3,230,924.00 
Spares 
 
Purchase Cost Quantity Bare Module Factor Bare Module Cost 
 
Filter Integrity Tester $4,500.00 5 1 $22,500.00 
 
Bioinactivation System $10,000.00 1 3.5 $35,000.00 
 
Tube Fusers $15,300.00 1 1 $15,300.00 
 
Tube Sealers $10,200.00 1 1 $10,200.00 
Storage 
 
Purchase Cost Quantity Bare Module Factor Bare Module Cost 
 
Incubator $3,700.00 4 1.74 $25,752.00 
 
Storage Tanks $1,682.00 8 4.16 $55,976.96 
 
Media Storage Tanks-200 L $1,682.00 8 4.16 $55,976.96 
 
Media Storage Tanks-500 L $2,915.00 8 4.16 $97,011.20 
 
Freeze Dryer $4,500.00 4 2.05 $36,900.00 
 
Biosafety Cabinet $10,000.00 1 1.10 $11,000.00 
 
Bag Holders $1,000.00 18 1.10 $19,800.00 
      Total Permanent Investment 
    
 
Cost of Site Preparations: 5.0% of Total Bare Module Costs 
 
Cost of Service Facilities: 5.0% of Total Bare Module Costs 
Allocated Costs for utility plants and related facilities: $0 
 
Cost of Contingencies/Contractor Fees: 18.0% of Direct Permanent Investment 
 
Cost of Retrofit: $0 
 
Cost of Royalties: $0 
 
Cost of Plant Start-Up: 10.0% of Total Depreciable Capital 
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11.2.2 Working Capital & Utilities 
 
 The working capital of a facility is defined as the sum of the cash reserves, 
inventory, and accounts receivable, minus the accounts payable. The cash reserves 
typically include 30 days of raw materials, utilities, operation, and maintenance. For the 
majority of cases, 30 days of accounts receivable for products at sales price and 30 days 
of feedstocks for accounts payable can be assumed. The inventory is assumed to be 7 
days worth of liquid and solid products at sales price; however, this was very dependent 
on the material being considered. For the raw materials, such as media, cell culture 
supplies, and chemical ingredients, an inventory of 30 days was assumed.  
 
11.2.3 Other Variable Costs 
 The other variable costs include the selling/transferring of expenses and the 
management incentive compensation. These factors are included in the Profitability 
Analysis spreadsheet. 
Working Capital 
       
         
 
Accounts Receivable 
  
=> 
 
30 Days 
 
Cash Reserves (excluding Raw Materials) 
 
=> 
 
30 Days 
 
Accounts Payable 
  
=> 
 
30 Days 
 
VLP for Influenza 
Vaccine Inventory 
   
=> 
 
28 Days 
 
Raw Materials 
   
=> 
 
90 Days 
         O ther Variable 
Costs 
    
 
General Expenses 
   
      
   
Selling / Transfer 
Expenses: 3.00% of Sales 
   
Direct Research: 10.00% of Sales 
   
Allocated Research: 0.50% of Sales 
   
Administrative Expense: 2.00% of Sales 
   
Management Incentive 
Compensation: 1.25% of Sales 
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11.2.4 F ixed Costs 
 With a total of four months of operation (120 days), and 3 shifts per day, 71 
employees will be required in both the Quality and Manufacture sectors. The upstream 
and downstream processes will require 6 workers each per shift.  The fixed costs also 
include the wages and benefits of maintenance, quality control, and technical assistants. 
Section 10.5 on labor costs and structure goes into further detail regarding the personnel 
and services surrounding all units as well as their respective salaries and benefits. 
 
 
11.2.5 Depreciation 
 The MACRS Tax-Basis Depreciation for 5 years was used for this manufacturing 
process. According to Product and Process Design Principles, the percentages of Total 
Depreciable Capital beginning with year 1 are: 20%, 32%, 19.2%, 11.52%, and 5.76%.  
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11.3 Input Summary 
 
General Information               
  
Process  Title:   Manufacturing of Insect Cell Culture VLP-­based Influenza Vaccine 
     
  
Product:   API for Influenza Vaccine 
              
  
Plant  Site  Location:   Research Triangle Park, NC 
              
  
Site  Factor:   1.10 
                 
  
Operating  Hours  per  Year:   4383 
                 
  
Operating  Days  Per  Year:   183 
                 
  
Operating  Factor:   0.5003 
                 
                          
                          Product Information               
This  Process  will  Yield  
                    
     
10,924 doses  of  API  for  Influenza  Vaccine  per  hour  
        
     
262,177 doses  of  API  for  Influenza  Vaccine  per  day  
        
     
47,880,000 doses  of  API  for  Influenza  Vaccine  per  year  
        
                        
  
Price   $8.12  /doses 
            
                          Chronology                 
  
Distribution of Production  Depreciation 
 
Product Price 
Year Action Permanent Investment Capacity 7  year  MACRS  
     2013   Production   100%   81.0%   14.29%  
  
$8.12    
  2014   Production   0%   90.0%   24.49%  
  
$8.12    
  2015   Production   0%   90.0%   17.49%  
  
$8.12    
  2016   Production   0%   90.0%   12.49%  
  
$8.12    
  2017   Production  
  
90.0%   8.93%  
  
$8.12    
  2018   Production  
  
90.0%   8.92%  
  
$8.12    
  2019   Production  
  
90.0%   8.93%  
  
$8.12    
  2020   Production  
  
90.0%   4.46%  
  
$8.12    
  2021   Production  
  
90.0%  
     
$8.12    
  2022   Production  
  
90.0%  
     
$8.12    
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11.4. Profitability Analysis 
 11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 	  
Equipment Costs 
      
        Equipment Descr iption 
    
Bare Module Cost 
        Test Tubes 
  
Fabricated Equipment 
 
$255 
 1 Shaker Flasks (250 mL) 
 
Fabricated Equipment 
 
$596 
 6 Shaker Flasks (2 L) 
 
Fabricated Equipment 
 
$5,106 
 6 Shaker Flasks (3 L) 
 
Fabricated Equipment 
 
$1,969 
 4 Disposable Bioreactors (50 L) 
 
Fabricated Equipment 
 
$3,552,956 
 4 Disposable Bioreactors (500 L) 
 
Fabricated Equipment 
 
$3,889,051 
 4 Disposable Bioreactors (2000 L) 
 
Fabricated Equipment 
 
$15,482,621 
 4 Reactor Totes (50 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (500 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (2000 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Depth Filtration Units 
 
Fabricated Equipment 
 
$39,600 
 8 Sterile Filtration Units 
 
Fabricated Equipment 
 
$79,200 
 8 Chromatography Columns 
  
Fabricated Equipment 
  
$1,460,800 
 4 Disk-Stack Centrifuges 
 
Process Machinery 
 
$3,248,000 
 4 Viral Inactivation Tanks 
 
Process Machinery 
 
$74,880 
 16 Holding Tanks 
 
Process Machinery 
 
$111,954 
 8 Resin Tanks 
 
Process Machinery 
 
$55,977 
 4 Tangential Flow Filtration Units 
 
Process Machinery 
 
$1,856,000 
 27 Pumps 
  
Process Machinery 
 
$413,424 
 9 Heat Exchangers 
 
Process Machinery 
 
$3,229,942 
 4 Incubators 
  
Storage 
  
$25,752 
 8 Storage Tanks 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (200 L) 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (500 L) 
 
Storage 
  
$97,011 
 Biosafety Cabinet 
 
Storage 
  
$11,000 
 18 Bag Holders 
  
Storage 
  
$19,800 
 Filter Integrity Tester 
 
Spares 
  
$4,500 
 Bioinactivation System 
 
Spares 
  
$35,000 
 Tube Fusers 
  
Spares 
  
$15,300 
 Tube Sealers 
 
Spares 
  
$10,200 
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11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 
	  	   	  
Variable Cost Summary           
  
Variable Costs at 100% Capacity: 
        
                    
  
General Expenses 
           
                    
     
Selling  /  Transfer  
Expenses:  
     
  $11,667,303    
     
Direct  Research:  
     
  $38,891,009    
     
Allocated  Research:  
     
  $149,730,384    
     
Administrative  Expense:  
     
  $7,778,202    
     
Management  Incentive  Compensation:  
  
  $4,861,376    
                    
  
Total General Expenses 
        
  $212,928,273    
                    
  
Raw Materials $0.015991  
per  doses  of  API  for  Influenza  
Vaccine   $765,658    
                  
  
Byproducts 
  
$0.000000  
per  doses  of  API  for  Influenza  
Vaccine   $0    
                  
  
Utilities 
  
$0.018525  
per  doses  of  API  for  Influenza  
Vaccine   $886,971    
                    
  
Total Variable Costs 
        
 $214,580,902  
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11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 
	  	   	  
Fixed Cost Summary           
                    
                    
  
Operations 
              
                    
     
Direct  Wages  and  Benefits  
     
  $364,000    
     
Direct  Salaries  and  
Benefits  
     
  $54,600    
     
Operating  Supplies  and  Services  
  
  $21,840    
     
Technical  Assistance  to  Manufacturing  
  
  $-­        
     
Control  Laboratory  
     
  $-­        
                    
     
Total Operations 
     
 $440,440  
                    
  
Maintenance 
           
     
Wages  and  Benefits  
     
  $1,522,744    
     
Salaries  and  Benefits  
     
  $380,686    
     
Materials  and  Services  
     
  $1,522,744    
     
Maintenance  Overhead  
     
  $76,137    
                    
     
Total Maintenance 
     
 $3,502,310  
                    
  
Operating Overhead 
           
                    
     
General  Plant  Overhead:  
     
  $164,864    
     
Mechanical  Department  Services:  
  
  $55,729    
     
Employee  Relations  Department:  
  
  $137,000    
     
Business  Services:  
     
  $171,830    
                    
     
Total Operating 
Overhead 
     
 $529,423  
                    
  
Property Taxes and Insurance 
        
                  
     
Property  Taxes  and  Insurance:  
  
  $676,775    
                    
  
Other Annual Expenses 
           
                    
     
Rental  Fees  (Office  and  Laboratory  
Space):  
  
  $-­        
     
Licensing  Fees:  
     
  $-­        
     
Miscellaneous:  
     
  $-­        
                    
     
Total Other Annual Expenses 
  
 $-­    
                    
  
Total Fixed Costs 
        
 $5,148,948  
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11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 	  
Investment Summary             
                       Bare Module Costs 
                 
 
Fabricated Equipment 
        
  $24,518,054    
  
  
Process Machinery 
        
  $8,990,177    
  
  
Spares 
           
  $65,000    
  
  
Storage 
           
  $265,517    
  
  
Other Equipment 
        
  $-­        
  
  
Catalysts 
           
  $-­        
  
  
Computers, Software, Etc. 
        
  $-­        
  
                       
  
Total Bare Module Costs: 
           
 $33,838,748  
                       Direct Permanent Investment 
              
                       
  
Cost of Site Preparations: 
        
  $-­        
  
  
Cost of Service Facilities: 
        
  $-­        
  
  
Allocated Costs for utility plants and related facilities: 
  
  $-­        
  
                      
  
Direct Permanent Investment 
        
 $33,838,748  
                      
                       Total Depreciable Capital 
                 
                       
  
Cost of Contingencies & Contractor Fees 
  
  $-­        
  
                       
                       
  
Total Depreciable Capital 
           
 $33,838,748  
                       Total Permanent Investment 
              
                       
  
Cost of Land: 
        
  $-­        
  
  
Cost of Royalties: 
        
  $-­        
  
  
Cost of Plant Start-­Up: 
        
  $-­        
  
                       
  
Total Permanent Investment -­ Unadjusted 
     
  $33,838,748    
  
Site Factor 
              
1.10  
  
Total Permanent Investment 
        
 $37,222,623  	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11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 
 
 
Profitability  Measures                      
                      The Internal Rate of Return (IRR) for this project is 
     
Negative  IRR  
                  
 
The Net Present Value (NPV) of this project in 2013 is 
  
  $619,244,200    
                      
                      ROI Analysis (Third Production Year) 
        
                      
  
Annual Sales 
 
 350,019,079  
          
  
Annual Costs 
 
 (198,271,760) 
          
  
Depreciation 
 
 (2,977,810) 
          
  
Income Tax 
 
 (6,694,628) 
          
  
Net Earnings 
 
 142,074,882  
          
  
Total Capital Investment  93,336,250  
        
  
ROI 
 
152.22% 
          	  	   	  
	   140	  
11.4.1 Profitability Analysis Results for 20% Efficiency in Downstream 
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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 
 
General Information               
  
Process  Title:   Manufacturing of Insect Cell Culture VLP-­based Influenza Vaccine 
     
  
Product:   API for Influenza Vaccine 
              
  
Plant  Site  Location:   Research Triangle Park, NC 
              
  
Site  Factor:   1.10 
                 
  
Operating  Hours  per  Year:   4383 
                 
  
Operating  Days  Per  Year:   183 
                 
  
Operating  Factor:   0.5003 
                 
                          
                          Product Information               
This  Process  will  Yield  
                    
     
19,663 doses  of  API  for  Influenza  Vaccine  per  hour  
        
     
471,918 doses  of  API  for  Influenza  Vaccine  per  day  
        
     
86,184,000 doses  of  API  for  Influenza  Vaccine  per  year  
        
                        
  
Price   $8.12  /doses 
            
                          Chronology                 
  
Distribution of Production  Depreciation 
 
Product Price 
Year Action Permanent Investment Capacity 7  year  MACRS  
     2013   Production   100%   81.0%   14.29%  
  
$8.12    
  2014   Production   0%   90.0%   24.49%  
  
$8.12    
  2015   Production   0%   90.0%   17.49%  
  
$8.12    
  2016   Production   0%   90.0%   12.49%  
  
$8.12    
  2017   Production  
  
90.0%   8.93%  
  
$8.12    
  2018   Production  
  
90.0%   8.92%  
  
$8.12    
  2019   Production  
  
90.0%   8.93%  
  
$8.12    
  2020   Production  
  
90.0%   4.46%  
  
$8.12    
  2021   Production  
  
90.0%  
     
$8.12    
  2022   Production  
  
90.0%  
     
$8.12    
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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 
 
Equipment Costs 
      
        Equipment Descr iption 
    
Bare Module Cost 
        Test Tubes 
  
Fabricated Equipment 
 
$255 
 1 Shaker Flasks (250 mL) 
 
Fabricated Equipment 
 
$596 
 6 Shaker Flasks (2 L) 
 
Fabricated Equipment 
 
$5,106 
 6 Shaker Flasks (3 L) 
 
Fabricated Equipment 
 
$1,969 
 4 Disposable Bioreactors (50 L) 
 
Fabricated Equipment 
 
$3,552,956 
 4 Disposable Bioreactors (500 L) 
 
Fabricated Equipment 
 
$3,889,051 
 4 Disposable Bioreactors (2000 L) 
 
Fabricated Equipment 
 
$15,482,621 
 4 Reactor Totes (50 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (500 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (2000 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Depth Filtration Units 
 
Fabricated Equipment 
 
$39,600 
 8 Sterile Filtration Units 
 
Fabricated Equipment 
 
$79,200 
 8 Chromatography Columns 
  
Fabricated Equipment 
  
$1,460,800 
 4 Disk-Stack Centrifuges 
 
Process Machinery 
 
$3,248,000 
 4 Viral Inactivation Tanks 
 
Process Machinery 
 
$74,880 
 16 Holding Tanks 
 
Process Machinery 
 
$111,954 
 8 Resin Tanks 
 
Process Machinery 
 
$55,977 
 4 Tangential Flow Filtration Units 
 
Process Machinery 
 
$1,856,000 
 27 Pumps 
  
Process Machinery 
 
$413,424 
 9 Heat Exchangers 
 
Process Machinery 
 
$3,229,942 
 4 Incubators 
  
Storage 
  
$25,752 
 8 Storage Tanks 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (200 L) 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (500 L) 
 
Storage 
  
$97,011 
 Biosafety Cabinet 
 
Storage 
  
$11,000 
 18 Bag Holders 
  
Storage 
  
$19,800 
 Filter Integrity Tester 
 
Spares 
  
$4,500 
 Bioinactivation System 
 
Spares 
  
$35,000 
 Tube Fusers 
  
Spares 
  
$15,300 
 Tube Sealers 
 
Spares 
  
$10,200 
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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 
 
Variable Cost Summary           
  
Variable Costs at 100% Capacity: 
        
                    
  
General Expenses 
           
                    
     
Selling  /  Transfer  
Expenses:  
     
  $21,001,145    
     
Direct  Research:  
     
  $70,003,816    
     
Allocated  Research:  
     
  $269,514,691    
     
Administrative  Expense:  
     
  $14,000,763    
     
Management  Incentive  Compensation:  
  
  $8,750,477    
                    
  
Total General Expenses 
        
  $383,270,892    
                    
  
Raw Materials $0.008884  
per  doses  of  API  for  Influenza  
Vaccine   $765,658    
                  
  
Byproducts 
  
$0.000000  
per  doses  of  API  for  Influenza  
Vaccine   $0    
                  
  
Utilities 
  
$0.010292  
per  doses  of  API  for  Influenza  
Vaccine   $886,971    
                    
  
Total Variable Costs 
        
 $384,923,520  	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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 	  
Fixed Cost Summary           
                    
                    
  
Operations 
              
                    
     
Direct  Wages  and  Benefits  
     
  $364,000    
     
Direct  Salaries  and  
Benefits  
     
  $54,600    
     
Operating  Supplies  and  Services  
  
  $21,840    
     
Technical  Assistance  to  Manufacturing  
  
  $-­        
     
Control  Laboratory  
     
  $-­        
                    
     
Total Operations 
     
 $440,440  
                    
  
Maintenance 
           
     
Wages  and  Benefits  
     
  $1,522,744    
     
Salaries  and  Benefits  
     
  $380,686    
     
Materials  and  Services  
     
  $1,522,744    
     
Maintenance  Overhead  
     
  $76,137    
                    
     
Total Maintenance 
     
 $3,502,310  
                    
  
Operating Overhead 
           
                    
     
General  Plant  Overhead:  
     
  $164,864    
     
Mechanical  Department  Services:  
  
  $55,729    
     
Employee  Relations  Department:  
  
  $137,000    
     
Business  Services:  
     
  $171,830    
                    
     
Total Operating 
Overhead 
     
 $529,423  
                    
  
Property Taxes and Insurance 
        
                  
     
Property  Taxes  and  Insurance:  
  
  $676,775    
                    
  
Other Annual Expenses 
           
                    
     
Rental  Fees  (Office  and  Laboratory  
Space):  
  
  $-­        
     
Licensing  Fees:  
     
  $-­        
     
Miscellaneous:  
     
  $-­        
                    
     
Total Other Annual Expenses 
  
 $-­    
                    
  
Total Fixed Costs 
        
 $5,148,948  
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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 	  
Investment Summary             
                       Bare Module Costs 
                 
 
Fabricated Equipment 
        
  $24,518,054    
  
  
Process Machinery 
        
  $8,990,177    
  
  
Spares 
           
  $65,000    
  
  
Storage 
           
  $265,517    
  
  
Other Equipment 
        
  $-­        
  
  
Catalysts 
           
  $-­        
  
  
Computers, Software, Etc. 
        
  $-­        
  
                       
  
Total Bare Module Costs: 
           
 $33,838,748  
                       Direct Permanent Investment 
              
                       
  
Cost of Site Preparations: 
        
  $-­        
  
  
Cost of Service Facilities: 
        
  $-­        
  
  
Allocated Costs for utility plants and related facilities: 
  
  $-­        
  
                      
  
Direct Permanent Investment 
        
 $33,838,748  
                      
                       Total Depreciable Capital 
                 
                       
  
Cost of Contingencies & Contractor Fees 
  
  $-­        
  
                       
                       
  
Total Depreciable Capital 
           
 $33,838,748  
                       Total Permanent Investment 
              
                       
  
Cost of Land: 
        
  $-­        
  
  
Cost of Royalties: 
        
  $-­        
  
  
Cost of Plant Start-­Up: 
        
  $-­        
  
                       
  
Total Permanent Investment -­ Unadjusted 
     
  $33,838,748    
  
Site Factor 
              
1.10  
  
Total Permanent Investment 
        
 $37,222,623  	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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 	  
Profitability  Measures                      
                      The Internal Rate of Return (IRR) for this project is 
     
Negative  IRR  
                  
 
The Net Present Value (NPV) of this project in 2013 is 
  
  $1,168,887,900    
                      
                      ROI Analysis (Third Production Year) 
        
                      
  
Annual Sales 
 
 630,034,343  
          
  
Annual Costs 
 
 (351,580,117) 
          
  
Depreciation 
 
 (2,977,810) 
          
  
Income Tax 
 
 (12,396,439) 
          
  
Net Earnings 
 
 263,079,977  
          
  
Total Capital Investment  137,831,826  
        
  
ROI 
 
190.87% 
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11.4.2 Profitability Analysis for 36% Efficiency for Downstream 	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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 
 
General Information               
  
Process  Title:   Manufacturing of Insect Cell Culture VLP-­based Influenza Vaccine 
     
  
Product:   API for Influenza Vaccine 
              
  
Plant  Site  Location:   Research Triangle Park, NC 
              
  
Site  Factor:   1.10 
                 
  
Operating  Hours  per  Year:   4383 
                 
  
Operating  Days  Per  Year:   183 
                 
  
Operating  Factor:   0.5003 
                 
                          
                          Product Information               
This  Process  will  Yield  
                    
     
27,310 doses  of  API  for  Influenza  Vaccine  per  hour  
        
     
655,441 doses  of  API  for  Influenza  Vaccine  per  day  
        
     
119,700,000 doses  of  API  for  Influenza  Vaccine  per  year  
        
                        
  
Price   $8.12  /doses 
            
                          Chronology                 
  
Distribution of Production  Depreciation 
 
Product Price 
Year Action Permanent Investment Capacity 7  year  MACRS  
     2013   Production   100%   81.0%   14.29%  
  
$8.12    
  2014   Production   0%   90.0%   24.49%  
  
$8.12    
  2015   Production   0%   90.0%   17.49%  
  
$8.12    
  2016   Production   0%   90.0%   12.49%  
  
$8.12    
  2017   Production  
  
90.0%   8.93%  
  
$8.12    
  2018   Production  
  
90.0%   8.92%  
  
$8.12    
  2019   Production  
  
90.0%   8.93%  
  
$8.12    
  2020   Production  
  
90.0%   4.46%  
  
$8.12    
  2021   Production  
  
90.0%  
     
$8.12    
  2022   Production  
  
90.0%  
     
$8.12    
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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 	  
Equipment Costs 
      
        Equipment Descr iption 
    
Bare Module Cost 
        Test Tubes 
  
Fabricated Equipment 
 
$255 
 1 Shaker Flasks (250 mL) 
 
Fabricated Equipment 
 
$596 
 6 Shaker Flasks (2 L) 
 
Fabricated Equipment 
 
$5,106 
 6 Shaker Flasks (3 L) 
 
Fabricated Equipment 
 
$1,969 
 4 Disposable Bioreactors (50 L) 
 
Fabricated Equipment 
 
$3,552,956 
 4 Disposable Bioreactors (500 L) 
 
Fabricated Equipment 
 
$3,889,051 
 4 Disposable Bioreactors (2000 L) 
 
Fabricated Equipment 
 
$15,482,621 
 4 Reactor Totes (50 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (500 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (2000 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Depth Filtration Units 
 
Fabricated Equipment 
 
$39,600 
 8 Sterile Filtration Units 
 
Fabricated Equipment 
 
$79,200 
 8 Chromatography Columns 
  
Fabricated Equipment 
  
$1,460,800 
 4 Disk-Stack Centrifuges 
 
Process Machinery 
 
$3,248,000 
 4 Viral Inactivation Tanks 
 
Process Machinery 
 
$74,880 
 16 Holding Tanks 
 
Process Machinery 
 
$111,954 
 8 Resin Tanks 
 
Process Machinery 
 
$55,977 
 4 Tangential Flow Filtration Units 
 
Process Machinery 
 
$1,856,000 
 27 Pumps 
  
Process Machinery 
 
$413,424 
 9 Heat Exchangers 
 
Process Machinery 
 
$3,229,942 
 4 Incubators 
  
Storage 
  
$25,752 
 8 Storage Tanks 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (200 L) 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (500 L) 
 
Storage 
  
$97,011 
 Biosafety Cabinet 
 
Storage 
  
$11,000 
 18 Bag Holders 
  
Storage 
  
$19,800 
 Filter Integrity Tester 
 
Spares 
  
$4,500 
 Bioinactivation System 
 
Spares 
  
$35,000 
 Tube Fusers 
  
Spares 
  
$15,300 
 Tube Sealers 
 
Spares 
  
$10,200 
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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 
 
Variable Cost Summary           
  
Variable Costs at 100% Capacity: 
        
                    
  
General Expenses 
           
                    
     
Selling  /  Transfer  
Expenses:  
     
  $29,168,257    
     
Direct  Research:  
     
  $97,227,522    
     
Allocated  Research:  
     
  $374,325,960    
     
Administrative  Expense:  
     
  $19,445,504    
     
Management  Incentive  Compensation:  
  
  $12,153,440    
                    
  
Total General Expenses 
        
  $532,320,683    
                    
  
Raw Materials $0.006396  
per  doses  of  API  for  Influenza  
Vaccine   $765,658    
                  
  
Byproducts 
  
$0.000000  
per  doses  of  API  for  Influenza  
Vaccine   $0    
                  
  
Utilities 
  
$0.007410  
per  doses  of  API  for  Influenza  
Vaccine   $886,971    
                    
  
Total Variable Costs 
        
 $533,973,312  
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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 
 
 
Fixed Cost Summary           
                    
                    
  
Operations 
              
                    
     
Direct  Wages  and  Benefits  
     
  $364,000    
     
Direct  Salaries  and  
Benefits  
     
  $54,600    
     
Operating  Supplies  and  Services  
  
  $21,840    
     
Technical  Assistance  to  Manufacturing  
  
  $-­        
     
Control  Laboratory  
     
  $-­        
                    
     
Total Operations 
     
 $440,440  
                    
  
Maintenance 
           
     
Wages  and  Benefits  
     
  $1,522,744    
     
Salaries  and  Benefits  
     
  $380,686    
     
Materials  and  Services  
     
  $1,522,744    
     
Maintenance  Overhead  
     
  $76,137    
                    
     
Total Maintenance 
     
 $3,502,310  
                    
  
Operating Overhead 
           
                    
     
General  Plant  Overhead:  
     
  $164,864    
     
Mechanical  Department  Services:  
  
  $55,729    
     
Employee  Relations  Department:  
  
  $137,000    
     
Business  Services:  
     
  $171,830    
                    
     
Total Operating 
Overhead 
     
 $529,423  
                    
  
Property Taxes and Insurance 
        
                  
     
Property  Taxes  and  Insurance:  
  
  $676,775    
                    
  
Other Annual Expenses 
           
                    
     
Rental  Fees  (Office  and  Laboratory  
Space):  
  
  $-­        
     
Licensing  Fees:  
     
  $-­        
     
Miscellaneous:  
     
  $-­        
                    
     
Total Other Annual Expenses 
  
 $-­    
                    
  
Total Fixed Costs 
        
 $5,148,948  	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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 	  
Investment Summary             
                       Bare Module Costs 
                 
 
Fabricated Equipment 
        
  $24,518,054    
  
  
Process Machinery 
        
  $8,990,177    
  
  
Spares 
           
  $65,000    
  
  
Storage 
           
  $265,517    
  
  
Other Equipment 
        
  $-­        
  
  
Catalysts 
           
  $-­        
  
  
Computers, Software, Etc. 
        
  $-­        
  
                       
  
Total Bare Module Costs: 
           
 $33,838,748  
                       Direct Permanent Investment 
              
                       
  
Cost of Site Preparations: 
        
  $-­        
  
  
Cost of Service Facilities: 
        
  $-­        
  
  
Allocated Costs for utility plants and related facilities: 
  
  $-­        
  
                      
  
Direct Permanent Investment 
        
 $33,838,748  
                      
                       Total Depreciable Capital 
                 
                       
  
Cost of Contingencies & Contractor Fees 
  
  $-­        
  
                       
                       
  
Total Depreciable Capital 
           
 $33,838,748  
                       Total Permanent Investment 
              
                       
  
Cost of Land: 
        
  $-­        
  
  
Cost of Royalties: 
        
  $-­        
  
  
Cost of Plant Start-­Up: 
        
  $-­        
  
                       
  
Total Permanent Investment -­ Unadjusted 
     
  $33,838,748    
  
Site Factor 
              
1.10  
  
Total Permanent Investment 
        
 $37,222,623  	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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 	  
Profitability  Measures                      
                      The Internal Rate of Return (IRR) for this project is 
     
Negative  IRR  
                  
 
The Net Present Value (NPV) of this project in 2013 is 
  
  $1,649,826,200    
                      
                      ROI Analysis (Third Production Year) 
        
                      
  
Annual Sales 
 
 875,047,698  
          
  
Annual Costs 
 
 (485,724,929) 
          
  
Depreciation 
 
 (2,977,810) 
          
  
Income Tax 
 
 (17,385,523) 
          
  
Net Earnings 
 
 368,959,436  
          
  
Total Capital Investment  176,765,455  
        
  
ROI 
 
208.73% 
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11.4.3 Profitability Analysis for 50% Efficiency for Downstream 	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11.4.4	  Profitability Analysis for Pandemic	  Case 	  
	   	  
General  Information                                     
  
Process  Title:   Manufacturing  of  Insect  Cell  Culture  VLP-­based  Influenza  Vaccine  
     
  
Product:   API  for  Influenza  Vaccine  
              
  
Plant  Site  Location:   Research  Triangle  Park,  NC  
              
  
Site  Factor:   1.10  
                 
  
Operating  Hours  per  Year:   4383  
                 
  
Operating  Days  Per  Year:   183  
                 
  
Operating  Factor:   0.5003  
                 
                          
                          Product  Information                                     
This  Process  will  Yield  
                    
     
78,653   doses  of  API  for  Influenza  Vaccine  per  hour  
        
     
1,887,671   doses  of  API  for  Influenza  Vaccine  per  day  
        
     
344,736,000   doses  of  API  for  Influenza  Vaccine  per  year  
        
                          
  
Price   $5.44     /doses  
              
                          Chronology                                          
     
Distribution  of   Production     Depreciation  
  
Product  Price  
Year   Action   Permanent  Investment   Capacity   7  year  MACRS  
     2013   Production   100%   81.0%   14.29%  
  
$8.12    
  2014   Production   0%   90.0%   24.49%  
  
$8.12    
  2015   Production   0%   90.0%   17.49%  
  
$8.12    
  2016   Production   0%   90.0%   12.49%  
  
$8.12    
  2017   Production  
  
90.0%   8.93%  
  
$8.12    
  2018   Production  
  
90.0%   8.92%  
  
$8.12    
  2019   Production  
  
90.0%   8.93%  
  
$8.12    
  2020   Production  
  
90.0%   4.46%  
  
$8.12    
  2021   Production  
  
90.0%  
     
$8.12    
  2022   Production  
  
90.0%  
     
$8.12    
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11.4.4 Profitability Analysis for Pandemic Case 
	  
Equipment Costs 
      
        Equipment Descr iption 
    
Bare Module Cost 
        Test Tubes 
  
Fabricated Equipment 
 
$255 
 1 Shaker Flasks (250 mL) 
 
Fabricated Equipment 
 
$596 
 6 Shaker Flasks (2 L) 
 
Fabricated Equipment 
 
$5,106 
 6 Shaker Flasks (3 L) 
 
Fabricated Equipment 
 
$1,969 
 4 Disposable Bioreactors (50 L) 
 
Fabricated Equipment 
 
$3,552,956 
 4 Disposable Bioreactors (500 L) 
 
Fabricated Equipment 
 
$3,889,051 
 4 Disposable Bioreactors (2000 L) 
 
Fabricated Equipment 
 
$15,482,621 
 4 Reactor Totes (50 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (500 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Reactor Totes (2000 L) 
 
Fabricated Equipment 
 
$4,400 
 4 Depth Filtration Units 
 
Fabricated Equipment 
 
$39,600 
 8 Sterile Filtration Units 
 
Fabricated Equipment 
 
$79,200 
 8 Chromatography Columns 
  
Fabricated Equipment 
  
$1,460,800 
 4 Disk-Stack Centrifuges 
 
Process Machinery 
 
$3,248,000 
 4 Viral Inactivation Tanks 
 
Process Machinery 
 
$74,880 
 16 Holding Tanks 
 
Process Machinery 
 
$111,954 
 8 Resin Tanks 
 
Process Machinery 
 
$55,977 
 4 Tangential Flow Filtration Units 
 
Process Machinery 
 
$1,856,000 
 27 Pumps 
  
Process Machinery 
 
$413,424 
 9 Heat Exchangers 
 
Process Machinery 
 
$3,229,942 
 4 Incubators 
  
Storage 
  
$25,752 
 8 Storage Tanks 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (200 L) 
 
Storage 
  
$55,977 
 8 Media Storage Tanks (500 L) 
 
Storage 
  
$97,011 
 Biosafety Cabinet 
 
Storage 
  
$11,000 
 18 Bag Holders 
  
Storage 
  
$19,800 
 Filter Integrity Tester 
 
Spares 
  
$4,500 
 Bioinactivation System 
 
Spares 
  
$35,000 
 Tube Fusers 
  
Spares 
  
$15,300 
 Tube Sealers 
 
Spares 
  
$10,200 
 
        	   	  
	   157	  
11.4.4	  Profitability Analysis for Pandemic	  Case 	  	   	  
Variable  Cost  Summary                           
  
Variable  Costs  at  100%  Capacity:  
        
                    
  
General  Expenses  
           
                    
     
Selling  /  Transfer  
Expenses:  
     
  $56,260,915    
     
Direct  Research:  
     
  $187,536,384    
     
Allocated  Research:  
     
  $722,015,078    
     
Administrative  Expense:  
     
  $37,507,277    
     
Management  Incentive  Compensation:  
  
  $23,442,048    
                    
  
Total  General  Expenses  
        
  $1,026,761,702    
                    
  
Raw  Materials   $0.002221  
per  doses  of  API  for  Influenza  
Vaccine   $765,658    
                    
  
Byproducts  
  
$0.000000  
per  doses  of  API  for  Influenza  
Vaccine   $0    
                    
  
Utilities  
  
$0.002573  
per  doses  of  API  for  Influenza  
Vaccine   $886,971    
                    
  
Total  Variable  Costs  
        
  $1,028,414,331    
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11.4.4	  Profitability Analysis for Pandemic	  Case 
	  	   	  
Fixed  Cost  Summary                           
                    
                    
  
Operations  
              
                    
     
Direct  Wages  and  Benefits  
     
  $364,000    
     
Direct  Salaries  and  
Benefits  
     
  $54,600    
     
Operating  Supplies  and  Services  
  
  $21,840    
     
Technical  Assistance  to  Manufacturing  
  
  $-­        
     
Control  Laboratory  
     
  $-­        
                    
     
Total  Operations  
     
  $440,440    
                    
  
Maintenance  
           
     
Wages  and  Benefits  
     
  $1,522,744    
     
Salaries  and  Benefits  
     
  $380,686    
     
Materials  and  Services  
     
  $1,522,744    
     
Maintenance  Overhead  
     
  $76,137    
                    
     
Total  Maintenance  
     
  $3,502,310    
                    
  
Operating  Overhead  
           
                    
     
General  Plant  Overhead:  
     
  $164,864    
     
Mechanical  Department  Services:  
  
  $55,729    
     
Employee  Relations  Department:  
  
  $137,000    
     
Business  Services:  
     
  $171,830    
                    
     
Total  Operating  Overhead  
     
  $529,423    
                    
  
Property  Taxes  and  Insurance  
        
                    
     
Property  Taxes  and  Insurance:  
  
  $676,775    
                    
  
Other  Annual  Expenses  
           
                    
     
Rental  Fees  (Office  and  Laboratory  
Space):  
  
  $-­        
     
Licensing  Fees:  
     
  $-­        
     
Miscellaneous:  
     
  $-­        
                    
     
Total  Other  Annual  Expenses  
  
  $-­        
                    
  
Total  Fixed  Costs  
        
  $5,148,948    
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11.4.4	  Profitability Analysis for Pandemic	  Case 	  
	   	  
Investment  Summary                                
                       Bare  Module  Costs  
                 
  
Fabricated  Equipment  
        
  $24,518,054    
  
  
Process  Machinery  
        
  $8,990,177    
  
  
Spares  
           
  $65,000    
  
  
Storage  
           
  $265,517    
  
  
Other  Equipment  
        
  $-­        
  
  
Catalysts  
           
  $-­        
  
  
Computers,  Software,  Etc.  
        
  $-­        
  
                       
  
Total  Bare  Module  Costs:  
           
  $33,838,748    
                       Direct  Permanent  Investment  
              
                       
  
Cost  of  Site  Preparations:  
        
  $-­        
  
  
Cost  of  Service  Facilities:  
        
  $-­        
  
  
Allocated  Costs  for  utility  plants  and  related  facilities:  
  
  $-­        
  
                       
  
Direct  Permanent  Investment  
        
  $33,838,748    
                       
                       Total  Depreciable  Capital  
                 
                       
  
Cost  of  Contingencies  &  Contractor  Fees  
  
  $-­        
  
                       
                       
  
Total  Depreciable  Capital  
           
  $33,838,748    
                       Total  Permanent  Investment  
              
                       
  
Cost  of  Land:  
        
  $-­        
  
  
Cost  of  Royalties:  
        
  $-­        
  
  
Cost  of  Plant  Start-­Up:  
        
  $-­        
  
                       
  
Total  Permanent  Investment  -­  Unadjusted  
     
  $33,838,748    
  
Site  Factor  
              
1.10  
  
Total  Permanent  Investment  
        
  $37,222,623    
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11.4.4	  Profitability Analysis for Pandemic	  Case 	  
	   	  
Profitability  Measures                      
                     	  The  Internal  Rate  of  Return  (IRR)  for  this  project  is  
     
Negative  IRR  
                    
	  
The  Net  Present  Value  (NPV)  of  this  project  in  2013  is  
  
  $7,038,423,300    
                     	  
                     	  ROI  Analysis  (Third  Production  Year)  
        
                     	  
  
Annual  Sales  
  
  2,520,137,370    
         	  
  
Annual  Costs  
  
  (930,721,846)  
         	  
  
Depreciation  
  
  (2,977,810)  
         	  
  
Income  Tax  
  
  (71,389,697)  
         	  
  
Net  Earnings  
  
  1,515,048,017    
         	  
  
Total  Capital  Investment     374,328,533    
        
  
ROI  
  
404.74%  
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11.4.4	  Profitability Analysis for Pandemic	  Case 	  
  
	   162	  
11.5 Sensitivity Analysis 
 11.5.1 E fficacy and Dosing 
Presently, live attenuated influenza virus vaccines are considered to be both safe 
and effective in preventing acute illness and serious complications (Nichol). The 
effectiveness of the vaccine changes seasonally as the virus evolves, so the WHO must 
identify strains that will be a threat each influenza season for vaccine manufacturers to 
target. This annual process requires that the vaccine be reformulated. Influenza vaccines 
were first manufactured in 1943, and use among high-risk patients has been 
recommended since 1963.  At that point in history, organizations began to collect data to 
determine vaccine efficacy.  
A common method for measuring the efficacy of a vaccine in preventing the virus 
from infecting the patient is Vaccine Effectiveness (VE). The Center for Disease Control 
????????????????????????????????????????????????????????????????????????????????
[influenza] vaccine for preventing laboratory-confirmed [influenza] virus infection 
????????????????? 
The CDC reported the 2012-2013 VE to be 62% on January 11, 2013 
?????????????). This was reported with a 95% confidence interval of 51% to 71% for the 
VE. A 95% confidence interval sets the range of VE for which there is a 95% chance of 
the VE being between for a larger data sample. On February 21, 2013, the CDC reported 
the VE for the influenza vaccine to be 56% with a 95% confidence interval of 47% to 
63% ???????????????????????????????????????????). Note that this data was collected 
based solely on 2697 United States ????????????????????????????????????????.  This level of 
efficacy for the seasonal influenza vaccine is considered low compared to that of 
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vaccines for Rubella and tetanus, which have efficacies larger than 95% and 90%, 
respectively (Palache). 
The magnitude of these values seems to be consistent over time. Data collected by 
the NIH shows that for 2011, aggregated vaccine efficacy for patients 18 to 65 was 59% 
(Hombach). A similar study conducted in 2003 by the NIH revealed a vaccine efficacy of 
68% with a 95% confidence interval of 49% to 79% for the 2003 seasonal influenza 
vaccine for healthy patients age 18 to 65 (Hombach). Despite the slight change the 
seasonal influenza vaccine, the 95% interval for the vaccine efficacy is consistent year to 
year. 
There is a variance in efficacy between the Type A and Type B influenza strains. 
The influenza virus is classified into three types: A, B, and C. Types A and B are 
responsible for epidemic respiratory illness, which is why they are primarily included in 
the seasonal influenza vaccine. A recent study shows that the human body generally 
elicits a larger and more effective response to Type B vaccinations. A study released 
February 18, 2003 proved that the influenza vaccine for Type B had a VE of 78% in 
European patients (Golec). The vaccine administered was trivalent, and the VE for both 
Type A strains were only 62% and 42% for the same patients (Golec). This was 
consistent with data collected by the CDC for United States Patients. The data collected 
by the CDC showed a vaccine efficacy of 70% for Type B and 55% for Type A 
?????????????). Both studies showed an overall VE of 62% for the 2013 influenza 
vaccine (Golec). 
For the influenza vaccine, VE tends to vary depending on the age of the patient 
group. Data for childhood vaccinations for the influenza virus will regularly record a 90% 
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vaccine efficacy in the United States (Hombach). Global data disagrees; one study 
conducted on 247517 patients aged 18 years and younger showed that the vaccine 
prevented 61% of clinical cases of influenza (Hickling). This is excluding data from the 
Russia. When data from Russia was included, the vaccine effectively prevented 36% of 
clinical cases of influenza (Hickling). The discrepancy is most likely due to harsher 
winter conditions as well as a lower standard of living in the region for which the data 
was excluded. The data for children shows a large discrepancy from data for the age 65 
and older group. The data collected by the CDC for the patients age 65 and up group 
showed a VE of 9%, far below the 51% to 71% interval presented for the 2012-2013 
influenza vaccine for all age groups aggregated ??????????????? 
Current egg-based vaccine production methods for preventing influenza consist 
primarily of monomeric hemagglutinin (HA) antigen.  There has been no industry or 
regulatory standard for neuraminidase (NA) antigen in the vaccines. Live viruses contain 
both HA and NA antigens arranged in a particular pattern giving them biological activity. 
This may explains why vaccines containing monomeric units of mostly the HA antigen 
does not elicit a broad level immune response necessary to fully protect the larger 
population from the influenza virus (Palkonyay).  
Virus-like Particles (VLPs) are a noninfectious and non-replicating method of 
presenting the proper influenza antigens to B and T cells to elicit an immune response. 
Since VLPs are self-assembling, they correctly fold and display the trimeric HA spikes of 
????????????????????????????????? ?). These self-assembling particles are multivalent 
because they display multiple antigens as well, which innately gives them a larger 
immunogenicity than monomeric antigens present in egg-based influenza vaccines.  
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Joel R Haynes, Senior Director of Vaccine Development at TakedaTM, believes 
that producing VLPs in insect cells will lead to enhanced immunogenicity. This is due to 
the insect-cell glycosylation patterns and the possibility that the VLPs produced in insect 
cells also contain a finite quantity of insect cell-derived lipid raft-associated proteins. 
Patients immune systems will recognize these as foreign bodies and potentially enhance 
the immunogenicity compared to the live or attenuated virus vaccines (Bodimeade). 
Recent studies have shown that VLPs have a higher immunogenicity compared to 
live or attenuated viruses, as well as recombinant hemagglutinin. One study conducted by 
Rick A. Bright et al. showed that VLPs produced in insect cells for hemagglutinin (HA), 
neuraminidase (NA), and influenza core matrix (M1) proteins all elicited an immune 
response that protected mice from a deadly dose of the H5N1 strain of the avian influenza 
virus. Both intramuscular (IM) injection and intranasal (IN) injection elicited the proper 
response to protect the mice from the deadly dose of H5N1. Bright et al. used a 
hemagglutinin inhibition (HAI) assay to determine the functionality of the antigens 
produced in the subject mice. An HAI titer greater than 40 is usually considered to be 
50% effective in preventing the seasonal influenza virus strain of interest. Both IM and 
IN injected VLPs in mice had measured HAI titers greater than 40; similar results were 
obtained in ferrets (Wood).  VLP vaccines present a promising and viable future in 
protecting against the avian influenza strain based on the studies conducted by Bright et 
al. (Bright 2007) 
The WHO has collected data from many clinical trials over the past 20 years to 
????????????????????????????????????????????????????????????????????????????????????
accepted that one dose of vaccine containing 15????????????????????????????????????????
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will stimulate hemagglutination-inibition antibody levels consistent with immunity in 
most primed individuals. (Suresh????????????????????????????????????????????????????
years to 65 years old is 0.5mL (Angelmar), therefore a trivalent vaccine must contain 
45???????????????????????????????90??????????????????????????????????????????????????
age must receive a more concentrated dose in order to overcome lower efficacy of the 
vaccine of such patients.  Typically, children 6 months to 35 months of age will receive 
an influenza vaccine dose of 0.25mL (Angelmar). Patients 65 years and older qualify for 
?????????????????????????????-Dose®, which contains four times the amount of antigen 
as other vaccines (Angelmar). 
Due to the larger immune response typically affiliated with VLPs, our group has 
chosen a dosage of 5 micrograms of each strain of influenza antigen per dose. For our 
trivalent seasonal influenza vaccine, the total dose will be 15 micrograms. The 
formulation group will concentrate the protein so that the suspension concentration is 5 
micrograms of each of the three identified vaccine strain antigens in 0.5mL. Since VLPs 
have been shown to elicit up to 5-fold larger immune response compared to other 
vaccination methods (Kushnir), a 3-fold reduction in dose compared to current 
vaccination dosing should elicit a broad immune response capable of protecting the 
patient from influenza transmission. Our clinical trials group will confirm the 
immunogenicity of a dose on an annual basis and assess the need to increase or decrease 
the dose accordingly. 
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11.5.2 G ross Revenue 
A sensitivity analysis was conducted on production capability to account for 
unpredictable events, market trends, market demand, production level, and other factors 
capable of affecting the number of doses produced annually. Unpredictable events can be 
beneficial or detrimental to gross revenue.  
The number of doses produced annually can increase if the amount of protein 
required to elicit an immune response decreases. Due to antigenic drift, the strain of 
influenza targeted by an influenza vaccine changes each season. Some strains are more 
immunogenic to the general population, in which case, it may be plausible for a vaccine 
to contain less protein. On the contrary, some strains may elicit a smaller than usual 
immune response, in which case, the protein per dose must be increased. This process is 
uncommon with the influenza vaccine, and generally the only variable that affects dosing 
is addition of adjuvants in order to increase the immunogenicity of the VLP influenza 
vaccine. 
The number of batches produced annually will also affect the gross revenue of the 
company. If the company is able to increase the number of batches produced in a 6 month 
time period, protein production and therefore the number of doses produced will increase. 
If a batch becomes contaminated, protein is lost; this decreases the number of doses 
provided to the market, decreasing gross revenue. If a batch is lost due to contamination, 
production may need to be extended to fulfill market share. Our company expects to 
produce 6 batches of each strain, allowing us to produce approximately 86,000,000 doses 
of trivalent seasonal influenza vaccine. A Gantt chart is included in section 10.1 to show 
the time period needed to produce 6 batches.  
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Downstream processing of the VLPs will heavily affect the number of doses sent 
to market. If the equipment is not running properly, the efficiency of the process 
decreases, and protein is removed with adventitious materials. Downstream processing 
equipment must be properly maintained, calibrated, and tested regularly to ensure 
maximum unit efficiency. The sensitivity of the gross revenue generated by this process 
is primarily a function of the number of doses produced annually, which is highly 
dependent upon the downstream process efficiency. Thus, efficiency of VLP retention 
throughout the purification process is the variable having the greatest effect on gross 
revenue.	  
If a pandemic occurs, the government may approve production of a monovalent 
influenza vaccine. The WHO is responsible for determining the strain of relevance for 
each year. Our production facility has 4 operating lines, and, typically, three are used for 
production of a seasonal trivalent vaccine. All 4 lines can be converted to pandemic 
production lines for production of monovalent vaccines when the WHO declares a 
pandemic. During a pandemic our facility is capable of accommodating up to four-fold 
greater vaccine production than the traditional annual trivalent VLP vaccine. Our plant 
has a greater capacity for transfer to pandemic production mode compared to traditional 
egg-based plants, since recombinant technology including BEVS produces a much 
smaller lag time associated with growth and upstream production of the virus than the lag 
time associated with egg-based production. This change over can occur at the beginning 
of the next batch cycle, contingent upon R&D providing baculovirus to properly infect 4 
production lines with the single pandemic strain identified by the WHO. For a pandemic 
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situation, it is expected that the selling price of a vaccine will match the buying price of 
the government during non-pandemic conditions. 
Our design process is capable of maximally producing 0.1995 kg of VLP, given a 
95% efficiency of the upstream process. In industry, the lowest recovery of VLP is 
typically occurs downstream in the purification process. For the purposes of our process, 
we have assumed 95% recovery from fermentation in the upstream process and 36% 
recovery from the purification process downstream. Producing 6 batches of each strain 
annually, we are able to produce 86,184,000 doses of trivalent influenza vaccine 
containing 5 micrograms of each strain. Of the vaccines produced, 77.8% will be sold to 
the private sector at $8.50 (USD) per dose. The remaining 22.2% of the doses will be 
sold to government organizations at $6.80 (USD) per dose. The weighted average price 
per dose sold is $8.12 (USD). These calculations are based off of data collected by the 
Center for Disease Control (CDC) in 2007 and 2008 (HIDA Market Brief). The 
profitability analysis for this scenario is found in section 11.4. The calculated Net Present 
Value is found; to account for potential inefficiency on the downstream side, we 
conducted a sensitivity analysis for a range of 20% to 50% efficiency on the downstream 
side. This gives a production range of 47,880,000 to 119,700,000	  doses of trivalent 5-
microgram influenza vaccine. The net earnings for 86,184,000 is predicted to be 
$263,079,977 (USD). The spread sheets demonstrating the sensitivity analysis are 
contained in ?????????????????????????????????????????????????????????????????? ????
information. 
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F igure 11.1. This shows the percent of doses supplied to private and public sector. It was used to calculate the 
weighted value of a dose of influenza vaccine based on the markets to which we supply. We have chosen to supply 
77.8% of our doses to the private sector and 22.2% of doses to the government sector. (HIDA Market Brief) 
During a pandemic, the facility will run 4 lines in parallel, each producing 6 
batches in total. Each line will produce the same strain, allowing a maximum production 
of 334,736,000 doses of a monovalent 5-microgram influenza vaccine. During pandemic 
production, it is more likely that the doses will be sold at a government sector price, and 
even more likely at a reduced government sector price. Our group estimates that the 
purchasing price per dose will decrease 20% from $6.80 (USD) to $5.44 (USD) in the 
government sector during a pandemic. This would generate $1,515,048,017 (USD) in net 
earnings. A more dynamic range of purchasing prices at which the vaccines may be sold 
can be found in Appendix B section 11.4. 
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12.0 Conclusions and Recommendations 
 This proposal has explored in depth the feasibility of starting up a flexible facility 
to produce an influenza vaccine from SF2 insect cells.  This vaccine company aims to 
remain a large competitor in the influenza vaccine industry for the United States and 
European markets by supplying vaccines to fulfill regular demand, as well as having the 
capability of scaling up during a pandemic.  With the use of a non-egg based platform, 
this new vaccine avoids potential limitations from egg allergies or shortages.  In addition, 
the production of VLPs for use in the vaccine increases the safety and consistency of the 
product.  In regards to the manufacturing facility, the selection of single-use disposable 
equipment enables increased efficiency of product turnover and flexibility to produce a 
separate product during the off-season for influenza. 
 By analyzing the current influenza vaccine market, it was established that the VLP 
can be produced at approximately $0.01 per dose, which will be sold for an average of 
$8.12 per dose.  It should be noted that this cost does not include formulation and 
packaging, only manufacturing of the VLP.  Based on the economics of facility and 
production costs in conjunction with projected revenues, it was found that the project 
would be feasible with a return on investment (ROI) of 190.87% (See Section 11.4).  As 
a result, we recommend this project as a profitable endeavor for the company due to its 
safety and efficacy. 
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Appendix A ? Calculations 
G rowth Rate 
 The doubling time of an insect cell in batch suspension culture is given by 
   ??? ?
???
??
   (A.1) 
???????s is the growth rate of the SF2 cells during the exponential growth phase (Figure 
A.1), defined as the increase in cell mass per unit cell mass per unit time. In our 
following calculations, we used a specific growth rate of 0.034hr-1 as a reasonable 
estimate of the average growth rate of the SF2 cells. This number was obtained from 
studies stating maximal growth rates of Sf9 cells, from which SF2 cells are derived. 
Experimentally, SF2 cells grow much more quickly than Sf9 cells, suggesting that our 
estimate, while on the upper end of Sf9 growth rates, is conservative when considering 
SF2 cells. (Cox 2009) 
G rowth Curve 
 Figure A.1 depicts a typical growth curve for cells in suspension culture, such as 
the insect-derived SF2 cell line.  
 
 
 
 
 
 
 
F igure A .1. Cell growth curve consisting of four distinct phases, lag, log, stationary, 
and death. The log of the number of cells or cell concentration(y-axis) is plotted 
against linear time (x-axis). This basic model of cell growth holds true for most cell 
types. From  Börje Lindström, LTU, Sweden 
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The typical growth curve is split into four distinct phases: lag, log, stationary, and death. 
The amount of time a suspension culture will remain in each phase is dependent upon the 
cell line. The lag phase occurs when a high density is diluted and the cells must adapt to 
the new conditions and a lowered density. This lag may have to do with soluble factors 
being less concentrated than in the high density culture or an adjustment to the change in 
medium composition. After readjusting to their new environment, the cells enter a 
logarithmic (exponential) growth phase, characterized by equation A.1, which we assume 
the cells maintain throughout our process for simplicity, a reasonable assumption at lower 
cell density and in fed-batch cultures with tight pH, osmolality, and nutrient control. 
After reaching a critical cell density where the medium is depleted of many nutrients or 
the cells are too crowded to grow, the cells enter the stationary growth phase, where the 
cell density changes very little and cells are grow slowly or senesce rather than divide. 
Finally, the nutrients are fully depleted from the medium if not replenished, and the cells 
begin to die at an exponential rate. We avoided the modeling of the lag, stationary, and 
death phases of cell proliferation, since our process aims to maintain cells in the 
exponential growth phase through specially configured medium, supplementation, and 
minimizing the time spent in each bioreactor. 
 When infected with Baculovirus, the SF2 cells will reach the death phase soon after 
induction, which is the method of VLP production and release into the medium. 
Therefore, the death phase is an important factor in designing the infection and harvest 
protocols.  
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V LP Production & Y ield 
 The VLP production rate is a function of several key factors: cell line, cell 
density, nutrient concentration, and the recombinant protein itself. The VLP works by 
combining two essential proteins that associate at the cell surface to induce each budding 
event. The HA protein will be produced predominantly, expressed under an earlier 
promoter to insure its greater production levels, and the M1 matrix protein will be 
produced in smaller amounts to coordinate budding. As discussed previously, these two 
proteins are essential and sufficient to induce budding events in SF2 cells to create 
influenza VLPs (Section 2.1) 
 Protein production in SF2 cells will be at minimum the production level attained 
in High-Five cells, from which protein production characteristics were derived and 
transferred into Sf9 cells. Thus, a conservative estimate of the specific HA production is 
on the order of 15mg/109 cells. This figure takes into account the fed-batch operating 
mode and escalated protein production levels of SF2 cells compared to Sf9 cells. The 
enhanced high density culture cell viability and, therefore, the volumetric protein 
production is dependent upon the optimization of the growth medium and feed medium 
as well as the TOI and MOI. With all of these parameters optimized in the laboratory 
research stage, we can expect a specific HA yield of 15mg/109 cells to be associated with 
VLPs (Rausch 2012). 
  A key assumption in the mass balance is that cells are on average 300pg of dry 
mass, which is a good assumption for metabolically normal eukaryotes. (Popescu 2008). 
Furthermore, it was assumed that this dry mass accounts for about 30% of the cell 
weight, certainly a liberal estimate. From these values, dry mass and wet mass were 
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calculated to determine the loss of water from the process due to centrifugation for 
biomass removal. 
 Sf2 cells consume glucose at a rate of 2.07 pmol/cell-day based on an averaged 
data set from a number of metabolic measurement literature for insect cells. This value 
led to an estimated 53mM glucose concentration required to sustain the cells for the 3.32 
days spent in each fermentation culture. This is the same concentration as in prepared 
EXCELL-405 medium from Sigma Aldrich, necessitating no additional glucose purchase 
or medium formulation. Medium utilization was estimated based on recommendations 
from Sigma Aldrich that medium should be changed every 3-4 days. This data implies a 
maximum of five days for medium use, so medium consumption was estimated to be 
about 66.4% on average. 
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Appendix- Batch T imes 
 Based on the SF2 cell growth profile, it was found that SF2 cells maintain a 
doubling time between 18-24 hours in suspension culture during log phase growth 
conditions.  Both the lag and stationary phases are neglected, and for the most 
conservative analysis, 24 hours is used as the doubling time.  
 For batch time estimations, it was desired to reach the maximum allowable cell 
density for protein production in the 2000L fermenter, which is 1.40x107 cells/mL.  To 
minimize the scale-up time, the cells will grow at a ten-fold in each reactor.  The growth 
of cells in the log phase is given by 
? ? ???
?
??  
where X is the final cell density, X0 is the initial cell density, t is the time spent in the 
??????????????d is the doubling time.  Based on this, it was found that time for each scale-
up is 3.32 days.  Total scale-up time adds up to 19.93 days, and the initial cell density 
needed in the first 100 mL shake flask is 2.80x105 cells/mL 
 
 
Reactor 
Filled 
Volume 
Size (mL) 
Cell density 
(initial) 
(cells/mL) 
# cells 
(initial) 
Cell density 
(final) 
(cells/mL) 
# cells 
(final) 
Time 
(hrs) 
Time 
(days) 
250 mL 50 2.80E+05 1.40E+07 2.80E+06 1.40E+08 79.73 3.32 
2 L 250 5.60E+05 1.40E+08 5.60E+06 1.40E+09 79.73 3.32 
3 L 1000 1.40E+06 1.40E+09 1.40E+07 1.40E+10 79.73 3.32 
50 L 10000 1.40E+06 1.40E+10 1.40E+07 1.40E+11 79.73 3.32 
500 L 100000 1.40E+06 1.40E+11 1.40E+07 1.40E+12 79.73 3.32 
2000 L 1000000 1.40E+06 1.40E+12 1.40E+07 1.40E+13 79.73 3.32 
        
     Total 478.36 19.93 
 
 To find the total batch time for the upstream process, time for vial thawing, 
harvest time after cell growth, and time to transfer the cell broth between reactors must be 
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accounted for as well. Furthermore, this table accounts for only the batch time required 
for cell growth. Additional time must be provided (an additional two days) at the end of 
each batch cycle for virus production. This additional step results in a single-batch time 
of about 22 days. Addition of virus occurs ideally one day after beginning the 2000L 
bioreactor fermentation. Upon virus addition, the medium is supplemented with 100L 
additional medium, bringing the final reaction volume to 1000L and putting the culture in 
fed-batch mode. This supplementation is associated with a dramatic increase in the 
production of recombinant baculovirus product and sustains the culture in the protein 
production phase until the harvest time (Carinhas 2010). The harvest time has similarly 
been optimized by the research team to be 72 hours post-infection. This timing insures 
that the maximum number of cells has engaged in protein production and that the VLPs 
are not subject to proteases and other enzymes that result in degradation (Bright 2007). 
 
  
	   186	  
Appendix -- Toxicology Studies 
 
 The toxicological properties of the VLPs and any process reagents must be tested 
to insure adequate product safety. Laboratory studies will determine that each batch is 
completely void of remaining baculovirus particles and unable to form plaques. The first 
few batches produced of each HA strain VLP will be subjected to animal testing to 
determine any deleterious effects of over vaccination and the specific dose response to 
influenza vaccination on a number of VLP basis. A maximum dose before toxicity will 
be determined in several species to prevent potential overdosing of humans in clinical 
trials. 
 
Proof of Concept Studies 
 Each stage of the downstream purification process will undergo rigorous 
validation to insure adequate immunogenicity and utmost safety of the VLP product and 
to insure that none of the unit operation deactivates the VLPs or renders them unable to 
vaccinate. In a laboratory scale, VLP product from fermentation will be subjected to a 
variety of chromatography buffer preparations to insure the VLPs remain intact in 
processing buffers. They will also be subjected to differing concentrations of detergents 
for baculovirus deactivation to reassess the effects on immunogenicity. Finally, the VLP 
products will be tested in animals for efficacy and undergo the appropriate clinical trials 
in order to garner FDA approval and to demonstrate the validity of VLP vaccines. 
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Vaccine Formulation 
 Upon final preparation of the VLPs in freeze-dried form, the formulation team 
will determine the dose requirements for the specific strains of any particular influenza 
season based on vaccine studies and laboratory analysis. This team will also be 
responsible to determine the minimum effective vaccine dose and the dose response 
curve for a given HA variant. This data will be cross-referenced with the WHO database 
each year to determine the required production capacity and operating conditions to best 
fulfill the demand for influenza vaccines. The vaccine formulation, mixing of strains, 
dosing, and stabilization for transport and sale are outside the scope of this manufacturing 
feasibility study. 
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Heat Exchanger Calculations 
 
 
Purchase Cost: 
  
 Water M edium     
T i 47 4     
T f 14 27  Ad   
µ 0.000404 0.000404 Pa*S ui 0.042589438 m/s 
? 1000 1000 kg/m3 Aci 0.0002935  
k 0.58 0.58 W/mK Nt 1.029741615  
Di 0.01905   L 1.5 m 
Do 0.0254   At 0.11969468  
Ai 0.08977101   Np 4.054970786 Assume F t = 1 
       
Am 0.069344305      
       
Q  0.00075 m3/s    
uo 0.05 m/s     
Nu 1.441086794      
hi 43.87560842      
Nuo 3.582558523      
ho 81.80645447      
       
Uo est 10      
Qdot 72.105      
T L M 14.42695041      
Ad 0.499793775      
       
1/U 0.047612917      
Uo 21.00270411      
       
Qwater 0.886738088 kg/s     
 53.20428531      
Cb  $22,226.87  
Fp 0.983253195 
Fm 3.514991792 
Fl 1.42 
Cp   $109,082.82  
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Purchase Cost Calculations: 
 To determine the purchase cost of the heat exchangers that will be used in this 
facility, the following equations were used: 
 
 
Where, 
  
 
and FL  (the length correction factor), was determined by extrapolating for a tube length 
of 5 ft. 
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Appendix A ? Labor Force and Structure 
  
Based on influenza vaccine production of six months, with approximately two 
????????????????????????????????????????? ??????????????????????????????????????????
production.  For each of the three influenza strains, two operators will be needed to 
operate the upstream process, and two operators will be needed to operate the 
downstream process.  Assuming the plant operates daily in three 8-hour shifts, with 
operators working 5-days a week, approximately 51 operators will need to be hired.  
Months of operation 4 
Days of operation 120 
Shifts per day 3 
Total shifts 360 
  
Upstream process operators per shift  6 
Downstream process operators per shift 6 
  
Total employees per day 36 
  
Days/shifts worked per floor engineer 85.7 
  
Total floor engineers 51 
 
 Salaries were estimated using the average salaries of manufacturing 
pharmaceutical employees in Raleigh, North Carolina.  The contract specialist manager is 
only paid for 40 hours a month, and contractors and operators are paid an hourly wage for 
160 hours a week.  For the contract specialist manager, an average of 3 hours of overtime 
per month are taken into account, and for contractors and operators, 12 hours of overtime 
per month are taken into account. 
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Appendix A ? Labor Force and Structure 
 
Position 
Number of 
Positions Salary (k) Hourly 
Hours per 
month 
Overtime 
per month Total (k) 
Quality Assurance group                
     Contract Specialists 4 53          212 
     Contract Specialist 
Manager 1   32 40 3 17.09 
Process Engineering 
group                
    Head engineer- 
supervisory physical 
scientist 1 82          82.00 
    Systems engineer 3 70          210.00 
    Floor engineers 5 55                275.00  
    Operators 51   38.46 160 12 4189.68 
 Procurement group                
    Warehouse 
engineering manager 1 37          37.00 
    Contractors 5   22 160 12 234.96 
                 
Total (annual) 71            1752.58 
                 
Total (4 months of 
operation) 71            584.19 
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Appendix A 
Cost Analysis of Single-Use Disposable Facility vs. T raditional Stainless Steel 
Facility 
 
Using a 7-year MACRS table, the cost of each facility was estimated based on 
depreciable capital, profits, and taxes.  Cost estimations were evaluated based on a 
monoclonal antibody process in a 2000L fermentation scale from 2012 (Sinclair, Monge). 
 
Doses 100 million 
Cost per dose $8.12 
Nominal Interest Rate 20.7% 
Income Tax Rate 4.5% 
Dollars to Euros Exchange Rate 1.3 
 
Single-Use Disposable Facility Cost (in millions of dollars) 
  Investment Cost:  19,670,3555 Euros           
Year 
Total Depreciable 
Capital Depreciation Profit Net Earnings 
Discounted Cash 
Flow Cash Flow (PV)  Cumulative PV 
1 25.6     0 -25.6 -21.2 -21.2 
2   3.65 812 772 776 532 511 
3   6.26 812 769 776 441 952 
4   4.47 812 771 776 365 1320 
5   3.19 812 772 776 303 1620 
6   2.28 812 772 776 251 1870 
7   2.28 812 773 776 208 2080 
8   2.28 812 773 776 172 2250 
9     812 775 775 143 2390 
10     812 775 775 118 2510 
 
Traditional Stainless Steel Facility Cost (in millions of dollars) 
  Investment Cost:  24,970,532 Euros           
Year 
Total Depreciable 
Capital Depreciation Profit Net Earnings 
Discounted Cash 
Flow Cash Flow (PV)  Cumulative PV 
1 32.46 
 
  0 -32.5 -26.9 -26.9E 
2   4.64 812 771 776 532 506 
3   7.95 812 768 776 441 947 
4   5.68 812 770 776 365 1310 
5   4.05 812 772 776 303 1620 
6   2.90 812 773 776 251 1870 
7   2.90 812 773 776 208 2070 
8   2.90 812 773 776 172 2250 
9     812 775 775 143 2390 
10     812 775 775 118 2510 
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Appendix B ? Sensitivity Analysis 
 
20% Downstream E fficiency 
 
Change in Dose due to E fficacy 
  .   
$8.5/dose 
private sector  
$6.8/dose from 
Gov.'t 
Percent 
Change in 
Dose 
Dose 
(microgr
ams) 
Forcasted Protein 
Production per Batch 
(kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-20% 4 0.0399 6 
59,850,0
00.00 508,725,000.00 
406,980,000.0
0 
-15% 4.25 0.0399 6 
56,329,4
11.76 478,800,000.00 
383,040,000.0
0 
-10% 4.5 0.0399 6 
53,200,0
00.00 452,200,000.00 
361,760,000.0
0 
-5% 4.75 0.0399 6 
50,400,0
00.00 428,400,000.00 
342,720,000.0
0 
0% 5 0.0399 6 
47,880,0
00.00 406,980,000.00 
325,584,000.0
0 
5% 5.25 0.0399 6 
45,600,0
00.00 387,600,000.00 
310,080,000.0
0 
10% 5.5 0.0399 6 
43,527,2
72.73 369,981,818.18 
295,985,454.5
5 
15% 5.75 0.0399 6 
41,634,7
82.61 353,895,652.17 
283,116,521.7
4 
20% 6 0.0399 6 
39,900,0
00.00 339,150,000.00 
271,320,000.0
0 	  
 
Change in Number of Batches 	  
Change in 
Number of 
Batches 
Dose 
(microgr
ams) 
Forcasted Protein 
Production per 
Batch (kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-2 5 0.0399 4 
31,920,
000.00 
271,320,000.0
0 
217,056,000.0
0 
-1 5 0.0399 5 
39,900,
000.00 
339,150,000.0
0 
271,320,000.0
0 
0 5 0.0399 6 
47,880,
000.00 
406,980,000.0
0 
325,584,000.0
0 
1 5 0.0399 7 
55,860,
000.00 
474,810,000.0
0 
379,848,000.0
0 
2 5 0.0399 8 
63,840,
000.00 
542,640,000.0
0 
434,112,000.0
0 	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Appendix B ? Sensitivity Analysis 
 
20% Downstream E fficiency 
Change in Selling Price 
Percent 
Change in 
Selling 
Price 
Dose 
(micro
grams
) 
Forcasted 
Protein 
Production per 
Batch (kg) 
Forecaste
d Number 
of Batches 
Forec
asted 
Doses 
Private 
Sector 
Selling 
Price 
Gov.'t 
Sector 
Selling 
Price 
G ross 
Private 
Revenue 
($USD) 
G ross 
Gov.'t 
Revenue 
($USD) 
-20% 5 
0.0399 
6 
47,88
0,000.
00 6.8 5.44 
325,584,00
0.00 
260,467,2
00.00 
-15% 5 
0.0399 
6 
47,88
0,000.
00 7.225 5.78 
345,933,00
0.00 
276,746,4
00.00 
-10% 5 
0.0399 
6 
47,88
0,000.
00 7.65 6.12 
366,282,00
0.00 
293,025,6
00.00 
-5% 5 
0.0399 
6 
47,88
0,000.
00 8.075 6.46 
386,631,00
0.00 
309,304,8
00.00 
0% 5 
0.0399 
6 
47,88
0,000.
00 8.5 6.8 
406,980,00
0.00 
325,584,0
00.00 
5% 5 
0.0399 
6 
47,88
0,000.
00 8.925 7.14 
427,329,00
0.00 
341,863,2
00.00 
10% 5 
0.0399 
6 
47,88
0,000.
00 9.35 7.48 
447,678,00
0.00 
358,142,4
00.00 
15% 5 
0.0399 
6 
47,88
0,000.
00 9.775 7.82 
468,027,00
0.00 
374,421,6
00.00 
20% 5 
0.0399 
6 
47,88
0,000.
00 10.2 8.16 
488,376,00
0.00 
390,700,8
00.00 
 
Pandemic Scale-Up 
Dose 
(microgra
ms) 
Forcasted Protein 
Production per Batch 
(kg) 
Forecasted 
Number of 
Batches 
Forecaste
d Doses 
Gov.'t Sector 
Selling Price 
G ross Gov.'t 
Revenue ($USD) 
5 0.0399 24 
191,520,0
00.00 5.44 1,041,868,800.00 
5 0.0399 24 
191,520,0
00.00 5.78 1,106,985,600.00 
5 0.0399 24 
191,520,0
00.00 6.12 1,172,102,400.00 
5 0.0399 24 
191,520,0
00.00 6.46 1,237,219,200.00 
5 0.0399 24 
191,520,0
00.00 6.8 1,302,336,000.00 
5 0.0399 24 
191,520,0
00.00 7.14 1,367,452,800.00 
5 0.0399 24 
191,520,0
00.00 7.48 1,432,569,600.00 
5 0.0399 24 
191,520,0
00.00 7.82 1,497,686,400.00 
5 0.0399 24 
191,520,0
00.00 8.16 1,562,803,200.00 	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Appendix B ? Sensitivity Analysis 
 
36% Downstream E fficiency 
 
Change in Dose due to E fficacy 	  
I .) Change in 
Dose due to 
E fficacy  
.   
$8.5/dose 
private sector  
$6.8/dose 
from Gov.'t 
Percent 
Change in Dose 
Dose 
(microg
rams) 
Forcasted Protein 
Production per 
Batch (kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-20% 4 0.07182 6 107,730,000.00 
915,705,000.0
0 
732,564,000.0
0 
-15% 4.25 0.07182 6 101,392,941.18 
861,840,000.0
0 
689,472,000.0
0 
-10% 4.5 0.07182 6 95,760,000.00 
813,960,000.0
0 
651,168,000.0
0 
-5% 4.75 0.07182 6 90,720,000.00 
771,120,000.0
0 
616,896,000.0
0 
0% 5 0.07182 6 86,184,000.00 
732,564,000.0
0 
586,051,200.0
0 
5% 5.25 0.07182 6 82,080,000.00 
697,680,000.0
0 
558,144,000.0
0 
10% 5.5 0.07182 6 78,349,090.91 
665,967,272.7
3 
532,773,818.1
8 
15% 5.75 0.07182 6 74,942,608.70 
637,012,173.9
1 
509,609,739.1
3 
20% 6 0.07182 6 71,820,000.00 
610,470,000.0
0 
488,376,000.0
0 	  	  
Change in Number of Batches 	  
Change in 
Number of 
Batches 
Dose 
(microgr
ams) 
Forcasted Protein 
Production per 
Batch (kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-2 5 0.07182 4 57,456,000.00 
488,376,000.0
0 
390,700,800.0
0 
-1 5 0.07182 5 71,820,000.00 
610,470,000.0
0 
488,376,000.0
0 
0 5 0.07182 6 86,184,000.00 
732,564,000.0
0 
586,051,200.0
0 
1 5 0.07182 7 100,548,000.00 
854,658,000.0
0 
683,726,400.0
0 
2 5 0.07182 8 114,912,000.00 
976,752,000.0
0 
781,401,600.0
0 	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36% Downstream E fficiency 
Change in Selling Price 
Percent 
Change in 
Selling 
Price 
Dose 
(micro
grams
) 
Forcasted 
Protein 
Production per 
Batch (kg) 
Forecaste
d Number 
of Batches 
Forec
asted 
Doses 
Private 
Sector 
Selling 
Price 
Gov.'t 
Sector 
Selling 
Price 
G ross 
Private 
Revenue 
($USD) 
G ross 
Gov.'t 
Revenue 
($USD) 
-20% 5 0.07182 6 
86,18
4,000.
00 
6.8 5.44 586,051,200.00 
468,840,9
60.00 
-15% 5 0.07182 6 
86,18
4,000.
00 
7.225 5.78 622,679,400.00 
498,143,5
20.00 
-10% 5 0.07182 6 
86,18
4,000.
00 
7.65 6.12 659,307,600.00 
527,446,0
80.00 
-5% 5 0.07182 6 
86,18
4,000.
00 
8.075 6.46 695,935,800.00 
556,748,6
40.00 
0% 5 0.07182 6 
86,18
4,000.
00 
8.5 6.8 732,564,000.00 
586,051,2
00.00 
5% 5 0.07182 6 
86,18
4,000.
00 
8.925 7.14 769,192,200.00 
615,353,7
60.00 
10% 5 0.07182 6 
86,18
4,000.
00 
9.35 7.48 805,820,400.00 
644,656,3
20.00 
15% 5 0.07182 6 
86,18
4,000.
00 
9.775 7.82 842,448,600.00 
673,958,8
80.00 
20% 5 0.07182 6 
86,18
4,000.
00 
10.2 8.16 879,076,800.00 
703,261,4
40.00 
Pandemic Scale-Up 
Dose 
(microgra
ms) 
Forcasted Protein 
Production per Batch 
(kg) 
Forecasted 
Number of 
Batches 
Forecaste
d Doses 
Gov.'t Sector 
Selling Price 
G ross Gov.'t 
Revenue ($USD) 
5   0.07182   24   344,736,000.00   5.44   1,875,363,840.00  
5   0.07182   24   344,736,000.00   5.78   1,992,574,080.00  
5   0.07182   24   344,736,000.00   6.12   2,109,784,320.00  
5   0.07182   24   344,736,000.00   6.46   2,226,994,560.00  
5   0.07182   24   344,736,000.00   6.8   2,344,204,800.00  
5   0.07182   24   344,736,000.00   7.14   2,461,415,040.00  
5   0.07182   24   344,736,000.00   7.48   2,578,625,280.00  
5   0.07182   24   344,736,000.00   7.82   2,695,835,520.00  
5   0.07182   24   344,736,000.00   8.16   2,813,045,760.00  	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Appendix B ? Sensitivity Analysis 
 
50% Downstream E fficiency 
 
Change in Dose due to E fficacy 
I .) Change in 
Dose due to 
E fficacy  
.   
$8.5/dose 
private sector  
$6.8/dose 
from Gov.'t 
Percent 
Change in Dose 
Dose 
(microg
rams) 
Forcasted Protein 
Production per 
Batch (kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-20% 4 0.09975 6 
149,625
,000.00 
1,271,812,500.
00 
1,017,450,000
.00 
-15% 4.25 0.09975 6 
140,823
,529.41 
1,197,000,000.
00 
957,600,000.0
0 
-10% 4.5 0.09975 6 
133,000
,000.00 
1,130,500,000.
00 
904,400,000.0
0 
-5% 4.75 0.09975 6 
126,000
,000.00 
1,071,000,000.
00 
856,800,000.0
0 
0% 5 0.09975 6 
119,700
,000.00 
1,017,450,000.
00 
813,960,000.0
0 
5% 5.25 0.09975 6 
114,000
,000.00 
969,000,000.0
0 
775,200,000.0
0 
10% 5.5 0.09975 6 
108,818
,181.82 
924,954,545.4
5 
739,963,636.3
6 
15% 5.75 0.09975 6 
104,086
,956.52 
884,739,130.4
3 
707,791,304.3
5 
20% 6 0.09975 6 
99,750,
000.00 
847,875,000.0
0 
678,300,000.0
0 	  	  
Change in Number of Batches 	  	  
Change in 
Number of 
Batches 
Dose 
(microgr
ams) 
Forcasted Protein 
Production per 
Batch (kg) 
Forecasted 
Number of 
Batches 
Forecas
ted 
Doses 
G ross Private 
Revenue 
($USD) 
G ross Gov.'t 
Revenue 
($USD) 
-2 5 0.09975 4 
79,800,
000.00 
678,300,000.0
0 
542,640,000.0
0 
-1 5 0.09975 5 
99,750,
000.00 
847,875,000.0
0 
678,300,000.0
0 
0 5 0.09975 6 
119,700
,000.00 
1,017,450,000.
00 
813,960,000.0
0 
1 5 0.09975 7 
139,650
,000.00 
1,187,025,000.
00 
949,620,000.0
0 
2 5 0.09975 8 
159,600
,000.00 
1,356,600,000.
00 
1,085,280,000.
00 	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50% Downstream E fficiency 
Change in Selling Price 
Percent 
Change in 
Selling 
Price 
Dose 
(micro
grams
) 
Forcasted 
Protein 
Production per 
Batch (kg) 
Forecaste
d Number 
of Batches 
Forec
asted 
Doses 
Private 
Sector 
Selling 
Price 
Gov.'t 
Sector 
Selling 
Price 
G ross 
Private 
Revenue 
($USD) 
G ross 
Gov.'t 
Revenue 
($USD) 
-20% 5 0.09975 6 
119,7
00,00
0.00 6.8 5.44 
813,960,00
0.00 
651,168,0
00.00 
-15% 5 0.09975 6 
119,7
00,00
0.00 7.225 5.78 
864,832,50
0.00 
691,866,0
00.00 
-10% 5 0.09975 6 
119,7
00,00
0.00 7.65 6.12 
915,705,00
0.00 
732,564,0
00.00 
-5% 5 0.09975 6 
119,7
00,00
0.00 8.075 6.46 
966,577,50
0.00 
773,262,0
00.00 
0% 5 0.09975 6 
119,7
00,00
0.00 8.5 6.8 
1,017,450,
000.00 
813,960,0
00.00 
5% 5 0.09975 6 
119,7
00,00
0.00 8.925 7.14 
1,068,322,
500.00 
854,658,0
00.00 
10% 5 0.09975 6 
119,7
00,00
0.00 9.35 7.48 
1,119,195,
000.00 
895,356,0
00.00 
15% 5 0.09975 6 
119,7
00,00
0.00 9.775 7.82 
1,170,067,
500.00 
936,054,0
00.00 
20% 5 0.09975 6 
119,7
00,00
0.00 10.2 8.16 
1,220,940,
000.00 
976,752,0
00.00 
 
Pandemic Scale-Up 
Dose 
(microgra
ms) 
Forcasted Protein 
Production per Batch 
(kg) 
Forecasted 
Number of 
Batches 
Forecaste
d Doses 
Gov.'t Sector 
Selling Price 
G ross Gov.'t 
Revenue ($USD) 
5 0.09975 24 
478,800,0
00.00 5.44 2,604,672,000.00 
5 0.09975 24 
478,800,0
00.00 5.78 2,767,464,000.00 
5 0.09975 24 
478,800,0
00.00 6.12 2,930,256,000.00 
5 0.09975 24 
478,800,0
00.00 6.46 3,093,048,000.00 
5 0.09975 24 
478,800,0
00.00 6.8 3,255,840,000.00 
5 0.09975 24 
478,800,0
00.00 7.14 3,418,632,000.00 
5 0.09975 24 
478,800,0
00.00 7.48 3,581,424,000.00 
5 0.09975 24 
478,800,0
00.00 7.82 3,744,216,000.00 
5 0.09975 24 
478,800,0
00.00 8.16 3,907,008,000.00 
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Appendix C ? SuperPro Stream Reports 
Overall Process Data 
Annual Operating Time 
  
2922 hours 
 Annual Throughput 
  
83,790,000 doses 
 Number of Batches per Year 
  
3 per strain 
  
      Stream Details Upstream Process  
Stream Name Initial Charge S-101 S-102 S-104 S-105 
Source Input P-1 P-2 P-3 P-4 
Destination P-1 P-2 P-3 P-4 P-6 
Activity 0.00  0.00  0.00  0.00  0.00  
Temperature (??? 28.00 28.00 28.00 28.00 28.00 
Pressure (bar) 1.01 1.01 1.01 1.01 1.01 
Component Flowrates (g/batch) 
Biomass 0.04 0.04 0.42 4.20 4.20 
Media 3.08 3.08 7.70 61.60 308.00 
Water 100.00 100.00 250.00 2000.00 10000.00 
Total (g/batch) 103.12 103.12 258.12 2065.80 10312.20 
Total (L/batch) 103.12 103.12 258.12 2065.80 10312.20 
      Stream Name S-106 S-117 S-118 S-119 S-120 
Source P-6 P-7 P-16 P-17 P-18 
Activity (U/ml) 0.00 0.00 0.00 0.00 0.00 
Temperature (??? 28.00 28.00 28.00 28.00 4.00 
Pressure 1.01 1.01 1.01 1.01 1.01 
Component Flowrates (g/batch) 
Biomass 4.20 42.00 0.00 4200.00 38.08 
Media 308.00 3080.00 34188.00 30800.00 0.00 
Water 10000.00 100000.00 1110000.00 1000000.00 100000.00 
Total (g/batch) 10312.20 103122.00 1144188.00 1035000.00 100038.08 
Total (L/batch) 10312.20 103122.00 1144188.00 1035000.00 100038.08 
      Stream Name S-107 S-108 S-109 S-110 S-103 
Source P-8 P-9 P-10 P-11 P-12 
Destination P-9 P-10 P-11 P-12 P-4 
Activity 0.00 0.00 0.00 0.00 0.00 
Temperature (??? 4.00 4.00 4.00 28.00 28.00 
Pressure 1.01 1.01 1.01 1.01 1.01 
Component F lowrates (g/batch) 
Biomass 0.00 0.00 0.00 0.00 0.00 
Media 3080.00 3080.00 3080.00 3080.00 138.60 
Water 100000.00 100000.00 100000.00 100000.00 4500.00 
Total (g/batch) 103080.00 103080.00 103080.00 103080.00 4638.60 
Total (L/batch) 103080.00 103080.00 103080.00 103080.00 4638.60 
      Stream Name S-112 S-113 S-114 S-115 S-116 
Source P-12 P-12 P-13 P-14 P-15 
Destination P-6 P-7 P-14 P-15 P-16 
Activity 0.00 0.00 0.00 0.00 0.00 
Temperature (??? 28.00 28.00 4.00 4.00 4.00 
Pressure 1.01 1.01 1.01 1.01 1.01 
Component F lowrates (g/batch) 
Biomass 0.00 0.00 0.00 0.00 0.00 
Media 308.00 3080.00 15400.00 15400.00 34188.00 
Water 10000.00 100000.00 500000.00 500000.00 1110000.00 
Total (g/batch) 10308.00 103080.00 515400.00 515400.00 1144188.00 
Total (L/batch) 10308.00 103080.00 515400.00 515400.00 1144188.00 
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Appendix C ? SuperPro Stream Reports 
Stream Details Downstream Process 
Stream Name F R O M USP S-102 S-103 Det. Charge S-104 
Source Input P-1 P-12 Input P-9 
Destination P-1 P-9 P-9 P-12 P-3 
Activity 0.00  0.00  0.00  0.00  0.00  
Temperature (??? 28.00 28.00 28.00 28.00 28.00 
Pressure (bar) 1.01 1.01 1.01 1.01 1.01 
Component Flowrates (kg/batch) 
Biomass 4200.00 0.00 0.00 0.00 0.00 
Water 1000000.00 990200.00 990200.00 200000.00 1100200.00 
VLP 200.00 0.00 200.00 0.00 189.00 
Medium 30800.00 30800.00 30800.00 0.00 30800.00 
Baculovirus 0.00 0.00 0.00 0.00 0.00 
TNBP 0.00 0.00 0.00 3150.00 3150.00 
Triton X-100 0.00 0.00 0.00 10500.00 10500.00 
Total (g/batch) 1035200.00 1021000.00 1021200.00 213650.00 1144839.00 
Total (L/batch) 1035200.00 1021000.00 1021200.00 213650.00 1144839.00 
      Stream Name S-105 S-106 S-107 I E X Resin S-101 
Source P-3 P-7 P-11 Input P-4 
Destination P-7 P-4 P-4 P-11 P-18 
Activity 0.00  0.00  0.00  0.00  0.00  
Temperature (??? 28.00 28.00 28.00 28.00 28.00 
Pressure (bar) 1.01 1.01 1.01 1.01 1.01 
Component Flowrates (g/batch) 
Biomass 0.00 0.00 0.00 0.00 0.00 
Water 200000.00 200000.00 0.00 0.00 20000.00 
VLP 190.00 190.00 0.00 0.00 162.00 
Medium 5600.00 5600.00 0.00 0.00 0.00 
Baculovirus 0.00 0.00 0.00 0.00 0.00 
TNBP 573.00 573.00 0.00 0.00 0.00 
Triton X-100 1909.00 1909.00 0.00 0.00 0.00 
Total (g/batch) 208272.00 0.00 0.00 0.00 0.00 
Total (L/batch) 208272.00 208272.00 0.00 0.00 20162.00 
      Stream Name S-108 SE C Resin S-111 S-114 S-109 
Source P-18 Input P-5 P-19 P-6 
Destination P-5 P-10 P-19 P-6 P-8 
Activity 0.00  0.00  0.00  0.00  0.00  
Temperature (??? 28.00 28.00 28.00 28.00 28.00 
Pressure (bar) 1.01 1.01 1.01 1.01 1.01 
Component Flowrates (g/batch) 
Biomass 0.00 0.00 0.00 0.00 0.00 
Water 20000.00 200000.00 20000.00 20000.00 10000.00 
VLP 162.00 0.00 154.00 154.00 146.00 
Medium 0.00 864.00 0.00 0.00 0.00 
Baculovirus 0.00 5680.00 0.00 0.00 0.00 
Tris-HCL 0.00 171.05 4.80 0.00 0.00 
NaCl 0.00 0.00 14.00 0.00 0.00 
Total (g/batch) 20162.00 0.00 20172.80 20154.00 0.00 
Total (L/batch) 20162.00 206715.05 20172.80 20154.00 10146.00 
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Appendix C -- Gantt Chart Data 
 
      Fermentation 
 
3.32 d each stage 
  
        Fill Times 
    
Tank charging & draining is always 42 LPM 
 
1L 0.024 min 0 days 
  
 
10L 0.238 min 0 days 
  
 
100L 2.38 min 0 days 
  
 
1000L 23.81 min 0 days 
   
 
 
 
Batch 1       
Task Start Date Gap T ime T ime (days) End Date 
Innoculate 100 mL 0   3.32 3.32 
Innoculate 500 mL 3.32   3.32 6.64 
Innoculate 4L Flask 6.64   3.3234725 9.9634725 
Fill 20L Bioreactor 9.9634725   2.75463E-06 9.963475255 
Ferment 20L Bioreactor 9.963475255   3.32 13.28347525 
Fill 200L Bioreactor 13.28347525   2.75463E-05 13.2835028 
Ferment 200L Bioreactor 13.2835028   3.32 16.6035028 
Fill 2000L Bioreactor 16.6035028   0.000275579 16.60377838 
Ferment 2000L Bioreactor 16.60377838   3.32 19.92377838 
Fill Hold Tank 1 19.92377838   0.000275579 19.92405396 
Centrifuge 19.92405396   0.347083333 20.27113729 
Fill Inactivation Tank 20.27113729   0.000275579 20.27141287 
Inactivation 20.27141287   0.020833333 20.2922462 
Tangential Flow Filtration 20.2922462   0.347083333 20.63932954 
Fill Hold Tank 2 20.2922462   0.347358912 20.63960512 
Ion Exchange Chromatography 20.63960512   5 25.63960512 
Fill Hold Tank 3 25.63960512   0.000275579 25.63988069 
Size Exclusion 25.63988069   5 30.63988069 
Fill Hold Tank 4 30.63988069   0.000275579 30.64015627 
Tangential Flow Filtration 30.64015627   0.347083333 30.98723961 
Fill Hold Tank 5 30.64015627   0.347358912 30.98751519 
Packaging into Vial 30.98751519   5.92593 36.91344519 
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Batch 2       
Start Date Gap T ime 1 T ime (days) End Date 
0 0 3.32 3.32 
0 0 3.32 3.32 
0 0 3.3234725 3.3234725 
9.963475255 3.281803079 0.041669421 10.00514468 
13.28347525 0.041669421 3.32 16.60347525 
13.2835028 3.32 0.041694213 13.32519701 
16.6035028 0.041694213 3.32 19.9235028 
16.60377838 3.32 0.041942245 16.64572063 
19.92377838 0.041942245 3.32 23.24377838 
19.92405396 3.32 1.630782063 21.55483602 
20.27113729 4.603423151 0.347083333 20.61822063 
3.667358912 4.950506484 0.000275579 3.667634491 
20.2922462 4.975783243 0.020833333 20.31307954 
19.94461173 4.632594937 0.347083333 20.29169506 
20.63960512 4.632319358 0.347358912 20.98696403 
25.63960512 0.000275579 5 30.63960512 
25.63988069 5 0.000275579 25.64015627 
30.63988069 0.000275579 5 35.63988069 
30.64015627 5 0.000275579 30.64043185 
30.98723961 4.652916667 0.347083333 31.33432294 
30.98751519 4.652090021 1.273839979 32.26135516 
36.91344519 0 5.92593 42.83937519 
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Batch 3       
Start Date Gap T ime 2 T ime (days) End Date 
0 0 3.32 3.32 
0 0 3.32 3.32 
0 0 3.3234725 3.3234725 
10.00514468 3.281803079 0.041669421 10.0468141 
16.60347525 0.041669421 3.32 19.92347525 
13.32519701 3.32 0.041694213 13.36689123 
19.9235028 0.041694213 3.32 23.2435028 
16.64572063 3.32 0.041942245 16.68766287 
23.24377838 0.041942245 3.32 26.56377838 
21.55483602 1.689217937 3.013743403 24.56857942 
4.704076849 4.356153585 0.347083333 5.051160183 
3.667634491 4.702031255 0.000275579 3.667910069 
20.31307954 4.66924063 0.020833333 20.33391287 
19.59697725 4.50924063 0.347083333 19.94406058 
20.98696403 4.50924063 0.347358912 21.33432294 
30.63960512 0.000275579 5 35.63960512 
25.64015627 5 0.000275579 25.64043185 
35.63988069 0.000275579 5 40.63988069 
30.64043185 5 0.000275579 30.64070743 
31.33432294 4.652916667 0.347083333 31.68140627 
32.26135516 3.671233238 2.254696762 34.51605193 
42.83937519 0 5.92593 48.76530519 
 
Batch 4       
Start Date Gap Time 3 Time (days) End Date 
0 0 3.32 3.32 
0 0 3.32 3.32 
0 0 3.3234725 3.3234725 
10.0468141 3.281803079 0.041669421 10.08848352 
19.92347525 0.041669421 3.32 23.24347525 
13.36689123 3.32 0.041694213 13.40858544 
23.2435028 0.041694213 3.32 26.5635028 
16.68766287 3.32 0.041942245 16.72960512 
26.56377838 0.041942245 3.32 29.88377838 
24.56857942 0.5452 4.755043545 29.32362297 
5.051160183 4.967960212 0.347083333 5.398243516 
3.667910069 5.309416241 0.000275579 3.668185648 
20.33391287 5.250399148 0.020833333 20.3547462 
19.24934277 4.70924063 0.347083333 19.5964261 
21.33432294 4.70924063 0.347358912 21.68168185 
35.63960512 0.000275579 5 40.63960512 
25.64043185 5 0.000275579 25.64070743 
40.63988069 0.000275579 5 45.63988069 
30.64070743 5 0.000275579 30.64098301 
31.68140627 4.652916667 0.347083333 32.02848961 
34.51605193 2.741330053 3.184599947 37.70065187 
48.76530519 0 5.92593 54.69123519 
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Batch 5       
Start Date Gap T ime 4 T ime (days) End Date 
0 0 3.32 3.32 
0 0 3.32 3.32 
0 0 3.3234725 3.3234725 
10.08848352 3.281803079 0.041669421 10.13015294 
23.24347525 0.041669421 3.32 26.56347525 
13.40858544 3.32 0.041694213 13.45027965 
26.5635028 0.041694213 3.32 29.8835028 
16.72960512 3.32 0.041942245 16.77154736 
29.88377838 0.041942245 3.32 33.20377838 
29.32362297 0.3652 4.555043545 33.87866651 
5.398243516 4.592055729 0.347083333 5.745326849 
3.668185648 4.969469349 0.000275579 3.668461227 
20.3547462 5.033726493 0.020833333 20.37557954 
18.90170829 4.688407297 0.347083333 19.24879162 
21.68168185 4.688407297 0.347358912 22.02904076 
40.63960512 0.000275579 5 45.63960512 
25.64070743 5 0.000275579 25.64098301 
45.63988069 0.000275579 5 50.63988069 
30.64098301 5 0.000275579 30.64125859 
32.02848961 4.652916667 0.347083333 32.37557294 
37.70065187 1.849642068 4.076287932 41.7769398 
54.69123519 0 5.92593 60.61716519 
 
Batch 6       
Start Date Gap Time 5 Time (days) End Date 
0 0 3.32 3.32 
0 0 3.32 3.32 
0 0 3.3234725 3.3234725 
10.13015294 3.281803079 0.041669421 10.17182236 
26.56347525 0.041669421 3.32 29.88347525 
13.45027965 3.32 0.041694213 13.49197387 
29.8835028 0.041694213 3.32 33.2035028 
16.77154736 3.32 0.041942245 16.81348961 
33.20377838 0.041942245 3.32 36.52377838 
33.87866651 0.3652 4.755043545 38.63371006 
5.745326849 4.714055729 0.347083333 6.092410183 
3.668461227 4.934629029 0.000275579 3.668736806 
20.37557954 4.924669688 0.020833333 20.39641287 
18.55407381 4.688407297 0.347083333 18.90115714 
22.02904076 4.688407297 0.347358912 22.37639968 
45.63960512 0.000275579 5 50.63960512 
25.64098301 5 0.000275579 25.64125859 
50.63988069 0 5 55.63988069 
30.64125859 5 0.000275579 30.64153417 
32.37557294 4.652916667 0.347083333 32.72265627 
41.7769398 0.957954083 4.967975917 46.74491572 
60.61716519 0 5.92593 66.54309519 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 3.4 
Revision Date 04/26/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : D-(+)-Glucose 
 
Product Number : G7528 
Brand : Sigma 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance according to GHS. 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Synonyms : Dextrose 
 
Formula : C6H12O6  
Molecular Weight : 180.16 g/mol 
 
No ingredients are hazardous according to OSHA criteria. 
 
4. FIRST AID MEASURES 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Immersion protection 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: > 480 min 
Material tested:Dermatril® (Aldrich Z677272, Size M) 
 
Splash protection 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
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Break through time: > 30 min 
Material tested:Dermatril® (Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 873000, e-mail sales@kcl.de, test method: 
EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial 
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as 
offering an approval for any specific use scenario. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form crystalline, powder 
 
Colour white 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
Melting point/range: 150 - 152 °C (302 - 306 °F) 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility soluble 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
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Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 25,800 mg/kg 
Remarks: Behavioral:Coma. Cyanosis Diarrhoea 
Inhalation LC50 
no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
Genotoxicity in vitro - mouse - lymphocyte 
Mutation in mammalian somatic cells. 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
 
no data available 
Teratogenicity 
no data available 
 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
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no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: LZ6600000 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards 
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
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SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Glucose 
CAS-No. 
50-99-7 
Revision Date 
 
New Jersey Right To Know Components 
 
Glucose 
CAS-No. 
50-99-7 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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Material Safety Data Sheet
Calcium chloride, Anhydrous MSDS
Section 1: Chemical Product and Company Identification
Product Name: Calcium chloride, Anhydrous
Catalog Codes: SLC5011, SLC2221, SLC4012, SLC4798,
SLC1006
CAS#: 10043-52-4
RTECS: EV9800000
TSCA: TSCA 8(b) inventory: Calcium chloride, Anhydrous
CI#: Not available.
Synonym:  
Chemical Name: Calcium Chloride, Anhydrous
Chemical Formula: CaCl2
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
Calcium chloride, Anhydrous 10043-52-4 100
Toxicological Data on Ingredients: Calcium chloride, Anhydrous: ORAL (LD50): Acute: 1000 mg/kg [Rat]. 1940 mg/kg
[Mouse].
Section 3: Hazards Identification
Potential Acute Health Effects:
Hazardous in case of skin contact (irritant), of eye contact (irritant), of ingestion, of inhalation. Slightly hazardous in case of
skin contact (permeator).
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Not available. MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for
bacteria and/or yeast. TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance
may be toxic to heart, cardiovascular system. Repeated or prolonged exposure to the substance can produce target organs
damage.
Section 4: First Aid Measures
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Eye Contact:
Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Cold water may be used. Get medical attention.
Skin Contact:
In case of contact, immediately flush skin with plenty of water. Cover the irritated skin with an emollient. Remove contaminated
clothing and shoes. Cold water may be used.Wash clothing before reuse. Thoroughly clean shoes before reuse. Get medical
attention.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical
attention.
Serious Inhalation: Not available.
Ingestion:
Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious
person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight clothing such as a collar,
tie, belt or waistband.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Non-flammable.
Auto-Ignition Temperature: Not applicable.
Flash Points: Not applicable.
Flammable Limits: Not applicable.
Products of Combustion: Not available.
Fire Hazards in Presence of Various Substances: Not applicable.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions: Not applicable.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Furan-2-peroxycarboxylic acid + calcium chloride causes explosion at room
temperature.
Section 6: Accidental Release Measures
Small Spill:
Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by spreading water on
the contaminated surface and dispose of according to local and regional authority requirements.
Large Spill:
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water on the
contaminated surface and allow to evacuate through the sanitary system.
Section 7: Handling and Storage
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Precautions:
Keep locked up.. Do not ingest. Do not breathe dust. Wear suitable protective clothing. In case of insufficient ventilation,
wear suitable respiratory equipment. If ingested, seek medical advice immediately and show the container or the label. Avoid
contact with skin and eyes. Keep away from incompatibles such as moisture.
Storage:
Hygroscopic. Keep container tightly closed. Keep container in a cool, well-ventilated area. Do not store above 30°C (86°F).
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal Protection: Safety glasses. Synthetic apron. Gloves (impervious).
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a specialist BEFORE
handling this product.
Exposure Limits: Not available.
Section 9: Physical and Chemical Properties
Physical state and appearance: Solid. (Crystalline solid.)
Odor: Odorless.
Taste: Saline.
Molecular Weight: 110.99 g/mole
Color: Colorless. White. Off-white.
pH (1% soln/water): 9 [Basic.]
Boiling Point: 1670°C (3038°F)
Melting Point: 772°C (1421.6°F)
Critical Temperature: Not available.
Specific Gravity: 2.15 (Water = 1)
Vapor Pressure: Not applicable.
Vapor Density: Not available.
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water, acetone.
Solubility:
Easily soluble in cold water, hot water, acetone. Freely soluble in alcohol. Soluble in Acetic Acid.
Section 10: Stability and Reactivity Data
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Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Incompatible materials, moisture.
Incompatibility with various substances: Reactive with moisture.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity:
Hygroscopic. Reacts violently (violent boiling) with water, generating heat. Forms flammable gases and evolves hydrogen
when reacted with zinc. Solutions attack some metals. Generates heat and violent polymerization occurs when mixed with
methyl vinyl ether. Bromine trifluoride reacts violently with and attacks calcium chloride.
Special Remarks on Corrosivity: Not available.
Polymerization: Will not occur.
Section 11: Toxicological Information
Routes of Entry: Absorbed through skin. Inhalation. Ingestion.
Toxicity to Animals: Acute oral toxicity (LD50): 1000 mg/kg [Rat].
Chronic Effects on Humans:
MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast. May cause damage to
the following organs: heart, cardiovascular system.
Other Toxic Effects on Humans:
Hazardous in case of skin contact (irritant), of ingestion, of inhalation. Slightly hazardous in case of skin contact (permeator).
Special Remarks on Toxicity to Animals:
Lowest Published Lethal Dose: LDL [Rabbit] - Route: Oral; Dose: 1384 mg/kg
Special Remarks on Chronic Effects on Humans:
May affect genetic material based on animal data. May cause cancer (tumorigenic) based on animal data.
Special Remarks on other Toxic Effects on Humans:
Acute Potential Health Effects: Skin: May cause severe irritation and possible burns, especially if skin is wet. Contact with dry
skin causes mild irritation. Contact of solid with moist/wet skin or skin contact with strong solutions may cause marked irritation
or possible burns. Eyes: May cause severe irritation, possible transient corneal injury, and possible eye burns. Inhalation: May
cause severe irritation of the upper respiratory tract with pain, inflammation and possible burns. Ingestion: May cause severe
gastrointestinal (digestive) tract irritation with nausea, vomiting and possible burns. May affect cardiovascular system (cardiac
disturbances, slow heart beat), behavior (seizures), metabolism, blood, and brain, respiration (rapid respiration). Chronic
Potential Health Effects: effects may be delayed.
Section 12: Ecological Information
Ecotoxicity: Ecotoxicity in water (LC50): 100 mg/l 96 hours [Fish].
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
Toxicity of the Products of Biodegradation: The products of degradation are less toxic than the product itself.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
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Waste Disposal:
Waste must be disposed of in accordance with federal, state and local environmental control regulations.
Section 14: Transport Information
DOT Classification: Not a DOT controlled material (United States).
Identification: Not applicable.
Special Provisions for Transport: Not applicable.
Section 15: Other Regulatory Information
Federal and State Regulations: TSCA 8(b) inventory: Calcium chloride, Anhydrous
Other Regulations: EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances.
Other Classifications:
WHMIS (Canada): CLASS D-2B: Material causing other toxic effects (TOXIC).
DSCL (EEC):
R36- Irritating to eyes. S2- Keep out of the reach of children. S22- Do not breathe dust. S24- Avoid contact with skin.
HMIS (U.S.A.):
Health Hazard: 2
Fire Hazard: 0
Reactivity: 1
Personal Protection: C
National Fire Protection Association (U.S.A.):
Health: 2
Flammability: 0
Reactivity: 2
Specific hazard:
Protective Equipment:
Gloves (impervious). Synthetic apron. Wear appropriate respirator when ventilation is inadequate. Safety glasses.
Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 04:31 PM
Last Updated: 06/09/2012 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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1 Identification of the substance/mixture and of the company/undertaking
· Product Identifier
· Product Name: Bacto TC Yeastolate
· Catalog Number: 255771
· Details of the supplier of the safety data sheet
· Manufacturer/Supplier:
BD Diagnostic Systems
7 Loveton Circle
Sparks, MD 21152
Telephone: (410) 771 - 0100  or (800) 638 – 8663
· Information Department: Technical Service
· Emergency telephone number:
In case of a chemical emergency, spill, fire, exposure, or accident, contact BD Diagnostic
Systems (410) 771-0100 or (800)-638-8663, or ChemTrec at (800) 424-9300.
2 Composition/information on ingredients
· Chemical characterization: Substances
· CAS No. Description:
. 
3 Hazards identification
· Classification of the substance or mixture
The substance is not classified according to the Globally Harmonized System (GHS).
· Classification according to Directive 67/548/EEC or Directive 1999/45/EC
This product contains no hazardous constituents, or the concentration of all chemical
constituents are below the regulatory threshold limits described by Occupational Safety
Health Administration Hazard Communication Standard 29 CFR 1910.1200, the Canada's
Workplace Hazardous Materials Information System (WHMIS)  and the European Directive
67/548/EEC and 1999/45/EC.
Void
· Label elements
· Labelling according to EU guidelines:
Observe the general safety regulations when handling chemicals
The substance is not subject to classification according to the sources of literature known to
us.
The product is not subject to identification regulations pertaining to regulations on hazardous
materials.
· NFPA ratings (scale 0-4)
0
0
0
Health = 0
Flammability = 0
Reactivity = 0
(Contd. on page 2)
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· HMIS ratings (scale 0-4)
  HEALTH
  FIRE
  REACTIVITY
0
0
0
Health = 0
Flammability = 0
Reactivity = 0
· Other hazards
4 First aid measures
· General information No special measures required.
· After inhalation Seek medical treatment in case of complaints.
· After skin contact Immediately wash with water and soap and rinse thoroughly.
· After eye contact
Rinse opened eye for several minutes under running water. If symptoms persist, consult a
doctor.
· After swallowing If symptoms persist consult doctor.
· Information for doctor Show this product label or this MSDS.
5 Firefighting measures
· Suitable extinguishing agents
CO2, ABC multipurpose dry chemical or water spray. Fight larger fires with water spray or
alcohol resistant foam.
· Special hazards arising from the substance or mixture
No further relevant information available.
· Protective equipment: No special measures required.
6 Accidental release measures
· Personal precautions, protective equipment and emergency procedures Not required.
· Environmental precautions: Wipe up with damp sponge or mop.
· Methods and material for containment and cleaning up: No special measures required.
· Reference to other sections No dangerous substances are released.
7 Handling and storage
· Handling
· Precautions for safe handling No special measures required.
· Information about protection against explosions and fires:
No special measures required.
· Storage
· Requirements to be met by storerooms and receptacles: < 30 ?
· Information about storage in one common storage facility:
Store away from oxidizing agents.
(Contd. on page 3)
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· Further information about storage conditions:
Store in cool, dry conditions in well sealed containers.
· Specific end use(s) No further relevant information available.
8 Exposure controls/personal protection
· Additional information about design of technical systems:
No further data; see Section 7.
· Components with limit values that require monitoring at the workplace: Not required.
· Additional information: The lists that were valid during the creation were used as basis.
· Personal Protective Equipment
· General protective and hygienic measures
The usual precautionary measures for handling chemicals should be followed.
· Breathing equipment:
In case of brief exposure, use a chemical fume hood or a NIOSH/MSHA-approved respirator.
· Protection of hands:
Chemical resistant gloves (i.e. nitrile, or equivalent).
· Eye protection: Safety glasses
· Body protection: Protective work clothing (lab coat).
9 Physical and chemical properties
· General Information
· Appearance:
Form: Solid.
Color: According to product specification
· Odor: Characteristic
· Change in condition Undetermined
· Melting point/Melting range: Not determined
· Boiling point/Boiling range: Not determined
· Flash point: Not applicable
· Flammability (solid, gaseous) Product is not flammable.
· Danger of explosion: Product does not present an explosion hazard.
· Density: Not determined
· Solubility in / Miscibility with
Water: Soluble
Solids content: 100.0 %
(Contd. on page 4)
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· Other information No further relevant information available.
10 Stability and reactivity
· Thermal decomposition / conditions to be avoided:
No decomposition if used according to specifications.
· Incompatible materials: No further relevant information available.
· Hazardous decomposition products: No dangerous decomposition products known.
11 Toxicological information
· Acute toxicity:
· Primary irritant effect:
· on the skin: No irritating effect.
· on the eye: No irritating effect.
· Sensitization: No sensitizing effects known.
· Additional toxicological information:
The product is not subject to OSHA classification according to internally approved calculation
methods for preparations.
When used and handled according to specifications, the product does not have any harmful
effects according to our experience and the information provided to us.
The substance is not subject to classification.
12 Ecological information
· Aquatic toxicity: No further relevant information available.
· Persistence and degradability No further relevant information available.
· Behavior in environmental systems:
· Bioaccumulative potential No further relevant information available.
· Ecotoxical effects:
· Other information:
The ecological effects have not been thoroughly investigated, but currently none have been
identified.
· Additional ecological information:
· General notes: Generally not hazardous for water.
13 Disposal considerations
· Waste treatment methods
· Recommendation
Smaller quantities can be disposed of with solid waste.
Dispose of material in accordance with federal (40 CFR 261.3), state and local requirements.
(Contd. on page 5)
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This product is not considered a RCRA hazardous waste.
· Uncleaned packagings:
· Recommendation: Disposal must be made according to state and federal regulations.
· Recommended cleansing agent: Water, if necessary with cleansing agents.
14 Transport information
· UN-Number
· DOT, ADR, ADN, IMDG, IATA Void
· UN proper shipping name
· DOT, ADR, ADN, IMDG, IATA Void
· Transport hazard class(es)
· DOT, ADR, ADN, IMDG, IATA
· Class Void
· Packing group
· DOT, ADR, IMDG, IATA Void
· Environmental hazards:
· Marine pollutant: No
· Special precautions for user Not applicable.
· Transport in bulk according to Annex II of
MARPOL73/78 and the IBC Code Not applicable.
· Transport/Additional information: If a "void" appears in the Hazard Class section
for the type of transportation, this indicates the
product is not regulated for transportation.
· UN "Model Regulation": - 
15 Regulatory information
· SARA Section 355 (extremely hazardous substances)
Substance is not listed.
· SARA Section 313 (specific toxic chemical listings)
Substance is not listed.
· TSCA (Toxic Substances Control Act)
Substance is not listed.
(Contd. on page 6)
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· California Proposition 65 - Chemicals known to cause cancer
Substance is not listed.
· California Proposition 65 - Chemicals known to cause reproductive toxicity for
females:
Substance is not listed.
· California Proposition 65 - Chemicals known to cause reproductive toxicity for males:
Substance is not listed.
· California Proposition 65 - Chemicals known to cause developmental toxicity:
Substance is not listed.
· Carcinogenic categories
· NTP (National Toxicology Program)
Substance is not listed.
· TLV (Threshold Limit Value established by ACGIH)
Substance is not listed.
· Product related hazard information:
Observe the general safety regulations when handling chemicals
The substance is not subject to classification according to the sources of literature known to
us.
The product is not subject to identification regulations pertaining to regulations on hazardous
materials.
· National regulations
· Water hazard class: Generally not hazardous for water.
16 Other information
To the best of our knowledge, the information contained herein is accurate. However, neither
Becton, Dickinson and Company or any of its subsidiaries assumes any liabilities whatsoever
for the accuracy or completeness of the information contained herein. Final determination of
suitability of any material is the sole responsibility of the user. All materials may present
unknown hazards and should be used with caution. Although certain hazards are described
herein, we can not guarantee that these are the only hazards that exist.
· Department issuing MSDS:
Environmental, Health & Safety
Created by Michael J. Spinazzola
· Contact: Technical Service Representative
· Abbreviations and acronyms:
ADR: Accord européen sur le transport des marchandises dangereuses par Route (European Agreement
concerning the International Carriage of Dangerous Goods by Road)
RID: Règlement international concernant le transport des marchandises dangereuses par chemin de fer
(Regulations Concerning the International Transport of Dangerous Goods by Rail)
IMDG: International Maritime Code for Dangerous Goods
IATA: International Air Transport Association
ICAO: International Civil Aviation Organization
(Contd. on page 7)
 USA
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acc. to ISO/DIS 11014
Date Prepared: 11/01/2011 Reviewed On: 07/15/2011
Product Name: Bacto TC Yeastolate
(Contd. of page 6)
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ACGIH: American Conference of Governmental Industrial Hygienists
CAS: Chemical Abstracts Service (division of the American Chemical Society)
NFPA: National Fire Protection Association (USA)
HMIS: Hazardous Materials Identification System (USA)
 USA
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 5.2 
Revision Date 11/05/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Sodium pyruvate 
 
Product Number : 80443 
Brand : Sigma-Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS). 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Formula : C3H3NaO3  
Molecular Weight : 110.04 g/mol 
 
No ingredients are hazardous according to OSHA criteria. 
 
4. FIRST AID MEASURES 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
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Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form powder 
 
Colour white 
Safety data 
pH 7 
 
Melting 
point/freezing point 
Melting point/range: > 300 °C (> 572 °F) - lit. 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility soluble 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
no data available 
Inhalation LC50 
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no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
 
Teratogenicity 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: Not available 
 
12. ECOLOGICAL INFORMATION 
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Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium pyruvate 
CAS-No. 
113-24-6 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium pyruvate 
CAS-No. 
113-24-6 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
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16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 3.6 
Revision Date 04/24/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : L-Glutamine 
 
Product Number : G8540 
Brand : Sigma 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance according to GHS. 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Synonyms : (S)-2,5-Diamino-5-oxopentanoic acid 
L-Glutamic acid 5-amide 
 
Formula : C5H10N2O3 C5H10N2O3  
Molecular Weight : 146.14 g/mol 
 
No ingredients are hazardous according to OSHA criteria. 
 
4. FIRST AID MEASURES 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx) 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
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specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form powder 
 
Colour white 
Safety data 
pH 5.0 - 6 at 14.6 g/l at 25 °C (77 °F) 
 
Melting 
point/freezing point 
Melting point/range: 185 °C (365 °F) 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility 14.6 g/l at 20 °C (68 °F) - completely soluble 
 
Partition coefficient: 
n-octanol/water 
log Pow: -4.609 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, nitrogen oxides (NOx) 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
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Acute toxicity 
Oral LD50 
LD50 Oral - rat - 7,500 mg/kg 
Inhalation LC50 
no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
 
Teratogenicity 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
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Additional Information 
RTECS: MA2275100 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards 
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
L-Glutamine 
CAS-No. 
56-85-9 
Revision Date 
 
New Jersey Right To Know Components 
 
L-Glutamine 
CAS-No. 
56-85-9 
Revision Date 
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California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 4.3 
Revision Date 12/31/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Sodium bicarbonate 
 
Product Number : S8875 
Brand : Sigma-Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS). 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Synonyms : Sodium hydrogen carbonate 
 
Formula : CHNaO3  
Molecular Weight : 84.01 g/mol 
 
No ingredients are hazardous according to OHSA criteria. 
 
4. FIRST AID MEASURES 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash protection 
Material: Nitrile rubber 
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Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial 
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as 
offering an approval for any specific use scenario. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form crystalline 
 
Colour no data available 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
300 °C (572 °F) 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Auto-ignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density 2.160 g/cm3 
 
Water solubility 50 g/l 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapor 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
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Possibility of hazardous reactions 
no data available 
Conditions to avoid 
Exposure to moisture. 
Materials to avoid 
Strong acids, Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 4,220 mg/kg 
Inhalation LC50 
no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
Skin - Human - Mild skin irritation - 3 d 
Serious eye damage/eye irritation 
Eyes - rabbit - Mild eye irritation - 30 s 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
 
no data available 
Teratogenicity 
no data available 
 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
 Sigma-Aldrich - S8875 Page 5  of  6 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
Exposure to large amounts can cause:, Gastrointestinal disturbance, Heavy or prolonged skin exposure may result in the 
absorption of harmful amounts of material. 
Synergistic effects 
no data available 
Additional Information 
RTECS: VZ0950000 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
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SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium hydrogencarbonate 
CAS-No. 
144-55-8 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium hydrogencarbonate 
CAS-No. 
144-55-8 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
 
 
 
 
Product Specification
Product Number: K4894
CAS Number: 9003-11-6
Formula: (C3H6O.C2H4O)x
TEST Specification________________________________________________________________________
Appearance (Color)            White
Appearance (Form)             Conforms
Prill/Cast Solid
Solubility (Color)            Colorless
Solubility (Turbidity)        Clear
100 mg/ml H2O
Cloud Point                   >  100 °C_
10% Solut ion
Brookfield Viscosity          700 - 1300 cps
at 77 deg C
pH                            5.0 - 7.5
2.5% solut ion
Water Content                 <  0.75 %_
COLOR TEST (APHA)             <  100_
(50:50 in MeOH)
Cell Culture Test             Pass
Insect Cell Test              Pass
Plant Cell Culture Test       Pass
Note                          -------------------------
Kolliphor is a registered trademark of BASF
Recommended Retest Period     -------------------------
2 years
Specif icat ion: PRD.3.ZQ5.10000023427
Sigma-Aldrich w arrants, that at the t ime of the quality release or subsequent retest date this product conformed to the information contained in
this publicat ion.  The current Specif icat ion sheet may be available at Sigma-Aldrich.com.  For further inquiries, please contact Technical Service.
Purchaser must determine the suitability of the product for its part icular use.  See reverse side of invoice or packing slip for addit ional terms
and condit ions of sale.
1 of 1
3050 Spruce Street, Saint Louis, MO 63103, USA
Website:  www.sigmaaldrich.com
Email USA:      techserv@sial.com
Outside USA:  eurtechserv@sial.com
Product Name:
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 4.2 
Revision Date 05/08/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Pluronic® F-68 
 
Product Number : P1300 
Brand : Sigma 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
GHS Classification 
Skin irritation (Category 3) 
GHS Label elements, including precautionary statements 
Pictogram none 
 
Signal word Warning 
 
Hazard statement(s) 
H316 Causes mild skin irritation. 
 
Precautionary 
statement(s) 
none 
HMIS Classification 
Health hazard: 1 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 1 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
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Synonyms : Polyoxyethylene-polyoxypropylene block copolymer 
 
Formula : (C3H6O.C2H4O)x  
 
No ingredients are hazardous according to OSHA criteria. 
 
4. FIRST AID MEASURES 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure adequate 
ventilation. Avoid breathing dust. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for 
disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
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Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Eye protection 
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and approved under 
appropriate government standards such as NIOSH (US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form solid 
 
Colour colourless 
Safety data 
pH 6.0 - 7 
 
Melting 
point/freezing point 
no data available 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility no data available 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
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Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 9,380 mg/kg 
LD50 Oral - mouse - 15,000 mg/kg 
Inhalation LC50 
no data available 
Dermal LD50 
LD50 Dermal - rabbit - 20,000 mg/kg 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
Skin - rabbit - Mild skin irritation - 24 h 
Serious eye damage/eye irritation 
Eyes - rabbit - Mild eye irritation - 24 h 
Eyes - rabbit - No eye irritation - OECD Test Guideline 405 
Respiratory or skin sensitization 
rabbit - Did not cause sensitization on laboratory animals. 
Germ cell mutagenicity 
Tests on bacterial or mammalian cell cultures did not show mutagenic effects. 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
 
Teratogenicity 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
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Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
Effects due to ingestion may include:, Diarrhoea, Weakness, To the best of our knowledge, the chemical, physical, and 
toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: MD0911050 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
Toxicity to fish static test LC50 - other fish - > 10,000 mg/l  - 96 h 
Method: OECD Test Guideline 203 
Persistence and degradability 
no data available 
Bioaccumulative potential 
Bioaccumulation is unlikely. 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards 
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
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SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Polyethylene glycol, propoxylated 
CAS-No. 
9003-11-6 
Revision Date 
 
New Jersey Right To Know Components 
 
Polyethylene glycol, propoxylated 
CAS-No. 
9003-11-6 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 4.9 
Revision Date 02/19/2013 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : ?????????-100 
 
Product Number : X100 
Brand : Sigma-Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
Harmful by ingestion., Irritant 
GHS Classification 
Acute toxicity, Oral (Category 4) 
Skin irritation (Category 3) 
Eye irritation (Category 2A) 
Acute aquatic toxicity (Category 2) 
Chronic aquatic toxicity (Category 2) 
GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H302 Harmful if swallowed. 
H316 Causes mild skin irritation. 
H319 Causes serious eye irritation. 
H411 Toxic to aquatic life with long lasting effects. 
 
Precautionary statement(s) 
P273 Avoid release to the environment. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if 
present and easy to do. Continue rinsing. 
HMIS Classification 
Health hazard: 2 
Flammability: 1 
Physical hazards: 0 
NFPA Rating 
Health hazard: 2 
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Fire: 1 
Reactivity Hazard: 0 
 
Health hazard: 2 
Fire: 1 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Ingestion Harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Synonyms : t-Octylphenoxypolyethoxyethanol 
4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol 
Polyethylene glycol tert-octylphenyl ether 
 
Formula : (C2H4O)nC14H22O  
 
Component Concentration 
p-tertiary-Octylphenoxy polyethyl alcohol 
 CAS-No. 
 
9002-93-1 
 
90 - 100 % 
 
4. FIRST AID MEASURES 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Use personal protective equipment. Avoid breathing vapours, mist or gas. Ensure adequate ventilation. 
Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
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Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
Packaged under inert gas.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose 
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the 
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an industrial 
hygienist and safety officer familiar with the specific situation of anticipated use by our customers. It should not be 
construed as offering an approval for any specific use scenario. 
 
Eye protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin and body protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the 
concentration and amount of the dangerous substance at the specific workplace. 
Hygiene measures 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form liquid, clear 
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Colour light yellow 
Safety data 
pH 9.7 
 
Melting 
point/freezing point 
6 °C (43 °F) 
 
Boiling point > 200 °C (> 392 °F) 
 
Flash point 251 °C (484 °F) - closed cup 
 
Ignition temperature no data available 
 
Auto-ignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure < 1.33 hPa (< 1.00 mmHg) at 20 °C (68 °F) 
 
Density 1.0700 g/cm3 
 
Water solubility soluble 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evapouration rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
Strong acids, Strong bases, Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 1,800 mg/kg 
Inhalation LC50 
no data available 
Dermal LD50 
LD50 Dermal - rabbit - 8,000 mg/kg 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
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no data available 
Serious eye damage/eye irritation 
Eyes - rabbit - Moderate eye irritation - 24 h 
Respiratory or skin sensitisation 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
 
no data available 
Teratogenicity 
no data available 
 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Ingestion Harmful if swallowed.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: MD0907700 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
Toxicity to fish LC50 - Pimephales promelas (fathead minnow) - 8.9 mg/l  - 96.0 h 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
EC50 - Daphnia - 26 mg/l  - 48 h 
Persistence and degradability 
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Biodegradability Biotic/Aerobic Biochemical oxygen demand 
Result: 36 % - Not readily biodegradable.  
Method: Closed Bottle test 
 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
 
Chemical Oxygen 
Demand (COD) 
 2.19 mg/g       
 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Toxic to aquatic life with long lasting effects. 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
UN number: 3082 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substances, liquid, n.o.s. (p-tertiary-Octylphenoxy polyethyl alcohol) 
Reportable Quantity (RQ):   
Marine pollutant: Marine pollutant  
Poison Inhalation Hazard: No 
 
IMDG 
UN number: 3082  Class: 9 Packing group: III EMS-No: F-A, S-F 
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (p-tertiary-Octylphenoxy 
polyethyl alcohol) 
Marine pollutant: No 
 
IATA 
UN number: 3082 Class: 9 Packing group: III 
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (p-tertiary-Octylphenoxy polyethyl alcohol) 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
Harmful by ingestion., Irritant  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
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Pennsylvania Right To Know Components 
 
p-tertiary-Octylphenoxy polyethyl alcohol 
CAS-No. 
9002-93-1 
Revision Date 
 
New Jersey Right To Know Components 
 
p-tertiary-Octylphenoxy polyethyl alcohol 
CAS-No. 
9002-93-1 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2013 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
 
 
 
 
_____________________________________________________________________________________________
SAFETY DATA SHEET
_____________________________________________________________________________________________
Identification of the substance/preparation  
24 hour Emergency Response (Transport): 866-536-0631
301-431-8585
Outside of the U.S. +1-301-431-8585
Product code
11300027
11300027
Revision Date
Company/Undertaking Identification  
Product name  ???????????????????????????? ?????????????
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Page  1 / 6
1 . I d e n t i f i c a t i o n  o f  t h e  s u b s t a n c e /m i x t u r e  a n d  o f  t h e  c o m p a n y/u n d e r t a k i n g
01-May-2012
Product name ??????????????????????????????????????????
www.lifetechnologies.com
INVITROGEN CORPORATION
5250 MAINWAY DRIVE
BURLINGTON, ONT
CANADA L7L 6A4
800/263-6236
Product code
Life Technologies
5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
+1 760 603 7200
4 . F i r s t  a i d  m e a s u r e s
Principle Routes of Exposure/
Potential Health effects  
GHS - Classification 
Eyes May cause eye irritation with susceptible persons.
Signal Word
not hazardous
Skin May cause skin irritation in susceptible persons.
Inhalation May be harmful by inhalation.
Ingestion May be harmful if swallowed.
3 . C o m p o s i t i o n/i n f o r m a t i o n  o n  i n g r e d i e n t s
The product contains no substances which at their given concentration, are considered to be hazardous to health. We
recommend handling all chemicals with caution.
Specific effects 
Carcinogenic effects none
Mutagenic effects none
2 . H a z a r d s  i d e n t i f i c a t i o n
Reproductive toxicity none
Sensitization none
Health Hazard 
Target Organ Effects No known effects under normal use conditions.
_____________________________________________________________________________________________
not hazardous
HMIS 
11300027
Health
Revision Date
0
Product name  ???????????????????????????? ?????????????
Reactivity
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0
not hazardous
Flammability 0
01-May-2012
www.lifetechnologies.com
Physical Hazards 
Product code
Personal protective equipment 
Eye contact
See Section 12 for additional information.
Rinse immediately with plenty of water, also under the eyelids, for at least 15
minutes. If symptoms persist, call a physician.
Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment.
5 . F i r e -f i g h t i n g  m e a s u r e s
6 . A c c i d e n t a l  r e l e a s e  m e a s u r e s
Inhalation
7 . H a n d l i n g  a n d  s t o r a g e
Move to fresh air. If symptoms persist, call a physician. If not breathing, give
artificial respiration.
Hand protection Impervious gloves.
Eye protection Safety glasses with side-shields.
Skin contact
Skin and body protection. Lightweight protective clothing.
Handling Always wear reccommended Personal Protective Equipment. No special handling
advice required.
Hygiene measures Handle in accordance with good industrial hygiene and safety practice.
Personal precautions Use personal protective equipment.
Storage Keep in a dry, cool and well-ventilated place.
Environmental exposure 
controls 
Prevent product from entering drains.
Rinse with plenty of water. If symptoms arise, call a physician.
Suitable extinguishing media
Methods for cleaning up Take up mechanically and collect in suitable container for disposal.
8 . E x p o s u r e  c o n t r o l s/p e r s o n a l  p r o t e c t i o n
Water spray. Carbon dioxide (CO2). Foam. Dry chemical.
_____________________________________________________________________________________________
Notes to physician
Exposure limits  
Treat symptomatically.
Special protective equipment for firefighters
Environmental precautions  
Wear self-contained breathing apparatus and protective
suit.
11300027
The product does not contain any hazardous materials with occupational exposure limits established.
Revision Date
Ingestion
Product name  ???????????????????????????? ?????????????
Page  3 / 6
Never give anything by mouth to an unconscious person. If symptoms persist, call
a physician. Do not induce vomiting without medical advice.
01-May-2012
Engineering measures Ensure adequate ventilation, especially in confined areas.
www.lifetechnologies.com
Prevent further leakage or spillage if safe to do so.
Product code
No information available
Ingestion May be harmful if swallowed.
Stability Stable under normal conditions.
Carcinogenic effects none
Form
Materials to avoid
Mutagenic effects none
No dangerous reaction known under conditions of normal use.
Reproductive toxicity none
powder
Hazardous decomposition
products
Sensitization none
None under normal use
polymerization
Target Organ Effects No known effects under normal use conditions.
Hazardous polymerisation does not occur.
9 . P h y s i c a l  a n d  c h e m i c a l  p r o p e r t i e s
1 2 . E c o l o g i c a l  i n f o r m a t i o n
1 1 . T o x i c o l o g i c a l  i n f o r m a t i o n
Oxidizing properties
Ecotoxicity effects No information available.
No information available.
Mobility No information available.
Appearance
Acute toxicity  
Biodegradation Inherently biodegradable
Water solubility
Bioaccumulation Does not bioaccumulate.
no data available
No information available
not hazardous
Principle Routes of Exposure/
Potential Health effects 
General Information 
Eyes
_____________________________________________________________________________________________
May cause eye irritation with susceptible persons.
1 0 . S t a b i l i t y  a n d  r e a c t i v i t y
Odor
Skin May cause skin irritation in susceptible persons.
Inhalation
11300027
May be harmful by inhalation.
Revision Date
°F  no data available
Product name  ???????????????????????????? ?????????????
°F  no data available
Page  4 / 6
Melting point/range °C  no data available
Autoignition temperature
°C  no data available
01-May-2012
Boiling Point/Range °F  no data available
www.lifetechnologies.com
Flash point
°C  no data available
Product code
°F  no data available
°C  no data available
For research use only. Not intended for human or animal diagnostic or therapeutic uses.
Proper shipping name Not classified as dangerous in the meaning of transport regulations
1 3 . D i s p o s a l  c o n s i d e r a t i o n s
The above information was acquired by diligent search and/or investigation and the recommendations are based on
prudent application of professional judgment.  The information shall not be taken as being all inclusive and is to be
used only as a guide.  All materials and mixtures may present unkown hazards and should be used with caution.
Since the Company cannot control the actual methods, volumes, or conditions of use, the Company shall not be held
liable for any damages or losses resulting from the handling or from contact with the product as described herein.
THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRENTY, EXPRESSED OR IMPLIED,
INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PUPOSE.
Hazard class none
End of Safety Data Sheet
Subsidiary Class none
Packing group
1 6 . O t h e r  i n f o r m a t i o n
none
IATA 
UN-No None
Reason for Revision (M)SDS sections updated.
Dispose of in accordance with local regulations.
1 4 . T r a n s p o r t  i n f o r m a t i o n
WHMIS hazard class:
Non-controlled
_____________________________________________________________________________________________
This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR
SARA 313
This product is not regulated by SARA.
1 5 . R e g u l a t o r y  i n f o r m a t i o n
U.S. State Regulations 
11300027
U.S. Federal Regulations 
Revision Date
Product name  ???????????????????????????? ?????????????
Page  5 / 601-May-2012
Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)
This product does not contains HAPs.
California Proposition 65
This product does not contain chemicals listed under Proposition 65
www.lifetechnologies.com
Product code
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                      1.  PRODUCT AND COMPANY INFORMATION______________________________________________________________________________
 
 
  INVITROGEN CORPORATION                 GIBCO PRODUCTS
  1600 FARADAY AVE.                      INVITROGEN CORPORATION
  CARLSBAD, CA 92008                     3175 STALEY ROAD P.O. BOX 68
  760/603-7200                           GRAND ISLAND, NY 14072
                                         716/774-6700
 
  INVITROGEN CORPORATION                 INVITROGEN CORPORATION
  3 FOUNTAIN DR.                         P.O. BOX 12-502
  INCHINNAN BUSINESS PARK                PENROSE
  PAISLEY, PA4 9RF                       AUCKLAND 1135
  SCOTLAND                               NEW ZEALAND
  44-141 814-6100                        64-9-579-3024
 
  INVITROGEN CORPORATION                 INVITROGEN AUSTRALIA PTY LIMITED
  2270 INDUSTRIAL ST.                    2A/14 LIONEL ROAD
  BURLINGTON, ONT                        MOUNT WAVERLY VIC 3149
  CANADA L7P 1A1                         AUSTRALIA
  905/335-2255                           1-800-331-627
 
  EMERGENCY NUMBER (SPILLS, EXPOSURES):  301/431-8585 (24 HOUR)
                                         800/451-8346 (24 HOUR)
  NON-EMERGENCY INFORMATION:             800/955-6288
 
 
  Product Name:  GRACE'S INSECT CELL CULTURE MEDIUM, POWDER
  Stock Number:  11300
 
  NOTE: If this product is a kit or is supplied with more than one material,
  please refer to the MSDS for each component for hazard information.
 
  Product Use:
  These products are for laboratory research use only and are not intended for
  human or animal diagnostics, therapeutic, or other clinical uses.
 
  Synonyms:
  Not available.
 
  ______________________________________________________________________________
                  2.  COMPOSITION, INFORMATION ON INGREDIENTS______________________________________________________________________________
 
 
  The following list shows components of this product classified as hazardous
  based on physical properties and health effects:
 
  Component                                    CAS No.        Percent
  L-GLUTAMINE                                  56-85-9       0.5 - 1.5
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  ______________________________________________________________________________
                           3.  HAZARDS IDENTIFICATION______________________________________________________________________________
 
 
  ***************************** EMERGENCY OVERVIEW ****************************
  Occupational exposure presents little or no health hazard.
  *****************************************************************************
 
  Potential Health Effects:
  Eye:
  Can cause minor irritation, tearing and reddening.
 
  Skin:
  Can cause minor skin irritation, defatting, and dermatitis.
 
  Inhalation:
  Can cause minor respiratory irritation, dizziness, weakness, fatigue,
  nausea, and headache.
  No toxicity expected from inhalation.
 
  Ingestion:
  Mildly irritating to mouth, throat, and stomach. Can cause abdominal
  discomfort.
 
  Chronic:
  No data on cancer.
 
  ______________________________________________________________________________
                             4.  FIRST AID MEASURES______________________________________________________________________________
 
 
  Eye:
  Use an eye wash to remove a chemical from your eye regardless of the level
  of hazard. Flush the affected eye for at least twenty minutes. Tilt the
  head to prevent chemical from transferring to the uncontaminated eye. Seek
  medical advice after flushing.
 
  Skin:
  Wash with soap and water. Get medical attention if irritation develops or
  persists.
 
  Inhalation:
  Remove to fresh air. If breathing is difficult, have a trained individual
  administer oxygen.
 
  Ingestion:
  Minimal risk of harm if swallowed. Do not induce vomiting. Seek medical
  attention immediately. Provide medical care provider with this MSDS.
 
  Note To Physician:
  Treat symptomatically.
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  ______________________________________________________________________________
                           5.  FIRE FIGHTING MEASURES______________________________________________________________________________
 
 
  Flashpoint Deg C:
                                  Not available.
  Upper Flammable Limit %:
                                  Not available.
  Lower Flammable Limit %:
                                  Not available.
  Autoignition Temperature Deg C:
                                  Not available.
 
 
  Extinguishing Media:
  Use alcohol resistant foam, carbon dioxide, or dry chemical when fighting
  fires. Water or foam may cause frothing if liquid is burning but it still
  may be a useful extinguishing agent if carefully applied to the surface of
  the fire. Do Not direct a stream of water into the hot burning liquid.
  Use water spray/fog for cooling.
 
  Firefighting Techniques/Equipment:
  Do not enter fire area without proper protection including self-contained
  breathing apparatus and full protective equipment. Fight fire from a safe
  distance and a protected location due to the potential of hazardous vapors
  and decomposition products.
 
  Hazardous Combustion Products:
  Includes carbon dioxide, carbon monoxide, dense smoke.
 
  ______________________________________________________________________________
                        6.  ACCIDENTAL RELEASE MEASURES______________________________________________________________________________
 
 
  Accidental releases may be subject to special reporting requirements and other
  regulatory mandates. Refer to Section 8 for personal protection equipment
  recommendations.
 
  Spill Cleanup:
  No health affects expected from the clean-up of this material if contact
  can be avoided. Follow personal protective equipment recommendations found
  in  Section VIII of this MSDS .
  No special spill clean-up considerations. Collect and discard in regular
  trash.
 
  ______________________________________________________________________________
                            7.  HANDLING AND STORAGE______________________________________________________________________________
 
 
  Storage of some materials is regulated by federal, state, and/or local laws.
 
  Storage Pressure:
  Ambient
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  ______________________________________________________________________________
                        7.  HANDLING AND STORAGE (CONT.)______________________________________________________________________________
 
 
  Handling Procedures:
  Mildly irritating material. Avoid unnecessary exposure.
  Keep closed or covered when not in use.
 
  Storage Procedures:
  Store in a cool dry place. Isolate from incompatible materials.
  Suitable for most general chemical storage areas.
 
  ______________________________________________________________________________
                   8.  EXPOSURE CONTROLS, PERSONAL PROTECTION______________________________________________________________________________
 
 
  Exposure Limits:
                                   OSHA PEL                AGCIH TWA
  Component                        (ppm)                   (ppm)
  L-GLUTAMINE                      Not established.        Not established.
 
  Engineering Controls:
  No exposure limits exist for the constituents of this product. General
  room ventilation might be required to maintain operator comfort under
  normal conditions of use.
 
  Personal Protective Equipment:
 
  Eye:
  Safety glasses should be the minimum eye protection.
  Wear chemical goggles.
 
  Skin:
  Not normally considered a skin hazard. Where use can result in skin
  contact, practice good personal hygiene and wear a barrier cream and/or
  impervious surgical style gloves. Wash hands and other exposed areas with
  mild soap and water before eating, drinking, and when leaving work.
  Gloves should be used as minimum hand protection.
 
  Respiratory:
  No respiratory protection will be needed under normal industrial operating
  conditions.
 
  ______________________________________________________________________________
                      9.  PHYSICAL AND CHEMICAL PROPERTIES______________________________________________________________________________
 
 
  Appearance/physical state:     Powder.
  Odor:                          No odor.
                                 Not established.
                                 Not established.
                                 Not established.
                                 Not established.
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                  9.  PHYSICAL AND CHEMICAL PROPERTIES (CONT.)______________________________________________________________________________
 
                                 Not established.
                                 Not established.
                                 Not established.
  Octanol/water Partition Coeff: Not established.
  Volatiles:                     Not established.
                                 Not established.
                                 Not established.
 
  ______________________________________________________________________________
                         10.  STABILITY AND REACTIVITY______________________________________________________________________________
 
 
  Stability:
  Stable under normal conditions.
 
  Conditions to Avoid:
  Strong oxidizing agents.
 
  Hazardous Decomposition Products:
  Carbon monoxide.  Carbon dioxide.  Toxic gases.  Nitrogen oxides.  Hydrogen
  chloride.
 
  Hazardous Polymerization:
  Hazardous polymerization will not occur.
 
  ______________________________________________________________________________
                         11.  TOXICOLOGICAL INFORMATION______________________________________________________________________________
 
 
  Acute Toxicity:
 
  Dermal/Skin:
  Not determined.
 
  Inhalation/Respiratory:
  Not determined.
 
  Oral/Ingestion:
  L-GLUTAMINE: 7500 MG/KG
 
  Target Organs: No data found.
 
  Carcinogenicity:
 
  NTP:
  Not tested.
 
  IARC:
  Not listed.
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                     11.  TOXICOLOGICAL INFORMATION (CONT.)______________________________________________________________________________
 
  OSHA:
  Not regulated.
 
  Other Toxicological Information
 
  ______________________________________________________________________________
                           12. Ecological Information______________________________________________________________________________
 
  Ecotoxicological Information: No ecological information available.
 
  Environmental Fate (Degradation, Transformation, and Persistence):
  Bioconcentration is not expected to occur.
 
  ______________________________________________________________________________
                          13.  DISPOSAL CONSIDERATIONS______________________________________________________________________________
 
 
  Regulatory Information:
  Not applicable.
 
  Disposal Method:
  Clean up and dispose of waste in accordance with all federal, state, and
  local environmental regulations.
 
  ______________________________________________________________________________
                           14.  TRANSPORT INFORMATION______________________________________________________________________________
 
 
  Proper Shipping Name:  Not Determined.
  Subsidiary Hazards:
 
  ______________________________________________________________________________
                          15.  REGULATORY INFORMATION______________________________________________________________________________
 
 
  UNITED STATES:
 
  TSCA:
  This product is solely for research and development purposes only and may not
  be used, processed or distributed for a commercial purpose.  It may only be
  handled by technically qualified individuals.
 
  Prop 65 Listed Chemicals:               PROP 65                     PERCENT
  No Prop 65 Chemicals.
 
                         No 313 Chemicals
 
 
 
  CANADA:
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  DSL/NDSL:
  Not determined.
 
  COMPONENT                              WHMIS Classification
  L-GLUTAMINE                            Not classified as hazardous.
 
  EUROPEAN UNION:
 
  PRODUCT RISK PHRASES:
                           None assigned.
  PRODUCT SAFETY PHRASES:
                           Not applicable.
  PRODUCT CLASSIFICATION:
                           Not classified as hazardous
 
                                         EINECS
  Component                              Number
  L-GLUTAMINE                            200-292-1
 
  ______________________________________________________________________________
                             16.  OTHER INFORMATION______________________________________________________________________________
 
 
  HMIS Rating 0-4:
  FIRE:       Not determined.
  HEALTH:     Not determined.
  REACTIVITY: Not determined.
 
  Abbreviations
  N/A - Data is not applicable or not available
  SARA - Superfund and Reauthorization Act
  HMIS - Hazard Material Information System
  WHMIS - Workplace Hazard Materials Information System
  NTP - National Toxicology Program
  OSHA - Occupational Health and Safety Administration
  IARC - International Agency for Research on Cancer
  PROP 65 - California Safe Drinking Water and
            Toxic Enforcement Act of 1986
  EINECS - European Inventory of Existing Commercial
           Chemical Substances
 
  The above information was acquired by diligent search and/or investigation
  and the recommendations are based on prudent application of professional
  judgment. The information shall not be taken as being all inclusive and is
  to be used only as a guide. All materials and mixtures may present unknown
  hazards and should be used with caution. Since Invitrogen Corporation cannot
  control the actual methods, volumes, or conditions of use, the Company shall
  not be held liable for any damages or losses resulting from the handling or
  from contact with the product as described herein. THE INFORMATION IN THIS
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  MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY
  IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 5.0 
Revision Date 12/03/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Tributyl phosphate 
 
Product Number : 240494 
Brand : Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen 
Target Organs 
Blood, Central nervous system 
GHS Classification 
Acute toxicity, Inhalation (Category 4) 
Acute toxicity, Dermal (Category 5) 
Acute toxicity, Oral (Category 4) 
Skin irritation (Category 2) 
Eye irritation (Category 2B) 
Carcinogenicity (Category 2) 
Acute aquatic toxicity (Category 2) 
GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H302 + H332 Harmful if swallowed or if inhaled 
H313 May be harmful in contact with skin. 
H315 + H320 Causes skin and eye irritation. 
H351 Suspected of causing cancer. 
H401 Toxic to aquatic life. 
 
Precautionary statement(s) 
P281 Use personal protective equipment as required. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if 
present and easy to do. Continue rinsing. 
 Aldrich - 240494 Page 2  of  7 
HMIS Classification 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 1 
Physical hazards: 0 
NFPA Rating 
Health hazard: 3 
Fire: 1 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Ingestion Harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Formula : C12H27O4P  
Molecular Weight : 266.31 g/mol 
 
Component Concentration 
Tributyl phosphate 
 CAS-No. 
EC-No. 
Index-No. 
 
126-73-8 
204-800-2 
015-014-00-2 
 
 -  
 
4. FIRST AID MEASURES 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate 
personnel to safe areas. 
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Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Components with workplace control parameters 
 
Components CAS-No. Value Control 
parameters 
Basis 
Tributyl 
phosphate 
126-73-8 TWA 
 
0.2 ppm  
 
USA. ACGIH Threshold Limit Values (TLV) 
Remarks Eye & Upper Respiratory Tract irritation Headache Nausea Substances for which there is a 
Biological Exposure Index or Indices (see BEI® section), see BEI® for Acetylcholinesterase 
Inhibiting Pesticide 
 
  TWA 
 
0.2 ppm  
2.5 mg/m3 
USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 
1910.1000 
  TWA 
 
5 mg/m3 USA. Occupational Exposure Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 
 
0.2 ppm  
2.5 mg/m3 
USA. NIOSH Recommended Exposure Limits 
Personal protective equipment 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose 
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the 
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
Splash protection 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 
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If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial 
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as 
offering an approval for any specific use scenario. 
 
Eye protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin and body protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the 
concentration and amount of the dangerous substance at the specific workplace. 
Hygiene measures 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form liquid 
 
Colour colourless 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
Melting point/range: -79 °C (-110 °F) - lit. 
 
Boiling point 180 - 183 °C (356 - 361 °F) at 29 hPa (22 mmHg) - lit. 
 
Flash point 145 °C (293 °F) - closed cup 
 
Ignition temperature 410 °C (770 °F) 
 
Auto-ignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure 36 hPa (27 mmHg) at 178 °C (352 °F) 
 9.7 hPa (7.3 mmHg) at 150 °C (302 °F) 
 
Density 0.979 g/cm3 at 25 °C (77 °F) 
 
Water solubility no data available 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapor 
density 
9.19 
 - (Air = 1.0) 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
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Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents, Strong bases 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 1,552 mg/kg 
Inhalation LC50 
LC50 Inhalation - rat - 1 h - 28,000 mg/m3 
Dermal LD50 
LD50 Dermal - rabbit - > 3,100 mg/kg 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
Skin - rabbit - Mild skin irritation 
Serious eye damage/eye irritation 
Eyes - rabbit - Mild eye irritation 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
 
no data available 
 
Carcinogenicity 
Carcinogenicity - rat - Oral 
Tumorigenic:Neoplastic by RTECS criteria. Kidney, Ureter, Bladder:Tumors. 
Carcinogenicity - mouse - Oral 
Tumorigenic:Neoplastic by RTECS criteria. Liver:Tumors. 
Limited evidence of carcinogenicity in animal studies 
 
 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
Reproductive toxicity - rat - Oral 
Effects on Newborn: Growth statistics (e.g., reduced weight gain). 
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no data available 
Teratogenicity 
Developmental Toxicity - rat - Oral 
Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). 
 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Ingestion Harmful if swallowed.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Signs and Symptoms of Exposure 
CNS stimulation., To the best of our knowledge, the chemical, physical, and toxicological properties have not been 
thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: TC7700000 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
Toxicity to fish LC50 - Carassius auratus (goldfish) - 8.8 mg/l  - 96 h 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - 3.6 mg/l  - 48 h 
 
Toxicity to algae EC50 - Desmodesmus subspicatus (green algae) - 1.1 mg/l  - 72 h 
Persistence and degradability 
Bioaccumulative potential 
Bioaccumulation Oryzias latipes - 38 d  
Bioconcentration factor (BCF): 21 - 35 
 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Toxic to aquatic life. 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
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Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
Pennsylvania Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
New Jersey Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 5.0 
Revision Date 12/03/2012 
Print Date 03/31/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Tributyl phosphate 
 
Product Number : 240494 
Brand : Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen 
Target Organs 
Blood, Central nervous system 
GHS Classification 
Acute toxicity, Inhalation (Category 4) 
Acute toxicity, Dermal (Category 5) 
Acute toxicity, Oral (Category 4) 
Skin irritation (Category 2) 
Eye irritation (Category 2B) 
Carcinogenicity (Category 2) 
Acute aquatic toxicity (Category 2) 
GHS Label elements, including precautionary statements 
Pictogram 
  
Signal word Warning 
 
Hazard statement(s) 
H302 + H332 Harmful if swallowed or if inhaled 
H313 May be harmful in contact with skin. 
H315 + H320 Causes skin and eye irritation. 
H351 Suspected of causing cancer. 
H401 Toxic to aquatic life. 
 
Precautionary statement(s) 
P281 Use personal protective equipment as required. 
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if 
present and easy to do. Continue rinsing. 
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HMIS Classification 
Health hazard: 2 
Chronic Health Hazard: * 
Flammability: 1 
Physical hazards: 0 
NFPA Rating 
Health hazard: 3 
Fire: 1 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Ingestion Harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Formula : C12H27O4P  
Molecular Weight : 266.31 g/mol 
 
Component Concentration 
Tributyl phosphate 
 CAS-No. 
EC-No. 
Index-No. 
 
126-73-8 
204-800-2 
015-014-00-2 
 
 -  
 
4. FIRST AID MEASURES 
General advice 
Consult a physician. Show this safety data sheet to the doctor in attendance.Move out of dangerous area. 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. 
In case of skin contact 
Wash off with soap and plenty of water. Consult a physician. 
In case of eye contact 
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Evacuate 
personnel to safe areas. 
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Environmental precautions 
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the environment 
must be avoided. 
Methods and materials for containment and cleaning up 
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed containers for 
disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist. 
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
Components with workplace control parameters 
 
Components CAS-No. Value Control 
parameters 
Basis 
Tributyl 
phosphate 
126-73-8 TWA 
 
0.2 ppm  
 
USA. ACGIH Threshold Limit Values (TLV) 
Remarks Eye & Upper Respiratory Tract irritation Headache Nausea Substances for which there is a 
Biological Exposure Index or Indices (see BEI® section), see BEI® for Acetylcholinesterase 
Inhibiting Pesticide 
 
  TWA 
 
0.2 ppm  
2.5 mg/m3 
USA. OSHA - TABLE Z-1 Limits for Air Contaminants - 
1910.1000 
  TWA 
 
5 mg/m3 USA. Occupational Exposure Limits (OSHA) - Table Z-1 
Limits for Air Contaminants 
  TWA 
 
0.2 ppm  
2.5 mg/m3 
USA. NIOSH Recommended Exposure Limits 
Personal protective equipment 
Respiratory protection 
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose 
combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the 
respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components 
tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
Splash protection 
Material: butyl-rubber 
Minimum layer thickness: 0.3 mm 
Break through time: 480 min 
Material tested:Butoject® (KCL 897 / Aldrich Z677647, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 
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If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial 
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as 
offering an approval for any specific use scenario. 
 
Eye protection 
Face shield and safety glasses Use equipment for eye protection tested and approved under appropriate 
government standards such as NIOSH (US) or EN 166(EU). 
Skin and body protection 
Complete suit protecting against chemicals, The type of protective equipment must be selected according to the 
concentration and amount of the dangerous substance at the specific workplace. 
Hygiene measures 
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of 
workday. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form liquid 
 
Colour colourless 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
Melting point/range: -79 °C (-110 °F) - lit. 
 
Boiling point 180 - 183 °C (356 - 361 °F) at 29 hPa (22 mmHg) - lit. 
 
Flash point 145 °C (293 °F) - closed cup 
 
Ignition temperature 410 °C (770 °F) 
 
Auto-ignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure 36 hPa (27 mmHg) at 178 °C (352 °F) 
 9.7 hPa (7.3 mmHg) at 150 °C (302 °F) 
 
Density 0.979 g/cm3 at 25 °C (77 °F) 
 
Water solubility no data available 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapor 
density 
9.19 
 - (Air = 1.0) 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
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Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents, Strong bases 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Oxides of phosphorus 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 1,552 mg/kg 
Inhalation LC50 
LC50 Inhalation - rat - 1 h - 28,000 mg/m3 
Dermal LD50 
LD50 Dermal - rabbit - > 3,100 mg/kg 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
Skin - rabbit - Mild skin irritation 
Serious eye damage/eye irritation 
Eyes - rabbit - Mild eye irritation 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
 
no data available 
 
Carcinogenicity 
Carcinogenicity - rat - Oral 
Tumorigenic:Neoplastic by RTECS criteria. Kidney, Ureter, Bladder:Tumors. 
Carcinogenicity - mouse - Oral 
Tumorigenic:Neoplastic by RTECS criteria. Liver:Tumors. 
Limited evidence of carcinogenicity in animal studies 
 
 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
Reproductive toxicity - rat - Oral 
Effects on Newborn: Growth statistics (e.g., reduced weight gain). 
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no data available 
Teratogenicity 
Developmental Toxicity - rat - Oral 
Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted fetus). 
 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.  
Ingestion Harmful if swallowed.  
Skin Harmful if absorbed through skin. Causes skin irritation.  
Eyes Causes eye irritation.  
Signs and Symptoms of Exposure 
CNS stimulation., To the best of our knowledge, the chemical, physical, and toxicological properties have not been 
thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: TC7700000 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
Toxicity to fish LC50 - Carassius auratus (goldfish) - 8.8 mg/l  - 96 h 
 
Toxicity to daphnia 
and other aquatic 
invertebrates 
EC50 - Daphnia magna (Water flea) - 3.6 mg/l  - 48 h 
 
Toxicity to algae EC50 - Desmodesmus subspicatus (green algae) - 1.1 mg/l  - 72 h 
Persistence and degradability 
Bioaccumulative potential 
Bioaccumulation Oryzias latipes - 38 d  
Bioconcentration factor (BCF): 21 - 35 
 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. 
Toxic to aquatic life. 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
 Aldrich - 240494 Page 7  of  7 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional waste 
disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a 
chemical incinerator equipped with an afterburner and scrubber.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
Target Organ Effect, Harmful by ingestion., Irritant, Carcinogen  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
Acute Health Hazard, Chronic Health Hazard 
Massachusetts Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
Pennsylvania Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
New Jersey Right To Know Components 
 
Tributyl phosphate 
CAS-No. 
126-73-8 
Revision Date 
1993-04-24 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
 
 
 
 
Material Safety Data Sheet
Section 1. Chemical Product and Company Identification
Product Name Product Code
Formalin Solution 10% Neutral Buff. pH 7.0 28600
Manufacturer's Name Emergency Telephone Number
StatLab Medical Products, Inc. 800-424-9300
Address (Number, Street, City, State, and ZIP Code) Telephone Number for Information
407 Interchange st. 800-442-3573 x 2
Date Prepared
McKinney Tx 75071 10/14/2003 (rev 10/20/05)
Signature of Preparer (optional
Section 2. Composition/Information on Ingredients
Component CAS # OSHA PEL ACGIH TLV
Other Limits 
Recommended Percent
Formaldehyde 50-00-0 0.75 ppm C 0.3 mg/m3 3-4
Methyl Alcohol 67-56-1 200 ppm 250 ppm 1-1.5
Sodium Phosphate Monobasic 10049-21-5 N/A N/A <1
     Monohydrate  
Sodium Phosphate Dibasic 7558-79-4 N/A N/A <1
Water, Deionized 7732-18-5 N/A N/A Balance
Section 3. Hazards Identification
Emergency Overview
Contains Formaldehyde, a suspected carcinogen.  Irritating to the eyes, respiratory
system and skin.  May cause sensitization by inhalation or skin contact.  May
be fatal if swallowed.  If ingested, dilute with water, induce vomiting then
call a physician.  Wash areas of contact with water.  If inhaled, remove to 
fresh air.
Potential Health Effects
Target Organs Eyes, skin, respiratory system.
Eye Causes irritation, redness and pain.
Skin May cause irritation, redness and pain.  Frequent or prolonged
exposure may cause hypersensitivity leading to contact dermatitis.
Ingestion May cause severe abdominal pain, vomiting, headache and diarrhea.
Inhalation Causes irritation of respiratory tract.  Symptoms may include 
sore throat, coughing and shortness of breath.
Chronic/Carcinogenicity IARC-Formaldehyde is probably carcinogenic.  NTP-Formaldehyde
is reasonably anticipated to be a carcinogen.  OSHA-Yes (Formaldehyde)
Teratology Mutation data cited in "Registry of Toxic Effects of Chemical
Substances" on Formaldehyde.
Reproduction Reproductive effects cited in "Registry of Toxic Effects
of Chemical Substances"  on Formaldehyde.
Mutagenicity
Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name Formalin Solution 10% Neutral Buff. pH 7.0 28600
Section 4. First Aid Measures
Eye Irrigate immediately with large quantity of water for at
least 15 minutes.
Skin Flush with water for at least 15 minutes.
Ingestion Dilute immediately with water or milk.  Induce vomiting.
Call a physician.
Inhalation Remove to fresh air.  Give artificial respiration if necessary.
All Other Means of Exposure CONTACT POISON CONTROL CENTER IMMEDIATELY.  Be prepared to 
provide hazardous ingredient information from Section 2.
Section 5. Fire Fighting Measures
Flammable Properties Flash Point N/A Method N/A
Flammable Limits Lower N/A Upper N/A
Autoignition Temperature
Hazardous Combustion Products
Extinguishing Media Use any means suitable for extinguishing the surrounding
fire.  (Water spray, dry chemical, alcohol foam, or carbon dioxide.)
Fire & Explosion Hazards Not considered to be a fire or explosion hazard. 
Fire Fighting Instructions Use normal procedures/instructions.
Fire Fighting Equipment Use protective clothing and breathing equipment appropriate
for the surrounding fire.
Section 6. Accidental Release Measures
Ventilate area of leak or spill.  Cover spill with 1:1:1 mixture of Sodium Carbonate, clay
cat litter and sand.  Scoop into container and transport to fume hood.  Add the 
mixture to cold water (about 10 mL water for each 1 mL of Formaldehyde solution).
Slowly add household bleach (2.5 mL bleach for each 1 mL of Formaldehyde solution).
Allow to stand for 20 minutes.  Decant liquid to drain.  Flush with water.  Treat
solid residue as normal refuse.
Section 7. Handling and Storage
Handling/Storage As with all chemicals, wash hands thoroughly after handling.
Avoid contact with eyes.  Protect from freezing and physical damage.  Use with
adequate ventilation.  Store at controlled room temperature, 15-30°C.
SAFETY STORAGE CODE: HEALTH
Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name Formalin Solution 10% Neutral BuffProduct Code 28600
Section 8. Exposure Controls, Personal Protection
Engineering Controls Use of a fume hood is recommended.
Respiratory Protection If the exposure level is exceeded, wear a full facepiece
respirator equipped with a formaldehyde cartridge.
Skin Protection Gloves
Eye Protection Safety glasses or goggles.
Permissible Exposure Levels (see also Section 2)
Component CAS # OSHA PEL ACGIH TLV
Other Limits 
Recommended Percent
Formaldehyde 50-00-0 0.75 ppm C 0.3 mg/m3 3-4
Methyl Alcohol 67-56-1 200 ppm 250 ppm 1-1.5
Sodium Phosphate Monobasic 10049-21-5 N/A N/A <1
     Monohydrate  
Sodium Phosphate Dibasic 7558-79-4 N/A N/A <1
Water, Deionized 7732-18-5 N/A N/A Balance
Section 9. Physical and Chemical Properties
Boiling Point approx. Specific Gravity (H2O = 1) approx.
100°C 1.02
Vapor Pressure (mm Hg) Melting Point approx.
N/A 0°C
Vapor Density (AIR = 1) Evaporation rate
(Butyl Acetate = 1)
Solubility in Water Physical State
Infinite
Appearance and Odor Other
Clear, colorless/pungent odor pH: 7.0
Section 10. Stability and Reactivity
Chemical Stability Stable under normal conditions of use and storage.
Incompatibility Strong oxidizers, strong alkalies, acids, phenol, urea.
Hazardous Decomposition Products May form Carbon Dioxide, Carbon Monoxide and 
Formaldehyde when heated to decomposition.
Hazardous Polymerization Nonhazardous polymerization may occur, forming 
paraformaldehyde, a white solid.
Section 11. Toxological Information
LD50, Oral, Rat: (Formaldehyde) 100 mg/kg;  LD50, Oral, Rat: (Sodium Phosphate
Diabasic) 17,000 mg/kg; Details of toxic effects not reported other than lethal
dose value.
Statlab Medical Products, Inc.
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Material Safety Data Sheet
Product Name Formalin Solution 10% Neutral BuffProduct Code 28600
Section 12. Ecological Information
Ecotoxicological Information:  Formaldehyde is expected to be slightly toxic
to aquatic life.
Chemical Fate Information:  Formaldehyde is expected to readily biodegrade when 
released into water.
Section 13. Disposal Considerations
Whatever cannot be saved for recovery or recycling should be disposed of in a 
RCRA approved waste disposal facility.  Dispose of in accordance with local,
state, and federal regulations.
Section 14. Transport Information
GROUND SHIPMENTS: Not regulated
AIR SHIPMENTS: Aviation Regulated Liquid n.o.s. (formaldehyde), 9, UN3334
NOTE: It is ultimately the shippers responsibility to make hazard class
determination based on their best information available.
Section 15. Regulatory Information
OSHA Status:  This item meets the OSHA Hazard Communication Standard (29 CFR 1910.1200)
definition of a hazardous material.
TSCA Status:  All components of this solution are listed on the TSCA Inventory.
CERCLA  Reportable Quantity:  Formaldehyde, RQ 100 pounds.
SARA TITLE III:
Section 302 Extremely Hazardous Substances: Formaldehyde TPQ 500 pounds
Section 311/312 Hazardous Categories:  No
Section 313 Toxic Chemicals: Formaldehyde, 0.1% De Minimus concentration
RCRA Status:  No
California Proposition 65: No listed (Formaldehyde gas is listed)
Florida:  Formaldehyde is listed on the state Toxic Substances List.
Pennsylvania: Formaldehyde is listed as an environmental and special hazard on the
     Hazardous Substances List.
Section 16. Other Information
NFPA Ratings: Health: 2 Flammability: 2 Reactivity: 0 Special Notice Key: None
HMIS® Ratings: Health: 4 Flammability: 2 Reactivity: 0 Protective Equipment: C
(protective eyewear and gloves)
When handled properly by qualified personnel, the product described herein does not present a significant health or safety hazard.
Alteration to its characteristics by concentration, evaporation, addition of other substances, or other means may present hazards
not specifically addressed herein and which must be evaluated by the user.  The information furnished herein is believed to be
accurate and represents the best data currently available to us.  No warranty, expressed or implied, is made and STATLAB MEDICAL
PRODUCTS, INC. assumes no legal responsibility or liability whatsoever resulting from its use.
Statlab Medical Products, Inc.
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Material Safety Data Sheet
beta-Propiolactone MSDS
Section 1: Chemical Product and Company Identification
Product Name: beta-Propiolactone
Catalog Codes: SLP4486
CAS#: 57-57-8
RTECS: RQ7350000
TSCA: TSCA 8(b) inventory: beta-Propiolactone
CI#: Not available.
Synonym:   2-Oxetanone
Chemical Formula: C3H4O2
Contact Information:
Sciencelab.com, Inc.
14025 Smith Rd.
Houston, Texas 77396
US Sales: 1-800-901-7247
International Sales: 1-281-441-4400
Order Online: ScienceLab.com
CHEMTREC (24HR Emergency Telephone), call:
1-800-424-9300
International CHEMTREC, call: 1-703-527-3887
For non-emergency assistance, call: 1-281-441-4400
Section 2: Composition and Information on Ingredients
Composition:
Name CAS # % by Weight
{beta-}Propiolactone 57-57-8 100
Toxicological Data on Ingredients: beta-Propiolactone: VAPOR (LC50): Acute: 25 ppm 4 hour(s) [Rat].
Section 3: Hazards Identification
Potential Acute Health Effects:
Very hazardous in case of ingestion, of inhalation. Hazardous in case of skin contact (irritant), of eye contact (irritant). Slightly
hazardous in case of skin contact (permeator). Corrosive to skin and eyes on contact. Liquid or spray mist may produce tissue
damage particularly on mucous membranes of eyes, mouth and respiratory tract. Skin contact may produce burns. Inhalation
of the spray mist may produce severe irritation of respiratory tract, characterized by coughing, choking, or shortness of breath.
Severe over-exposure can result in death.
Potential Chronic Health Effects:
CARCINOGENIC EFFECTS: Classified + (PROVEN) by OSHA. Classified 2B (Possible for human.) by IARC. Classified
A2 (Suspected for human.) by ACGIH, 2 (Reasonably anticipated.) by NTP. MUTAGENIC EFFECTS: Not available.
TERATOGENIC EFFECTS: Not available. DEVELOPMENTAL TOXICITY: Not available. The substance is toxic to kidneys,
lungs, liver, digestive system. Repeated or prolonged exposure to the substance can produce target organs damage.
Repeated or prolonged contact with spray mist may produce chronic eye irritation and severe skin irritation. Repeated or
prolonged exposure to spray mist may produce respiratory tract irritation leading to frequent attacks of bronchial infection.
Repeated exposure to an highly toxic material may produce general deterioration of health by an accumulation in one or many
human organs.
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Section 4: First Aid Measures
Eye Contact:
Check for and remove any contact lenses. Immediately flush eyes with running water for at least 15 minutes, keeping eyelids
open. Cold water may be used. Do not use an eye ointment. Seek medical attention.
Skin Contact:
If the chemical got onto the clothed portion of the body, remove the contaminated clothes as quickly as possible, protecting
your own hands and body. Place the victim under a deluge shower. If the chemical got on the victim's exposed skin, such
as the hands : Gently and thoroughly wash the contaminated skin with running water and non-abrasive soap. Be particularly
careful to clean folds, crevices, creases and groin. Cold water may be used. If irritation persists, seek medical attention. Wash
contaminated clothing before reusing.
Serious Skin Contact:
Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate medical
attention.
Inhalation: Allow the victim to rest in a well ventilated area. Seek immediate medical attention.
Serious Inhalation:
Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or waistband. If
breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth resuscitation. WARNING: It may
be hazardous to the person providing aid to give mouth-to-mouth resuscitation when the inhaled material is toxic, infectious or
corrosive. Seek immediate medical attention.
Ingestion:
Do not induce vomiting. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that
the toxic material was ingested; the absence of such signs, however, is not conclusive. Loosen tight clothing such as a collar,
tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth resuscitation. Seek immediate medical attention.
Serious Ingestion: Not available.
Section 5: Fire and Explosion Data
Flammability of the Product: Combustible.
Auto-Ignition Temperature: Not available.
Flash Points: OPEN CUP: 70°C (158°F).
Flammable Limits: LOWER: 2.9%
Products of Combustion: These products are carbon oxides (CO, CO2).
Fire Hazards in Presence of Various Substances: Flammable in presence of heat.
Explosion Hazards in Presence of Various Substances:
Risks of explosion of the product in presence of mechanical impact: Not available. Risks of explosion of the product in
presence of static discharge: Not available.
Fire Fighting Media and Instructions:
SMALL FIRE: Use DRY chemical powder. LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Special Remarks on Fire Hazards: Not available.
Special Remarks on Explosion Hazards: Not available.
Section 6: Accidental Release Measures
Small Spill:
Dilute with water and mop up, or absorb with an inert dry material and place in an appropriate waste disposal container.
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Large Spill:
Combustible material. Corrosive liquid. Keep away from heat. Keep away from sources of ignition. Stop leak if without risk.
Absorb with DRY earth, sand or other non-combustible material. Do not get water inside container. Do not touch spilled
material. Use water spray curtain to divert vapor drift. Prevent entry into sewers, basements or confined areas; dike if needed.
Eliminate all ignition sources. Call for assistance on disposal. Be careful that the product is not present at a concentration level
above TLV. Check TLV on the MSDS and with local authorities.
Section 7: Handling and Storage
Precautions:
Keep locked up Keep container dry. Keep away from heat. Keep away from sources of ignition. Ground all equipment
containing material. Do not ingest. Do not breathe gas/fumes/ vapour/spray. Never add water to this product Wear suitable
protective clothing In case of insufficient ventilation, wear suitable respiratory equipment If ingested, seek medical advice
immediately and show the container or the label. Avoid contact with skin and eyes
Storage:
Flammable materials should be stored in a separate safety storage cabinet or room. Keep away from heat. Keep away from
sources of ignition. Keep container tightly closed. Keep in a cool, well-ventilated place. Ground all equipment containing
material. Keep container dry. Keep in a cool place.
Section 8: Exposure Controls/Personal Protection
Engineering Controls:
Provide exhaust ventilation or other engineering controls to keep the airborne concentrations of vapors below their respective
threshold limit value. Ensure that eyewash stations and safety showers are proximal to the work-station location.
Personal Protection:
Splash goggles. Lab coat. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.
Personal Protection in Case of a Large Spill:
Splash goggles. Full suit. Vapor respirator. Boots. Gloves. A self contained breathing apparatus should be used to avoid
inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist BEFORE handling this
product.
Exposure Limits:
TWA: 0.5 (ppm) TWA: 1.5 (mg/m3) Consult local authorities for acceptable exposure limits.
Section 9: Physical and Chemical Properties
Physical state and appearance: Liquid.
Odor: Pungent.
Taste: Not available.
Molecular Weight: 72.06 g/mole
Color: Colorless.
pH (1% soln/water): Not available.
Boiling Point: Decomposes. (155°C or 311°F)
Melting Point: -33.4°C (-28.1°F)
Critical Temperature: Not available.
Specific Gravity: 1.48 (Water = 1)
Vapor Pressure: 3.4 mm of Hg (@ 20°C)
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Vapor Density: 2.5 (Air = 1)
Volatility: Not available.
Odor Threshold: Not available.
Water/Oil Dist. Coeff.: Not available.
Ionicity (in Water): Not available.
Dispersion Properties: See solubility in water.
Solubility: Soluble in cold water.
Section 10: Stability and Reactivity Data
Stability: The product is stable.
Instability Temperature: Not available.
Conditions of Instability: Not available.
Incompatibility with various substances: Not available.
Corrosivity: Non-corrosive in presence of glass.
Special Remarks on Reactivity: Not available.
Special Remarks on Corrosivity: Not available.
Polymerization: Yes.
Section 11: Toxicological Information
Routes of Entry: Eye contact. Inhalation. Ingestion.
Toxicity to Animals:
WARNING: THE LC50 VALUES HEREUNDER ARE ESTIMATED ON THE BASIS OF A 4-HOUR EXPOSURE. Acute toxicity
of the vapor (LC50): 25 ppm 4 hour(s) [Rat].
Chronic Effects on Humans:
CARCINOGENIC EFFECTS: Classified + (PROVEN) by OSHA. Classified 2B (Possible for human.) by IARC. Classified
A2 (Suspected for human.) by ACGIH, 2 (Reasonably anticipated.) by NTP. The substance is toxic to kidneys, lungs, liver,
digestive system.
Other Toxic Effects on Humans:
Very hazardous in case of ingestion, of inhalation. Hazardous in case of skin contact (irritant). Slightly hazardous in case of
skin contact (permeator).
Special Remarks on Toxicity to Animals: Not available.
Special Remarks on Chronic Effects on Humans: Not available.
Special Remarks on other Toxic Effects on Humans: Not available.
Section 12: Ecological Information
Ecotoxicity: Not available.
BOD5 and COD: Not available.
Products of Biodegradation:
Possibly hazardous short term degradation products are not likely. However, long term degradation products may arise.
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Toxicity of the Products of Biodegradation: The products of degradation are more toxic.
Special Remarks on the Products of Biodegradation: Not available.
Section 13: Disposal Considerations
Waste Disposal:
Section 14: Transport Information
DOT Classification: CLASS 6.1: Poisonous material.
Identification: : Toxic liquids n.o.s. : UN2810 PG: Not available.
Special Provisions for Transport: Not available.
Section 15: Other Regulatory Information
Federal and State Regulations:
California prop. 65: This product contains the following ingredients for which the State of California has found to cause cancer,
birth defects or other reproductive harm, which would require a warning under the statute: beta-Propiolactone California prop.
65: This product contains the following ingredients for which the State of California has found to cause cancer which would
require a warning under the statute: beta-Propiolactone Pennsylvania RTK: beta-Propiolactone Florida: beta-Propiolactone
Minnesota: beta-Propiolactone Massachusetts RTK: beta-Propiolactone New Jersey: beta-Propiolactone TSCA 8(b) inventory:
beta-Propiolactone SARA 313 toxic chemical notification and release reporting: beta-Propiolactone CERCLA: Hazardous
substances.: beta-Propiolactone
Other Regulations: OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
Other Classifications:
WHMIS (Canada):
CLASS B-3: Combustible liquid with a flash point between 37.8°C (100°F) and 93.3°C (200°F). CLASS D-1A: Material causing
immediate and serious toxic effects (VERY TOXIC). CLASS D-2A: Material causing other toxic effects (VERY TOXIC). CLASS
E: Corrosive liquid.
DSCL (EEC):
R26- Very toxic by inhalation. R36/38- Irritating to eyes and skin. R45- May cause cancer.
HMIS (U.S.A.):
Health Hazard: 0
Fire Hazard: 2
Reactivity: 0
Personal Protection: h
National Fire Protection Association (U.S.A.):
Health: 0
Flammability: 2
Reactivity: 0
Specific hazard:
Protective Equipment:
Gloves. Lab coat. Vapor respirator. Be sure to use an approved/certified respirator or equivalent. Wear appropriate respirator
when ventilation is inadequate. Splash goggles.
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Section 16: Other Information
References: Not available.
Other Special Considerations: Not available.
Created: 10/09/2005 06:12 PM
Last Updated: 06/09/2012 12:00 PM
The information above is believed to be accurate and represents the best information currently available to us. However, we
make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume
no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for
their particular purposes. In no event shall ScienceLab.com be liable for any claims, losses, or damages of any third party or for
lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if ScienceLab.com
has been advised of the possibility of such damages.
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 5.2 
Revision Date 11/05/2012 
Print Date 02/11/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Sodium pyruvate 
 
Product Number : 80443 
Brand : Sigma-Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS). 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Formula : C3H3NaO3  
Molecular Weight : 110.04 g/mol 
 
No ingredients are hazardous according to OSHA criteria. 
 
4. FIRST AID MEASURES 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
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In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
Keep in a dry place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
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Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form powder 
 
Colour white 
Safety data 
pH 7 
 
Melting 
point/freezing point 
Melting point/range: > 300 °C (> 572 °F) - lit. 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility soluble 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
no data available 
Inhalation LC50 
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no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
no data available 
Serious eye damage/eye irritation 
no data available 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
 
Teratogenicity 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: Not available 
 
12. ECOLOGICAL INFORMATION 
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Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium pyruvate 
CAS-No. 
113-24-6 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium pyruvate 
CAS-No. 
113-24-6 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
 Sigma-Aldrich - 80443 Page 6  of  6 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 4.3 
Revision Date 12/31/2012 
Print Date 02/11/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : Sodium bicarbonate 
 
Product Number : S8875 
Brand : Sigma-Aldrich 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS). 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
Synonyms : Sodium hydrogen carbonate 
 
Formula : CHNaO3  
Molecular Weight : 84.01 g/mol 
 
No ingredients are hazardous according to OHSA criteria. 
 
4. FIRST AID MEASURES 
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If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid dust formation. Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Sweep up and shovel. Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Precautions for safe handling 
Provide appropriate exhaust ventilation at places where dust is formed.  
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection is not required. Where protection from nuisance  levels of dusts are desired, use type N95 
(US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate 
government standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Full contact 
Material: Nitrile rubber 
Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
Splash protection 
Material: Nitrile rubber 
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Minimum layer thickness: 0.11 mm 
Break through time: 480 min 
Material tested:Dermatril® (KCL 740 / Aldrich Z677272, Size M) 
 
data source: KCL GmbH, D-36124 Eichenzell, phone +49 (0)6659 87300, e-mail sales@kcl.de, test method: EN374 
If used in solution, or mixed with other substances, and under conditions which differ from EN 374, contact the 
supplier of the CE approved gloves. This recommendation is advisory only and must be evaluated by an Industrial 
Hygienist familiar with the specific situation of anticipated use by our customers. It should not be construed as 
offering an approval for any specific use scenario. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the 
specific work-place., The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form crystalline 
 
Colour no data available 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
300 °C (572 °F) 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Auto-ignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density 2.160 g/cm3 
 
Water solubility 50 g/l 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapor 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
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Possibility of hazardous reactions 
no data available 
Conditions to avoid 
Exposure to moisture. 
Materials to avoid 
Strong acids, Strong oxidizing agents 
Hazardous decomposition products 
Hazardous decomposition products formed under fire conditions. - Carbon oxides, Sodium oxides 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
LD50 Oral - rat - 4,220 mg/kg 
Inhalation LC50 
no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
Skin - Human - Mild skin irritation - 3 d 
Serious eye damage/eye irritation 
Eyes - rabbit - Mild eye irritation - 30 s 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
 
no data available 
Teratogenicity 
no data available 
 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
 Sigma-Aldrich - S8875 Page 5  of  6 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
Exposure to large amounts can cause:, Gastrointestinal disturbance, Heavy or prolonged skin exposure may result in the 
absorption of harmful amounts of material. 
Synergistic effects 
no data available 
Additional Information 
RTECS: VZ0950000 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
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SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
Sodium hydrogencarbonate 
CAS-No. 
144-55-8 
Revision Date 
 
New Jersey Right To Know Components 
 
Sodium hydrogencarbonate 
CAS-No. 
144-55-8 
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
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SIGMA-ALDRICH sigma-aldrich.com 
Material Safety Data Sheet 
Version 5.1 
Revision Date 01/20/2012 
Print Date 04/07/2013 
 
1. PRODUCT AND COMPANY IDENTIFICATION 
Product name : EX-CELL(TM) 420 w/L-glutamine 
 
Product Number : 24420C 
Brand : Sigma 
 
Supplier : Sigma-Aldrich 
3050 Spruce Street 
SAINT LOUIS MO  63103 
USA 
   
Telephone : +1 800-325-5832 
Fax : +1 800-325-5052 
Emergency Phone # (For 
both supplier and 
manufacturer) 
: (314) 776-6555 
Preparation Information : Sigma-Aldrich Corporation 
Product Safety - Americas Region 
1-800-521-8956 
 
2. HAZARDS IDENTIFICATION 
Emergency Overview 
OSHA Hazards 
No known OSHA hazards 
 
Not a dangerous substance or mixture according to the Globally Harmonised System (GHS). 
HMIS Classification 
Health hazard: 0 
Flammability: 0 
Physical hazards: 0 
NFPA Rating 
Health hazard: 0 
Fire: 0 
Reactivity Hazard: 0 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Ingestion May be harmful if swallowed.  
 
3. COMPOSITION/INFORMATION ON INGREDIENTS 
 
No ingredients are hazardous according to OHSA criteria. 
 
4. FIRST AID MEASURES 
If inhaled 
If breathed in, move person into fresh air. If not breathing, give artificial respiration. 
In case of skin contact 
Wash off with soap and plenty of water. 
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In case of eye contact 
Flush eyes with water as a precaution. 
If swallowed 
Never give anything by mouth to an unconscious person. Rinse mouth with water. 
 
5. FIREFIGHTING MEASURES 
Conditions of flammability 
Not flammable or combustible. 
Suitable extinguishing media 
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. 
Special protective equipment for firefighters 
Wear self contained breathing apparatus for fire fighting if necessary. 
Hazardous combustion products 
 
6. ACCIDENTAL RELEASE MEASURES 
Personal precautions 
Avoid breathing vapors, mist or gas. 
Environmental precautions 
Do not let product enter drains. 
Methods and materials for containment and cleaning up 
Keep in suitable, closed containers for disposal. 
 
7. HANDLING AND STORAGE 
Conditions for safe storage 
Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed 
and kept upright to prevent leakage.  
 
8. EXPOSURE CONTROLS/PERSONAL PROTECTION 
 
Contains no substances with occupational exposure limit values. 
Personal protective equipment 
Respiratory protection 
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK (EU EN 14387) 
respirator cartridges. Use respirators and components tested and approved under appropriate government 
standards such as NIOSH (US) or CEN (EU). 
Hand protection 
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching 
glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in 
accordance with applicable laws and good laboratory practices. Wash and dry hands. 
 
Eye protection 
Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH 
(US) or EN 166(EU). 
Skin and body protection 
impervious clothing, The type of protective equipment must be selected according to the concentration and amount 
of the dangerous substance at the specific workplace. 
Hygiene measures 
General industrial hygiene practice. 
 
9. PHYSICAL AND CHEMICAL PROPERTIES 
Appearance 
Form liquid 
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Colour no data available 
Safety data 
pH no data available 
 
Melting 
point/freezing point 
no data available 
 
Boiling point no data available 
 
Flash point no data available 
 
Ignition temperature no data available 
 
Autoignition 
temperature 
no data available 
 
Lower explosion limit no data available 
 
Upper explosion limit no data available 
 
Vapour pressure no data available 
 
Density no data available 
 
Water solubility no data available 
 
Partition coefficient: 
n-octanol/water 
no data available 
 
Relative vapour 
density 
no data available 
 
Odour no data available 
 
Odour Threshold no data available 
 
Evaporation rate no data available 
 
 
10. STABILITY AND REACTIVITY 
Chemical stability 
Stable under recommended storage conditions.  
Possibility of hazardous reactions 
no data available 
Conditions to avoid 
no data available 
Materials to avoid 
no data available 
Hazardous decomposition products 
Other decomposition products - no data available 
 
11. TOXICOLOGICAL INFORMATION 
Acute toxicity 
Oral LD50 
no data available 
Inhalation LC50 
no data available 
Dermal LD50 
no data available 
Other information on acute toxicity 
no data available 
Skin corrosion/irritation 
no data available 
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Serious eye damage/eye irritation 
Eyes: no data available 
Respiratory or skin sensitization 
no data available 
Germ cell mutagenicity 
no data available 
 
Carcinogenicity 
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as 
probable, possible or confirmed human carcinogen by IARC. 
ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by ACGIH. 
NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a 
known or anticipated carcinogen by NTP. 
OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a 
carcinogen or potential carcinogen by OSHA. 
Reproductive toxicity 
no data available 
 
Teratogenicity 
 
no data available 
Specific target organ toxicity - single exposure (Globally Harmonized System) 
no data available 
Specific target organ toxicity - repeated exposure (Globally Harmonized System) 
no data available 
Aspiration hazard 
no data available 
Potential health effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.  
Ingestion May be harmful if swallowed.  
Skin May be harmful if absorbed through skin. May cause skin irritation.  
Eyes May cause eye irritation.  
Signs and Symptoms of Exposure 
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. 
Synergistic effects 
no data available 
Additional Information 
RTECS: Not available 
 
12. ECOLOGICAL INFORMATION 
Toxicity 
 
no data available 
Persistence and degradability 
no data available 
Bioaccumulative potential 
no data available 
Mobility in soil 
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no data available 
PBT and vPvB assessment 
no data available 
Other adverse effects 
no data available 
 
13. DISPOSAL CONSIDERATIONS 
Product 
Offer surplus and non-recyclable solutions to a licensed disposal company.  
Contaminated packaging 
Dispose of as unused product.  
 
14. TRANSPORT INFORMATION 
DOT (US) 
Not dangerous goods 
 
IMDG 
Not dangerous goods 
 
IATA 
Not dangerous goods 
 
15. REGULATORY INFORMATION 
OSHA Hazards 
No known OSHA hazards  
SARA 302 Components 
SARA 302: No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302. 
SARA 313 Components 
SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold 
(De Minimis) reporting levels established by SARA Title III, Section 313. 
SARA 311/312 Hazards 
No SARA Hazards 
Massachusetts Right To Know Components 
No components are subject to the Massachusetts Right to Know Act. 
Pennsylvania Right To Know Components 
 
EX-CELL(TM) 420 w/L-glutamine 
CAS-No. 
 -  
Revision Date 
 
New Jersey Right To Know Components 
 
EX-CELL(TM) 420 w/L-glutamine 
CAS-No. 
 -  
Revision Date 
 
California Prop. 65 Components 
This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other 
reproductive harm. 
 
16. OTHER INFORMATION 
Further information 
Copyright 2012 Sigma-Aldrich Co. LLC. License granted to make unlimited paper copies for internal use only. 
The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a 
guide. The information in this document is based on the present state of our knowledge and is applicable to the 
product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the 
product. Sigma-Aldrich Corporation and its Affiliates shall not be held liable for any damage resulting from handling or 
from contact with the above product. See www.sigma-aldrich.com and/or the reverse side of invoice or packing slip for 
additional terms and conditions of sale. 
turning science into solutions
Biosafe®
Single-Use Aseptic Transfer Systems
A Complete Range… 
…of Bags for a Variety of Applications
The Biosafe range of bags is designed 
to best fit your requirements for aseptic 
transfer of stoppers, pumps, tools,  
QC test devices, fluids and powders 
into critical processing areas.
Autoclavable Biosafe Bags
– Open autoclavable Biosafe bags 
are filled on-site prior to autoclave 
sterilization and aseptic transfer.
– Prefilled autoclavable Biosafe bags 
are delivered ready-to-sterilize by 
your component supplier.
– Entry of stoppers, tools, pump into 
isolators, RABS and cleanrooms.
Gamma Irradiatable Biosafe Bags
– Prefilled Biosafe bags are delivered gamma sterilized 
by your component supplier for the entry of stoppers 
(prefillable syringe, vial, carpule), QC test devices and 
any other gamma sterilizable parts.
– Gamma irradiated Biosafe bags are used for the removal of
waste, tools, pumps and QC test devices from critical areas.
– Rapid Aseptic Fluid Transfer (RAFT) System is a sterile 
system designed for the aseptic transfer of liquids.
Dummy Service Connector
For sterilization and maintenance 
of the Biosafe Ports.
Gamma Irradiated 
Double-Connector Biosafe Bags
Specifically designed for the two-step
transfer of components from autoclave
(using the Biosafe Biosteam Port) into
an isolator.
The Biosafe® Port
The Biosafe range of aseptic transfer
ports offers reliable and easy-to-use
solutions that meet your specific 
needs and applications. The unique
design of the Biosafe system 
enables the secure transfer 
of components, fluids and 
powders while maintaining 
the integrity of the 
critical area.
Biosafe Monolever Port
For the aseptic transfer 
of components and 
fluids into isolators, 
RABS and cleanrooms.
Biosafe Biosteam® Port
– When installed on autoclaves, the
steamable version of the Biosafe Port
allows reliable aseptic discharging 
of bulk stoppers from the autoclave 
into double-connector gamma 
irradiated bags prior to transfer 
into an isolator.
– Allows the contained addition 
of powders into formulation 
vessels.
Biosafe Automatic Port
Automated aseptic 
transfer of components
into isolators and RABS.
The 
Highest 
Quality 
Assurance
– Manufactured in ISO 9001 
and ISO 13485 certified facilities
– 100% quality control on Biosafe 
Ports – Dimensional and leak testing
– 100% quality control on Biosafe bag 
connector assemblies
– Biosafe bags assembled in Class C 
(ISO 7) cleanrooms
Biosafe Three-Lever Port
For the aseptic transfer of 
fluids into cleanrooms.
Achieving Safe, Easy-to-Use & Reliable Aseptic Transfer
Enhanced Sterility Assurance in 
Aseptic Processing
– Offers a contained and single-use 
technology for safer aseptic transfer.
– Limits the number and complexity of 
personnel interventions in the aseptic
processing area. 
– Offers a completely closed aseptic
process.
Safer Processing of Potent Drugs
– Maintains the barrier integrity of RABS
and isolators and security of operators.
Ease-of-Use
– The magnet on the port allows easy 
centering and secure docking of the
Biosafe bag.
Process Safety
– Mechanical interlock securities prevent
door opening when a bag is not connect-
ed or from disconnecting a bag if the
Biosafe Port is not closed.
– Automatic inter-door vacuum integrity
test of Biosafe Port and connector.
Versatile Technoloy
– The range of Biosafe systems is designed
to best fit a variety of applications while
ensuring a high level of containment. 
– Biosafe is a unique technology for the
aseptic transfer of components, fluids
and powders.
Simplified Maintenance and Sterilization
– When connected to the Biosafe Port, the
dummy service connector facilitates the
sterilization of the critical area, the inner
side of the Biosafe Port and maintenance
operations.
Proven Containment
– Biosafe Ports and connectors are 100%
leak tested during production.
– Packaging Biosafe bags under vacuum
can offer an additional guaranty of
integrity.
Practical and Economical Benefits
– The Biosafe bags eliminate cleaning and
sterilization required for traditional
transfer containers.
– The RAFT System simplifies facility 
layout and reduces higher classification
cleanroom area by keeping large volume
support solutions outside the cleanroom.
1 2 3
In|Out Aseptic Transfer Clean- Isolator RABS Auto- Formulation
into room clave vessel
Biosafe 110 Three-Lever TTI Port •
Biosafe 110 Monolever Port • • •*
Biosafe 110 Automatic Port • •*
Biosafe 110 Biosteam Port • •
* The Biosafe Port with outside opening is the best choise to prevent air turbulence in RABS
Biosafe Aseptic Transfer Systems
1. Biosafe bag approach
2. Magnetic docking
3. Transfer
Services to Filling Line in Aseptic Processing
Removal of waste
The RAFT System is used
for the aseptic transfer
of bulk final product
onto the filling line
within an isolator, 
RABS or cleanroom.
Entry of sterile fluid
Removal of
Petri dishes
Applied to filling lines, the
Biosafe technology is the
answer to a variety af aseptic
transfer applications around
the filling process.
Entry of tools
Entry of QC test devices
The inner sleeve of Biosafe
bags guides the components
during transfer.
Entry of stoppers or caps
Bulk autoclave discharging
with the Biosafe Biosteam
Port on the autoclave.
Entry of stoppers or caps
Upstream & Downstream Processing
Seed 
transfer
Transfer of
cell culture
media and
other solu-
tions to
bioreactor
Transfer of
buffers for
centrifuga-
tion and 
clarification
Transfer of
buffers to
chromato-
graphy
Transfer of
buffers to
purification
Transfer of
buffers to
recovery
operation
Transfer of
buffers to
chromato-
graphy 
column
Transfer of
buffers to
UF/DF system
Transfer of
powder for
buffer and
media 
formulation
The RAFT System provides easy-to-use and
reliable through-the-wall aseptic transfer
of fluids between biomanufacturing zones.
The attached diagram demonstrates 
segregation of media and buffer solutions
maintained in the materials hall, enabling
substantial reduction of higher classifi-
cation cleanroom areas.
The Biosafe Biosteam Port can 
be cleaned and sterilized in-place
along with the formulation vessel.
The Biosafe bags are used for the
contained transfer of powders for
media and buffer preparation.
Entry of powder
Sales and Service Contacts
For further contacts, visit www.sartorius-stedim.com
Europe
Germany
Sartorius Stedim Biotech GmbH
August-Spindler-Strasse 11
37079 Goettingen
Phone +49.551.308.0
Fax +49.551.308.3289
www.sartorius-stedim.com 
Sartorius Stedim Systems GmbH
Schwarzenberger Weg 73–79
34212 Melsungen
Phone +49.5661.71.3400
Fax +49.5661.71.3702
www.sartorius-stedim.com
France
Sartorius Stedim Biotech S.A.
Z.I. des Paluds
Avenue de Jouques – BP 1051
13781 Aubagne Cedex
Phone +33.442.845600
Fax +33.442.845619
Sartorius Stedim France
4, rue Emile Baudot
91127 Palaiseau Cedex
Phone +33.1.6919.2100
Fax +33.1.6920.0922
Austria
Sartorius Stedim Austria GmbH
Franzosengraben 12
A-1030 Vienna
Phone +43.1.7965763.18
Fax +43.1.796576344
Belgium
Sartorius Stedim Belgium N.V.
Leuvensesteenweg, 248/B
1800 Vilvoorde
Phone +32.2.756.06.80
Fax +32.2.756.06.81
Denmark
Sartorius Stedim Nordic A/S
Hoerskaetten 6D, 1.
DK-2630 Taastrup
Phone +45.7023.4400
Fax +45.4630.4030
Italy
Sartorius Stedim Italy S.p.A.
Via dell’Antella, 76/A
50012 Antella-Bagno a Ripoli (FI)
Phone +39.055.63.40.41
Fax +39.055.63.40.526
Netherlands
Sartorius Stedim Netherlands B.V.
Edisonbaan 24
3439 MN Nieuwegein
Phone +31.30.6025080
Fax +31.30.6025099
Spain
Sartorius Stedim Spain SA
C/Isabel Colbrand 10–12, 
Planta 4, Oficina 121
Polígono Industrial de Fuencarral
28050 Madrid
Phone +34.91.3586102
Fax +34.91.3588804
Switzerland
Sartorius Stedim Switzerland GmbH
Lerzenstrasse 21
8953 Dietikon
Phone +41.1.746.50.00
Fax +41.1.746.50.50
U.K.
Sartorius Stedim UK Limited
Longmead Business Park
Blenheim Road, Epsom
Surrey KT19 9 QQ
Phone +44.1372.737159
Fax +44.1372.726171
America
USA
Sartorius Stedim North America Inc.
131 Heartland Blvd.
Edgewood, New York 11717
Toll-Free +1.800.368.7178
Fax +1.631.254.4253
Sartorius Stedim SUS Inc.
1910 Mark Court
Concord, CA 94520
Phone +1.925.689.6650
Toll Free +1.800.914.6644
Fax +1.925.689.6988
Asia|Pacific
India
Sartorius Stedim India Pvt. Ltd.
10, 6th Main, 3rd Phase Peenya
KIADB Industrial Area
Bangalore – 560 058
Phone +91.80.2839.1963|0461
Fax +91.80.2839.8262
Japan
Sartorius Stedim Japan K.K.
KY Building, 8–11 
Kita Shinagawa 1-chome
Shinagawa-ku
Tokyo 140-0001
Phone +81.3.3740.5407
Fax +81.3.3740.5406
Malaysia
Sartorius Stedim Malaysia Sdn. Bhd.
Lot L3-E-3B, Enterprise 4
Technology Park Malaysia
Bukit Jalil
57000 Kuala Lumpur
Phone +60.3.8996.0622
Fax +60.3.8996.0755
Singapore
Sartorius Stedim Singapore Pte. Ltd.
10, Science Park Road, The Alpha
#02-25, Singapore Science Park 2
Singapore 117684
Phone +65.6872.3966
Fax +65.6778.2494
Australia
Sartorius Stedim Australia Pty. Ltd.
Unit 17/104 Ferntree Gully Road
Waverley Business Park
East Oakleigh, Victoria 3166
Phone +61.3.9590.8800
Fax +61.3.9590.8828
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Sartorius Stedim Aseptics S.A
Z.I. de Saux 
Rue Ampère
65000 Lourdes
Phone +33.5.62.42.73.73
Fax +33.5.62.42.08.44
Biosafe and Biosteam are 
registered trademarks of 
Sartorius Stedim Aseptics S.A.
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Sterile Tube Fuser &  
Hot Lips Tube Sealer®   
 
 
Catalog 
The Sterile Tube Fuser and Hot Lips Tube Sealer II provide a complete solution to aseptic fluid 
handling in pharmaceutical and biotech environments.  These products allow for leakproof 
aseptic connections and thermal seals of large bore thermoplastic tubing.  This catalog 
includes features, specifications and pricing information for both products.  Please contact 
Wave Biotech for additional technical or validation information. 
 
                                                                                    
  
    
                                                                                                                                                                                
   
 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sterile Tube Fuser - IRc 
    Hot Lips Tube Sealer II 
 
Sterile Tube Fuser - IRcWW 
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The Sterile Tube Fuser  
 
is a fully automated device for welding together thermoplastic tubing in a sterile operation 
without the need for a laminar flow cabinet. The machine is useful for connecting tubing 
between sterile containers, bags, and process equipment. The unit can connect large diameter 
(up to 7/8” OD) tubing for the rapid and easy transfer of large volumes. Major uses are 
bioprocessing and aseptic pharmaceutical applications. 
 
The compact Sterile Tube Fuser (STF-IRc) uses infrared technology to control depyrogenation 
and welding temperatures.  Disposable, single-use, PTFE coated blades are used in the 
process.  The new, long awaited wet welding model, STF-IRcWW allows welding of liquid-filled 
C-Flex tubing. 
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Applications 
 
? Sterile media and buffer transfer. 
? Connection of bioreactors for feed and harvest. 
? Process fluid transfer. 
? In-process pooling. 
? Final fill operations. 
 
 
 
Features 
 
? Welds any thermoplastic tubing from 6.4mm to 22.2mm OD (! in. to 7/8 in.) using 
interchangeable holders. 
? Wet welding of 6.4,11.2,12.5 and 15.5mm OD C-Flex available in STF-IRcWW model. 
? Use C-Flex®, PharMed®, Tygon®/PVC or similar tubing. 
? Thermal weld provides exceptional strength. 
? Make aseptic connections without a laminar flow cabinet. 
? New, more compact design; portable. 
? User-programmable for various tubing types. 
? Requires only electrical service. 110/220VAC universal voltage. 
? Proven, validated performance for GMP operations. 
 
 
Specifications 
 
Power:    110/220 VAC (auto switching) 1 Amp max.  
Size:    381mm x 325mm x 254mm (15” L x 13” W x 10” H) 
Weight:    16 Kg  (35 lbs) 
Max tubing OD:   22mm  (7/8”) 
Min tubing OD:   6.4mm  (!”) 
Approvals:    CE, EMV 
Typical fusing cycle:  ~2 minutes 
Cutting blades:   non-sterile, PTFE-coated, single-use 
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Quick Selection Guide - COMPONENTS 
PART NUMBER DESCRIPTION IMAGE 
STF-IRc 
 
Sterile Tube Fuser -IRc -Compact - equipped with TUBE1-IR 
(15.5mm OD tube holder set).  Pre-programmed for C-Flex, 
Sanipure ,PharMed and Tygon/PVC. 110/220VAC (auto 
switching).   
 
 
STF-IRcWW Sterile Tube Fuser - IRc for Liquid-Filled Welding - equipped 
with TUBE1 -IR/WW (15.5mm OD wet welding tube holder 
set).  Pre-programmed for C-Flex.  110/220VAC universal 
voltage.   
 
 
TUBE1-IR Tube holder set for 15.5mm  (5/8”) OD tubing. 
TUBE2-IR Tube holder set for 19.1mm (3/4”) OD tubing. 
TUBE3-IR Tube holder set for 11.2mm (7/16” ) OD tubing. 
TUBE4-IR Tube holder set for 6.4mm (1/4”) OD tubing. 
TUBE5-IR Tube holder set for 8.0mm (5/16”) OD tubing. 
TUBE6-IR Tube holder set for 9.6mm (3/8”) OD tubing. 
TUBE7-IR Tube holder set for 12.5mm (1/2”) OD tubing. 
TUBE8-IR Tube holder set for 22.2mm (7/8”) OD tubing. 
 
TUBE1-IR/WW Tube holder set for 15.5mm (5/8”) OD tubing.  For use with 
wet welding STF-IRcWW only. 
TUBE3-IR/WW Tube holder set for 11.2mm (7/16”) OD tubing.  For use 
with wet welding STF-IRcWW only. 
TUBE4-IR/WW Tube holder set for 6.4mm (1/4”) OD tubing.  For use 
with wet welding STF-IRcWW only. 
TUBE7-IR/WW Tube holder set for 12.5mm (1/2”) OD tubing.  For use 
with wet welding STF-IRcWW only. 
 
BLADES-IR/50 Single use stainless steel cutting blades with PTFE coating. 
Non-sterile. 50 blades/package.  
STF-IRc.003214 
 
Two color thermal printer option for compact Sterile Tube 
Fuser - IRc.  Includes one roll of paper. 
 
STF-IRc-CALKIT Calibration verification kit for Sterile Tube Fuser.  Includes Maintenance manual, Validation 
documents, PCKit, BLADESENSOR-K, & security key for access. 
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The Hot Lips Tube Sealer II 
 
is an ultraportable device for heat sealing thermoplastic tubing.  The leakproof, tamperproof 
seal produced is ideal for ensuring inoculum, products, media and buffers do not leak as with 
tubing clamps or plugs on bioprocess bags and other vessels.   Hot Lips is a fully automated 
device for sealing thermoplastic tubing from 6.4mm (1/4") OD to 31.8mm (1.25") OD in a sterile 
operation without the need for a laminar flow hood.  Major uses are for sealing bags prior to 
transport, or after sampling and process fluid transfer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Applications 
 
? Use wherever a tamperproof, leakproof seal is desired. 
? Sealing bioprocess bags and bioreactors. 
? In-process pooling. 
? Sampling operations. 
? Storage vessel closure. 
 
 
Features 
 
? Seals any thermoplastic tubing from 6.4mm (1/4") OD to 31.8mm (1.25") OD. 
? Use PharMed, C-Flex, PVC, Sanipure or similar tubing. 
? Thermal seal provides tamperproof protection. 
? Compact and ultraportable. 
? User-programmable for various tubing types. 
? Requires only electrical service 110/220VAC, auto switching. 
? No compressed air or cooling water needed. 
? No accessories required for operation. 
? Made in the U.S.A. Proven, validatable performance. 
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Specifications 
 
Power:   110/220 VAC universal voltage  
Size:   165mm x 356mm x 203mm  (6.5” W x 14” D x 8” H) 
Weight:   8 Kg (18 lb) 
Max tubing OD:   31.8mm (1.25”) 
Min tubing OD:   6.4mm (0.25” ) 
Typical sealing cycle:   <2 minutes 
 
 
 
Quick Selection Guide - COMPONENTS 
PART NUMBER DESCRIPTION IMAGE 
HLTS-II 
 
Hot Lips Tube Sealer II - pre-programmed to 
thermally seal C-Flex, Sanipure, PVC, Tygon, 
& PharMed thermoplastic tubing 6.4mm (1/4") 
OD to 31.8mm (1.25") OD.  110/220VAC 
(auto switching) universal voltage.  Please 
confirm plug type required where applicable. 
No accessories or disposables required. 
 
HLTS-PCKIT PC kit for Hot Lips Tube Sealer.  Allows user reset of register and reprogramming.  
Includes hardware and software. 
HLTS-II-CALKIT Calibration verification kit includes Maintenance manual, Validation documents, PCKit 
with security key and jaw distance calibration tool. 
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Features Benefits
Multiple manu- High security of supply
facturing sites
All connections Safe and robust
extensively qualified
Full compliance Highest sterility 
with ISO11137 assurance level
Standard design Most designs available
from stock
Designed to fit Market leading  
Palletank® space saving bag 
containment system
3” ID bottom drain Quick transfer of
process fluid
Various bag & filter  High flexibility
sizes
Standard Flexel® 3D for Palletank®
Bag Chamber:  Multiple layer film
construction, 
including EVOH gas
barrier layer
ULDPE contact layer
Tubing: Silicone, TPE
Fittings: MPX Couplings,
Female Luer Lock, 
MPC Male Coupling,
Triclamp, Needle-less
sampling port
Filters: Sartopore® 2 Gamma
Filter Capsule
Volumes: 100 L–1,000 L
Number of Ports: Standard silicone:
100 L–1,000 L: 3 
(2 top, 1 bottom)
Standard TPE: 
100 L–1,000 L: 4 
(3 top, 1 bottom)
Standard TPE 
& Sartopore® 2: 
100 L–1,000 L: 4 
(3 top, 1 bottom)
Sterilization: by Gamma Irradiation
Standard Flexel® 3D bioprocessing bags 
for Palletank® (US and Canada)
Description 
Flexel® 3D standard bags are designed for
processing, storage and transport of large
volume biopharmaceutical solutions in 
Sartorius Stedim Biotech’s proven Palletank®
containers. They provide a single-use alterna-
tive to traditional stainless steel vessels in a
large variety of applications.
Cost reduction and risk reduction
Single-use systems used in biopharmaceutical
manufacturing improve process safety as they
reduce the risk of cross contamination from
batch-to-batch and product-to-product.
Costly and time consuming CIP & SIP opera-
tions are minimized. This results not only 
in significant cost savings within the entire
manufacturing process, but also in the 
optimization of capacity utilization.
Applications
The multi-layer film construction of different
materials provides a strong structure with low
gas permeability and high chemical resistance
for the safe processing of a wide range of
biopharmaceutical fluids in a variety of 
applications such as:
– Buffers and media filtration & storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate filtration & hold
– Final product storage and transport
Flexibility
Standard Flexel® 3D bags are available as
stand-alone bags with silicone tubing, stand-
alone bags with C-Flex tubing and filter &
bag assemblies incorporating a variety of 
filter and bag sizes allowing easy adoption to
process volume and media. Multiple configu-
rations that also integrate thermoweldable 
TPE tubing are provided for flexible incor-
poration into your process. Thus, sterile con-
nection and disconnection devices like the 
BioWelder® and the BioSealer® can be used 
to allow safe connections and disconnections
from and to another process step. 
Female luer fittings with a needle free 
sampling port may be used for easy and 
convenient sampling, quick connects may 
be attached directly or adapted to a variety 
of connections and tri-clamps that are 
widely used in a production environment
assure maximum flexibility.
Fast operation
The new defined range of standard Flexel® 3D
bag systems incorporates 1,000 L standard
bag solutions that enable the user to empty
the bags quickly through a 3” ID tubing. 
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Security of Supply
Sartorius Stedim Biotech has established 
multiple manufacturing sites with consistent
industrial processes. The expertise of design-
ing Single Use solutions combined with 
collaborative supplier management and 
customer demand planning assures a state of
the art product supported by a robust supply
chain that can cope with strong market
growth.
Validation
Flexel® bags have been qualified applying the
most comprehensive and innovative test
regimes. Biological, chemical and physical
tests combined with extensive extractable
testings provide users of Flexel® 3D bags with
data representing the widest range of process
fluids in a variety of processing conditions. 
Full compliance with ISO11137 allows for a
validated claim of sterility on all Sartorius
Stedim Biotech single-use products with 
a sterility assurance level of 10-6 over the
shelf life. 
Quality Assurance
Sartorius Stedim Biotech Quality Systems for
Single-use products follow applicable ISO and
FDA regulations for Medical Devices. Design,
Manufacture and Sterilization processes are
conducted under conditions that mirror 
biopharmaceutical operations and meet
cGMP requirements.
Flexel® 3D bags for Palletank® are tested for
compliance to:
– USP <87>: Biological reactivity tests, 
in Vitro
– USP <88>: Biological reactivity tests, in Vivo
– USP <661>: Tests for plastic
– USP <788> and E.P. 2.9.19 : Particulate
– ISO 11737 : Bioburden
– ISO 11137 : Sterilization of Medical Devices
Supply Chain
The majority of standard Flexel® 3D bags 
for Palletank® systems are available from
stock. 
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Ordering Information
1. Standard Flexel® 3D bags with silicone tubes
Standard Flexel® 3D bags with silicone tubes (100 L to 500 L) Standard Flexel® 3D bags with silicone tubes (1,000 L)
Part number Description Tubing Top Port 1 Top Port 2  Bottom Port 1 Qty/Box
FXB207591 Flexel® 100L Silicone 1/2" + 11/16" + 1.5 m (60"), 1/2" + 11/16" + 1.5 m (60"), 1/2" + 11/16" + 1 m (40") 10
for Palletank® 1/2" MPX female + sealing plug 1/2" MPX female + sealing plug 1/2" MPX male 
with GammaTag™ + sealing cap
FXB207592 Flexel® 200L Silicone 1/2" + 11/16" +1.5 m (60"), 1/2" + 11/16" + 1.5 m (60"), 1/2" + 11/16" + 1 m (40"),  10
for Palletank® 1/2" MPX female + sealing plug 1/2" MPX female + sealing plug 1/2" MPX male 
with GammaTag™ + sealing cap
FXB207593 Flexel® 500L Silicone 1/2" + 11/16" + 1.5 m (60"), 1/2" + 11/16" + 1.5 m (60"),  1/2" + 11/16" + 1 m (40"),  3
for Palletank® 1/2" MPX female + sealing plug 1/2" MPX female + sealing plug 1/2" MPX male 
with GammaTag™ + sealing cap
Part number Description Tubing Top Port 1 Top Port 2 Bottom Port 1 Bottom Port 2 Qty/Box
FXB207595 Flexel® 1000L Silicone 1/2" + 11/16" + 1.5 m 1/2" + 11/16" + 1.5 m 1/2" + 11/16" + 1 m 1/2" + 11/16" + 1 m 5
for Palletank® (60") (60") (40") (40") 
– Silicone 1/2" MPX female 1/2" MPX male 1/2" MPX male 1/2" MPX male 
+ sealing plug + sealing plug + sealing cap + sealing cap
1
2
Bottom port 
11
1
1
1
1
1
2
Bottom port 1Bottom port 2
11
1
1
1
1
1
1
Ordering Information
2. Standard Flexel® 3D bags with TPE tubes
Standard Flexel® 3D bags with TPE tubes (100 L to 500 L) Standard Flexel® 3D bags with TPE tubes (1,000 L) Standard Flexel® 3D bags with TPE tubes 
High Flow Rate (1,000 L)
Part number Description Tubing Top Port 1 Top Port 2 Top Port 3 Bottom Port 1 Qty/Box
FXB110925 Flexel® 100L  Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 4
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– PTE 374 1/2" MPX male 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
+ sealing cap sampling port
FXB110927 Flexel® 200L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 1/2" MPX male 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
+ sealing cap sampling port
FXB110929 Flexel® 500L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 1/2" MPX male 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
+ sealing cap sampling port
FXB110930 Flexel® 1000L  Silicone  1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 1/2" MPX male 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
+ sealing cap sampling port
FXB111157 Flexel® 1,000L Silicone 1/2"+ 3/4"+ 1.5 m 3/4"+ 1-1/8"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 3/4"+ 1-1/8"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– HIGH FLOW 374 1/2" MPX male silicone LL female + needle free silicone
– TPE + sealing cap 1-1/2" Tri-Clamp sampling port 1-1/2" Tri-Clamp
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Ordering Information
3. Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps
Standard Flexel® 3D bags with TPE tubes and  Standard Flexel® 3D bags with TPE tubes and Standard Flexel® 3D bags with TPE tubes and 
Sartopore® 2 Gamma MidiCaps (100 L to 500 L) Sartopore® 2 Gamma MaxiCaps (1,000 L) Sartopore® 2 Gamma MaxiCaps - High Flow rate (1,000 L)
Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps, 0.2 µm (100 L to 500 L)
Part number Description Tubing Top Port 1 Top Port 2 Top Port 3 Bottom Port 1 Qty/Box
FXB110962 Flexel® 100L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 3
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 8, sampling port
– Gamma 0.2 µm, filter inlet 1.5" 
sanitary flange
1,000 cm2
FXB110964 Flexel® 200L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE  374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 9, sampling port
– Gamma 0.2 µm, filter inlet 1.5" 
sanitary flange  
2,000 cm2
FXB110966 Flexel® 500L  Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE    374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 0, sampling port
– Gamma 0.2 µm, filter inlet 1.5" 
sanitary flange 
4,500 cm2
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Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MidiCaps, 0.1 µm (100 L to 500 L)
Part number Description Tubing Top Port 1 Top Port 2 Top Port 3 Bottom Port 1 Qty/Box
FXB110975 Flexel® 100L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 3
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 8, sampling port
– Gamma 0.1 µm, filter inlet 1.5" 
sanitary flange
1,000 cm2
FXB110976 Flexel® 200L  Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 9, sampling port
– Gamma 0.1 µm, filter inlet 1.5" 
sanitary flange 
2,000 cm2
FXB110977 Flexel® 500L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 2
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MidiCaps size 0, sampling port
– Gamma 0.1 µm, filter inlet 1.5" 
sanitary flange
4,500 cm2
Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MaxiCaps, 0.2 and 0.1 µm (1,000 L)
Part number Description Tubing Top Port 1 Top Port 2 Top Port 3 Bottom Port 1 Qty/Box
FXB110967 Flexel® 1,000L  Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 1
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE  374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MaxiCaps size 2, sampling port
– Gamma 0.2 µm, filter inlet 1.5" 
sanitary flange
1.2 m2
FXB110978 Flexel® 1,000L Silicone 1/2"+ 3/4"+ 1.5 m 1/2"+ 3/4"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 1/2"+ 3/4"+ 1.5 m 1
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
– TPE 374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– Sartopore® 2 MaxiCaps size 2, sampling port
– Gamma 0.1 µm, filter inlet 1.5" 
sanitary flange 
1.2 m2
Standard Flexel® 3D bags with TPE tubes and Sartopore® 2 Gamma MaxiCaps (1,000 L - High flow rate)
Part number Description Tubing Top Port 1 Top Port 2 Top Port 3 Bottom Port 1 Qty/Box
FXB111153 Flexel® 1,000L  Silicone 1/2"+ 3/4"+ 1.5 m 3/4"+ 1-1/8"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 3/4"+ 1-1/8"+ 1.5 m 1
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
HIGH FLOW 374 Sartopore® 2 Gamma, silicone LL female + needle free silicone 
– TPE MaxiCaps size 2, 1-1/2" Tri-Clamp sampling port 1-1/2" Tri-Clamp
– Sartopore® 2 0.2 µm, filter inlet 1.5" 
– Gamma sanitary flange 
1.2 m2
FXB111154 Flexel® 1,000L  Silicone 1/2"+ 3/4"+ 1.5 m 3/4"+ 1"+ 1.5 m 1/8"+ 1/4"+ 1.1 m 3/4"+ 1"+ 1.5 m 1
for Palletank® + Clear C-Flex® (60") (60") (40") (60")
HIGH FLOW  374 Sartopore® 2 Gamma, 1–1/2" Tri-Clamp LL female + needle free 1–1/2" Tri-Clamp
– TPE MaxiCaps size 2, sampling port Silicone
– Sartopore® 2 0.1 µm, filter inlet 1.5" 
– Gamma sanitary flange  
1.2 m2
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Key features & benefits
Patented system Perfect fit and 
protection of the
Flexel® 3D Bag in its
Palletank®
Standard design Most design are
available from stock
Stackable version Space saving 
containment system
Technology integration For a successful 
support Single-Use manu-
facturing imple-
mentation and 
validation
Flexel® 3D Palletank® for storage
Introduction
The Palletank® for storage are stainless steel
containers designed for the safe and robust
storage of biopharmaceutical fluids contained
in Flexel® 3D Bags. They are available in 
volumes of 50 L, 200 L and 500 L to be used
with 50 L, 100 L|200 L and 500 L Flexel® 3D
bags. The Flexel® 3D Bag are manufactured 
according to a patented design that precisely
fits the Palletank®.
Applications 
Palletank® Systems that incorporate Flexel®
3D Bags have been designed for the safe 
processing of a wide range of biopharmaceu-
tical fluids in a variety of applications such as:
– Buffers and media storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate hold
– Final product transport
Space-saving
The stackable version of the Flexel® 3D 
Palletank® for storage enables users to meet
the complex in-process demands as well as
the high requirements for storage while 
maximizing the utilization of the available
clean room area. It saves up to 50% of the
space required for cylindrical drums.
Safety
Flexel® 3D Bags coupled with the rigid 
structure of Palletank® provide a stable 
and secure solution for processing, storage
and transportation of buffers, media, 
intermediates and final bulk products.
Palletank® family 
Besides the Palletank® for storage, the 
product range of Palletank® container
includes the following lines specifically 
developed for the various application 
requirements on fluid management in the
biopharmaceutical industry: 
– Palletank® for shipping
– Palletank® for in-process fluid handling
– Palletank® for weighing
– Palletank® for recirculation mixing
Technology Integration Support
Sartorius Stedim Biotech supports users from
the design & implementation phase of a new
production facility with the most comprehen-
sive support program that ensures successful
design implementation and validation of 
Single-Use Manufacturing.
Security of Supply
Sartorius Stedim Biotech has established 
multiple manufacturing sites with consistent
industrial processes. The expertise of design-
ing Single-Use solutions based on collabora-
tive supplier management and customer
demand planning assures a state of the art
and robust supply chain that can cope with
strong market growth.
Quality Assurance
Flexel® 3D Palletank® Systems are designed,
developed and manufactured in accordance
with a ISO 9001 certified Quality Manage-
ment System. They undergo extensive testing
before shipping
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Specifications
1. Palletank® for storage
Description Palletank® 200 L Palletank® 500 L
for storage for storage
Bag Volume(s) 100 L or 200 L 500 L
Construction 304L Stainless Steel
Material
Surface Bead Blasted 
Finishing
Dimensions 789+592+891 mm 1192+792+1010 mm 
(w+d+h) (31.2+23.3+35.1 in) (46.9+31.2+39.7 in)
Weight 35 kg (77.17 lb) 92 kg (202.8 lb)
Bottom Gate 1 1
Stackability No No
2. Palletank® for storage stackable
Description Palletank® 50 L for Palletank® 200 L for Palletank® 500 L for
storage stackable storage stackable storage stackable 
Bag Volume(s) 50 L 100 L or 200 L 500 L
Construction 304L Stainless Steel
Material
Surface Bead Blasted
Finishing
Dimensions 490 + 490 + 750 mm 789 + 592 + 915 mm 1192 + 792 + 1060 mm
(w+d+h) (19,3 + 19,3 + 29,5 in) (31.2 + 23.3 + 36 in) 46.9 + 31.2 + 41.7 in
Weight 24 kg (52.8 lb) 48.4 kg (106.7 lb) 87.5 kg (192.9 lb)
Bottom Gate | 1 1 1
Sliding Gate
Stackability 3 high 3 high 2 high
(Static)
3. Ancillary products
3.1. Dolly
Description Dolly for Palletank® Dolly for Palletank® Dolly for Palletank®
50 L for Storage 200 L for Storage 500 L for Storage 
and Shipping and Shipping and Shipping
Construction 304L  and polyamide (wheels)
Material
Surface Glass Bead blasted
Finishing
Dimensions 490+490+185 mm 815+615+188 mm 1215+815+161 mm
(w+d+h) (19.3+19.3+7.3 in) (32.1+24.2+6.4 in) (47.8+32.1+6.4 in)
Weight (approx.) 7 kg (15.4 lb) 10 kg (22 lb) 18 kg (39.7 lb)
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3.2. Weighing platforms
The IFS4 flat-bed scales are entirely constructed of stainless steel and have an extremely low
height, making it ideally suited for floor installation without a pit or anchoring. The ramp is
securely attached to the scale using special retainers for prevention of force shunt. This high-
quality platform can be connected to any of a wide range of indicators, for use as a Class III
legal measuring instrument or without legal verification. The CIS1 Combics 1 indicator allows
strain gauge weighing with flat bed scales as well as with load cells to be connected.
IFS4-150GG-I IFS4-300LI-I IFS4-1000RN-I
Weighing 150 kg 300 kg 1000 kg
capacity (330.7 lb) (661.4 lb) (2204.6 lb)
Platform size 600 + 600 mm 1000 + 800 mm 1500 + 1250 mm
(23.6 + 23.6 in) (39.3 + 31.5 in) (59 + 49.2 in)
Height Standard: 35 mm Standard: 35 mm Standard: 45 mm
Load Plate AISI304 |1.4301 (V2A) AISI304 |1.4301 (V2A)  AISI304 |1.4301 (V2A) 
bead-blasted bead-blasted bead-blasted
Resolution 30.000 d 30.000 d 30.000 d
Readability 5 g 10 g 50 g
Suitable with 50 L 200 L 500 L
Palletank®
Storage and 
Storage Stackable
Refer to specific Sartorius Mechatronics datasheet for Combics indicators ranges, 
printers and other accessories specifications and ordering information.
Integrated features
Features Benefits Palletank® for storage Palletank® for storage 
stackable
Level marks allow rapid visual monitoring of the fluid level in the bag • • * 
Integrated pallet allows easy carriage by pallet-jack or forklift • •
Tubing & Fitting Tray simplifies fluid handling operations & provides a • •
convenient and secure place for inlet & outlet tubing 
assemblies during transport.
Lid protects the bag against dust and light • *
Bottom gate | allows passage of large bore tubing, 1,5” tri clamps, QC bags • •
Sliding gate and filters; facilitates bag positioning and maintain in position
Stacking corner enables the stacking of Flexel® 3D Systems in order to •
maximise the utilisation of available clean room area
Dolly (accessory) facilitates the movement of material throughout a facility • •
* Except 50 L volume
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Ordering Information
Order Code Description
FXC110888 Palletank® 200 L for storage 
FXC110889 Palletank® 500 L for storage
FXC113946 Palletank® 50 L for storage stackable
FXC110733 Palletank® 200 L for storage stackable 
FXC110734 Palletank® 500 L for storage stackable
FXA113988 Dolly for Palletank® 50 L for storage
FXS102254 Dolly for Palletank® 100 L|200 L for storage & shipping
FXS102256 Dolly for Palletank® 500 L for storage & shipping
Features & Benefits
PP and ABS containers Low cost and robust  
storage solution
Stackable when full Minimize floor 
space utilizations
Foldable and collapsible 
when empty
Minimize storage 
volume 
Low tare weight Easy setting and 
maneuverability
Smooth scratch-
resistant plastic surface 
Clean room 
compatible
Standard product Available from stock
Flexel® 3D Plastic Palletank® for Storage
Introduction
The Plastic Palletank® for storage represents 
a cost-effective containment solution for the 
storage and processing of biopharmaceutical 
fluids contained in Flexel® 3D Bags. Their flat, 
smooth surfaces and rounded corners facili-
tate cleaning and sanitization for clean room 
operations. The Plastic Palletank® for storage 
are foldable for minimal storage space when 
empty. They are also stackable for optimal 
floor space utilization when filled with bio-
pharmaceutical solutions. They are available 
as standard products with volumes of 
200 L, 500 L and 1000 L that perfectly fit 
with 100 L|200 L, 500 L and 1000 L Flexel® 
3D Bags.
Applications 
The Plastic Palletank® for storage with 
Flexel® 3D Bags have been designed for 
the safe storage and processing of a wide 
range of biopharmaceutical fluids in 
a variety of applications such as:
– Buffers and media storage
– Bulk harvest
– Product pooling
– Fraction collection
– Sample collection
– Bulk intermediate hold
Optimal space utilization
The Plastic Palletank® for storage allows for 
secure stacking, up-to 3-high, to meet the 
complex in-process and storage requirements, 
while maximizing the utilization of the 
available clean room area. It saves up-to 50% 
of the space required for cylindrical drums.
When not in use, the collapsible tank can be 
folded to approximately half of its height for 
intermediate storage.
Volume Floor space required Space 
savingPlastic 
Palletank® 
for storage
Drum
200 L 9 + 200 L 
Stacked 
3-high 
1.5 m2 (16.1 sq ft)
9 + 200 L 
3.2 m2 
(34.4 sq ft)
50%
500 L 6 + 500 L 
Stacked 
2-high 
3 m2 (32.3 sq ft)
6 + 500 L 
3.7 m2 
(40 sq ft)
20%
1000 L 2 + 1000 L 
Stacked 2-high 
1.3 m2 (14 sq ft)
2 + 1000 L 
2.3 m2 
(25 sq ft)
40%
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Easy setting and use
One person can easily prepare a Plastic 
 Palletank® for storage; the walls are raised 
and locked in place by hand. Their low tare 
weight ensures easier operator manipulation 
and facilitates intra facility transfer.
Hygienic design
The Plastic Palletank® for storage is not 
subject to rust and corrosion due to all plastic 
construction. The containers are made from 
a robust, scratch-resistant plastic material. 
The dismountable flat, smooth walls and the 
rounded corners facilitate cleaning opera-
tions. The Plastic Palletank® for storage is 
compatible with cleaning and decontamina-
ting agents commonly used in the biophar-
maceutical industry.
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Specifications
1. Plastic Palletank® for storage
Description STD Plastic Palletank® for storage
200 L 500 L 1000 L
Part Number FXC116215 FXC116216 FXC116217
Bag Volume(s) 100 L | 200 L 500 L 1000 L
Main Constrution Material PP ABS ABS
Dimensions 
(w + d + h)
Approx.
Unfolded 805 + 607 + 
969 mm  
32 + 24 + 38 in.
1215 + 805 + 
1086 mm  
48 + 31 + 43 in.
1225 + 1022 + 
1437 mm  
48 + 40 + 57 in.
Folded 805 + 607 + 
510 mm  
32 + 24 + 20 in.
1215 + 805 + 
572 mm  
48 + 31 + 22 in.
1225 + 1022 + 
598 cm  
48 + 40 + 23 in.
Weight incl. lid (approx.) 25 kg (55 lb) 79 kg (174 lb) 125 kg (275 lb)
Bottom Gate 1 1 2
Stackability  
-Static
Folded 5 3 3
Unfolded 
and full
3 2 2
2. Ancillary products
a. Dolly
Description STD Palletank® Accessory Dolly
200 L 500 L 1000 L
Part Number FXA116630 FXA116631 FXA116632
Construction Material 304 L and polyamide (wheels)
Surface Finishing Glass bead blasted
Dimensions (w + d + h) 807 + 607 + 214 mm 
32 + 24 + 8 in.
1207 + 807 + 214 mm 
47 + 32 + 8 in.
1207 + 1007 + 214 mm 
47 + 39 + 8 in.
Weight (approx.) 10 kg (22 lb) 20 kg (44 lb) 22 kg (48 lb)
b. Weighing Platform
IFS4-300LL-I IFS4-600RN-I IFS4-1500RN-I
Weighing Capacity 300 kg | 1322 lb 600 kg | 1322 lb 1500 kg | 3306 lb
Platform Size (D + W) 1000 + 1000 mm 
39 + 39 in.
1500 + 1250 mm 
59 + 49 in.
1500 + 1250 mm 
59 + 49 in.
Height Standard:  
35 mm | 1.4 in.
Standard: 
45 mm | 1.8 in.
Standard:  
45 mm | 1.8 in.
Load Plate AISI304 | 1.4301 (V2A) 
bead blasted
AISI304 | 1.4301 (V2A)  
bead blasted
AISI304 | 1.4301 (V2A) 
bead blasted
Resolution 30.000 d 30.000 d 30.000 d
Readability 10 g 20 g 50 g
Suitable with Plastic 
Palletank® storage
200 L 500 L 1000 L
Please contact your Sartorius Mechatronics Sales Representative for detailed ordering information.
Ordering Information
FXC116215 STD Plastic Palletank® Storage 
200 L
FXC116216 STD Plastic Palletank® Storage 
500 L
FXC116217 STD Plastic Palletank® Storage 
1000 L
FXA116630 STD Palletank® Accessory Dolly 
200 L (Plastic Storage)
FXA116631 STD Palletank® Accessory Dolly 
500 L (Plastic Storage)
FXA116632 STD Palletank® Accessory Dolly 
1000 L (Plastic Storage)
a. Dolly
b. Weighing Platform
XDR Single-Use Bioreactors
DATA SHEET
?????????????????????????????????????
Introduction
The XDR Single-Use Bioreactor is a fully-integrated system that deliv-
ers proven stirred-tank performance across a wide range of cell lines. 
Single use technology eliminates time consuming and costly clean in 
place (CIP), steam in place (SIP) and cleaning validation procedures. The 
system’s turnkey design enables fast installation and startup as well as 
rapid batch-to-batch turnover and increased process !exibility com-
pared to "xed stainless steel hard piped vessels.
??????????????????????????????????????????????????????????????? ????
???????????????????????????????????????????????????????????????????
sign enables each XDR to oper ate down to 20% of maximum working 
?????????????????????????????? ?????????????????? ??????????????????????
additional seed reactor and related costs. Each reactor system includes 
a stainless steel vessel, vital process instrumentation, state-of-the-art 
control automation, and an optimized single-use bioreactor bag assem-
bly. For high-density microbial applications, ask about the XDR-50 Turbo 
SYSTEM SNAPSHOT
??Fully-integrated, turnkey GMP system 
??Proven, scalable stirred tank performance 
across a wide range of cell lines
??Single-use design eliminates CIP/SIP
??Operating volumes of 10L to 2,000L
??Essential process instrumentation included 
and fully characterized
??Integrated temperature control and dimpled 
vessel jacket for e!cient heat transfer
??Powerful, user-friendly control system 
??Predictive modeling and Xcellerex process 
expertise eliminates start-up headaches and 
ensures process e!ciency
model.
?E!cient, Convenient Vessel Design  The vessel features a dimpled jacket  
heat transfer surface for e#cient heating and cooling, a high performance bottom-
mounted magnetic drive agitator system that facilitates loading and coupling of 
the single-use bag assembly, load cells for weight measurement, an exhaust "lter  
heater box, !exible hoses for the heat transfer !uid, and a tubing manager.
?Critical Process Instrumentation   Mass !ow controllers,  
peristaltic pumps, and probe transmitters are built into the  
cabinet adjacent to the vessel, and an external temperature  
control unit is available as an option for process heating/cooling. 
?????????????????????????????????????????? ??? ??? ?????????
full functionality.
XDR 2000 ?
agitator includes a HDPE bottom mounted impeller and a 
??????????????????????????????????? ?????????????????????
steel disks and optional drilled holes that together impart 
the system with tremendous !exibility crucial for today’s cell 
culture processes. Xcellerex also maintains multiple supply 
sources to guard against supply chain disruptions.
 
Expert process support from Xcellerex   With years 
of experience running and supporting GMP biomanufactur-
ing operations, Xcellerex designed the XDR system to deliver 
complete process control from the mo ment each system 
starts up. No other single-use bioreactor is available with the 
XDR’s depth of characterization, process support, and GMP-
??????????????????????????????????????????????????????????????????
automation with instrumentation, functionality, pro cess mod-
eling, tech transfer, and scalability.
Key XDR Advantages
? 5:1 turndown means each XDR can operate at 20% of maximum working 
volume, doing the work of multiple reactors
? True plug-and-play performance:  Connect gases and power and get 
started
? Robust, self-installing magnetically-driven bottom-mount  impeller:   
No rotating seals, insertable shafts and connection hassles
? Jacketed vessel ensures uniform temperature distribution throughout 
reactor
? Flexible control systems automate temperature shifts, feeds, changes to 
sparge composition   
? Multiple probe con!gurations available, including pH, DO, CO2, and 
biomass
? Accurate gas control using mass "ow controllers on all systems (optional 
MFC for headspace on XDR50)
? Bag material sourced from multiple manufacturers for supply chain security
? Single-use design eliminates time consuming CIP, SIP and cleaning valida-
tions procedures
? XDR Single Use Reactor Systems are Factory Acceptance Tested (FAT) prior 
to delivery and Site Acceptance Tested (SAT) upon installation
? Each XDR Single Use Reactor System is shipped with a Turnover Package 
which includes XDR Operating Manual, System Speci!cations, FAT  
commissioning report, system drawings, component operating manuals, 
calibration records, and optional IQ/OQ protocols
? Xcellerex process experience and know how is built into every XDR 
System:  our process development expertise ensures that the process is 
up and running right the !rst time
? Xcellerex o#ers extensive XDR-speci!c predictive modeling and expert 
scale-up support
? Enhanced sparge control and CO2 stripping capabilities not o#ered on 
other single use systems
? Designed and fully characterized to deliver scalable cGMP processes from 
10L to 2000L
? Xcellerex has years of cGMP manufacturing experience operating the XDR 
system.  GMP product made in the XDR is currently being used in clinical 
trials and commercial XDR facilities are currently being prepared for com-
missioning.
?????????????????????????????????????
?Powerful, User-Friendly Controls  The XDR is 
????????? ???????????????????????????????????????? 
featuring intuitive pro cess controls, 
data historian, and robust automa-
tion hardware/software. The system 
enables precise process control, 
and o"ers convenient real-time 
trending and other valuable data. 
When coupled with Xcellerex’s 
process development experience 
and predictive modeling support, 
the XDR control platform assures optimized #rst-run 
process performance and reliability through tech 
transfer and scale-up.
?Robust Single-Use Components  The XDR irradiated 
?????????????????????????????????????? ????????? ???????
?????????????????????????????????????????? ????????????????????
sampling and probe ports, a disposable pressure sensor, 
#ltered gas lines, and high-functioning agitator system. The 
SYSTEM SPECIFICATIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
BIOREACTOR
Max Working Volume (L) 50 200 500 1000 2000
Min Working Volume (L) 10 40 100 200 400
Volume turn-down ratio 5:1 5:1 5:1 5:1 5:1
Tank ID (in) 12 22 30 38 48
H/D 2.5 1.5 1.5 1.5 1.5
Vessel Material of Construction Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS Jacketed 304 SS
Filter Heater Box 1 1 1 1 1
Bag Hoist NA NA NA Automated Automated
Impeller Bottom mounted, magnetically-driven, single-use impeller integrated with bag assembly
Impeller type M40E
Impeller diameter (in) 8 8 10 12 16
Di/Dt 0.67 0.36 0.33 0.33 0.33
Impeller location Center 900 150 o" center 150 o" center 150 o" center 150 o" center
Sparger
Standard Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks Stanless steel sintered disks
Optional
Drilled Hole Drilled Hole Drilled Hole Drilled Hole Drilled Hole
CO2 stripping CO2 stripping CO2 stripping CO2 stripping CO2 stripping
PROCESS INSTRUMENTATION
pH probes 1 2 2 2 2
DO probes 1 2 2 2 2
MFCs (Brooks)
Standard 4 4 4 4 4
Additional (optional) 2 2 2 2 2
Pumps 3 Pumps are standard.     Additional pumps are available as an option
Temperature Control Unit Optional:  3 kw heater Optional:  9 kw heater
Optional:  3 kw heater/ 
0.5 ton chiller combo Optional:  9 kw heater/ 1.5 hp chiller combo
Load Cells 3 4 4 4 4
Utility Requirements Process gases  /  110V, single phase, 60 hz  /  TCU:  230V, 3 phase, 60 hz (EU: 380V, 3 phase, 50 hz)
E-Stop Integrated Safety Circuit for pumps, agitator, TCU, and #lter heater
CONTROL UNIT (see page 5 for additional detail)
Integrated Control Panel Built to GAMP5 standards/ 21 CFR Part 11 Compliant
Hardware Rockwell/ Allen Bradley
Operator Interface Wonderware HMI
Data Historian Wonderware
Programming Rockwell Allen Bradley/Wonderware Archestra
NOTE:  This document describes standard systems and commonly requested options. Additional custom-engineered systems are also available to meet unique application needs. Ask your Xcellerex representative for details.
?????????????????????????????????????
???????????????????????????????????????????????????????
PERFORMANCE CONTROL SPECIFICATIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
pH Range 2-12 pH units 
Accuracy  ± 0.05 pH units
DO Range 0-100% atmospheric saturation 
Accuracy  ± 1.0% of setpoint
Sparge Rate (slpm) Air* 0-5 0-5 0-10 0-10 0-20
*Additional MFC/sparge 
ranges can be supplied 
based on application 
requirements
02* 0-5 0-5 0-10 0-10 0-20
C02* 0-5 0-5 0-10 0-10 0-20
Air Headsweep* 0-10 0-10 0-20 0-20 0-25
Temperature Range 4-60 0C 
Accuracy ± 0.1 0C
Bag Pressure Range 0 - 30 psig    (0 - 2068 mbar)
Accuracy ± 0.1 psig  (± 6.89 mbar)
Agitation (rpm) 0-360 0-360 0-250 0-140 0-115
Load Cell Accuracy ± 0.02% of max bag volume
NOTE:   For high-density microbial applications, please ask about the XDR-50 Turbo system.
SYSTEM DIMENSIONS
XDR-50 XDR-200 XDR-500 XDR-1000 XDR-2000
Width (Vessel & Instrumentation) 43.375 in(111 cm)
52.25 in
(133 cm)
57 in 
(145 com)
64 in 
(163 cm)
23.375 in 
(182 cm)
Depth (Vessel & Instrumentation) 28 in(71 cm)
37 in 
(94 cm)
48 in 
(122 cm)
52 in 
(132 cm)
61 in 
(155 cm)
Height (Vessel & Instrumentation) 73.5 in(187 cm)
85.125 
(216 cm)
93.75 in 
(238 cm)
115 in 
(292 cm)
140 in
(356 cm)
HMI Control Unit Dimensions:   23.375 in x 30.75 in x 56.75 in (60 cm x 78 cm x 144 cm)
?????????????????????????????????????
FULLY-INTEGRATED XDR BIOREACTOR BAG ASSEMBLY
 
USP Class VI??
?????????????????????????
Gamma Irradiated??
Validation Guide ??
 
 
Standard “o!-the-shelf” designs impart "exibility for a wide range of 
cell  culture and microbial processes.
??????????????????????????????????????????????????????????
Each bag comes complete with:
 
C-"ex tubing (for tube-to-tube aseptic welding)??
Aseptic connectors??
Multiple feed/addition lines??
Harvest line??
Exhaust #lter??
Sparge #lter??
Overlay #lter??
Pressure sensor??
Sampling ports??
Probe ports??
Thermowell (for temperature probe)??
Proprietary XDR impeller/sparge system??
???????????????????????????????????????????????????????
?????????????????????????????????????
CONTROL AUTOMATION PLATFORM
The XDR Control Platform is comprised of a Rockwell/Allen Bradley controller with Wonderware HMI 
and data historian. The platform delivers precise process control and o!ers a level of "exibility and 
convenience that is unmatched in the industry.
In addition to robust control architecture, the XDR features a highly intuitive user interface that speeds 
operator training and e#ciency.
?Intuitive, Powerful Interface
The XDR control system user interface was designed to provide fast and easy, yet comprehensive 
control over process con$guration to the operator.  The easy-to-read screens enable dynamic adjust-
ment to key variables, and enable the operator to review complete con$guration schemes at a glance. 
The high clarity touchscreen display provides an intuitive, visual interface that operators can use with 
con$dence.  (See Screen 1)
The XDR system enables rapid understanding and interpretation of active control strategies through 
the use of graphical symbols.  (See Screen 2)
In addition, set-point automation tables enable the easy automation of set-point changes, permitting 
live adjustments to ramp or step to new value.  (See Screen 3)
?Powerful Control Strategies for Fast Response, Tight Control
?? Cascade control strategies of pH, DO, and volume result in very tight control of critical process 
conditions. 
?? Flexible closed loop control of critical process parameters support improved yields:
? ????????????? ?????????
? ??????? ?????? ??????????????
?? ??????????????????????????????? ??????????????
????? ?????? ????????(See Screen 4)
????? ??? ?????
?? ??????????????????????????????????????????????????????????????????????????????????????  
?Comprehensive, Real-Time Data Capture, Reporting and Trending
?? ??????????? ??????????????????????????????????????????????????????? ?????????????? 
accessible look-up.
?? ???????????????????????? ??????????????????????????????????????????? ??????????????????????????
?? ??????? ??????????????????????????????????????????????????????????????????
?? ?????????????????????????????????
Screen 1 - System Overview
Screen 2 - Cascade Loop Control
Screen 3 -Set Point Automation Tables
Screen 4 - DO Strategy Set-Up Screen
XDR PERFORMANCE DATA
?????????????????????????????????????
CHO Process -Titer Data
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CHO Perfuson Process-Cell Culture Data
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Figure 1:  CHO Process - Titer Data  (XDR vs. 10L Glas  Reactor)
Figure 2:  CHO Process - Viability Data  (XDR vs. 10L Glass Reactor)
Figure 3:  CHO Perfusion Process - Viability Data  (XDR vs. 10L Glass Reactor)
Figures 1-3 illustrate examples of !rst-run data 
for a series of CHO processes, demonstrating the 
XDR system’s ability to achieve immediate process 
equivalence.  Additional, extensive data is available 
on request.
FIGURE 1:    XDR achieved equivalent or better titer 
during scale-up from a 10 liter glass reactor to a 
200 L XDR to a 1000 liter XDR.
FIGURE 2:    XDR achieved equivalent or better cell 
viability during scale-up from a 10 liter glass reac-
tor to a 200L XDR to a 1000 liter XDR.
FIGURE 3:    XDR achieved process equivalence for 
a perfusion process at the 200L and 1000L scale.
Xcellerex, Inc. Toll Free: 1-866-Xcellerex
?????????? ?????? ???????????????????
????????????? ????????? ??????????????????
USA www.xcellerex.com
? ??????????????
FOR ADDITIONAL INFORMATION
To learn more about XDR Single-Use Bioreactors or other Xcellerex systems or services, 
please contact customer service at:
??????????? ????????????????????????????????
??????????? ??????????????
??????? ? ???????????????????

Filtration
Fast. Easy. Clean.
Innovative
Zeta Plus™ Single-Use Depth Filtration Product Portfolio
Features & Benefits
The System of Choice for
Single-Use Depth Filtration
Zeta Plus™ Encapsulated System...
Ergonomically Designed Holder System:
   Large holders (Model# 16EZB and #16EZC [not shown]) can be pivoted between 
   horizontal and vertical positions.
! ?!"#$%&'(!&)$*+#,!$#*!-#&)$*+#,!$.!/$+(.!0'+,0.1
! ?!2+#+3$&!4&-+*!(5+&&(!/0'#!0$#*&+#,!(5'#.!6$5(-&'(1
! ?!7+#,&'!)8!./)9(.$,'!*'5.0!4+&.8$.+)#!/+.0+#!)#'!4+&.'8!0)&*'81
   Vertical flow path.
! ?!:-&&!-.+&+;$.+)#!)4!.0'!4+&.'8!3'*+$1
! ?!73$&&!4)).58+#.!*-8+#,!4+&.8$.+)#1
Innovative Capsule/Manifold Design:
!!!Translucent plastic shell (Standard Capsules).
! ?!"$(<!*'.'6.+)#!)4!.0'!&+=-+*!&'>'&!+#(+*'?!58)>+*+#,!8'$&!.+3'!3)#+.)8+#,!)4!.0'!4+&.8$.+)#!58)6'((1
!!!Solid core design with fully encapsulated shell.
! ?!"&+3+#$.'(!.0'!#''*!4)8!$!(.$+#&'((!(.''&!0)-(+#,!$#*!
! .0'!6&'$#+#,!(.'5!$4.'8!4+&.8$.+)#1
! ?!@)/!0)&*9-5!>)&-3'1
   Self guiding locking mechanism.
! ?!:$(.?!8'&+$%&'!$#*!8)%-(.!6$5(-&'9.)96$5(-&'!6)##'6.+>+.<1
   Lenticular style capsule design.
! ?!@+#'$8!(6$&$%+&+.<!48)3!(3$&&!.)!&$8,'!(<(.'3(1
! ?!A)#(+(.'#6<!%'./''#!(+#,&'9-('!$#*!6)#>'#.+)#$&!*'5.0!4+&.8$.+)#1
Zeta Plus™ fi lter media:
! ?!B).0!*)-%&'!&$<'8!$#*!(+#,&'!&$<'8!C'.$!D&-(!4+&.'8!3'*+$!$8'!$>$+&$%&'1
! ?!7-5'8+)8!5'84)83$#6'!+#!.08)-,05-.!$#*!4+&.8$.+)#!'44+6+'#6<1
1
Model# 16EZB
!"#$%#&'$()*+$,$-./'0+*)'&#1$23+&#4$5+$'$+5.6)#7*+#$1#0&"$
85)&9'&5:.$ +3+&#4$1#+56.#1$ 8:9$ &"#$ ;5:09:/#++5.6$ 5.1*+&93$
<"#9#$ *0+&9#'4$ /#))$ /*)&*9#$ /)'9585/'&5:.$ :9$ 1:<.+&9#'4$
540*95&3$9#4:=')$5+$9#>*59#1?$!"#$%#&'$()*+$-./'0+*)'&#1$
23+&#4$ /:.+5+&+$ :8$ &"9##$ 09:1*/&$ )5.#+@$ '$ +4'))$ +3+&#4$
&"'&$ 5+$ 51#')$ 8:9$ )';$ +/')#$09:1*/&5:.$:9$ +/')#7*0$ +&*15#+A$
'.1$ &<:$ )'96#9$ +3+&#4+$ &"'&$ '9#$ 1#+56.#1$ 8:9$ 09:1*/&5:.$
+/')#$ ;5:4'.*8'/&*95.6?$ -'/"$ +3+&#4$ 5+$ /:4095+#1$ :8$ '$
85)&#9$":)1#9A$ &:0$'.1$;:&&:4$4'.58:)1+A$'.1$ &"#$9#>*59#1$
.*4;#9$:8$/'0+*)#+?$
The Zeta Plus Encapsulated Systems for production scale 
biomanufacturing feature an ergonomically designed large 
holder (Models# 16EZB and 16EZC) that can be pivoted 
between horizontal and vertical positions, allowing for 
convenient loading and unloading, minimal footprint dur-
ing filtration, minimal fluid spills during unloading, and 
full utilization of the filter media. 
!"#$ /'0+*)#$ 1#+56.$ 8#'&*9#+$ '$ &9'.+)*/#.&$ 0)'+&5/$ +"#))$
B+&'.1'91$/'0+*)#+C$ 8:9$#'+3$ )5>*51$ )#=#)$1#&#/&5:.D$'$+#)8$
6*515.6$ ):/E5.6$4#/"'.5+4$ 8:9$ 8'+&$ '.1$ 9:;*+&$ /'0+*)#7
&:7/'0+*)#$ /:..#/&5:.D$ '.1$ &"#$ 5.1*+&93$ )#'15.6$ %#&'$
()*+$ 1#0&"$ 85)&#9$ 4#15'$ &"'&$ 09:=51#+$ +*0#95:9$ 85)&9'&5:.$
0#98:94'./#?
Zeta Plus™ Encapsulated
Standard Capsule Offering
With Polycarbonate Shells
Zeta Plus™ Encapsulated Capsule Offering
With Alkaline Resistant*
Polyphenylene / Polystyrene Shells
Zeta Plus™ Cartridges and Capsule Family Self Guiding Locking Mechanism Enables
Fast And Robust
Capsule-To-Capsule Connection
2
F$ G'+#1$:.$&#+&5.6$<5&"$HI$J'KL$'.1$MN$J'O)K$BG)#'/"C?$
2##$O"#45/')$O:40'&5;5)5&3$P*51#$BQR7RSRS7SRST7MUVW!(LPRTC$8:9$4:9#$5.8:94'&5:.?
Ergonomically Designed Filter Holders
!"#$%&%'(#)*$+,&-*.%)&"#&%'(*/0/&+1/*2&%)%3+*)+(&%42)#"*/&0)+*4#"&"%$5+*.%)&+"/*#($*#*6+"&%4#)*.%)&"#&%'(*.)'7*,#&-*&'*#))'7*
+#/0*#44+//* &'*,"'4+//* )%82%$/*#($*+..%4%+(&*2&%)%3#&%'(*'.* .%)&+"*1+$%#9*:'7+6+";*/&#4<%(5*4#"&"%$5+/*."'1*='&&'1*&'*
&',*4#(*=+*421=+"/'1+*#($*$%/1#(&)%(5*&-+*/,+(&*4#"&"%$5+/*%/*'.&+(*)#='"*%(&+(/%6+9*>2"&-+"1'"+;*.)2%$*/,%))/*$2"%(5*
&-+*2()'#$%(5*,"'4+//*4'2)$*=+*,"'=)+1#&%4*#($;*%(*/'1+*%(/&#(4+/;*1%5-&*+?,'/+*&-+*',+"#&'"/*&'*&-+*,"'4+//*.)2%$/9**
High Performance filter media
!-+*@+&#*A)2/B*C(4#,/2)#&+$*D0/&+1*2&%)%3+/*&-+*%($2/&"0*)+#$%(5*@+&#*A)2/*$+,&-*.%)&+"*1+$%#;*%(4)2$%(5*&-+*$'2=)+*
)#0+"*@+&#*A)2/*CE!*D+"%+/* .%)&+"*1+$%#*#($*1#(0*,',2)#"*/%(5)+* )#0+"*@+&#*A)2/* .%)&+"*1+$%#*',&%'(/* %(4)2$%(5*DA*
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4'(/%/&*'.*&7'*$%/&%(4&*)#0+"/;*'"*H3'(+/I*'.*.%)&+"*1+$%#*7%&-*&-+*2,/&"+#1*3'(+*1'"+*',+(*&-#(*&-+*$'7(/&"+#1*'(+9*
!-%/*/&"24&2"+*+(-#(4+/*&-+*4'(&#1%(#(&*-')$%(5*4#,#4%&0*'.*&-+*.%)&+"*1+$%#;*"+$24+/*,"+1#&2"+*,)255%(5*#($*-+),/*
+?&+($*/+"6%4+*)%.+9*F))*@+&#*A)2/*CE!*.%)&+"*1+$%#*5"#$+/*#"+*#6#%)#=)+*%(*/%(5)+J2/+*.'"1#&*%(4)2$%(5*#*/,+4%#)*5"#$+*
KLCMNOPFQ*&-#&*%/*$+/%5(+$*.'"*)%,%$*"+1'6#)9*
Applications
* ?*R)#"%.%4#&%'(*'.*1#11#)%#(*4+))*42)&2"+*-#"6+/&9
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#)&+"(#&%6+*#,,)%4#&%'(*.'"*&-+*@+&#*A)2/*C(4#,/2)#&+$*D0/&+1*%/*$'7(/&"+#1*%1,2"%&0*"+1'6#)9*!#<%(5*#$6#(&#5+*'.*
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Table 1a. Recommended Operating Parameters
Zeta Plus™
Encapsulated 
System
Zeta Plus™
Scale-Up
Capsules
Maximum
Operating Pressure
Inlet Pressure
Differential Pressure
3.4 bar (50 psi)
2.4 bar (35 psi)
3.1 bar (45 psi)
35 psi (2.4 bar)
Maximum
Operating
Temperature
40°C (104°F)
Recommended
Pre-use Rinse 54 L/m² (1.3 gal/ft²) 
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Figure 1.  Zeta Plus™ Encapsulated System
EZ16A
EZ16B
EZ16C
Innovative Capsule/Manifold Design
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Figure 2. Nominal Retention Ratings for Zeta Plus™ EXT Grades
(For reference only. Retention ratings may vary depending on application.)
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Top Manifold Bottom Manifold Small Capsule
0.23 m² Capsule
(with double layer or single layer media)
Large Capsule
1.6 m² Capsule (with double layer media)
2.5 m² Capsule (with single layer media)
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BC25
(25 cm²) E0170 (170 cm²)
and
E0340 (340 cm²) Small Holder Double layer: 0.23 - 1.6 m²
Single layer: 0.23 - 2.5 m²
Large Holder
Double layer: 1.6 - 11.2 m²
Single layer: 2.5 - 17.5 m²
Figure 5. Large Holder with Mechanical Polish Finish
Figure 3. The Zeta Plus™ Encapsulated System Single-Use Depth Filtration Product Portfolio
Figure 4. Zeta Plus™ Scale-Up Capsules
E01020 (1020 cm²)
Multi-Round System Model 
#16EZC5
Contact your 3M Purification
representative.
Figure 6. Multi-Round System
Figure 7. Single-Use Manifolds and Capsule Filter Schematic
Bottom Manifold
Outlet
Inlet
Manifold Stop
Female Connector
Top Manifold
Manifold Stop
O-Rings
Downstream Vent
Male Connector
E16 Multi-Cell Capsule
1.6 m2 Capsule
(with double layer media)
2.5 m2 Capsule
(with single layer media)
Straight Handle
T-Handle
Female ConnectorFemale
Connector
E16 Single-Cell Capsule
0.23 m2 Capsule
(with double layer
or single layer media)
Plastic Shell
apsule StopC
Table 2a. Zeta Plus™ Encapsulated System Capsule Filter and Manifold Specifications
Configuration
Small Capsule Large Capsule
Standard Alkaline Resistant1 Standard Alkaline Resistant1
Dimensions (Height x Diameter) 5.7 cm x 45.2 cm (2.2” x 17.8”) 20.3 cm x 45.2 cm (8.0” x 17.8”)
 Weight
     Dry 3.3 kg (7 lbs) 3.4 kg (8 lbs) 10.0 kg (22 lbs) 10.7 kg (24 lbs)
     Wet (post Blow-Down) 4.4 kg (10 lbs) 4.8 kg (11 lbs) 19.3 kg (43 lbs) 19.7 kg (43 lbs)
Materials of Construction
     fi lter media Filter aids, cellulose, binding resin Filter aids, cellulose, binding resin
     Outer Shell Polycarbonate Polyphenylene / Polystyrene Polycarbonate Polyphenylene / Polystyrene
     O-rings Silicone Silicone
     Separators, Spacers and Connectors Polypropylene Polypropylene
     Edge Seals Thermoplastic Elastomer Thermoplastic Elastomer
     Handles N/A Nylon
Hold-up Volume
     Capsule Fill Volume2
Double Layer:  ~ 1.1 L  (~ 0.3 gal) ~ 5.2 L (~ 1.4 gal)
Single Layer: ~ 2.6 L (~ 0.7 gal) ~ 4.2 L (~1 .1 gal)
     Post Blow-Down Hold-up Volume3 < 100 mL (<0.026 gal) < 100 mL (<0.026 gal)
Maximum Operating Line Pressure 3.4 bar (50 psig) 3.4 bar (50 psig)
Maximum Differential Pressure
     Forward 2.4 bar (35 psid) 2.4 bar (35 psid)
Sterilization 1 cycle autoclave (30 mins) at 126°C (259°F) 1 cycle autoclave (30 mins) at 126°C (259°F)
Effective Filtration Area 0.23 m² (2.4 ft²) Double layer:  1.6 m² (17.2 ft²)Single layer: 2.5 m² (27.0 ft²)
Top/Bottom Manifold
Dimensions (Height x Diameter) 5.2 cm x 45.2 cm ( 2.0” x 17.8” ) 5.2 cm x 45.2 cm ( 2.0” x 17.8” )
Connector 1.5" Sanitary Style 1.5" Sanitary Style
Material Polycarbonate Polyphenylene / Polystyrene Polycarbonate Polyphenylene / Polystyrene
Weight 4.5 kg (10 lbs) 4.5 kg (10 lbs) 4.5 kg (10 lbs) 4.5 kg (10 lbs)
Hold up volume < 250 mL (<0.07 gal) < 250 mL (<0.07 gal)
1 Based on testing with 1M NaOH and 5% NaClO (Bleach).  See Chemical Compatibility Guide (70-0202-2023-5/LITPHG03) for more information.
2  Capsule Fill Volume is defined as the volume of liquid that is required to fill the portion of the capsule outside the filter media.
3  Post Blow-Down Hold-up Volume is defined as the volume of the residual liquid after nitrogen gas blow-down.
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Table 2b: Zeta Plus Scale-Up Capsule Filter Specifications
170 cm² Capsule 340 cm² Capsule 1020 cm² Capsule
Dimensions
     Height x Diameter 4.1” x 8.5” (10.3 cm x 21.6 cm) 6.0” x 8.5” (15.2 cm x 21.6 cm)
Weight
     Dry - Single Layer 1.0 kg (2.2 lb) 1.0 kg (2.1 lb) 1.4 kg (3.0 lb)
     Dry - Double Layer 1.0 kg (2.2 lb) 1.0 kg (2.3 lb) 1.6 kg (3.5 lb)
     Wet Post Blow-Down - Single Layer 1.1 kg (2.4 lb) 1.1 kg (2.5 lb) 1.8 kg (4.0 lb)
     Wet Post Blow-Down - Double Layer 1.2 kg (2.6 lb) 1.3 kg (2.9 lb) 2.4 kg (5.2 lb)
Materials of Construction
     Capsule Shells Polysulfone
     Separator, Spacer, Vent Cap Polypropylene
     O-ring Fluorocarbon
     Endcap & Edge Seals Thermoplastic Elastomer
Volume
     Capsule1 Fill Volume - Single Layer 0.48 L 0.40 L 0.91 L
     Capsule1 Fill Volume - Double Layer 0.43 L 0.34 L 0.62 L
     Post2 Blow-Down Hold-up Volume - Single Layer < 40 mL < 40 mL < 40 mL
     Post2 Blow-Down Hold-up Volume - Double Layer < 40 mL < 40 mL < 40 mL
Miscellaneous
     Sterilization 1 cycle autoclave (30 min) @  126°C (259°F)
     Effective Filtration Area 170 cm² (0.18 ft²) 340 cm² (0.37 ft²) 1,020 cm² (1.10 ft²)
     Connector 1/2” Sanitary Style
1 Capsule Fill Volume is defi ned as the volume of liquid that is required to fi ll the portion of the capsule outside the fi lter media.
2 Post Blow-Down Hold-up Volume is defi ned as the volume of the residual liquid after nitrogen gas blow-down.
IMPORTANT NOTICE: Always operate the fi lter system within the maximum differential pressure of 2.4 bar (35 psig).
170 cm? & 340 cm? 
Capsules
1020 cm?  Capsule
Outlet
Inlet
Vent
Inlet
(Not Shown)
Outlet
Vent
Figure 8. Scale-Up Capsule Filter Schematics
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Table 3. Zeta Plus™ Encapsulated System Holder Specifications
Holder Model
Small Holder
(Model# 16EZA)
Large Holder
(Model# 16EZB)
Multi-Round Holder 
(Model# 16EZC)
Maximum Operating Pressure 3.4 bar (50 psi) 3.4 bar (50 psi) 3.4 bar (50 psi)
Materials of Construction
     Frame 304 Stainless Steel 304 Stainless Steel
Please contact your
3M Purification
representative for details.
     End Plates 304 Stainless Steel 304 Stainless Steel
     Support Rods 440 Stainless Steel 316 Stainless Steel
     Stand 304 Stainless Steel 304 Stainless Steel
     Hand Wheels 300 Series Stainless Steel 300 Series Stainless Steel
     Gear Box N/A Epoxy Coated Cast Iron Cover
     Locking Bar N/A 304 Stainless Steel
     Casters Stainless Steel Stainless Steel
N/A
     Wheels Phenolic Polyurethane
Surface Finish
     Standard Satin Glass Bead Finish(4814901 and 4815501)
Mechanical Polish Finish
(6123502) Please contact your
3M Purification
representative for details.     Special Electropolish Finish(4814902) N/A
Table 4. Zeta Plus™ Encapsulated System Holder Capacity
Model
Single Stage Two Stage
E16 Single-Cell 
Capsule
E16 Multi-Cell 
Capsule
E16 Single-Cell
Capsule
E16 Multi-Cell 
Capsule
16EZA 4 1 2 NA
16EZB NA 7 NA 6
Figure 9. Small Holder (Model# 16EZA) Dimensions
129 cm (51”)
Maximum
102 cm (40”)
Minimum
66 cm (26")
Width & Depth
9
210.7 cm
(83”)
108.7 cm
(42.8”)
205.9 cm (81.1”)
Maximum
113.9 cm
(45.5”)
 86.4 cm
(34.0”)
Horizontal Position
Vertical Position
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Figure 10. Large Holder (Model# 16EZB) Dimensions
 Manifold Ordering Information
Manifold Part 3M PIPart Number 3M ID
Manifold Set (Standard) 6128901 70020256221
Manifold Set (Alkaline Resistant*) 6129001 70020262369
 
Filter Holder Ordering Information
Model 
Name
3M Catalog ID
(U.S. Customers) Description 3M ID
16EZA 4814901 Standard Small Holder 70020233048
16EZA 4814902   Small Holder withElectropolish Finish 70020253889
16EZA 4815501 Modifi ed Small Holder Suitable for Autoclaving 70020236512
 
Model 
Name
3M Catalog ID
(U.S. Customers) Description 3M ID
16EZB 6123502 Large Holder withMechanical Polish Finish 70020252899
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Scale-Up Capsules - Double Layer
3M Catalog ID
(U.S. Customers)
EFA 
cm²
Material 
Code Grade
E
0170
0340
1020
FSA
05SP01A
10SP01A
10SP02A
30SP02A
30SP03A
60SP01A
60SP02A
60SP03A
60SP05A
90SP05A
90SP08A
60ZA05A
90ZA05A
90ZA08A
120ZA05A
120ZA08A
120ZA10A
DELI08A
DELP08A
Scale-Up Capsules - Single Layer
3M Catalog ID
(U.S. Customers)
EFA 
cm²
Material 
Code Grade
E
0170
0340
1020
FSA
05SP
10SP
30SP
50SP
60SP
90SP
30LA
50LA
60LA
90LA
30LP
50LP
60LP
90LP
30ZA
60ZA
90ZA
DELI
Ordering Guide
 
Capsule Filter Ordering Information - Double layer (U.S. Customers)
Catalog 
Number Configuration
Number of 
Cells
Gasket 
Material Grade
E16 E - StandardR - Alkaline Resistant*
01 - 1 Cell
07 - 7 Cell
A - Silicone
05SP01A
10SP01A
10SP02A
30SP02A
30SP03A
60SP01A
60SP02A
60SP03A
60SP05A
90SP05A
90SP08A
120ZA05A
120ZA08A
120ZA10A
60ZA05A
90ZA05A
90ZA08A
DELI08A
Capsule Filter Ordering Information - Single layer (U.S. Customers)
Catalog 
Number Configuration
Number of 
Cells
Gasket 
Material Grade
E16 E - StandardR - Alkaline Resistant*
01 - 1 Cell
11 - 11 Cell
A - Silicone
30LA
50LA
60LA
90LA
30LP
50LP
60LP
90LP
10SP
30SP
50SP
60SP
90SP
30ZA
60ZA
90ZA
DELI
* Based on testing with 1M NaOH and 5% NaClO (Bleach). See Chemical Compatibility Guide 
(70-0202-2023-5/LITPHG03) for more information. 
NOTES:
1. All Zeta Plus™ EXT media grades are 
available for order.
2. For further information regarding Zeta 
Plus EXT Series fi lter media, please 
reference 3M Purifi cation Literature 
70-0201-8862-2 (LITZPMEXT) or 
70-0201-8863-0 (LITZPMEXTSP1) and 
Chemical Compatibility Guide 70-0202-
2023-5 (LITPHG03)
3. DELI08A is a Zeta Plus EXT grade with 
two single layers of Delipid (DELI) media. 
4. Single layer 05SP media is offered in 
0.23 m² and 1.6 m² Capsule format. One 
part number example is E16E07A05SP.
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Standard Zeta Plus™ Encapsulated System Capsule Filters
3M Catalog ID
(U.S. Customers)
3M ID 
(International 
Customers)
3M Catalog ID
(U.S. Customers)
3M ID 
(International
Customers)
E16E01A05SP 70020288414 E16E07A05SP 70020288562
E16E01A05SP01A 70020239011 E16E07A05SP01A 70020236918
E16E01A10SP 70020288422 E16E07A10SP02A 70020236561
E16E01A10SP02A 70020239029 E16E07A120ZA08A 70020236926
E16E01A120ZA08A 70020238526 E16E07A30SP02A 70020236942
E16E01A30LA 70020288430 E16E07A60SP02A 70020236603
E16E01A30LP 70020288448 E16E07A60SP05A 70020236959
E16E01A30SP 70020288455 E16E07A60ZA05A 70020236967
E16E01A30SP02A 70020238534 E16E07A90SP05A 70020236629
E16E01A30ZA 70020288364 E16E07A90ZA05A 70020236975
E16E01A50LA 70020288471 E16E07A90ZA08A 70020236983
E16E01A50LP 70020288489 E16E11A10SP 70020288596
E16E01A50SP 70020274430 E16E11A30LA 70020288604
E16E01A60LA 70020288497 E16E11A30LP 70020288612
E16E01A60LP 70020288505 E16E11A30SP 70020288620
E16E01A60SP 70020288513 E16E11A30ZA 70020288638
E16E01A60SP02A 70020239078 E16E11A50LA 70020288646
E16E01A60SP05A 70020239094 E16E11A50LP 70020288653
E16E01A60ZA 70020283605 E16E11A50SP 70020288661
E16E01A60ZA05A 70020238542 E16E11A60LA 70020288679
E16E01A90LA 70020288521 E16E11A60LP 70020288687
E16E01A90LP 70020288539 E16E11A60SP 70020288695
E16E01A90SP 70020288547 E16E11A60ZA 70020288703
E16E01A90SP05A 70020239102 E16E11A90LA 70020288711
E16E01A90ZA 70020288356 E16E11A90LP 70020288729
E16E01A90ZA05A 70020239128 E16E11A90SP 70020288737
E16E01A90ZA08A 70020238559 E16E11A90ZA 70020288745
E16E01ADELI 70020256130 E16E11ADELI 70020288588
Alkaline Resistant* Zeta Plus™ Encapsulated System Capsule Filters
3M Catalog ID
(U.S. Customers)
3M ID 
(International 
Customers)
3M Catalog ID
(U.S. Customers)
3M ID 
(International
Customers)
E16R01A05SP 70020288992 E16R07A05SP 70020289008
E16R01A05SP01A 70020262609 E16R07A05SP01A 70020262740
E16R01A10SP 70020288794 E16R07A10SP02A 70020262757
E16R01A10SP02A 70020262625 E16R07A120ZA08A 70020262773
E16R01A120ZA08A 70020262641 E16R07A30SP02A 70020262799
E16R01A30LA 70020288802 E16R07A60SP02A 70020262823
E16R01A30LP 70020288810 E16R07A60SP05A 70020262849
E16R01A30SP 70020288828 E16R07A60ZA05A 70020262856
E16R01A30SP02A 70020262948 E16R07A90SP05A 70020262864
E16R01A30ZA 70020288364 E16R07A90ZA05A 70020262880
E16R01A50LA 70020288836 E16R07A90ZA08A 70020262898
E16R01A50LP 70020288844 E16R11A10SP 70020289024
E16R01A50SP 70020288851 E16R11A30LA 70020289032
E16R01A60LA 70020288869 E16R11A30LP 70020289040
E16R01A60LP 70020288877 E16R11A30SP 70020289057
E16R01A60SP 70020288885 E16R11A30ZA 70020289065
E16R01A60SP02A 70020262682 E16R11A50LA 70020289073
E16R01A60SP05A 70020262955 E16R11A50LP 70020289081
E16R01A60ZA 70020284587 E16R11A50SP 70020289099
E16R01A60ZA05A 70020262708 E16R11A60LA 70020289107
E16R01A90LA 70020288893 E16R11A60LP 70020289115
E16R01A90LP 70020288901 E16R11A60SP 70020289123
E16R01A90SP 70020288919 E16R11A60ZA 70020289131
E16R01A90SP05A 70020262716 E16R11A90LA 70020289149
E16R01A90ZA 70020288927 E16R11A90LP 70020289156
E16R01A90ZA05A 70020262963 E16R11A90SP 70020289164
E16R01A90ZA08A 70020262732 E16R11A90ZA 70020289172
E16R01ADELI 70020288786 E16R11ADELI 70020289016
Capsule 3M ID Numbers for International Customers
Zeta Plus™ ScaleUp Capsule 3M ID Numbers 
3M Catalog ID
(U.S. Customers)
3M ID 
(International 
Customers)
3M Catalog ID
(U.S. Customers)
3M ID 
(International
Customers)
3M Catalog ID
(U.S. Customers)
3M ID 
(International
Customers)
E0170FSA05SP01A 70020290170 E0340FSA05SP01A 70020290543 E1020FSA05SP01A 70020290915 
E0170FSA10SP01A 70020290196 E0340FSA10SP01A 70020290568 E1020FSA10SP01A 70020290931 
E0170FSA10SP02A 70020290204 E0340FSA10SP02A 70020290576 E1020FSA10SP02A 70020290949 
E0170FSA30SP02A 70020290279 E0340FSA30SP02A 70020290642 E1020FSA30SP02A 70020291012 
E0170FSA30SP03A 70020290287 E0340FSA30SP03A 70020290659 E1020FSA30SP03A 70020291020 
E0170FSA60SP01A 70020290360 E0340FSA60SP01A 70020290733 E1020FSA60SP01A 70020291103 
E0170FSA60SP02A 70020290378 E0340FSA60SP02A 70020290741 E1020FSA60SP02A 70020291111 
E0170FSA60SP03A 70020290386 E0340FSA60SP03A 70020290758 E1020FSA60SP03A 70020291129 
E0170FSA60SP05A 70020290394 E0340FSA60SP05A 70020290766 E1020FSA60SP05A 70020291137 
E0170FSA90SP05A 70020290451 E0340FSA90SP05A 70020290824 E1020FSA90SP05A 70020291194 
E0170FSA90SP08A 70020290469 E0340FSA90SP08A 70020290832 E1020FSA90SP08A 70020291202 
E0170FSA60ZA05A 70020290410 E0340FSA60ZA05A 70020290782 E1020FSA60ZA05A 70020291152 
E0170FSA90ZA05A 70020290485 E0340FSA90ZA05A 70020290857 E1020FSA90ZA05A 70020291228 
E0170FSA90ZA08A 70020290493 E0340FSA90ZA08A 70020290865 E1020FSA90ZA08A 70020291236 
E0170FSA120ZA05A 70020290212 E0340FSA120ZA05A 70020290584 E1020FSA120ZA05A 70020290956 
E0170FSA120ZA08A 70020290220 E0340FSA120ZA08A 70020290592 E1020FSA120ZA08A 70020290964 
E0170FSA120ZA10A 70020290238 E0340FSA120ZA10A 70020290600 E1020FSA120ZA10A 70020290972 
E0170FSADELI08A 70020290147 E0340FSADELI08A 70020290519 E1020FSADELI08A 70020290881 
E0170FSADELP08A 70020290154 E0340FSADELP08A 70020290527 E1020FSADELP08A 70020290899 
E0170FSA05SP 70020290162 E0340FSA05SP 70020290535 E1020FSA05SP 70020290907 
E0170FSA10SP 70020290188 E0340FSA10SP 70020290550 E1020FSA10SP 70020290923 
E0170FSA30SP 70020290261 E0340FSA30SP 70020290634 E1020FSA30SP 70020291004 
E0170FSA50SP 70020290329 E0340FSA50SP 70020290691 E1020FSA50SP 70020291061 
E0170FSA60SP 70020290352 E0340FSA60SP 70020290725 E1020FSA60SP 70020291095 
E0170FSA90SP 70020290444 E0340FSA90SP 70020290816 E1020FSA90SP 70020291186 
E0170FSA30ZA 70020290295 E0340FSA30ZA 70020290667 E1020FSA30ZA 70020291038 
E0170FSA60ZA 70020290402 E0340FSA60ZA 70020290774 E1020FSA60ZA 70020291145 
E0170FSA90ZA 70020290477 E0340FSA90ZA 70020290840 E1020FSA90ZA 70020291210 
E0170FSA30LA 70020290246 E0340FSA30LA 70020290618 E1020FSA30LA 70020290980 
E0170FSA50LA 70020290303 E0340FSA50LA 70020290675 E1020FSA50LA 70020291046 
E0170FSA60LA 70020290337 E0340FSA60LA 70020290709 E1020FSA60LA 70020291079
E0170FSA90LA 70020290428 E0340FSA90LA 70020290790 E1020FSA90LA 70020291160
E0170FSA30LP 70020290253 E0340FSA30LP 70020290626 E1020FSA30LP 70020290998
E0170FSA50LP 70020290311 E0340FSA50LP 70020290683 E1020FSA50LP 70020291053
E0170FSA60LP 70020290345 E0340FSA60LP 70020290717 E1020FSA60LP 70020291087
E0170FSA90LP 70020290436 E0340FSA90LP 70020290808 E1020FSA90LP 70020291178
E0170FSADELI 70020290139 E0340FSADELI 70020290501 E1020FSADELI 70020290873
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Enabling SCALABILITY 
from R&D to Large-Scale Production 
for Cell Culture Clarification
Zeta Plus™ Encapsulated Depth Filter Platform
Up to 1 Liter Up to 50 Liters Up to 400 Liters Up to 5,000 Liters Up to 25,000 Liters
Lab / 
R&D Scale-Up
Pilot 
Production
Large Scale
Production
Multi-Round
Production
Important Notice
The information described in this literature is accurate to the best of our knowledge. A variety of factors, however, can affect the performance of the Product(s) in a particular 
application, some of which are uniquely within your knowledge and control. INFORMATION IS SUPPLIED UPON THE CONDITION THAT THE PERSONS RECEIVING THE 
SAME WILL MAKE THEIR OWN DETERMINATION AS TO ITS SUITABILITY FOR THEIR USE. IN NO EVENT WILL 3M PURIFICATION INC. BE RESPONSIBLE FOR DAMAGES 
OF ANY NATURE WHATSOEVER RESULTING FROM THE USE OF OR RELIANCE UPON INFORMATION.
It is your responsibility to determine if additional testing or information is required and if this product is fi t for a particular purpose and suitable in your specifi c application. 
3M PURIFICATION INC. MAKES NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESS OR IMPLIED INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF 
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER NATURE HEREUNDER WITH RESPECT TO INFORMATION OR THE PRODUCT TO WHICH 
INFORMATION REFERS.
Limitation of Liability
3M Purifi cation Inc. will not be liable for any loss or damage arising from the use of the Product(s), whether direct, indirect, special, incidental, or consequential, regardless of 
the legal theory asserted, including warranty, contract, negligence or strict liability. Some states do not allow the exclusion or limitation of incidental or consequential damages, 
so the above limitation may not apply to you.
3M Purifi cation Inc.
400 Research Parkway 
Meriden, CT 06450
U.S.A.   
(800) 243-6894
(203) 237-5541  
Fax (203) 630-4530
www.3Mpurifi cation.com
3M is a trademark of 3M Company. 
Zeta Plus is a trademark of 
3M Company used under license.
© 3M 2012. All rights reserved.
70020239672
REV 0812
Your Local Distributor:
Fast. Easy. Clean.
Filtration
Innovative
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Drives L/S 
®
! Cartridges accept multiple tubing sizes 
for wide flow range
! Cartridges snap in and out for tubing 
changes; change tubing in one channel 
without disturbing others
! Finely adjust occlusion to increase 
accuracy
! Use only one cartridge, or load to 
capacity
! Digital dispensing drive features 
maintenance-free brushless motor
! Program dispensing parameters, 
including delay interval, for automated 
dispensing
! Four-channel, eight-roller pump offers 
lowest pulsation for better accuracy
! 1⁄10-hp continuous-duty brushless drive
! Tach feedback for ±0.1% drive speed 
control
! Remote control via DB25 female 
connector on drive
! IP33 rated, stackable ABS housing
! Membrane keypad with lockout
! See pages 1540–1541 for complete 
drive specifications
Catalog
number
Flow range†
(mL/min)
Pump head  
included
Tubing
included
Tubing sizes
accepted
Drive
included
Drive speed 
range (rpm)
Drive IP
rating
Power 
(50/60 Hz) Price
L/S eight-channel four-roller cartridge pump system
T-77919-20 0.0034 to 18
L/S Cartridge head 07519-06 
with eight small cartridges 
07519-80
Tygon E-LFL microbore tube 
set, 1.42-mm ID 06447-34;  
pk of 12
Microbore tube sets; 
L/S 13, L/S 14 07523-90 0.02 to 100 IP33
90 to 130 VAC, 2.2 A; 
190 to 260 VAC, 1.1 A  
L/S reduced-pulsation four-channel eight-roller cartridge pump system
T-77919-30 0.0024 to 12
L/S Cartridge head 07519-20 
with four small cartridges 
07519-85
Tygon E-LFL microbore tube 
set, 1.42-mm ID 06447-34;  
pk of 12
Microbore tube sets; 
L/S 13, L/S 14 07523-90 0.02 to 100 IP33
90 to 130 VAC, 2.2 A; 
190 to 260 V AC, 1.1 A  
†Flow range with included tubing; extend the flow range of these systems with additional sizes of tubing; order microbore two-stop tube sets below and L/S tubing on pages 1521–1527.
L/S® Cartridge Pump Systems
Low-flow capability with a high-accuracy digital drive
Additional Microbore Two-Stop Pump Tube Sets
Pump tubing 0.89 mm ID 1.42 mm ID 2.06 mm ID 2.79 mm ID
Flow rate per 
channel (mL/min)
Cartridge head 07519-06 0.0015 to 7.4 0.0034 to 18 0.0074 to 37 0.0126 to 63
Cartridge head 07519-20 0.0010 to 5.2 0.0024 to 12 0.0044 to 22 0.0068 to 34
Platinum-cured  
silicone
T-06421-26 T-06421-34 T-06421-42 T-06421-48
 /pk of 6  /pk of 6  /pk of 6  /pk of 6
Santoprene®
T-06431-26 T-06431-34 T-06431-42  T-06431-48
 /pk of 12  /pk of 12  /pk of 12  /pk of 12
Tygon® E-LFL
T-06447-26 T-06447-34 T-06447-42 T-06447-48
 /pk of 12  /pk of 12  /pk of 12  /pk of 12
Viton®
T-96428-26 T-96428-34 T-96428-42 T-96428-48
 /pk of 12  /pk of 12  /pk of 12  /pk of 12
Additional Cartridges
T-07519-80 Additional small cartridge 
for pump system 77919-20 
T-07519-85 Additional small cartridge 
for pump system 77919-30 
77919-20
How to Load Your Pump Head
1.  Select tubing, load tubing  
into cartridge, and set  
tubing retainers.
2.  Snap cartridge into place on 
pump head.
3.  Adjust occlusion using 
index scale on cartridge. 
Multiple-channel 
low-flow transfer 
and perfusion!
Specifications & Ordering Information
07519-80
imagination at work
GE Healthcare
Data file 28-9159-87 AC BioProcess prepacked columns
ReadyToProcess™ Columns
Fig 1. ReadyToProcess columns are easily connected to a chromatography 
system and can be disposed of after completed production.
ReadyToProcess columns are prepacked, prequalified, and  
presanitized process chromatography columns available 
with a range of BioProcess™ media in four different sizes: 
1.0 l, 2.5 l, 10 l, and 20 l (Fig 1).
ReadyToProcess columns are designed for purification of  
biopharmaceuticals for clinical phase I and II studies. 
Depending of the scale of operations they can also be used 
for full-scale manufacturing, as well as for preclinical studies. 
The columns can, however, be used in any chromatographic 
application for separation of various compounds, for example 
proteins, endotoxins, DNA, plasmids, vaccines, and viruses.
ReadyToProcess columns provide:
?? ?? ????????????? ???????????????? ???????????? 
steps redundant 
?? ???????????????????????????????????????????????? 
reducing cleaning validation demands
?? ??????????????????????????????????????????????????????
?? ??????????????????????????????????????????????????? 
larger scale
?? ???????????????????????????????
ReadyToProcess columns make several steps redundant 
(column packing, column qualification, and sanitization), and 
significant time saving can be achieved in the downstream 
processing. ReadyToProcess columns are closed units and 
the design allows easy disposal after completed production.
ReadyToProcess chromatography columns offer the possibility 
to work in a fully flexible mode in early clinical phases while  
keeping a conventional re-use option for large-scale 
manufacturing open. The chromatography media used in 
ReadyToProcess columns have a long track-record of use 
in full-scale manufacturing using conventional, large-scale 
chromatography, where columns can be used for tens or 
hundreds of cycles. The transition from ReadyToProcess format 
to full-scale manufacturing is therefore straightforward. 
Currently, the following BioProcess media are available in 
??????????????????????????? ??????????????????????????
?????????????????????????????????????????????????????????
(low sub). On request, also the following media are available: 
?????? ??????????????????????????????????????????????
?????????????
ReadyToProcess column characteristics
The hardware of ReadyToProcess columns follows the 
construction of BPG™ columns, with a media packing valve 
added, and is designed for upwards flow (Fig 2).
The columns have fixed bed heights of 200 mm, which 
is the optimum for contact time, flow, and capacity for 
modern chromatography media. Pressure/flow curves for 
????????????????????????????? ??????????????????????????
????????????????????????????????????????????????????????
operation with water at room temperature (20°C).
The polymer materials used to manufacture ReadyToProcess 
columns have been chosen for their biological and chemical 
compatibility with the samples, buffers, and solutions used 
during operation and during sanitization procedures.  
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Fig 3. Examples of pressure/flow curves for 2.5 and 20 l ReadyToProcess columns prepacked with (A)? ???????????????(B) Capto adhere, and  
(C) ???????????????????????????????????????
Fig 2. ReadyToProcess column with assembled nets and media packing 
valve. Arrows show flow direction.
Table 2. Characteristics of ReadyToProcess columns 
1 l 2.5 l 10 l 20 l
Inner diameter (mm) 80 ??? 251 ???
Inner cross section (cm2) 50 124 495 1012
Column volume (l) 1.0 2.5 9.9 20.2
Packed bed height (mm) 200 200 200 200
Net mesh (µm) ?? ?? ?? ??
Mechanical compression  
factor (%)*
≤15 ≤15 ≤15 ≤15
Outer height (mm) ??? ???? ???? 407
Outer diameter incl. lid (mm) 155 195 ???? 484
Weight (kg) ?? ??? ~25 ~55
Inlet TC25 connectors,  
tubing i.d. 
4.8 mm 
0.19”
???? ?
0.25”
9.5 mm
??????
12.7 mm
0.5”
Outlet TC25 connectors,  
tubing i.d. 
4.8 mm 
0.19”
???? ?
0.25”
9.5 mm
??????
12.7 mm
0.5”
Ambient temperature† (°C) ???? ????? ????? ????
Liquid temperature† (°C) 4-40 4–40 4–40 4–40
Maximum liquid pressure, bar‡ 4 4 4 4
Estimated shelf life (months) 18 18 18 18
* The mechanical compression factor varies depending on the medium.
† The temperature difference between the fluid running through the column and the ambient 
temperature in the room should never be greater than 20°C.
‡ While the maximum liquid pressure stated depends on the pressure rating of the column, 
restrictions for the maximum pressure drop over the column depend on the packed 
??????????????? ?????????????????????????????????????????????????? ??????????????????Table 1. List of wetted materials in ReadyToProcess columns
Trade name Material Column part
PP Polypropylene Column tube, lids, TC 
connections, support 
nets, support screens, 
stream stoppers, hose 
connections, welded 
tubing for inlet/outlet 
protection
PEEK Polyetheretherketone Plug at inlet tubing, filter 
holder, media packing 
valve
Tygon™ 2275 Polyolefin Hose (inlet tubing)
FPM Fluorocarbon rubber O-rings
EPDM Ethylenepropylenediene TC gaskets
The most important characteristics of the ReadyToProcess 
columns are listed in Table 2.
On delivery, ReadyToProcess columns are ready for immediate 
use. The columns are packed in clean-room environment 
??????????????????????????????????????????????????????????????
a well-packed column, each individual ReadyToProcess 
column is qualified by efficiency testing, that is, by analysis  
of theoretical plates per m packed bed (N/m) and asymmetry 
factor (As), as a part of the production procedure. Acceptance 
limits have been established for efficiency testing at 100 cm/h 
and the analysis results are specified in the Certificate of 
Analysis accompanying each column. After qualification, the  
columns are sanitized and equilibrated with storage solutions. 
???? ????????? ????????????? ???????????????????????????
???????????????????????????????????????????????????????
Reactivity Tests, “In Vivo” and FDA CFR 177. The material is 
free from material of animal origin or has been produced  
under manufacturing conditions complying with EMEA/410/01. 
The columns are designed to comply with hygienic 
requirements. Table 1 below lists the wetted materials. 
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Table 3. Characteristics of some of the chromatography media available in ReadyToProcess columns 
MabSelect SuRe Capto Q Capto S Capto adhere
Phenyl Sepharose 6 
Fast Flow (low sub)
Matrix Rigid, highly cross-
linked agarose
Rigid, highly cross-
linked agarose with 
dextran surface 
extenders
Rigid, highly cross-
linked agarose with 
dextran surface 
extenders
Rigid, highly cross-
linked agarose
Highly cross-linked 
agarose
Average particle size 85 µm 90 µm 90 µm 75 µm 90 µm
Functional group Alkali-stabilized 
protein A-derived
?????????????
??????????? ??????
??????????????
??????????????????
Multimodal strong 
anion exchanger
Phenyl
Dynamic binding 
capacity data
????? ????????????
ml medium at 2.4 min 
residence time
?????? ???????? ?????? ?? 
lysozyme/ml  
medium
NA ??? ????????
pH working range ???? 2–12 4–12 ?–12 ?–??
Cleaning-in-place 
stability
0.1–0.5 M NaOH 2–14 ???? 2–14 2–14
BioProcess media characteristics
BioProcess media are specifically designed to meet the 
demands of industrial biotechnology. This means that the  
medium is scalable from laboratory to production, is produced 
with validated manufacturing procedures, and can withstand 
standard CIP and sanitization-in-place procedures.
In addition, BioProcess media are supported with Regulatory 
????????????????????????????????????????????????????????
well as security of supply service.
Characteristics of some of the chromatography media 
???????????????????????????????????????????????????????????
Detailed information about each medium is available in the 
respective BioProcess medium data file.
The sanitization procedure removes both micro-organisms, 
including spore-forming organisms, and endotoxins. The 
columns are sampled for endotoxin analysis (acceptance 
?? ??????????????????????? ???????????????????? ?????????? ????
The results including the curve from the efficiency test as 
well as the endotoxin and microbiology analysis results are 
presented in the Certificate of Analysis, which is a part of 
the Product Documentation accompanying each column. 
As a last step, the column is equilibrated in 20% ethanol 
(20% ethanol with 0.2 M sodium acetate, pH 5.5 when 
applicable). There is no need to repeat either the efficiency 
test or the sanitization procedure.
Transport simulation studies
Transport simulation studies were performed at a certified 
testing facility (Packforsk AB) as follows: Vibration testing 
????????????????????????????????????????????????????????????
??????????????
Four column sizes, ReadyToProcess 1 l, ReadyToProcess 2.5 l,  
ReadyToProcess 10 l, and ReadyToProcess 20 l, were subjected 
to testing and the asymmetry factor and plate number were 
measured.
Acceptance criteria for the testing procedure performed at 
?????????????????????????? ???????????????????? 
? ???????????????????????????????????????????????????????????
?????????????????????????????????????????? ???????????????
and 4400 for Capto adhere. The asymmetry factor should be  
within the range 0.8 to 1.8, both before and after the testing.
The results in Figure 4 show that these parameters lie within 
the set limits, demonstrating that ReadyToProcess columns 
are stable and robust and can be transported without effect 
on their performance.
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Fig 4. Transport simulation studies on ReadyToProcess 2.5 l (a) and 
ReadyToProcess 20 l (b) columns show that both the number of theoretical 
plates, N/m, and the Asymmetry factor, As, were within the predefined 
ranges after testing. 
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Regulatory Product Documentation
Each ReadyToProcess column is accompanied with an 
extensive documentation package to help customers 
register a production process containing a chromatography 
step on a ReadyToProcess column. The documentation is 
divided into three parts.
?? Product Documentation – A certificate of conformance 
is provided, showing each wetted material’s conformance 
???????????????????????????????????? ???????????????????
EMEA/410/01). The certificate of conformance ensures 
full traceability of materials. The product documentation 
also contains a certificate of analysis showing packing 
performance as well as endotoxin and microbiology test 
results for the delivered column. The documentation is 
delivered with each column.
?? Regulatory Support Files (RSF) Addendum – Gives access  
to product information of the ReadyToProcess column 
including stability and quality, as well as a brief description 
of the preparation. 
?? RSF??????????????????????????????????????????????????
each BioProcess chromatography medium. 
????????????????????????????????????? 
www.gelifesciences.com/rsf
Scale-up study
A study was performed to verify that the results of a protein 
separation experiment give the same result regardless of 
column size or chromatography system used. A mixture of 
?????????????????????????????????????????? r????????????? 
lactoferrin (Mr 90 000), was applied to columns of different 
sizes, and eluted. The elution peaks in the resulting 
?????????????? ?????????????????????????? ???????????? 
??????? ??????????????????????????? ????????????????????????
????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????
Volume
A
280
Fig 6. ???????????????????????? ?????????????????????????
???????????????????????????????????????????????????????????
ReadyToProcess columns was possible and the results were 
similar regardless of the chromatography system used (Fig 5).
ReadyToProcess columns in the purification 
of monoclonal antibodies (MAbs) 
When choosing a process for large-scale purification, the 
possibility to scale up operations without too much process 
development is important.
To further demonstrate the scalability and assess the overall 
performance of ReadyToProcess columns, they were 
????????? ??????????????????????????????????????????????
in the purification of a MAb from cell culture supernatant. 
The processes were run side-by-side using a generally 
???????????????????????????????????????????? ???????????????
??????????????????????????????????????????????????????
?????????? ??????????????????????????????????????????????
studied, demonstrating that the purification process is directly 
scalable between XK and ReadyToProcess.
To investigate the effects of multiple runs on column 
????????????????? ?????????????????????? ???????????? 
?? ???????????????????????????????????????????? ????????????????
identical, showing that multiple runs with CIP between cycles  
could be run with retained performance.
Operation
Fast method development – fully scalable
The matrices used in ReadyToProcess columns are also 
available as bulk media. Fast method development can 
be achieved using Tricorn™ or XK columns for the first 
experiments. After optimizing the purification at laboratory 
scale, the process can be scaled up by keeping the 
residence time constant in order to maintain capacity. 
This can be achieved by increasing the column diameter 
and keeping the mobile phase velocity and sample-to-bed 
volume ratio constant.
28-9159-87 AC       5
??????????????????????????????????????????????????????????
liquid velocity (cm/h) constant (i.e., constant residence time) 
while increasing column bed diameter and flow rate (l/min). 
Yield and clearance of critical impurities may change when 
column bed height or residence time is changed and should 
be validated using the final bed height.
Storage
ReadyToProcess columns are delivered packed with 
chromatography media in a storage solution consisting 
???????????????????????????????????????????????????
delivered in 20% ethanol and 0.2 M sodium acetate pH 5.5.
??????????????????????????????????? ???????????????????
preferably stored at room temperature but can also be stored 
in a cold room (the storage temperature range for these 
???????????????????????????????????????? ??????????????
columns should be stored at 4°C to 8°C.
The column needs to be washed to clear it from the storage 
solution before starting the purification process. The wash 
will also adjust  the temperature of the column to the 
working temperature.
Equipment
ReadyToProcess columns are intended for use with 
??????????????????????????????????????????????????
used with standard chromatography systems, for example 
???????????????????????????????????????????????????????
????????????? ??????????????????????? ?????????? ????????????
velocity range. Alarm setting of pressure must be set in order 
not to exceed the maximal pressure for the packed column.
Ordering information
ReadyToProcess Columns
Product Column size  Code no.
????????????????????????? ????? ??????????
???????????????????????????? ?????? ??????????
??????????????????????????? ????? ??????????
??????????????????????????? ????? ??????????
????????????????????????? ???? ??????????
???????????????????????????? ?????? ??????????
??????????????????????????? ????? ??????????
??????????????????????????? ????? ??????????
ReadyToProcess Capto adhere 1  1 l 28-9511-09
ReadyToProcess Capto adhere 2.5  2.5 l 28-9017-14
ReadyToProcess Capto adhere 10 10 l 28-9017-15
???????????????????????????????? ????? ??????????
??????????????? ???????????????? ???? ??????????
??????????????? ??????????????????? ?????? ??????????
??????????????? ?????????????????? ????? ??????????
??????????????? ?????????????????? ????? ??????????
ReadyToProcess Phenyl  
??????????????????????????? ???? ??????????
ReadyToProcess Phenyl  
?????????????????????????????? ?????? ??????????
ReadyToProcess Phenyl  
????????????????????????????? ????? ??????????
ReadyToProcess Phenyl  
????????????????????????????? ????? ??????????
ReadyToProcess Capto MMC 1 1 l 28-9511-18 
ReadyToProcess Capto MMC 2.5 2.5 l 28-9291-20
ReadyToProcess Capto MMC 10 10 l 28-9291-21
ReadyToProcess Capto MMC 20 20 l 28-9291-22
???????????????????????????????? ???? ???????????
?????????????????????????????????? ?????? ??????????
????????????????????????????????? ????? ??????????
????????????????????????????????? ????? ??????????
????????????????????????????????? ??? ???????????
??????????????????????????????????? ?????? ??????????
?????????????????????????????????? ????? ??????????
?????????????????????????????????? ????? ??????????
??????????????????????????????????? ???? ???????????
????????????????????????????????????? ?????? ??????????
???????????????????????????????????? ????? ??????????
???????????????????????????????????? ????? ??????????
imagination at work
Application notes Code no.
Efficiency test of ReadyToProcess columns 28-9198-21
Purification of a monoclonal antibody using  
??????????????????????? ??????????
Data files Code no.
?????????? ??????????
Capto adhere 28-9078-88
?????? ??? ??????????
???????????????????? ??????????
??????????????? ??????????
??????????????????????????????????????? ??????????
??????????????????????????????????? ??????????
GE, imagination at work, and GE monogram are trademarks of General Electric Company.
?????????????????????????????????????????????????????????????????????????????????????? ???????????????
?????????????????????????????????????????????????????????????????????????????????
??????????????????????????? ????????????????????? ???????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????? ???????????????????????????????????????????? ??????????????????????????????? ???????????
???????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????
All third party trademarks are the property of their respective owners.
© 2007–2009 General Electric Company—All rights reserved 
???????????????????????????
All goods and services are sold subject to the terms and conditions of sale of the company within GE 
Healthcare which supplies them. A copy of these terms and conditions is available on request. Contact your 
local GE Healthcare representative for the most current information.
??????????????????? ????????????????????? 
Little Chalfont, Buckinghamshire, HP7 9NA 
??
GE Healthcare Europe, GmbH 
????????????????????????????????????? 
Germany
???????????????????????????????? 
????????????????????????? ????????????????????????????????????? 
???
????????????????????????????? 
?????????????????????????????????????????????????????????????? 
?????
For local office contact information, visit  
www.gelifesciences.com/contact
www.gelifesciences.com/ReadyToProcess
?????????????????????????????
?????????????
??????????????
??????
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Data SheetDat  Sheet
Part of the Mobius FlexReady family of application-specific 
solutions, the Mobius FlexReady Solution for Tangential 
Flow Filtration (TFF) is an easy-to-use system featuring 
an optimized single-use flowpath, and is designed to fully 
support your TFF needs. The system uses Millipore’s leading 
Pellicon® cassettes, which are ideally suited for purification or 
concentration/diafiltration of monoclonal antibodies, vaccines 
and therapeutic proteins.
  The Mobius FlexReady Solution for TFF consists of  
single-use Flexware® assemblies, innovative separation  
devices and process-ready hardware systems to deliver 
optimal operational flexibility, from process development to 
clinical production to small-scale commercial manufacturing. 
Accompanied by extensive Millipore support and services, 
the Mobius FlexReady Solution for TFF can help you maximize 
resource productivity and reduce risk.
Mobius® FlexReady Solution for TFF
Fast setup. Maximum adaptability.  
Pre-designed and optimized.
• Fast setup of hardware with easy installation of 
optimally designed Flexware assemblies 
• Maximum adaptability to your changing operational 
needs with single-use flowpaths
• Pre-designed and optimized for TFF to give you 
confidence and peace of mind
2MODULAR, OPTIMIZED DESIGN
Mobius FlexReady Solutions are ergonomically designed for 
fast setup, maximum adaptability to changing process needs 
and reduced operator error. Specially designed hardware 
conveniently holds filters and containers, right where you 
need them. The modular, interlocking multi-cart design lets 
you easily and safely move your system from one space 
to another. The filter end cart is designed to work with all 
Mobius FlexReady Solutions, leveraging your investment in 
capital equipment and maximizing resource utilization.
TWO SYSTEMS FOR  
OPTIMUM SCALABILITY
The TF-1 system contains a 10L retentate recycle container 
and, in typical conditions, will use Pellicon cassettes of up to 
0.5 m2 filtration area. The TF-2 system is designed with a 50L 
retentate recycle container and, in typical conditions, will use 
Pellicon cassettes of up to 2.5 m2 filtration area.
• Designed for minimum working volume and high recovery of 
protein at high concentrations
• Novel retentate recycle container with levitating mag-
netic impeller, retentate divertor, and vortex breaker for 
efficient mixing
• Retentate recycle tank mounted on load cells and inte-
grated transfer pump to enable fed batch and constant 
volume diafiltration operations
• Innovative low dead volume t-connectors, enabling 
the use of traditional pressure transducers 
• Flexware assemblies designed to fit the hardware and 
install quickly and easily 
• Constant ∆P and constant feed flow (calculated) operation 
• Ease of operation with an intuitive touch screen interface 
and user-defined process and alarm set points
Figure 2. Hardware system components move 
and connect easily for maximum mobility.
Figure 3. A pivoting retentate recycle tank  
design facilitates container loading.
Figure 1. The filter end cart works with all Mobius 
FlexReady Solutions for optimum equipment  
utilization. Tank Designed for Efficient Mixing
The retentate recycle tank is specifically designed for 
efficient concentration and diafiltration of proteins. An 
innovative single-use process container design incorporates 
a magnetically coupled levitating impeller, ensuring efficient 
mixing at high tank levels.  
 The Mobius FlexReady Solution for TFF provides maximum 
adaptability to your changing process needs, such as varying 
volume levels. The low-point retentate return with patented 
retentate diverter plate and vortex breaker on the container 
outlet, reduces air entrapment and ensures efficient mixing 
at low tank levels. The retentate recycle tank is mounted on 
load cells to enable fed-batch operation, diafiltration and final 
concentration based on set-point input. 
3 The system features a user-configurable set point for 
controlling tank volume during fed batch processing and 
diafiltration, as well as a final tank volume end point during 
ultrafiltration. The TMP value is calculated and shown on the 
main piping and instrumentation diagram (P&ID) on the inter-
face screen.
 The onscreen P&ID provides an easy way to monitor your 
process in real time, including pump speed, mixer speed, feed, 
retentate and filtrate pressures, tank temperature, calculated 
feed flow rate, ∆P, TMP, calculated filtrate flow rate, and total-
ized filtrate weight (requires optional weigh scale). A separate 
screen shows key process parameter changes over the course 
of the run.
Simple Data Management
The system automatically captures time-stamped data for  
the active parameters and separately logs the alarm and 
event history. These tab delimited/CSV files can be uploaded 
directly to your computer. The standard design includes a 
Profibus card allowing data export to a DCS. The data can also 
be exported to meet 21CFR Part 11 compliance.  An option is 
available to allow data export through an Ethernet IP protocol.
Low Dead Volume T-connector  
The Mobius FlexReady Solution for TFF features our innovative 
low dead volume t-connector built into the flowpath which 
is designed for use with traditional pressure transducers. 
A LLDPE septum provides the barrier between the process 
fluid and the transducer thereby eliminating the risk of 
contamination.
Pellicon® Cassettes 
Pellicon cassettes are the optimum tangential flow  
filtration (TFF) devices for solutions containing monoclonal 
antibodies, therapeutic proteins, albumin, hormones, vaccines 
and growth factors. These advanced, high-performance cas-
settes are ideal for today’s higher titer therapeutic antibod-
ies as well as the more demanding filtration processes that 
require greater operating pressures and temperatures.
Easy and Intuitive Operation
An intuitive, touch screen interface, makes the Mobius 
FlexReady Solution for TFF easy to operate. The system uses 
a combination of configurable process alarm set points and 
automated data acquisition. Transmembrane pressure (TMP) 
can be set with the help of an automated pressure control 
valve, and controlled through the touch screen interface  
along with set point operation for constant pump speed or 
constant ∆P. 
Figure 5. Pellicon Cassettes are ideal for higher 
titers and more demanding filtration processes.
Figure 4. The innovative low dead volume  
t-connector prevents pressure sensor contact with 
the fluid path.
Figure 6. The Automated Pressure Control Valve 
(PCV) features a clear outer door enabling a clear 
view during operation.  If the door is opened during 
operation, the valve automatically shuts off ensuring 
operator safety.
Figure 7. The P&ID provides real-time display of all 
active parameters.
4Figure 8. TFF Flowpath
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Select from Standard Flowpath Configurations for Each System  
TF-1 TF-2
Core Flexware Assemblies 10L retentate recycle container 50L retentate recycle container
Sterilizing-grade filter assembly for final 
collection
5L or 10L collecting container featuring 
Opticap® XL 600 capsule with Millipore 
Express® SHC membrane  
10L or 20L collecting container featuring 
Opticap® XL 600 capsule with Millipore 
Express® SHC membrane 
Process container for source 10L, 20L, 50L 50L, 250L
Process container for NaOH 10L, 20L, 50L 250L, 500L, 1,000L
Process container for buffer  10L, 20L, 50L 250L, 500L, 1,000L
Process container for WFI  10L, 20L, 50L, 250L 250L, 500L, 1,000L
Process container for filtrate  10L, 20L, 50L 250L (accommodates up to 2 process 
containers for filtrate)
Process container for waste 250L 1,000L
Pellicon 2 cassettes 0.1 m2 (1-5 cassettes) 0.5 m2 (1-5 cassettes)
2.5 m2 (1 cassette)
Pellicon 3 cassettes
 
0.11 m2 (1-4 cassettes)
 
0.56 m2 (1-4 cassettes)
1.14 m2 (1-2 cassettes)
Standardized Configurations for  
Reliable Results 
The flowpath has been carefully designed and tested by our 
design and applications engineers, resulting in a consistent, 
standardized flowpath. You are guaranteed that the flowpath is 
designed to fit the system and your TFF needs.  The flowpath 
(See Fig. 8) consists of:
 
• Core Flexware assemblies which includes the 
transfer manifold line and vent filter, retentate 
recycle container, retentate and feed lines, 
retentate flush line, and filtrate drain line 
• Sterilizing-grade filter assembly for final collection 
with sampling bag and NovaSeal™ Crimping Sleeve 
for sterile disconnect
• Optional Flexware assemblies including process 
containers for source, NaOH, buffer, WFI, filtrate, 
and waste, and integrity tester (IT) connector line 
• Pellicon cassettes
5SPECIFICATIONS
TF-1 TF-2
Recommended Operating Parameters
Retentate recycle tank 10L 50L
Flowrate 0.4 - 4.0 L/min 2 – 18 L/min
Surface area Pellicon 2 0.1 – 0.5 m2 0.5 - 2.5 m2
Surface area Pellicon 3 0.11 – 0.44 m2 0.56 – 2.28 m2
Min. working volume (based on feed flow of 
8 L/min/m2)
Min. working volume is the volume in the retentate 
recycle container, feed line, Pellicon filters, and 
retentate line.
Min. working volume is a function of the membrane 
surface area and the feed flowrate.
320 mL @ 0.1 m2
490 mL @ 0.5 m2 
1,350 mL @ 0.5 m2
2,400 mL @ 2.5 m2
Fluid operating temperature 20 - 45 °C (68 - 113 °F)
Max. operation pressure 50 psi (3.45 bar)
Environmental Requirements 20-25 °C, (68 - 113 °F) Relative humidity 10-90% (non condensing)
Utilities
Supply voltage 100 - 110 VAC,  
50/60 Hz, 1 phase
230 VAC,  
50/60 Hz, 1 phase
200 - 208 VAC,  
50/60 Hz, 3 phase
400 VAC,  
50/60 Hz, 3 phase
Compressed Air/N2 Clean, dry air or nitrogen source at 3.5 to 6.0 bar (50 – 90 psi) for connecting to Integritest® 4 and 
for bag inflation
Instrumentation
Filtrate weigh scale (optional) up to 60 kg (132.3 lbs) up to 600 kg (1,328 lbs)
Pressure transducer Sanitary diaphragm pressure transducer located at retentate and filtrate lines
High pressure cut-off switch Sanitary diaphragm pressure transducer located at feed and transfer pump outlet
Temperature sensor Located at retentate recycle container outlet
Weight load cells Located at retentate recycle tank (qty. of 4) 
Control Modes: Operations will be supervised by alarm setpoints
 Set point Details
 Constant ∆P (Pfeed – Pretentate) Operate at constant  ∆P or calculated constant feed flow rate
 Constant TMP
 
Operate at constant TMP or retentate pressure
 Constant retentate tank weight For fed batch concentration, for constant-volume diafiltration
 Cumulative filtrate For concentration or diafiltration endpoint determination volume/weight
Languages Supported
English
Weight (Approx.)
Filter support kit 10 kg (22 lbs) 30 kg (66.1 lbs)
Pump cart 330 kg (727.5 lbs)
Filter cart 150 kg (330.7 lbs)
Manifold plate 5 kg (11 lbs)
Dimensions  (H x W x D)
Pump cart 1910 x 1250 x 800 mm (75.1 x 49.2 x 31.5 in.) 
Filter cart 1050 x 1100 x 800 mm (41.3 x 43.3 x 31.5 in.) 
(Pfeed + Pretentate)
2 - Pfiltrate
6TF-1 TF-2
Materials of Construction  
(product contact)
Pellicon cassette liners UDEL P-1700 Polysulfone
Process container ULDPE (PureFlex™ film)
Low dead volume  
t-connector
LLDPE film (septum), Polysulfone (body nut), LLDPE (Gauge Protector), Silicone (o-ring)
Tubing Nylon-braided silicone, Bioprene®, Platinum-cured silicone tubing
Fittings Polypropylene, HDPE, polysulfone, silicone o-rings/gaskets, polyvinylidene difluoride
Connectors Polypropylene, silicone
Filters See individual datasheets
Materials of Construction  
(non-product contact)
Retentate recycle tank HDPE
Frame Stainless steel 304L
Panels Stainless steel 304L, Epoxy coating PMS233
Drip tray Stainless steel 304L
Non-painted exposed surfaces, e.g. shelves, in-
stallation bar, installation support, handle bars
Stainless steel 304L Polished 220 grid 
Bench Laminated glass
Pellicon holder Stainless steel 316L
Trays/bins Polyethylene
NovaSeal crimp Nickel-coated brass
Wheels Nylon non-marking wheels with locks
Low dead volume t-connector Polysulfone (body nut), nylon (washer), PVC (plug)
Manifold Plate
Plate Polycarbonate
Supports Stainless steel 316L
Pinch valves Glass-reinforced nylon
Filter Support Kit
Frame Stainless steel 304L
Support Stainless steel 304L/316L
Holder nuts Bronze
Pinch valves Glass-reinforced nylon
Filtrate Weigh Scale (Optional)
60 kg (132.3 lbs) Stainless steel 316TI
600 kg (1,328 lbs) Stainless steel 304
Flexware Assemblies
Mobius Bronze Certification: Each assembly is exposed to a gamma irradiation level of 25-40 kGy. 
Component materials meet criteria for USP<88> Biological Reactivity Test, Class VI Plastics.  
Flexware assemblies are compliant with EMEA410/01 Rev. 2.
Regulatory Information
The system is manufactured according to the ISO® 9001 quality standard.
The system is designed to be compliant with CE and EN 60204.
SPECIFICATIONS
7Description Catalogue No.
Core Hardware System
The core hardware system includes the pumping cart,  
filter cart with 2 trays (10L and 50L), and filter supports.
Mobius FlexReady System, TF-1 (10L retentate recycle tank)
100-110VAC 50/60Hz  
1 phase (North American)
MBSTA1
230VAC 50/60Hz 
1 phase (European)
MBSTA2
Mobius FlexReady System, TF-2 (50L retentate recycle tank) 
200 - 208VAC, 50/60Hz 
3 phase (North American)
MBSTB1
400VAC 50/60Hz 
3 phase (European)
MBSTB2
Hardware Accessories
Collapsible Containers
250L bin (holds 100L or 250L process 
containers)
MBSACC006U
1,000L bin (holds 500L, 750L, or 1,000L 
process containers)
MBSACC007U
Containment trays
10L tray (holds 5 or 10L process 
containers)
MBSACC005U
50L tray (holds 20L or 50L process 
container)
MBSACC004U
Filtrate Weigh Scale 
60 kg (132.3 lbs) for TF-1 MBSACC019U
600 kg (1,328 lbs) for TF-2 MBSACC020U
ORDERING INFORMATION
Pellicon Cassettes
All Pellicon cassettes must be purchased separately.  
See datasheets DS1324EN00 Rev. B, DS1209EN00 (Pellicon 3) 
and DS1210EN00 (Pellicon 2) for ordering information.
* For Zone and pricing information, contact your local Millipore  
  representative. 
TF-1 TF-2
Materials of Construction  
(product contact)
Pellicon cassette liners UDEL P-1700 Polysulfone
Process container ULDPE (PureFlex™ film)
Low dead volume  
t-connector
LLDPE film (septum), Polysulfone (body nut), LLDPE (Gauge Protector), Silicone (o-ring)
Tubing Nylon-braided silicone, Bioprene®, Platinum-cured silicone tubing
Fittings Polypropylene, HDPE, polysulfone, silicone o-rings/gaskets, polyvinylidene difluoride
Connectors Polypropylene, silicone
Filters See individual datasheets
Materials of Construction  
(non-product contact)
Retentate recycle tank HDPE
Frame Stainless steel 304L
Panels Stainless steel 304L, Epoxy coating PMS233
Drip tray Stainless steel 304L
Non-painted exposed surfaces, e.g. shelves, in-
stallation bar, installation support, handle bars
Stainless steel 304L Polished 220 grid 
Bench Laminated glass
Pellicon holder Stainless steel 316L
Trays/bins Polyethylene
NovaSeal crimp Nickel-coated brass
Wheels Nylon non-marking wheels with locks
Low dead volume t-connector Polysulfone (body nut), nylon (washer), PVC (plug)
Manifold Plate
Plate Polycarbonate
Supports Stainless steel 316L
Pinch valves Glass-reinforced nylon
Filter Support Kit
Frame Stainless steel 304L
Support Stainless steel 304L/316L
Holder nuts Bronze
Pinch valves Glass-reinforced nylon
Filtrate Weigh Scale (Optional)
60 kg (132.3 lbs) Stainless steel 316TI
600 kg (1,328 lbs) Stainless steel 304
Flexware Assemblies
Mobius Bronze Certification: Each assembly is exposed to a gamma irradiation level of 25-40 kGy. 
Component materials meet criteria for USP<88> Biological Reactivity Test, Class VI Plastics.  
Flexware assemblies are compliant with EMEA410/01 Rev. 2.
Regulatory Information
The system is manufactured according to the ISO® 9001 quality standard.
The system is designed to be compliant with CE and EN 60204.
Description Catalogue No.
Services
Choose from a suite of services, including installation, 
commissioning validation, training and annual performance 
review to meet your specific processing requirements. All 
services are performed by Mobius FlexReady services certified 
engineers.
 
Factory Acceptance Testing
 
SVCMBSTFAT
Installation and Operational Qualification 
Protocol Performance Zone* 1
SVCMBSTIQOQZ1 
Installation and Operational Qualification 
Protocol Performance Zone* 2
SVCMBSTIQOQZ2
Installation and Operational Qualification 
Protocol Performance Zone* 3
SVCMBSTIQOQZ3 
Installation and Operational Qualification 
Protocol, TF-1
DOCMBST1IQOQ 
Installation and Operational Qualification 
Protocol, TF-2
DOCMBST2IQOQ 
Annual Performance Review Zone* 1 SVCMBSTAPRZ1
Annual Performance Review Zone* 2 SVCMBSTAPRZ2
Annual Performance Review Zone* 3 SVCMBSTAPRZ3
Flexware Assemblies (Pellicon cassettes sold separately)
For flowpath drawing, see Fig. 7 on pg. 4. Consult with your sales 
representative to configure your TFF flowpath using standard, 
optimized options.  
 
Each system has a dedicated flowpath, and the flowpath  
components are not interchangeable between TF-1 and TF-2. 
Ensure you order the flowpath for the hardware system you 
have selected.
NovaSeal Crimping Solution
The flowpath includes the NovaSeal Crimping Sleeve for sterile 
disconnect of sample containers.  The NovaSeal Crimping Tool is 
sold separately.  See datasheet DS1040EN00 Rev. B for ordering 
information.
Millipore, Mobius, Flexware, Pellicon, Integritest, and Millipore Express are registered 
trademarks of Millipore Corporation. ISO is a registered trademark of the International 
Standards Organization. Bioprene is a registered trademark of Watson-Marlow Ltd.
The M mark and Advancing Life Science Together, PureFlex and NovaSeal are trademarks 
of Millipore Corporation. 
Lit. No. DS3125EN00  Rev. D      09/11  DP SBU-09-01518   Printed in U.S.A.  
© 2011 Millipore Corporation, Billerica, MA 01821 U.S.A. All rights reserved.
www.millipore.com/mobius
TO PLACE AN ORDER OR RECEIVE 
TECHNICAL ASSISTANCE
For additional information call your nearest Millipore office:
In the U.S. and Canada, call toll-free  
1-800-MILLIPORE (1-800-645-5476)
In the U.S., Canada and Puerto Rico, fax orders to  
1-800-MILLIFX (1-800-645-5439)
Outside of North America contact your local office.
To find the office nearest you: www.millipore.com/offices
Internet: www.millipore.com 
Technical Service: www.millipore.com/techservice
